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Theories based on clinical and neuroanatomical studies implicate the
muscarinic cholinergic system in normal and pathological emotion regulation.
Emotional and sensory experiences can be induced with intravenous administration of
the local anesthetic procaine hydrochloride, which selectively activates limbic regions
in humans and animals.  Procaine has a high affinity for muscarinic cholinergic
receptors in vitro.  This research tests three hypotheses: (1) procaine binds to
muscarinic receptors in vivo; (2) procaine alters functional connectivity among
cholinergic brain regions and their targets; and (3) procaine-induced emotions are
related to core cholinergic regions.
In Experiment I, anesthetized rhesus monkeys underwent positron emission
tomography (PET) studies before and after administration of six doses of procaine on
separate days using a radioligand with preferential binding to muscarinic M2
receptors ([18F]FP-TZTP).  Procaine blocked [18F]FP-TZTP in a dose-response
fashion uniformly across the brain, while significantly increasing tracer flow in limbic
compared with non-limbic regions.
In Experiment II, behavioral and physiological measures were assessed at
baseline and following procaine in 32 healthy controls and 15 patients with bipolar
disorder undergoing [15O] PET yielding regional cerebral blood flow (rCBF).
Procaine selectively increased rCBF in anterior paralimbic regions in healthy
controls, but to a lesser degree in patients. Regions connected via cholinergic
pathways showed significantly different functional connectivity in both groups with
procaine, however, prefrontal regions showed differential functional connectivity
with cholinergic brain regions in patients compared with controls.  Changes in
activity of cholinergic regions explained the variance in anxiety ratings in an opposite
manner in each group, and in euphoria ratings only in patients.
In conclusion, procaine binds directly with muscarinic receptors in vivo while
selectively increasing limbic activity in anesthetized monkeys.  Two key findings
herein  procaine-induced alterations in functional connectivity of core cholinergic
regions in humans, and the association of core cholinergic regional activity with
emotional experience  support theories implicating cholinergic contributions to
emotion regulation. Decreased anterior paralimbic activity and altered functional
connectivity of cholinergic regions in patients with bipolar illness compared with
controls revealed by procaine offers additional insight into the regional neurobiology
of the disease, and may ultimately be targeted in therapeutic approaches to bipolar
disorder.
CHOLINERGIC CONTRIBUTIONS TO EMOTION REGULATION
By
Brenda Ellen Benson
Dissertation submitted to the Faculty of the Graduate School of the
University of Maryland, College Park, in partial fulfillment




Professor Avis H. Cohen, Chair
Professor William Hodos
Professor Barry D. Smith
Assistant Professor Elizabeth M. Quinlan






This work dedicated to my mother, Emmie C. Benson, and my father, Rush T.
Benson, whose interests in sociology and engineering, respectively, unwittingly
contributed to my curiosity in brain-behavior relationships.
iii
Acknowledgements
The author wishes to thank several individuals for their tireless assistance in
the preparation of this dissertation.  I wish to thank all my committee members for
their comments, suggestions, and nudges that gave me the extraordinary incentive to
complete the project.  I gratefully thank Avis Cohen for the essential training in
neuroscience I received under her tutelage, and for the support and encouragement
she generously offers.  I am indebted to Terence Ketter from whom I learned brain
imaging methodologies and how to apply them to the study of mental illness. I owe
the most to Bill Hodos, for without his influence I would have never studied
neuroscience.  Catherine Carr has the perfected the knack on how to give the just-the-
right nudge at the just-the-right time that produces the desired effect of
accomplishment.  Betsy Quinlan exudes energetic confidence that was infectious and
stimulated new perspectives from which to view this work.  Robert M. Post provided
much needed guidance with respect to the development of the author’s scientific
thinking, practical assistance in editing and writing, and encouragement to see the
work to completion.  Lastly, I wish to express my love and gratitude to my daughter





Table of Contents ..................................................................................................... iv
List of Tables .........................................................................................................viii
List of Figures.......................................................................................................... ix
List of Abbreviations................................................................................................. x
Chapter 1: Introduction ....................................................................................... 1
1.1 Historical Perspectives............................................................................... 7
1.2 Neuroanatomy of Emotion....................................................................... 13
1.2.1 Basal Forebrain Nuclei..................................................................... 21
1.2.1.1 Functional Attributes of the Basal Forebrain............................. 30
1.2.2 The Anterior Cingulate..................................................................... 32
1.2.2.1 Cingulate Pathways .................................................................. 33
1.2.2.2 Functional Attributes of the Anterior Cingulate ........................ 39
1.2.3 The Amygdala ................................................................................. 42
1.2.3.1 Amydalar Nuclei ...................................................................... 44
1.2.3.2 Intrinsic Amygdalar Pathways .................................................. 47
1.2.3.3 Extrinsic Amygdalar Pathways................................................. 49
1.2.3.4 Functional Attributes of the Amygdala ..................................... 57
1.2.4 Thalamic and Striatal Relationships with the Limbic System............ 60
1.2.5 Neuroanatomical Circuits................................................................. 61
1.2.6 Neuroanatomy Summary.................................................................. 63
1.3 Neurobiology of Emotion ........................................................................ 66
1.3.1 Lesion Studies.................................................................................. 66
1.3.2 Normal versus Pathological Psychopharmacology............................ 71
1.3.3 Emotion Induction Studies ............................................................... 73
1.3.4 Interactions Between the Cholinergic and Other Neurotransmitter
                   Systems......................................................................................... 74
1.4 Theories of Emotion Regulation .............................................................. 76








1.5 The Muscarinic Cholinergic System Involvement in Emotion Regulation 89
1.5.1 Procaine as a Muscarinic Cholinergic Ligand................................... 92
1.5.2 Neuroanatomy.................................................................................. 93




Chapter 2: A Potential Cholinergic Mechanism of Procaine’s Limbic Activation .. 106
2.1 Abstract ................................................................................................. 107
2.2  Introduction ........................................................................................... 108
2.3 Methods................................................................................................. 113
2.3.1 Subjects ......................................................................................... 113
2.3.2 Experimental Design...................................................................... 113
2.3.3 Radiopharmaceutical...................................................................... 114
2.3.4 Procedure....................................................................................... 115
2.3.5 Imaging Data Collection and Analysis ........................................... 118
2.4 Results................................................................................................... 122
2.4.1 Control Values ............................................................................... 122
2.4.2 Peripheral Measures ....................................................................... 123
2.4.3 Global Effects ................................................................................ 124
2.4.4 Regional Effects............................................................................. 127
2.5 Discussion ............................................................................................. 129
2.6 Afterword: Linking Preclinical and Clinical Data................................... 136
Chapter 3: Alterations of Regional Cerebral Blood Flow with Procaine
                            Administration in Bipolar Illness................................................ 139
3.1 Introduction ........................................................................................... 139
3.2 Methods................................................................................................. 142
3.2.1 Subjects ......................................................................................... 142
3.2.2 Procaine Procedure and Behavioral Measures ................................ 143
3.2.3 PET Acquisition and Data Analysis................................................ 146
3.3 Results................................................................................................... 149
3.3.1 Emotional and Sensory Response to Procaine ................................ 149
3.3.2 Activation Studies .......................................................................... 157
3.3.2.1 Healthy Controls .................................................................... 157
3.3.2.2 Patients with Bipolar Disorder................................................ 163
3.2.3.3 Patient versus Controls Comparisons...................................... 166
3.3.3 Mood and Change in CBF Correlations in Patients......................... 168
3.4 Discussion ............................................................................................. 170
3.5 Conclusion............................................................................................. 175
Chapter 4: Alterations in Functional Connectivity With Procaine
                            Administration in Humans.......................................................... 176
4.1 Introduction ........................................................................................... 176
4.2 Methods................................................................................................. 180
4.2.1 Subjects ......................................................................................... 180
4.2.2 Procaine Procedure and Behavioral Measures ................................ 180
4.2.3 PET Acquisition and Data Analysis................................................ 181
4.2.4 Relationships Between Emotional Responses and rCBF................. 187
4.3 Results................................................................................................... 188
4.3.1 Emotional and Sensory Response to Procaine ................................ 188
4.3.2 Functional Connectivity Studies..................................................... 189
4.3.2.1 Healthy Controls at Baseline .................................................. 189
vi
4.3.2.2 Healthy Controls with Procaine .............................................. 192
4.3.2.3 Patients at Baseline................................................................. 194
4.3.2.4 Patients with Procaine ............................................................ 198
4.3.3 Multivariate Analysis of Behavioral and Cerebral Blood Flow
                     Relationships............................................................................. 200
4.3.3.1 Behavioral and Regional CBF Relationships .......................... 200
4.3.3.2 Multivariate Emotion and Cholinergic CBF Network Analysis204
4.4 Discussion ............................................................................................. 209
4.4.1 Cholinergic Pathway Confirmation ................................................ 210
4.4.2 Alternative Perspective of Activation Study Findings..................... 216
4.4.3 Emotion and CBF Relationships..................................................... 218
4.4.4 Consolidation of Findings .............................................................. 220
4.4.5 Limitations..................................................................................... 224
4.4.6 Conclusion ..................................................................................... 226
Chapter 5: Conclusions and Implications............................................................... 227
5.1 Overall Summary................................................................................... 227
5.2 Implications ........................................................................................... 238
5.2.1 Basal Forebrain Arousal Mechanisms ............................................ 238
5.2.2 Clinical Applications...................................................................... 243
5.2.3 The Cholinergic System from an Evolutionary Perspective. ........... 245
5.3 Explanation of Anomalous Results ........................................................ 247
5.4 Study Refinement and Future Directions................................................ 248
5.5 Conclusion............................................................................................. 252
Appendices ........................................................................................................... 253
Appendix A.  O-15 Emotion and Mood Questionnaire....................................... 255
Appendix B.  Extended Hamilton Psychiatric Rating for Depression ................. 256
Appendix C.  Young Mania Rating Scale .......................................................... 260
Appendix D.  Beck Depression Inventory.......................................................... 262
Appendix E.  Spielberger State-Anxiety ............................................................ 264
Appendix F.  Correlative Relationships Between Cholinergic Brain Regions
                         and ROIs Across the Brain in 32 Healthy Controls Using
                         Comparative Methods of Steiger. .............................................. 266
Appendix G.  Correlative Relationships Between Cholinergic Brain Regions
                          and ROIs Across the Brain in 15 Patients with Bipolar Disorder
                          Using Comparative Methods of Steiger .................................... 267
Appendix H.  Correlations Between Brain ROIs and Emotional and Sensory
                           Responses in 32 Healthy Controls at Baseline ......................... 268
Appendix I.  Correlations Between Brain ROIs and Emotional and Sensory
                         Responses in 32 Healthy Controls with Procaine Administration270
Appendix J.  Correlations Between Brain ROIs and Emotional and Sensory
                          Responses in 32 Healthy Controls -  Delta CBF / Delta Rating . 272
Appendix K.  Correlations Between Brain ROIs and Emotional and Sensory
                           Responses in 15 Patients with Bipolar Disorder at Baseline ..... 274
Appendix L.  Correlations Between Brain ROIs and Emotional and Sensory
                         Responses in 15 Patients with Bipolar Disorder with Procaine
                         Administration .......................................................................... 276
vii
Appendix M.  Correlations Between Brain ROIs and Emotional and Sensory
                            Responses in 15 Patients with Bipolar Disorder –
                            Delta CBF / Delta Rating........................................................ 278
Appendix N.  Multivariate Multiple Regression Analysis of the Relationship
                            Between Change in Emotion Ratings and Change in rCBF –
                            32 Healthy Controls – Negative Emotions .............................. 280
Appendix O.  Multivariate Multiple Regression Analysis of the Relationship
                           Between Change in Emotion Ratings and Change in rCBF –
                           32 Healthy Controls – Positive Emotions................................. 282
Appendix P.  Multivariate Multiple Regression Analysis of the Relationship
                          Between Change in Emotion Ratings and Change in rCBF –
                          15 Patients with Bipolar Disorder – Negative Emotions............ 284
Appendix Q.  Multivariate Multiple Regression Analysis of the Relationship
                           Between Change in Emotion Ratings and Change in rCBF –




Table 1.  Cortical Names of Brodmann Areas.......................................................... 19
Table 2.  Physio-Chemical Properties of Procaine Hydrochloride. ......................... 100
Table 3.  The Effects of Procaine Administration on the Functional Response
                   of the Cortex ....................................................................................... 124
Table 4.  Regional [18F]FP-TZTP Parameter Values .............................................. 128
Table 5.  Subjects Demographics and Illness Characteristics ................................. 145
Table 6.  Emotional and Sensory Reponses at Baseline and with Procaine............. 151
Table 7.  Significant Findings in Regional CBF Identified by Comparative
                 Analyses ............................................................................................... 159
Table 8.  Correlative Relationships Between Cholinergic Brain Regions and ROIs
                  Across the Brain in 32 Healthy Controls .............................................. 191
Table 9.  Correlative Relationships Between Cholinergic Brain Regions and ROIs
                  Across the Brain in 15 Patients with Bipolar Disorder.......................... 195
Table 10.  Correlative Relationships Between Cholinergic Brain Regions and ROIs
                  Across the Brain in 15 Patients with Bipolar Illness Compared to
                 32 Healthy Controls .............................................................................. 196
ix
List of Figures
Figure 1.  Cytoarchitectural Map of the Human Cortex............................................ 18
Figure 2.  Cortical Neuroanatomy of the Macaca mulatta........................................ 20
Figure 3.  Location of Cholinergic Cell Bodies........................................................ 22
Figure 4.  Cortical and Subcortical Connections with the Substantia Inominata. ...... 26
Figure 5.  Pathways Involving the Anterior Cingulate ............................................. 35
Figure 6.  Intrinsic Connections of the Amygdala. ................................................... 48
Figure 7.  Reciprocal Subcortical Connections of the Amygdala.............................. 51
Figure 8.  Reciprocal Cortical Connections of the Amygdala................................... 52
Figure 9.  Schematic Summarizing the Cholinergic Influences on the Brain. ........... 65
Figure 10.  Distributions of the Acetylcholine and Monoaminergic Projections ....... 68
Figure 11.  Structural Comparison Between Procaine and Acetylcholine. ................ 99
Figure 12.  Relative Affinities of Procaine............................................................. 102
Figure 13.  Effects of Procaine on [18F]TZTP Binding and Flow ........................... 125
Figure 14.  Dose-Response Relationship of Procaine and Global [18F]FP-TZTP
                       Binding ........................................................................................... 126
Figure 15.  Procaine-Induced Emotions:  Fear and Anxiety ................................... 152
Figure 16.  Procaine-Induced Emotions: Depression and Anger............................. 153
Figure 17.  Procaine-Induced Emotions: Euphoria and Good-Bad Feeling............. 154
Figure 18.  Procaine-Induced Emotions: Calmness and Tiredness.......................... 155
Figure 19.  Procaine-Induced Sensations: Visual and Auditory.............................. 156
Figure 20.  Effects of Procaine on rCBF in 32 Healthy Controls ............................ 161
Figure 21.  Procaine Increases Anterior Paralimbic rCBF in 32 Healthy Controls.. 162
Figure 22.  Effects of Procaine on rCBF in 15 Patients with Bipolar Disorder ....... 164
Figure 23.  Procaine Increases Anterior Paralimbic rCBF in 15 Patients with
                      Bipolar Disorder .............................................................................. 165
Figure 24.  Group Differences in Normalized rCBF at Baseline and with Procaine 167
Figure 25.  Group / Drug Interaction: 15 Patients vs 32 Controls,
                      Procaine vs Baseline ........................................................................ 169
Figure 26.  Mood Correlation with Change in rCBF in 15 Patients ........................ 169
Figure 27.  Location of Regions of Interest (ROIs) ................................................ 184
Figure 28.  Differential Relationships of Forebrain vs Brainstem rCBF with
                      Anxiety Response to Procaine in Patients vs Controls ...................... 202
Figure 29.  Differential Relationships of Forebrain vs Brainstem rCBF with
                      Euphoria Response to Procaine in Patients vs Controls..................... 203
Figure 30.  Testing the AChNet Model: Relationship to Anxiety Ratings .............. 206
Figure 31.  Testing the AChNet Model: Relationship to Euphoria Ratings............. 207
Figure 32.  Cholinergic Model in Healthy Controls ............................................... 230






















BP1..........................binding potential at baseline
BP2..........................binding potential with procaine
BPI...........................subtype I of bipolar disorder
BPII .........................subtype II of bipolar disorder
C0.............................initial radioactivity level
Ca++ .........................calcium
CA1-CA4.................Cornu Ammonis – hippocampus proper
cAMP ......................cyclic adenosine monophosphate
CBF .........................cerebral blood flow
CCK.........................cholescystekinin
ChAT.......................choline acetyl transferase
Ch2-VLDB ..............cholinergic portion of the vertical limb of the diagonal band
Ch3-HLDB ..............cholinergic portion of the horizontal limb of the diagonal
band
Ch4-NMB ................cholinergic portion of the nucleus basalis of Meynert
CI-979......................milameline
CNS .........................central nervous system





DRE.........................region of interest based on the work of Drevets et al., 1998
∆BP .........................change in binding potential
xi
∆BPmax...................maximum change in binding potential
EEG .........................electroencephalogram
EKG.........................electrocardiogram
fMRI ........................functional magnetic resonance imaging
GABA......................gamma-aminobutyric acid




GSR .........................galvanic skin response
HDRS ......................Hamilton Depression Rating Scale
HIV..........................human immunodeficiency virus
HLDB ......................horizontal limb of the diagonal band
HR ...........................heart rate
HVA ........................homovanillic acid





K1-base .......................radiotracer delivery at baseline





LAMP......................limbic associated modulatory protein
LOFC.......................lateral orbitofrontal cortex
M1 ...........................primary motor cortex
M2 ...........................secondary motor cortex
M1-M4......................muscarinic receptor subtypes
mAChR....................muscarinic receptors
MAOI ......................monoamine oxidase inhibitor
MAY........................region of interest based on the work of Mayberg et al., 2002
mCi..........................milli-Curie
MOFC......................medial orbitofrontal cortex
MPFC ......................medial prefrontal cortex
MRI .........................magnetic resonance imaging
Na+...........................sodium
nAChR.....................nicotinic receptors
NADPH-d ................nicotinamide adenine dinucleotide phosphate
NE ...........................norepinephrine
NGF.........................nerve growth factor




pCO2 ........................partial concentration carbon dioxide
PET..........................positron emission tomography
PGAC ......................pregenual anterior cingulate
PI .............................phosphotidylinositol
PR............................procaine
PTSD .......................post-traumatic stress disorder
QNB ........................quinuclidinyl benzilate
rCBF........................regional cerebral blood flow
rcontrols .......................Pearson product-moment correlation for controls
rpatients .......................Pearson product-moment correlation for patients
rbd.............................Pearson product-moment correlation for bipolars
rc ..............................Pearson product-moment correlation for controls
rp ..............................Pearson product-moment correlation for procaine
rbl .............................Pearson product-moment correlation for baseline
ROI..........................region of interest
RR ...........................respiration rate
S1 ............................primary somatosensory cortex
SEP..........................septal nuclei
SGAC ......................subgenual anterior cingulate
SI .............................substantia inominata
SPM99 .....................statistical parametric mapping, version 99
SSAS .......................Spielberger State Anxiety Scale
SSRI ........................selective serotonin reuptake inhibitors
SYS .........................systolic blood pressure
t1/2 ............................half-life
T1 ............................MRI specification






Vbase .........................volume of distribution at baseline
Vproc .........................volume of distribution with procaine
VApc .......................ventroanterior pars compacta
VLDB ......................vertical limb of the diagonal band
VLPFC.....................ventrolateral prefrontal cortex











“There can be no knowledge without emotion.  We may be
aware of a truth, yet until we have felt its force, it is not ours.
To the cognition of the brain must be added the experience of
the soul.”
Arnold Bennett (1867-1937), British Novelist, 18 March1897
Relating emotion regulation to the neuromodulatory effects of the muscarinic
cholinergic system may prove to be challenging, given the complex nature of
emotions. Emotions involve cognitive, motivational, expressive, and physiological
elements that can vary across time, according to environmental cues, and within and
between individuals.  Relying on any single entity to explain behavior may be viewed
as reductionistic.  However, the muscarinic cholinergic system has been tied to
learning and memory (Bartus et al., 1982; Gold, 2003), attention (Wenk, 1997;
Robbins and Everitt, 1995), consciousness (Delacour et al., 1997; Perry et al., 1999),
and emotions (Mesulam, 1995).  Mesulam describes the cholinergic projections as the
“pathway likely to constitute the single most substantial regulatory afferent system of
the cerebral cortex.”
The muscarinic cholinergic system may serve as a bridge between emotional
experience and underlying neurophysiological activity.   In this regard, Sarter and
colleagues (2001) suggests that cholinergic modulation may contribute to the top-
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down optimization of task- or modality-specific information.  This system is
associated with fear-conditioning of the amygdala and loss of fear response with basal
forebrain (BF) lesions (LeDoux, 1996), is implicated in arousal and attention
(Robbins and Everitt, 1995), is localized in key regions known to mediate emotion
(Mesulam, 1983; Flynn and Mash, 1993), and is hypothesized to be dysfunctional in
affective disorders (Janowsky, 1972a).
The current impetus for the focus on the muscarinic cholinergic system is
derived from a small body of literature linking the cholinergic system to limbic
activity — where limbic is defined inclusively as relating directly to emotions and
emotional behavior, as well as the autonomic and motivational connotations.  The key
points are summarized as follows.  (1) David Janowsky and colleagues (1972a)
theorized that there might exist an imbalance of cholinergic and adrenergic influences
on limbic regions in patients with mood disorders based on his studies of cholinergic
challenges in these patients (Janowsky et al., 1972b).  (2) The identification of
cholinergic receptors in the amygdala, a region theorized by many to be integral in
emotional processing (Amaral et al., 1992).  (3) The complex theory of emotion
regulation developed by LeDoux (1996) suggests a role for the cholinergic system.
(4) Animal studies showing increased limbic activity with procaine hydrochloride
(Post et al., 1981), a drug considered to be a local anesthetic but also known to bind
with muscarinic cholinergic receptors in vitro (Hisayama et al., 1989; Sharkey et al.,
1988).  (5) Anecdotal reports of emotional experiences occurring after local
anesthesia with Novocain (procaine hydrochloride) during dental procedures and after
routine antibiotic treatment with procaine-penicillin (Araskiewicz and Rybakowski,
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1993).  (6) Procaine induces selective cerebral blood flow hyperperfusion in the
anterior paralimbic structures in the humans together with brief intense emotional and
sensory experiences (Ketter et al., 1996).  These effects suggest an avenue for
examining the neuropsychopharmacology of emotional experiences, and possibly
tying emotion to muscarinic cholinergic system more directly.
This dissertation examines the role of the muscarinic cholinergic system in
emotion regulation and how the neuroanatomy, neurochemistry, and neurobiology of
this system position it as a potential player in mediating emotion.  Specifically, this
work will explore how the drug procaine can induce these emotional and sensory
experiences via a muscarinic mechanism.  This will entail two experiments.  A dose-
response study with anesthetized rhesus monkeys undergoing positron emission
tomography (PET) with a radioligand with preferential affinity for M2 muscarinic
cholinergic receptors will address the ability of procaine to bind to muscarinic
receptors in vivo.  As presented in Chapter 2, procaine does bind to these receptors at
the same time the flow of the radioligand increases preferentially in limbic areas.  In
view of the robust emotional and sensory experiences induced by procaine in humans,
an important question emerges regarding the relationship of brain regions known to
have direct and indirect cholinergic innervation to these behavioral effects.
The study of emotion can be examined in several ways, including inducing
emotions, either through self-induction or pharmacological induction paradigms, and
by comparing normal versus pathological emotions.  Both of these methods were
employed in experiments presented in Chapters 3 and 4, where procaine
administration in healthy controls is compared to patients with bipolar disorder during
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measurement of regional cerebral blood flow (rCBF) with PET.  The results suggest
that the functional connectivity between cholinergic regions and their primary targets
increases with procaine administration.  In addition, procaine-induced changes in
cerebral blood flow (CBF) in cholinergic regions are associated with changes in
emotions.
Before beginning a detailed review and analysis of the problem, definitions of
emotion and mood provide an understanding on the use of these related constructs
throughout this work.  The Oxford English Dictionary defines emotion as: “1. a
moving out, migration, transference from one place to another; 2. a moving, stirring,
agitation, perturbation (in a physical sense); 3. a political or social agitation, a tumult,
popular disturbance; 4. a. any agitation or disturbance of mind, feeling, passion, any
vehement or excited mental state; b. a mental ‘feeling’ or ‘affection’ (e.g., of
pleasure, or pain, desire or aversion, surprise, hope, or fear, etc) as distinguished from
cognitive or volitional states of consciousness.”
The word emotion is derived from the Latin exmovere, meaning to move out
or away, and is closely related to the English verb to emote.  This suggests emotion
can originate from an action viewpoint.  There are important cognitive, physiological,
and psychological components to emotion, as well.  The over one hundred definitions
of emotion (Kleinginna and Kleinginna, 1981) can be categorized by the experiential,
behavioral, cognitive, motivational, or physiological nature of their roots.  These
various approaches to defining emotion illustrate the diversity in theories of emotions
and its regulation.
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For purposes of this work, definitions of emotion and mood will be as follows.
Emotion can be defined as a patterned subjective experience of affective and bodily
responses that vary according to valence, intensity, expression and arousal, and may
include cognitive awareness of the process.   Emotions are considered brief affective
responses and their effects are thought to specific.
Mood is defined as a diffuse state of arousal that functions as a framework
that can influence affective, cognitive and behavioral processes.  It may or may not be
the focus of attention.  Generally, its effects are thought to be global and pervasive.
The recognition of meaning and significance of events leading to arousal facilitates a
self-regulatory process that reflects appraisal of life circumstances.
The example of anxiety suggests maybe semantics are also involved.
Depending on the context, we understand anxiety to be an emotion or a mood.  Thus,
the label attached does not imply categorization into emotion, mood or temperament.
The intensity of the emotion anxiety usually more severe and cannot be maintained as
long as a mood of anxiety.  On some, but not all, levels the quality of the experience
is similar.
As compared to emotion, moods are thought to be typically less intense
affective states and more time enduring. In mood disorders, the temporal domain is
significantly altered where moods can extend for weeks or years.  Moods are
considered less variability and more restricted range of intensity and arousal level
than emotions.  Moods are thought to be involved in the instigation of self-regulatory
processes. Mood can be comprised of set of emotions, and thus may be a more
general state; for example, contrast an emotion of anger with the mood of irritability.
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Some, but not all, researchers believe that emotion and moods also differ with respect
to intensity, with moods are typically less intense than an emotion.
Ketter et al., (2003) has further differentiated mood and emotion by the
presence or absence of precipitants, degree of autonomic arousal, the resulting
products, and possible neural substrates. Thus, in general, emotions tend to be brief,
distinct, and intense states that can occur in response to an acute precipitant, are
accompanied by autonomic arousal, result in some form of action, and may be
subserved by anterior paralimbic and brainstem structures.  On the other hand, moods
are more pervasive, composite and moderate conditions that may or may not have
precipitants, can vary in the level of autonomic arousal, usually result in cognitions,
and may be mediated by anterior cortical and limbic structures.
An examination of current emotion theory begins with a brief review of its
historical roots in philosophical, psychological, and physiological perspectives
(Section 1.1), and is followed by a detailed examination of important
neuroanatomical (Section 1.2) and neurobiological (Section 1.3) substrates believed
to be involved in emotional processing.  As suggested above, emotion theories can be
quite diverse.  Discussion of current emotion theory (Section 1.4) will be limited to
those more closely related to the theme of this dissertation.  Finally, specifics relating
the cholinergic system to emotional processing will lay the foundation for the
research presented herein (Section 1.5).
7
1.1 Historical Perspectives1
A philosophical approach dominated very early discourses on emotion.  The
study of emotion began simply as identification of emotions as a field of interest.
Philosophical discussions about the interface between emotions and the body
followed the discourse on conscious thought, ranging from those who believed there
was a physical basis for consciousness to dualist theories, a separation of the mind
and body.  Aristotle (367 BC) was not a dualist and believed that the body and psyche
are one.  In Rhetoric, he recognized the influence of emotion on “bonds of
association,” i.e., that emotion has a special strength on enhancing associations of the
mind.  Hippocrates (460 BC) connected conscious life, including emotions, to the
brain.  Herophilus (300 BC), based on dissections of human and animal brains,
proposed the brain as the center of the nervous system and the seat of intelligence.
Galen (170 AD) believed the soul was in the ventricles of the brain.  He advocated
the humoral theory of temperaments, or the four humors – blood/sanguine (warm-
hearted and volatile), black bile/melancholic (sad), yellow bile/choleric (quick to
anger and to action), and phlegm/congestion (sluggish).  This model remained
prominent for centuries and gave rise to terms describing temperament that are still
commonly used.
Plato (427 BC), as a dualist, believed that emotions of desire and appetite
were part of the irrational soul.  Some early philosophers emphasized a distinction
                                                 
1 Information in this section is drawn from readings in Nineteenth-Century Origins of Neuroscientific
Concepts (Clarke and Jacyna, University of California Press, 1987); The Emotional Brain (LeDoux J,
Simon & Schuster, 1996); and Great Psychologists, (Watson RT, JB Lippincott Press, 1963).
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between emotion and reason, believing that man was rational and knowing, with
emotions to be part of our primitive animal spirits (nervous energy associated with
physical sensation and movement) that must be minimized; reason was choice and
emotion was instinct.  Descartes (1596) set forth an extreme form of dualism,
separating reason and emotion, stating that it was “the effect of body on the mind
which produces passions.”  Nonetheless, he also presented a more advanced
physiological explanation of the animal spirits basic in human behavior.  This was
achieved by sensing the environment via the sense organs and nerves thereby creating
an impression on the pineal gland in the brain, where the soul apprehends this
stimulus, and causes the animal sprits to activate the passions, the “bodily
commotion” viscera and overt action or movement.  These ideas predate James-Lange
theory of emotion that “primacy is given to physiological processes prior to mental
experience”, but may be more in line with the thinking of Cannon because the lack of
visceral input into the brain in his model.
Descartes considered the primary passions to be admiration, love, hatred,
desire, joy, and sadness, and these could be combined to create introspective feelings
or emotions.  They served to cause 1) the flow of animal spirits, 2) the body to held
ready for goal objects encountered in the environment 3) the soul to desire the these
objects and 4) a persistent desire for these objects.  Although, his beliefs that emotion
debilitated the superior rational response by intervening between the environmental
cues and the response eventually fell out of favor, he introduced a more sophisticated
level of physiology into theories of emotion than his predecessors, and he set up a
tradition of categorizing emotions as either basic or composite.
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More recently, the physical basis of conscious thought was pursued in parallel
with the development of psychological theories describing the constructs of thought
and emotion and medical models of pathological emotional processing.   Wundt
(1874), who many consider as the father of modern psychology, promoted the view
that combinations of feelings and ideation yield emotions. He thought emotions could
be broken down into elements, with a direct analogy to chemical analysis of
substances, or the way pure tones could be broken down into loudness, pitch, density
and volume, and thus may have been influenced by Helmholtz.  Through
introspection and training subjects reported the “elements” of their emotions, and
from these studies Wundt proposed a three-dimensional theory, pleasantness-
unpleasantness, excitement-quiet, and tension-relaxation. Dimensional approaches to
the study emotion are prevalent in many current theories, including Plutchik (1993)
and Davidson (2002).
  At this time, psychiatry was just becoming recognized as a specialty of
medicine.   Emil Kraeplin, a student of Wundt, is credited with the most astute
differentiation and descriptions of what is now known as schizophrenia and bipolar
disorder, which are still referred to today.  In the early 1900’s, Jung examined the
association of affective determinants by studying the emotional preoccupation of his
psychiatric patients through their associations of a list of 100 words with the ultimate
goal to uncover the unconscious.  Concurrently, Freud in his study of unconscious
behavior developed his personality theory and the psychoanalytic approach, both of
which were based on examining the pathological emotional experiences of his
patients.  These psychoanalytic approaches were important because they stressed the
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experience as an integral component of emotion, but did little to advance
neuroanatomy and neurochemistry of affect.
Franz Josef Gall popularized localization of function to specific areas of the
brain, of which the holy-grail would be notion of the “grandmother cell”, with
phrenology.  Based on the bumps on the skull, different emotions were to be
controlled by various parts of the underlying brain.  For example, love was localized
in the occiput, lust the base of the occiput, and aggression (rage) the temporal region.
Flourens criticized this point of view, believing the whole cerebrum was needed for
conscious thought, including emotions.   Thus, a controversy of distributed networks
versus focal control emerged.
In the late 1800’s Hughlings Jackson (1876/1931) described change of affect
with right hemisphere damage resulting in negative (loss) and positive (“conservation
of next most voluntary”) changes in brain function, which he termed “dissolution.”
The term dissolution was used, acknowledging Spencer, as the opposite of evolution,
a reduction of automatic movement.  Broca showed the loss of speech could be
localized in the “third frontal convolution of the left hemisphere.”   These
contributions are reflected in current theories that specific functions, including
emotional behavior, are attributable to specific areas of the brain, and in the broader
context of whether the structure/function relationships can be defined in terms of
localization versus distributed networks.  Moreover, asymmetry in brain function is a
central feature to the current work of Davidson (2002).
Theories of relationships between physiological and psychological aspects of
emotional behavior became more intertwined to yield many current emotion theories.
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Several investigators highlight this progress from a physiological point of view.
Darwin (1872/1965) believed emotional expressions served practical functions.  For
example, dogs bare their teeth in preparation to bite.  This contrasts with Charles
Bell’s idea that the behavior is for emotional expression.   Darwin defined 3
principles of emotion expression:  1) the principle of serviceable habits – many
expressive movements are vestiges of originally practical movements (ex: startle as a
remainder of a larger flight reaction); 2) the principle of antithesis – opposite
impulses tend to show opposed movement (cat’s moves of affection are opposite of
attack movements); and 3) direct actions of the nervous system (ex, trembling as an
overflow into motor channels); these were originally voluntary movements that
evolved into reflex actions through inherited habits.
Spencer, a contemporary and associate of Darwin, developed a theory of
evolution based on philosophical, anthropological and geological arguments
preceding Darwin’s (1859); he may have even coined the phrase “survival of the
fittest.”   He studied the association of the elements of “feelings” and “relations
between feelings.”  He saw emotions as centrally initiated feelings that are related to
psychological processes, to physiology, and to the adjustment of the psychological
processes to environmental influences.
In 1884, James wrote the “bodily changes follow directly the PERCEPTION
of the existing fact, and that our feeling of the same changes as they occur IS the
emotion.”  His theory rested on the notion that visceral activity yields emotion and
limited his studies to emotions with distinct bodily expressions.  He and C.G. Lange
thus helped establish the organic basis of emotion espoused in The Emotions.   In
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contrast, Cannon and Bard claimed the viscera were not sensitive enough to
differentiate emotions, and react too slowly to be responsible for rapid emotions, and
noted emotions still occur even after vagotomies and sympathectomies.
However, the James-Lange theory was a stimulus to move emphasis away
from a philosophical approach towards psychology and physiology.  Maybe more
importantly, their work included a role of voluntary muscles in the expression of
emotions that laid the groundwork for research examining facial expressions and
posture in emotions.  Cannon and Bard proposed the hypothalamic theory – emotion
is produced by the hypothalamus that mediates input from the environment with
cortical efferent activity to control the somatic and visceral motor systems – which
served to initiate research the neurophysiology of emotion.  The hypothalamus is still
considered an important component of emotion theories.
In the early 1900’s psychology emphasized the development of systematic
methods of defining, measuring and describing psychological phenomena.  As
psychological events could not be measured overtly, the study of emotions was
significantly disadvantaged, leading to the dominance of behaviorists.  Watson (1930)
stated emotions are bodily reactions to specific stimuli, not experienced states.  Based
on his studies of infants he proposed three basic emotions – fear, rage and love, and
more complicated emotions were not inherited, but learned.  Pavlovian and
Skinnerian principles gained influence, linking environmental events to motivation
through conditioning, what is now appreciated as a fundamental brain process.
Although, behaviorism expressed an extremely limited view of emotional behavior,
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these associative principles served as a foundation for more complex notions, like the
fear-conditioning model of amygdalar function by Davis (1995) and LeDoux (1996).
Various portions of these early theories have contributed to the development
of current theories of emotion.  Subsequent researchers increasingly incorporated
brain structure, and its physiology as integral components in theories emotion.  In the
following sections will review the neuroanatomy and neurobiology of emotion
regulation before continuing with a discussion of current emotion theory.
1.2 Neuroanatomy of Emotion
The limbic system is considered a collection of neuroanatomical structures
that contribute significantly to emotion regulation.  In addition to mediating
emotional behavior, the limbic system plays a key role in endocrine regulation (via
the hypothalamus), as well as contributing to motivational and memory functions.
The term cerebri limbus, which was first used by Willis (1664), describes the cortical
border surrounding the brainstem that corresponds to the cingulate gyrus.  Broca
referred collectively to the cingulate gyrus, anterior olfactory region and
hippocampus as the grand lobe limbique, however, he associated it with the closely
related function of olfaction, rather than directly with emotion regulation.  The
cytoarchitecture of limbic cortex was initially described by Ramon y Cajal (1900,
1909) and Golgi (1883, 1903), when the field of neuroanatomy blossomed with their
development of neuronal staining techniques.
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Papez (1937) extended the Cannon-Bard theory of emotion regulation
(Cannon, 1927, 1929, 1931; Bard, 1928, 1929, 1934) by combining known
neuroanatomical connections of the limbic regions with the results of clinical studies
(Penfield, 1934; Ranson, 1934) describing emotional disturbances after lesions of the
cingulate and medial structures.  His neuroanatomical circuit described emotional
processing as part of his three-part theory of “man’s volitional energies”, which
encompassed the affective, cognitive, and motoric components of experiencing
emotion.  He may have been one of the first investigators identifying the cerebral
cortex as the locus of the cognitive component of feelings that arise from the various
aspects of the affective experience.  Previous work attributed cognitive aspects of
emotion to subcortical regions, the hypothalamus (Bard 1928) and the thalamus
(Masserman1943).
Yakovlev (1948) proposed a three-layer model of brain organization that
integrated structure-function relationships with evolutionary considerations.
Functions of emotion and affect occurred in the “intermediate layer” that also
included functions of motor synergy, personality, arousal, and motivation.  These
functions were thought to be subserved by the basal ganglia, limbic thalamus,
hippocampus and olfactory areas of orbitofrontal cortex (olfactory paleocortex).
Yakovlev’s phylogenetic designation of this “intermediate” layer developing
with the emergence of reptiles to early mammals preceded the triune brain theory of
MacLean (1949, 1952).   In the elaboration of three tiers of nervous system
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development, MacLean2 considered the middle paleomammalian stage, or “limbic
system,” the regions of the Papez circuit with the medial structures of Yakovlev.
Integrating clinical and animal of both lesion and stimulation studies, MacLean’s
work attributed motivation and emotional expression to three cortical regions, the
orbital frontal cortex, temporal lobe and the insula, and two subcortical structures, the
amygdala and the dorsomedial thalamus.
Currently, the limbic system is generally considered to be a collection of
cortical and subcortical structures, including the cingulate, parahippocampal gyri,
hippocampus, amygdala, septal nuclei (SEP), and hypothalamus, and parts of the
anterior nucleus of the dorsal thalamus and dorsal striatum.  Nauta (1958) includes
medial tegmental nuclei of the midbrain because of the reciprocal connections with
the amygdala and hippocampus.  Heimer argues that the ventral striatum should also
be considered part of the limbic system (2003).  While each of these regions may
participate in other functions, together in processing internal and external information
                                                 
2 MacLean’s indication as these regions as a middle stage of CNS development between reptiles and to
mammals implied that mammals were direct descendents of reptiles and appears to be founded on the
scala naturae, a hierarchical theory of evolution.  However, comparative neuroanatomists do not
accept this view.  It is more accurate to say that mammals and reptiles share a common ancestor among
the ancestral amniotes.  While the association of evolutionary progress to more sophisticated function
loosely works, the scala naturae is not accepted today because the rankings are based on homocentric
value judgments not biology; discrepancies exist, for example, some so-called “lower vertebrates” that
have acquired sophisticated sonar, radar, or electrosensory systems that are absent in so-called “higher
vertebrate” class mammals.
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they attach emotional valence to the organism’s circumstance and generate the
experience of emotions, cognitively and physically.
Several regions of the limbic system important to this thesis will be discussed
in detail, including the cholinergic basal forebrain nuclei, the anterior cingulate and
the amygdala.  The cholinergic portion of the basal forebrain nuclei consist of the
nucleus basalis of Meynert (NBM), and the nucleus of the horizontal limb of the
diagonal band (HLDB); collectively, these regions are sometimes referred to as the
substantia inominata (SI).  In neuroimaging studies, the anterior cingulate (AC) and
the amygdala (AM) are the structures most commonly activated in tasks where
emotions are self-induced (Ketter, et al. 2003).  The basal forebrain nuclei innervate
the amygdala and cingulate cortex, the orbitofrontal cortex, insula, thalamus, and
hypothalamus, as well as brainstem monoaminergic nuclei that are implicated in
mood regulation.  The discussion will end with two regions, the thalamus and the
striatum.  These regions have areas within well known to mediate limbic functions
and considerable connections with core limbic areas, but they also have considerable
cholinergic activity as well.   While the thalamus has long been considered to have
limbic functions, only recently has the striatum been appreciated in this regard
(Alexander et al., 1990).
Because of the direct relevance of this subject matter to humans, the majority
of the neuroanatomical findings reviewed are based on the species most closely-
related to humans for which there is a significant database, old-world Macaca
monkeys, either Macaca mulatta or Macaca fascicularis3; any departure will be
                                                 
3 These two Macaca species will have similar connections between brain regions, however, there will
be differences with respect to cytoarchitecture. (Saunders R, personal communicaton)
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noted.  Utilization of non-human primates thought to be closer to humans, such as the
chimpanzee or the gorilla, has not been customary, because they are considered an
endangered species, the use of these animals is cost-prohibitive, or in the case of the
gorilla, their size and strength makes them less manageable in a laboratory setting.
The literature concerning the neuroanatomy of the rat is extensive, and in general,
concurs with the monkey literature, however, there exists some meaningful
differences in cytoarchitecture, pathways, and neurochemistry that make it a less
optimal reference to human neuroanatomy.  In particular, the connectivity of the
amygdala differs somewhat between the two species (Aggleton and Saunders, 2000;
Amaral et al., 1992).  Nomenclature used throughout this dissertation as depicted in
Figures 1 and 2 follow the work of Brodmann (1909) and Bonin and Bailey (1947)
for human and monkey neuroanatomy, respectively.  Identification of brain regions
(Table 1) by using Brodmann areas (BA) is are common in brain imaging research.

























































Figure 1.  Cytoarchitectural Map of the Human Cortex.
Brodmann (1909) segmented the cortex using cytoarchitectonics.  His nomenclature
is used throughout clinical and preclinical work.   Top: lateral surface.  Bottom:
medial surface.  Black region represents the corpus callosum.
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Table 1.  Cortical Names of Brodmann Areas (BA)
BA Cortical Region
1, 2, 3 Primary somatosensory cortex
4 Supplementary motor cortex
5 Parietal association cortex
6 Primary motor cortex
7 Parietal association cortex
8 Frontal eye fields
9, 10 Dorsolateral prefrontal cortex
11 Orbitofrontal cortex
12 Orbito- and ventrolateral prefrontal cortex
17 Primary visual cortex
18, 19 Secondary visual cortex
20, 21 Inferior and Medial temporal cortex
22 Auditory association cortex
23, 31, 33 Posterior cingulate
24, 25 Anterior cingulate
26, 29, 30 Retrosplenial cortex
32 Anterior cingulate
35, 36, 37 Parahippocampal cortex
28, 38 Uncus
39, 40 Parieto-occipito-temporal association cortex
44, 45 Broca’s area
46 Dorsolateral prefrontal cortex
45, 47 Ventrolateral prefrontal cortex




















































Figure 2.  Cortical Neuroanatomy of the Macaca mulatta.   
These diagrams display the locations and nomenclature of cortical brain regions
developed by Bonin and Bailey (1947).  Top: lateral surface.  Middle: medial surface.
Bottom: ventral surface. Abbreviations: FA-FL: frontal cortex; TA-H: temporal
cortex; LA-LC: cingulate cortex; PB-PG: parietal cortex; OA-OC: occipital cortex.
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1.2.1 Basal Forebrain Nuclei
The basal forebrain contains a group of nuclei, or rather somewhat
undifferentiated cell clusters, dorsal to the anterior perforated substance at the ventral
region of the brain where the telencephalon meets the diencephalon (Figure 3).  It is
variably referred to as the ventral striatum, substantia inominata, or septum, although
these terms are not necessarily interchangeable. Many fibers of passage course
through this region, e.g. fornix, stria terminalis, diagonal band of Broca, medial
forebrain bundle, inferior thalamic peduncle, and ventral amygdalofugal pathway,
which make it possible for terminal and en passant synapses.   These regions
contribute axons to these pathways for eventual termination rostrally in the frontal
cortex and anterior cingulate, and caudally to the hypothalamus, midbrain and
hindbrain.
Heimer and Alheid (1991) consider the basal forebrain the ventral regions
under the dorsal striatum, pallidum and thalamus, thus containing both diencephalic
(hypothalamus) and telencephalic (nucleus accumbens, septum, substantia inominata,
the diagonal band nuclei, bed nucleus of the stria terminalis, hippocampus, amygdala,
olfactory cortex and olfactory tubercle) components. However, considering the basal
forebrain regions together, while adjacent to one another, as a unit as part of the
limbic system does not account for the differences in the function, connectivity, and
chemoarchitecture within this region.  They have subdivided this area into three
functionally related systems: the cholinergic cell groups, ventral striatopallidal










































Figure 3.  Location of Cholinergic Cell Bodies
Lateral (top) and medial (bottom) views of the human brain with approximate
location of the cholinergic cell bodies, including the substantia inominata and septal
nuclei, in the basal forebrain and the tegmentum (indicated in dark grey)
superimposed.  Although the cholinergic cell bodies do not extend to the cortex, the
lateral view gives an idea of their location from this perspective.  Numbers
correspond to Brodmann areas (1909). Black region represents the corpus callosum.
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The cholinergic cell groups are not totally distinct from the ventral
striatopallidal and extended amygdala systems, but are better characterized as
magnocellular corticopetal cell groups scattered across the forebrain from the septum
to the diagonal band and extend through the ventral pallidum and extended amygdala,
of which NBM is the major component.  These cells are the origins of the cholinergic
corticopetal projections in the rat and humans (Woolf, 1991; Mesulam, 1995) and
release acetylcholine (ACh) synaptically.  They also have diverse neuromodulatory
substances affecting the cell bodies, such as galanin, gamma-aminobutyric acid
(GABA), as well as other peptides (Záborszky, 1993).   This region has similar
connectivity as the extended amygdala, thus the function complements the extended
amygdala as integral in the forebrain system evaluating the significance of external
and internal events, and to effect appropriate behavioral responses through its
widespread and highly organized projections to autonomic, neuroendocrine, somatic
and visceral motor output.  This system seems to be situated to perform a key role in
motivational and adaptive behavior.  Furthermore, the projection pathways and
functions of the magnocellular cholinergic cell bodies, in many respects, suggests a
mechanism whereby procaine via cholinergic mechanisms could yield the affective,
hormonal, autonomic and blood flow activation pattern observed in humans (Ketter et
al., 1996; Kling et al., 1994; Kellner et al., 1987).
Mesulam (1995) has studied the basal forebrain extensively in human brain
tissue (note: any of the cholinergic studies by these authors cited herein are based on
human neuroanatomy).  Of the eight cholinergic cell groups delineated by Mesulam,
four are these nuclei of the basal forebrain.  His nomenclature corresponds to the
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nuclei as follows: the medial septal nuclei - Ch1; the vertical limb of the diagonal
band - Ch2 (Ch2-VLDB; also known as septum); the horizontal limb of the diagonal
band - Ch3 (Ch3-HLDB); and the nucleus basalis of Meynert - Ch4 (Ch4-NBM).
While these nuclei predominately express cholinergic markers throughout, there are
areas within the nuclei that lack this neurochemistry.  For example, within NBM,
there exists large and small cells, both cholinergic and non-cholinergic, of which the
90% of NBM is associated with the cholinergic marker ChAT 90% of NBM; thus the
use of the name Ch4-NBM when referring to the cholinergic portion.
The remaining four cholinergic clusters defined by Mesulam are in the
brainstem, either midbrain nuclei near the junction with the pons, the
pedunculopontine nucleus (Ch5), the lateral dorsal tegmental nucleus (Ch6), and
parabigeminal nucleus (Ch8), or part of the diencephalon, the habenula (Ch7).  For
purposes of the work herein, Ch5, Ch6 and Ch8 together are considered the tegmental
cholinergic cell body area (TEG) as represented in Figure 3.  Each group can be
further subdivided into smaller clusters that project to more selective targets; small
letters following the group name denotes these divisions.
Ch4-NBM is a relatively small, but tightly packed region.  It spans 13-14 mm
from the level of the olfactory tubercle to the anterior hippocampus on the medial
sagittal plane, and 18 mm within the substantia inominata in the transverse plane.  In
adult humans, this region contains ~200,000 neurons (Arendt et al., 1985),
approximately ten times the amount of neurons as the locus coeruleus (Vijayashankar
et al., 1979). The neurons are heteromorphic with isodendritic fields that overlap
across divisions, and extend into passing fiber tracts (Ramon-Moliner and Nauta,
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1966).  All neurons contain acetylcholinesterase (AChE) and choline
acetyltransferase (ChAT) in the perikara, dendrites and axons (Mesulam et al., 1989),
and 90% also express p75 nerve growth factor (NGF) receptors (Mufson et al., 1989).
Russchen and colleagues (1985a) have mapped the cholinergic projections of
the NBM in non-human primates.  They contend a continuum of cholinergic
innervation exists from the ventral basal forebrain surface to rostral and lateral
directions.  The heaviest innervation is seen in the amygdala, subgenual (SGAC) and
pregenual anterior cingulated (PGAC), medial orbitofrontal cortex (MOFC) and
anterior insula (AINS).
The cortex is innervated by the forebrain cluster Ch4-NBM (Figure 4), as well
as by midbrain clusters, Ch5 and Ch6 (Mesulam et al., 1983), and has no intrinsic
cholinergic innervation (Mesulam, 1995).  Ch4-NBM can be subdivided into six
divisions based on the topography of the projections (Mesulam, 1995).  For example,
within Ch4-NBM, Ch4am projects to the medial wall of the cortex including the
cingulate gyrus, while Ch4al projects to the amygdala, and to ventral orbitofrontal
and prefrontal cortices.  Ch4id and Ch4iv project to insular, dorsolateral prefrontal
(DLPFC), parietal, peristriate occipital, and mid-temporal cortices, while Ch4p
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Figure 4.  Cortical and Subcortical Connections with the Substantia Inominata.
Schematic of the known afferents and efferents of the basal forebrain cholinergic
nuclei.  The densest cholinergic innervation (thick arrows) appears to be preferential
to limbic structures.  Of note, both the amygdala and the anterior cingulate have
reciprocal connections with nucleus basalis. Numbers in parentheses are Brodmann’s
areas. Abbreviations: AC, anterior cingulate; B, basal nucleus amygdala; CE, central
nucleus amygdala; CG, central grey; C/P, caudate-putamen; DLPFC, Dorsolateral
prefrontal cortex; DR, dorsal raphe; Fpre, pre-commissural fornix; GP, globus
pallidus; LC, locus coeruleus; MOPFC, medial orbitofrontal cortex; MP, mammillary
peduncle; Ch2-VLDB, cholinergic portion of the vertical limb of the diagonal band;
Ch3-HLDB, cholinergic portion of the horizontal limb of the diagonal band; Ch4-
NBM, cholinergic portion of the nucleus basalis of Meynert; NACC, n. accumbens;
NST, n. solitary tract; OlfB, olfactory bulb; PBN, parabrachial n.; RF, reticular
formation; septal-Ch1, septal nuclei; SN, substantia nigra; SM, stria meduallaris; ST,
stria terminalis; TE, TG, TP, TPO: temporal regions;  VAP, ventral amygdalofugal
pathway; VTA, ventral tegmental area.
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The cytoarchitectural distribution of these cholinergic projections has been
studied with AChE, ChAT, and NGF, which co-localizes in many cholinergic
neurons.  All layers and regions of the cortex have dense cholinergic marker levels
(Mesulam and Geula, 1992), but there is preferential density of markers in layers I, II,
and upper III, and to limbic and paralimbic regions as well.  Unimodal sensory areas
have lighter levels of cholinergic markers.
Fields Ch4-NBM and Ch3-HLDB have major reciprocal projections with the
amygdala, as mentioned below in the description of amygdala  (Aggleton et al.,
1987).  These projections reciprocate back to the basal forebrain nuclei terminate
almost exclusively in the Ch4-NBM region.  The major amygdalar projections
innervate the basal and central nuclei, with the lateral nucleus having a lesser degree
of innervation.  The medial nucleus is unique in that it has almost no cholinergic
innervation.  The highest density of cholinergic markers occurs in the amygdala and
hippocampus.
Ch1 and Ch2 innervate the hippocampus primarily, with the densest
projections to the hippocampus proper — CA1 (molecular layer), CA2, CA3, and
CA4 —  (Aggleton et al., 1987) via the pre-commissural fornix.  The subiculum
receives lighter projections from the septal area (Ch1).  The septum receives
hippocampal efferents, with the rostral hippocampus projecting more so the lateral
septum and the caudal projections targeted the dorsal and medial aspects of the
septum.  The septal nuclei also innervate the habenula via the stria medullaris, the
central amygdala nucleus via the stria terminalis, the basal amygdala nucleus via the
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ventral amygdalofugal pathway, and the midbrain tegmentum via the medial
forebrain bundle.
While the dorsal and ventral striatum are typically associated with the
dopamine (DA) system, they also have considerable cholinergic innervation via
interneurons (Graybiel, 1990), as well as receiving projections from all four basal
forebrain nuclei.  The nucleus accumbens, caudate, putamen, and globus pallidus
(GP) receive projection from all four basal forebrain nuclei and Ch1 and Ch3
(HLDB) send 10 % or less.
Ch3 projects to the piriform and entorhinal cortex, but also to the olfactory
bulb where it provides cholinergic tone to olfaction.  Ch5 and Ch6 innervate the
thalamus, while Ch7 projects to the interpeduncular nucleus and Ch8 projects to the
superior colliculus.
Afferent projections to the substantia inominata magnocellular areas originate
from cortical and brainstem regions.  In the cortex, neurons from rostral and ventral
areas, rather than dorsal or caudal regions, innervate the magnocellular nuclei.  The
cortical projections include projections from subgenual area 25, orbitofrontal areas
(11 – 14), anterior insula, and rostroventral temporal areas 35, 36, TG, TE, entorhinal
and piriform cortex (Russchen et al., 1985a; Záborszky, 1993).  Sensory and motor
cortex does not innervate cholinergic regions of the basal forebrain (Záborszky,
1993).  The amygdala projections, as previously discussed, were primarily from basal
nucleus to the Ch4-NBM.  Brainstem projections originated from the midline
thalamic nuclei, throughout the hypothalamic nuclei, and many midbrain nuclei,
including the dorsal and median raphe, parabrachial nuclei, ventral tegmental area,
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pars compacta of the substantia nigra, central grey, pedunculopontine, reticular
formation, locus coeruleus, and nucleus of the solitary tract (Russchen et al., 1985a).
A good portion of the basal forebrain neurons are believed to be GABAergic
interspersed with cholinergic neurons (Sarter and Bruno, 2002).  The number of
GABAergic cortical projections is comparable to cholinergic corticopetal neurons.
The parvalbumin (PV - a marker predominately for GABA basal forebrain neurons)
positive cells are predominately located in the ventral and lateral globus pallidus
bordering the substantia inominata, while cholinergic regions are more medially and
ventrally located in the substantia inominata.  Záborszky (2002) suggests that specific
neuronal clusters exist within which either ACh or GABA predominates, and each
represents subdivisions of parallel basal ganglia circuits that mediate multilevel
processing concurrently.  In addition to the numerous GABAergic interneurons
within the basal forebrain and cortex, GABAergic pathways include projections from
the septal-diagonal band of Broca region to the cortex and hippocampus, striato-
pallidal and striato-nigral connections.  Jones (2004) believes ACh and GABA
function to balance neuronal excitability.
In summary, the most dense locus of cholinergic cell bodies in Ch4-NBM area
projects to anterior paralimbic regions, including the anterior cingulate, amygdala,
medial orbitofrontal cortex, and the insula, that send reciprocal projections back to the
this basal forebrain region as well.  These reciprocal pathways represent a
neuroanatomical basis of cholinergic influence on these essential limbic regions and
are another example of recurrent loops commonly found in the limbic system.
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1.2.1.1 Functional Attributes of the Basal Forebrain
Early investigations into the function of the basal forebrain suggested it was
important in learning and memory.  The finding of decreased number, size and
function of the cholinergic cells in Alzheimer’s disease encouraged this view (Bartus
et al., 1982; numerous others – see review Wenk, 1997). Ch4-NBM lesions in
animals were thought to impair their ability in learning and memory tasks (Bartus et
al., 1985; Olton and Wenk, 1987) as suggested by deficits on radial arm maze task in
rats (Wenk et al., 1986).  However, the degree of destruction was not correlated with
the degree of impairment, suggesting either an indirect relationship, or only partial
reliance on the cholinergic innervation.   Methods that produce more selective lesions,
IgG-192 saporin (Wiley et al., 1991), that are injected directly into the region of the
rat (rather than intracerebroventricular [ICV]) destroying more than 50% of the cells
are beginning to show that the main deficit may be attention to brief salient sensory
stimuli (Wenk, 1997; Robbins and Everitt, 1995), not learning and memory.
Expectancy (Stoehr and Wenk, 1995), variable associativity (Chiba et al. 1995), and
vigilance (McGaughy et al., 1996) are different aspects of attention that are affected
by NBM lesions.
Wenk (1997) hypothesized that the corticopetal Ch4-NBM system is involved
in the control of shifting attention to the potentially relevant stimuli that predict a
biologically significant event or outcome.  Thus, information of the emotional state,
rewarding properties of a stimulus, arousal level originating from the amygdala may
influence basal forebrain processing.  This is supported by single unit recordings of
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the NBM showing increased activity during attention to biologically relevant stimuli
(Burton et al., 1976; Wilson and Rolls, 1990).
Basal forebrain cholinergic and GABAergic neurons can be distinguished by
their physiological and pharmacological properties (Jones, 2004).  Cholinergic
neurons tend to be discharge at higher rates during cortical activation (compared to
slow wave activity) and are excited by NE release from the locus coeruleus,
glutamate from the reticular formation, and histamine from the hypothalamus.
GABAergic neurons discharge at higher rates with slow-wave cortical activity and
are inhibited by NE.  Thus, they appear to have reciprocal roles in arousal systems.
The ventral striatopallidal system (Heimer and Alheid, 1991) consists of the
nucleus accumbens (core; ventral striatum), olfactory tubercle (ventral striatum), and
subcommissural substantia inominata (ventral pallidum).  Projections of this ventral
system follows the convention in the dorsal striatopallidal system, where the ventral
striatum projects to the ventral pallidum and allocortical (hippocampal formation and
olfactory cortex), periallocortical (entorhinal) and frontal and temporal proisocortical
areas (insula, anterior cingulate, orbitofrontal, anterior temporal and perirhinal cortex)
project to these ventral regions.  Functionally, this system is analogous the dorsal
system as well, where the dorsal is part of the extrapyramidal motor system, the
ventral system is part of the limbic portions of the motor system, i.e., midline
thalamic.
The extended amygdala (Heimer and Alheid, 1991) includes the bed nucleus
of the stria terminalis, central and medial nuclei of the amygdala, the sublenticular
substantia inominata, and medial accumbens (shell), not unlike the original concept
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proposed by Johnston (1923).  Cortical projections to the extended amygdala are from
the same regions as the ventral striatopallidal system.  The analogy to the dorsal
striatopallidal system follows here also, although the output is to the hypothalamus
and brainstem, thus is visceromotor.  This pathway may be the basis of the hormonal
and autonomic changes observed with procaine in humans (Kling et al., 1994; Kellner
et al., 1987; Ketter et al., 1996).
In summary, the cholinergic cells of the basal forebrain appear to be ideally
located to modulate the amygdala and nearby medial prefrontal (MPFC) and
cingulate cortices to evaluate the incoming sensory stimuli for their level of
significance with the goal of mediating effective behavioral strategies.  This basal
forebrain region has reciprocal connections to regions activated with acute procaine
administration in humans that could contribute to the affective (amygdala), hormonal
(hypothalamus) and autonomic (brainstem) phenomena observed with procaine
challenge (Kellner et al., 1987; Kling et al., 1994; Ketter et al., 1996).
1.2.2 The Anterior Cingulate
The cingulate gyrus is a medial cortical structure that follows the inner aspect
of the contour of the corpus callosum.  Rostrally, it courses around the corpus
callosum and tucks under the genu of the callosum, and caudally it gradually merges
into the posterior parahippocampal gyrus.  A distinct boundary of cytoarchitectural
differences is observed between the anterior portion, which is agranular cortex (type
1) similar to motor cortex, and the posterior region, granular (type 2), although not
like koniocortex (type 5) cortex as described by Von Economo (1929).  The two
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regions can be segregated functionally as well.  Effector functions appear to be
predominately in the anterior cingulate, while sensory–related inputs are thought to be
associated with the posterior cingulate (Van Hoesen et al., 1993).  Afferent and
efferent connections with other brain regions often predominate, but not always.
While these distinctions exist, the anterior and posterior cingulate are coupled
anatomically and functionally upon examination of the intra-cingulate circuitry.
Functionally, the two regions interact via connections within the cingulate displaying
two different patterns.  First, the two extreme portions of anterior and posterior
cingulate have reciprocal connections that may be inhibitory (Van Hoesen et al.,
1993).  Second, the intermediate regions of both anterior and posterior cingulate
project to proximal cingulate cortex.  The functional result of this intra-connectivity is
bi-directional flow of information within the cingulate cortex (Van Hoesen et al.,
1993).  The rostral feed-forward network, or Van Hoesen’s “outflow system”, gathers
signals via afferents from sensory-related cortex in the posterior cingulate and passes
information rostrally to the anterior cingulate effector regions.  The caudal feedback
network provides anterior to posterior feedback to the posterior regions that project to
the effector region.
1.2.2.1 Cingulate Pathways
The cingulate gyrus has considerable efferent and afferent extra-cingulate
connections with multiple cortical and subcortical regions, allowing sensory-related
information to be integrated with the affective processing, and in turn permitting
modulation of somatic and visceral motor behavior.  Cortical pathways, often
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reciprocal, exist between the cingulate and the entire cortex.   Subcortical connections
are seen with the amygdala, hippocampus, striatum, thalamus, midbrain and
hindbrain.  A brief description of these connections follows and is summarized in
Figure 5; for a more complete review, see Van Hoesen et al., 1993.
Prefrontal cortical regions, including dorsolateral prefrontal cortex (BA areas
8,9,10 and 46) and medial and orbital prefrontal cortex (BA areas 11,12,13, and 14),
have reciprocal connections with the anterior cingulate regions 24 and 25, and
posterior cingulate area 23 (Brodmann designation, 1909).  The cingulate afferents
terminate in all layers of the cingulate and are suggestive of a topographical
organization, although topography has not thoroughly investigated (Van Hoesen et
al., 1993).  Orbitofrontal cortex also shows hints of topographical organization of
cingulate projections that encompass the entire cingulate.  Of note, caudal
orbitofrontal cortex may be connected with rostral cingulate (BA area 24a, b) and
more rostral orbitofrontal cortex connects with dorsal and posterior portions of the
cingulate.  Area 25, the closest in proximity to the cingulate, is reciprocally connected
to medial portion of orbitofrontal cortex (Vogt and Pandya, 1987).
The cingulate cortex connects, often reciprocally, with many levels of the
motor system, including motor cortex, the striatum and midbrain motor nuclei.  Both
primary motor cortex, M1 (BA 4) and supplementary motor cortex, M2 (BA 6) show
a somatotopic organization, with the face area of M1 projects to anterior cingulate,
hindlimbs to posterior cingulate, and the intermediate body areas represented by M1













































Figure 5.  Pathways Involving the Anterior Cingulate
Schematic of the known afferents and efferents of the anterior cingulate in a sagittal
view.  Bold text and arrow reflects cholinergic innervation. Relative position of
arrows on the cingulum is only generally specific; for example, the main targets of
the amygdala and basal forebrain are the subgenual (25) and pregenual (24a) regions
of the cingulate.  The regions inside the dotted line project mainly from the posterior
cingulate, however, there are minor anterior cingulate efferents to these regions.
Numbers in parentheses are Brodmann’s areas. Abbreviations:  AC, anterior
cingulate; DLPFC. Dorsolateral prefrontal cortex; DMNV, dorsal motor nucleus of
the vagus; DR, dorsal raphe; LC, locus coeruleus; MOPFC, medial orbitofrontal
cortex; Ch4-NBM, cholinergic portion of the nucleus basalis of Meynert; NST, n.
solitary tract; M1/M2, primary and secondary motor cortex; PAG, periaquaductal
grey; PN, pontine nuclei; RN, red n.; S1/S2, primary and secondary sensory cortex;
CA1, hippocampus; TF; TH; TE; TEO; TA; TPO; TP, temporal pole; VTA, ventral
tegmental area.  Data from Van Hoesen et al., 1993.
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These connections are also reciprocal.  Further studies showed that within each
subdivision 24c and 23c there exist somatotopic projections to M1 and M2 (Morecraft
and Van Hoesen, 1992), which also project to the cervical and lumbosacral segment
of the spinal cord (Hutchins et al., 1988).
Regions typically associated with sensory-related functions, such as the
parietal and occipital cortex, have the majority of their cingulate connections with the
dorsal posterior areas (Van Hoesen et al., 1993).  In the case of the parietal cortex,
both lateral and medal surfaces, have extensive and often reciprocal connections
(Baleydier and Mauguiere, 1980; Pandya and Kuypers, 1969) that terminate in layers
cortical I-VI (Selemon and Goldman-Rakic, 1988) of dorsal posterior cingulate.
These parietal connections are also intimately related to somatosensory cortex, S2
(BA 3,1, 2).  In contrast, the anterior cingulate connections with parietal cortex are
sparse, involving only the caudal portions of area 24 (Van Hoesen et al., 1993).
Temporal lobe regions involved in audition have reciprocal projections with
both anterior and posterior cingulate.  Anterior cingulate area 25 receives projections
from superior temporal association areas Ts3 and Ts2 (von Economo nomenclature),
while area 24 receives input from the Ts1 and the temporal pole.   Neurons spanning
the full length of TPO, on the dorsal bank of the superior temporal sulcus, project to
posterior regions 23, 30 and 29.  Rostral area 24 and 25 projects back to superior
temporal gyrus and sulcus (Müller-Preuss et al., 1980).  The temporal pole is the only
temporal region that has reciprocal connections to the anterior cingulate regions 24a,
b and c (Vogt and Pandya, 1987).  These connections provide opportunity for
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mediating neuronal activity related to auditory input and vocal expressions that may
have emotional content.
Two regions located under the temporal lobe, the insula and the claustrum,
appear to be involved in integrative functions of internal autonomic and external
sensory information, respectively.  Both regions have reciprocal connections with
dorsal cingulate, primarily areas 24 and 23, which are arranged topographically,
however, the claustrum also has projections to area 25.
The two major limbic regions in the medial temporal lobe, the amygdala and
the hippocampus, exhibit predominately distinct connections with the anterior and
posterior cingulate, respectively.   The amygdala connections will be discussed in
detail below, but briefly, the amygdaloid nuclei (basal, accessory, and medial) project
to anterior cingulate, areas 25, and 24 a, b.  The anterior cingulate has reciprocal
connections to the basal nucleus, but also projects to the central nucleus of the
amygdala.
While, the hippocampus and associated parahippocampal regions
predominately have reciprocal projections with the posterior cingulate via the post-
commissural fornix, the anterior region is not completely devoid of connections.
Hippocampal CA1 and subicular regions project directly to most of the rostral and
caudal cingulate (Rosene and Van Hoesen, 1977), and indirectly via connections to
parahippocampal areas like the perirhinal and entorhinal cortices, which project areas
23, 24 and 25 of the anterior cingulate.  Dorsal (24c) and posterior (23) cingulate
cortices send projections to perirhinal, presubiculum and posterior parahippocampal
regions TF and TH (nomenclature from Bonin and Bailey, 1947), but not to the
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hippocampus. Thus, the majority of the hippocampal and parahippocampal
connections, whether reciprocal or not, involve cingulate regions 23, 30 and 24c,
while areas 24a, 24b and 25 appear to have fewer connections.
Efferent projections of the thalamus to anterior cingulate areas 25, 24a and
24b originate primarily in the midline parataenial, central densocellular, and reuniens,
and mediodorsal (parvocellular division) nuclei, with slight variation with respect to
anterior cingulate subdivisions (Vogt et al., 1987).  Posterior cingulate regions receive
input primarily from anteroventral, anterodorsal, and laterdorsal (to area 29), or
anterior medial thalamic nuclei (to areas 23).  These connections may also be
reciprocal (Van Hoesen et al., 1993).
As in the case of all parts and types of cortex, the cingulate projects to the
striatum, both dorsal and ventral regions (Baleydier and Mauguiere, 1980).  The
terminal projection pattern from the cingulate mimics the patchy matrix described by
Graybiel (1990).  The anterior cingulate projects to the caudate, putamen and the
ventral striatum, while posterior cingulate has projects to only to the dorsal striatum
(Baleydier and Mauguiere, 1980).  Area 24 terminates more so in the putamen and 23
has stronger connections with the caudate.
Direct projections from the cingulate cortex to midbrain and hindbrain provide
pathways out of the limbic system to control visceromotor and skeletomotor effector
organs.  The corticorubral pathway from cingulate areas 24c and some of 23c is
distinctive, because this is the only limbic region projecting to the red nucleus, which
receives most of its afferents from the cerebellum.  Cingulopontine projections
originate in areas 23, 24, and 25 (Vilensky and Van Hoesen, 1981).
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1.2.2.2 Functional Attributes of the Anterior Cingulate
Early ablation and stimulation studies suggested that the anterior cingulate
was involved in autonomic regulation, including cardiovascular, pupillary dilation,
hormonal responses and motor inhibition (Smith 1945; Ward, 1948;Kaada, 1949,
1951; Frankel and Jenkins, 1975).  Ablation of cingulate area 24 in macaque monkeys
resulted in loss of “fear of man” and other affective behavioral changes (Smith, 1945;
Ward, 1948).  In addition, the avoidance reaction in the cats (McCleary, 1961) has
been shown to be involved in noiceptive processing that has been associated with the
anterior cingulate (dorsal and caudal portion) in man and animals, either in pain-
avoidance paradigms or in studies examining pain-affect neural correlates (Koyama et
al., 1998; Rainville et al., 1997).
Three anterior cingulate regions are of particular interest because their
projections to motor effector areas suggest their involvement in the expression of
emotion.  Rostral cingulate area 24(a, b) projects to the periaquaductal grey (PAG)
region in the midbrain; stimulation of these portions of area 24 produces vocalizations
associated with responses to noxious stimuli (Jürgens and Ploog, 1970; Müller-Preuss
and Jürgens, 1976) that are emotional, not communicative, in nature.  Ablation of the
PAG results in a loss of these emotional vocalizations evoked from cingulate
stimulation (Jürgens and Pratt, 1979).
Autonomic effector control appears to be exerted by the subgenual anterior
cingulate region, ventral to the region associated with vocalizations, that has
connections to the nucleus of the solitary tract and the dorsal motor nucleus of the
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vagus in the cat (Room et al., 1985; Willet et al., 1986) and has been demonstrated to
initiate gastric motility.  A dorsal region of the anterior cingulate, which projects to
the primary and supplementary motor cortex (Morecraft and Van Hoesen, 1991) and
spinal cord (Van Hoesen et al., 1993), has been associated with the planning of
movement, as evidenced by bursts of neuronal activity just prior to finger movement.
Stimulation of this region generates forelimb, hindlimb, axial, and tail movements in
monkeys (Mitz and Wise, 1987).
Anterior cingulate effector regions, areas 24 and 25, receive afferents from the
basal nucleus of the amygdala (Porrino et al. 1981; Amaral and Price, 1984) and have
some unique topographical features (Van Hoesen et al., 1993).  This projection
terminates most heavily in cortical layers II and I, and defines the boundary of the
cingulate and supplementary M2 regions, thus the termination region may contain
face representation (Muakkassa and Strick, 1979; Morecraft and Van Hoesen, 1992),
suggesting a pathway to control facial affect. There is no overlap with parietal inputs
to the region (Vogt and Pandya, 1987),
Vogt et al. (1992) and Devinsky et al. (1995) deduced from studies of lesions,
electrical stimulation, microelectrode recording, and PET that the cingulate cortex can
be separated into two functionally distinct regions, anterior and posterior cingulate.
The anterior region, including areas 24 and 25, mediates what they terms “executive
functioning”, or controlling the effector output, whether it be visceromotor,
skeletomotor and endocrine outflow.  Specifically, emotion, pain, maternal behavior,
visceromotor, skeletomotor and attention have attributed to anterior cingulate
function.  Furthermore, they posit that this region evaluates the emotional valence of
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an organism’s situation and integrates emotional information to modulate these
functions.  This role of the anterior region of the cingulate is further supported by the
neuroanatomical connections to the amygdala.
The anterior cingulate can be further subdivided in to affective and cognitive
components (Devinsky et al. 1995).  Affective regions include rostral areas 25, and
rostral/ventral areas 24 and 33, while cognitive region is the dorsal/caudal areas 24
and 32.  The affective region is involved in numerous emotional behaviors including
conditioned emotional learning, vocalizations associated with expressing internal
states, assessments of motivational content and assigning emotional valence to
internal and external stimuli, and maternal-infant interactions.  Area 25 projects to the
parasympathetic nucleus of the solitary tract (Terreberry and Neafsy, 1983, Willett et
al., 1986) and the dorsal motor nucleus of the vagus in the cat (Room et al., 1985,
Hurley et al. , 1991).  Area 24 projects to periaquaductal grey and intersects with area
25 (Vogt and Pandya, 1987) and orbitofrontal cortex (Morecraft et al. 1992). This
region has prominent connections to the amygdala and visceromotor regions of the
brainstem (Vogt and Pandya, 1987)
The posterior cingulate, including areas 29, 30, 23 and 31, serves an
evaluative role in behavior, monitoring sensory information and the orientation of the
organism with respect to its environment and its own memories.  Neurons in this
region are responsive to visual stimulation, and are involved in monitoring eye
movements, complementing motor commands.  Lesions disrupt tasks of spatial
orientation and spatial working memory, like the ability to swim to a hidden platform.
Anterograde and retrograde amnesia can occur from lesions of area 23a (Valenstein et
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al. 1987).  Disruptions of these memory functions are possibly related to the known
neuroanatomical connections to the hippocampus and surrounding parahippocampal
area (Squire et al., 2004).  Posterior cingulate, in contrast to the anterior cingulate, did
not activate with procaine-induced emotional and autonomic experiences (Ketter, et
al., 1996).
In summary, the anterior cingulate appears to contribute significantly to the
neural circuits mediating emotion, as well as autonomic regulation, pain processing
and attention, with an overarching executive function that contributes to orchestration
of situationally appropriate behavior.  Procaine-induced activation of the cingulate
cortex was quite striking in that a clear boundary of activation appears to segment the
anterior and posterior portions (Ketter et al., 1996).
1.2.3 The Amygdala
The amygdala, a group of medial temporal lobe nuclei originally termed by
Burdach (1819), became of particular interest to the study of emotional processing
primarily because ablation studies show striking emotional changes.  Klüver and
Bucy´s (1937, 1939) rediscovery of the Brown and Schäfer´s (1888) remarkable
effect of “psychic blindness” by temporal lobectomy provided rationale to include the
amygdala in MacLean´s limbic system.  Weiskrantz (1956) isolated this effect to the
amygdala by showing that amygdalar lesions produced impairment of avoidance
conditioning, and thus hypothesized that the function of the amygdala was to
associate the affective and reinforcing properties of the stimulus with its sensory
properties.  Geschwind (1965) believed the animals behaved in a bizarre manner due
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to the lack of the motivational significance of visual stimuli resulting via
disconnection of the inferotemporal visual processing cortices from the medial limbic
areas.  However, Schreiner and Kling (1953, 1956) portray dysfunction in sensory
processing, ingestion, and sexuality as well with amygdala lesions in cats.
The amygdala is a heterogeneous structure with respect to anatomy, function,
and neurochemistry.  This area has widespread cortical connections and has most
known neurochemical substrates.  Its main function appears to attach significance to
external and internal stimuli.  The following discussion integrates amygdalar
neurochemistry and neuroanatomy, and serves as a basis for integrating its function
and relationship to other limbic areas.
The amygdaloid complex is bounded ventrally by the uncus, caudally by the
hippocampus, and medially and rostrally by the substantia inominata, and dorsally by
the lentiform nucleus.  Johnston (1923) originally mapped the amygdalar nuclei
architectonically, and the refining of boundaries, cellular compositions, and pathways
remains an active area of research.  Terminology used herein will follow Amaral et
al., 1992, who have taken much of the current nomenclature and refined it further for
the monkey brain.  As noted above, the neurochemistry and neuroanatomy of the
amygdala in primates varies slightly from the rat (R. Saunders, personal
communication), thus the following information may differ from studies based on the
rat.
Currently, the core components of the amygdaloid complex are considered to
be the lateral nucleus, basal nucleus, accessory basal nucleus, and central nucleus,
while the superficial nuclei  (or areas) include the paralaminar nucleus,
44
periamygdaloid cortex, medial nucleus, the nucleus of the lateral olfactory tract, the
anterior and posterior cortical nuclei, intercalated nuclei and the
periamygdalohippocampal area.  Most of what is known about the amygdala is based
on the core regions, thus these areas will be reviewed in more detail.  Discussion of
the remaining regions will be limited to selected features, as appropriate to the theme
of this thesis.
1.2.3.1 Amydalar Nuclei
The lateral nucleus borders the external capsule rostrally and the putamen and
ventral horn of the lateral ventricle caudally.  Its cellular composition is
heterogeneous with small to medium-sized cells that can be separated into two major
subdivisions based on the staining differences in Nissl bodies and AChE.  The
ventrolateral compared to the dorsomedial portion is fairly densely packed and stains
more darkly for AChE.  Patches of tightly packed small neurons, which stain
intensely for AChE on the lateral border, make up the heterogeneous lateral capsular
nuclei (Amaral and Bassett 1989).
The neurochemistry of the lateral region with significant levels of cholinergic
M1, cholecystekinin (CCK), and galanin receptors, and the presence of GABAA
benzodiazepine receptors is suggested by the high levels of immunoreactivity to
antibodies of the GABAA receptor complex.  In addition, high levels of NAPDH-d (a
nitric oxide synthase), tyrosine hydroxylase (dopamine rate-limiting enzyme),
somatostatin, and corticotropin releasing factor (CRF) have been found in cells or
fibers in this region.
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The basal nucleus is the largest of the amygdaloid complex, which originally
encompassed the accessory basal nucleus. The terminology of its subdivisions used
by different authors is variable, although boundaries remain relatively constant.  The
parvicellular division, also known as the medial basal or basomedial region, has the
smallest cells of the basal nucleus. These densely packed cells stain darkly for Nissl
bodies.  Between this region and the magnocellular component of the basal nucleus
lays the intermediate division.  The cells in the magnocellular division are larger,
more densely packed and more darkly stained than the parvocellular division.  The
magnocellular division, or the lateral basal or basolateral region, is the largest of the
basal nucleus, and has the largest cells with many fibers coursing through it.
Moving dorsally from the parvicellular to magnocellular division yields three
gradients: relative cell size increases from small to large; staining density for Nissl
substance becomes darker; and cholinergic preparations with both markers increase in
intensity.  The chemoarchitecture is diverse, but as suggested above, there are high
levels of cholinergic markers, ChAT and AChE, M1 and M2 receptors.  Also reported
are high levels of CRF, NADPH-d (nicotinamide adenine dinucleotide phosphate),
somatostatin, and limbic system associated modulatory protein (LAMP), as well as
benzodiazepine and CCK receptors.
The accessory basal nucleus is situated between the most medial amygdalar
regions, the periamygdaloid cortex and the nucleus of the lateral olfactory tract, and
the intermediate fiber bundle, a fiber tract between the accessory and basal nuclei,
and extends the majority of rostral/caudal axis of the amygdaloid complex.  This
nucleus has parvicellular and magnocellular subdivisions, but also has a ventromedial
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division, which contains the highest intensity of cholinergic markers of the accessory
basal subdivisions. The entire nucleus is NADPH-d, somatostatin, LAMP, as well as
M1 and M2, benzodiazepine, CCK and galanin receptors.
Similar to the basal nucleus, a gradient of cell size and intensity of cholinergic
markers is observed spanning from the parvicellular with low cholinergic markers, to
magnocellular with moderate to high levels of cholinergic markers.  There is a
“superficial division” that separates the amygdalohippocampal region from the
accessory basal nucleus, which has architectonics more like the parvicellular than
magnocellular.
The central nucleus is situated at the caudal third of the amygdaloid complex
along with the posterior cortical nucleus, the amygdalohippocampal area and the
caudal end of medial nucleus.  The central nucleus has medial and lateral divisions
and high levels of multiple neurotransmitter and neuromodulatory system markers,
including tyrosine hydroxylase, serotonin, somatostatin, neuropeptide Y (NPY),
vasopressin, CRF, neurotensin, and galanin receptors. However, this region has
relatively lower levels of cholinergic markers.
The chemoarchitecture of the superficial nuclei is heterogeneous, but includes
considerable cholinergic activity.  The amygdalohippocampal area, the anterior
cortical nucleus of the amygdala, the medial nucleus, periamygdaloid cortex, the
nucleus of the olfactory tract and the anterior amygdaloid area have high levels of
cholinergic markers, including ChAT, AChE, and M1 receptors.
In summary, the lateral, basal, accessory basal and periamygdaloid cortex all
express markers, including M1 and M2 receptors (Flynn and Mash, 1993), of the
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cholinergic system.  Of sixteen markers for neurotransmitter or neuromodulatory
systems examined so far, only the cholinergic system, somatostatin and NADPD-d,
nitric oxide synthase, express such widespread amygdalar involvement.
1.2.3.2 Intrinsic Amygdalar Pathways
Intrinsic connections across the lateral to medial axis tend to project
predominately in a lateral to medial direction (Figure 6).  For example, the lateral
nucleus projects to all nuclei that are medial to it, and receives only minor afferents
from the basal and accessory nuclei.  This pattern is repeated across the lateral-medial
axis of the amygdala and suggests predominately unidirectional information flow
(Amaral et al. 1992).  Further details of these connections will focus on the four core
subdivisions; for a full examination of the connections, see review by Amaral et al.,
1992.  The basal nucleus sends efferents to the accessory basal and central nucleus,
with only modest reciprocal projections.  The accessory basal nucleus projects to the
central nucleus, as well as other more medial nuclei.  The central nucleus projects
primarily to more medial nuclei, but also projects to the lateral and basal nuclei.  The













Figure 6.  Intrinsic Connections of the Amygdala.
Schematic of the intrinsic connections of the amygdalar nuclei.  Information
processing generally flows in a lateral to medial direction.  Thick arrows emphasize
lateral to medial connections.  Right side of figure is lateral, top is dorsal.
Abbreviations:  AAA, anterior amygdala area; AB, accessory basal nucleus; B mc,
pc, basal nucleus, magnocellular and parvocellular; CE, central nucleus; Coa,p,
cortical nucleus, anterior and posterior; L, lateral nucleus; M, medial nucleus; PAC,
periamygdaloid nucleus; PL paralaminar nucleus.  After Aggleton and Saunders,
2000.
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1.2.3.3 Extrinsic Amygdalar Pathways
The extensive cortical and subcortical connections of the amygdala provide
diverse pathways to affect behavior and modulate information processing.
Subcortical pathways (Figure 7) exist between the basal forebrain, parahippocampal
regions, striatum, thalamus, hypothalamus and the brain stem, while cortical
connections (Figure 8) are seen with the prefrontal, cingulate, olfactory, insular,
temporal, and occipital cortices.  Of note, the parietal cortex is the only cortical area
devoid of direct amygdala connections, however, polymodal information does make
its way to the amygdala via sensory association areas in the temporal lobe.
The widespread amygdalar projections to rostral cortical regions are densest in
anterior cingulate, lateral and medial orbitofrontal, and agranular insular cortices
(Amaral and Price, 1984).  This set of adjacent regions form a continuous density
gradient emanating in two directions from the ventral subcallosum area, and
subsequently will be referred as the core amygdalar efferents.  In the medial to lateral
dimension on the ventral surface, the core amygdalar efferents extend from medial
orbitofrontal cortex (areas 13 and 14) laterally to anterior insula and lateral
orbitofrontal cortex (LOFC; area 12).  In a ventral to dorsal direction, in the medial
plane, core amygdalar efferents include anterior cingulate areas 25, 24 and 32.
Amygdalar connections diminish when moving beyond these regions, leaving some
areas of patchy (8,9,45,46, premotor and 6) or no (10) amygdalar innervation.
The basal nucleus projects to all core amygdalar efferent regions
topographically, and receives reciprocal projections from the anterior cingulate,
insula, and caudal orbitofrontal cortex.  The accessory basal nucleus, predominately
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the magnocellular region, projects to anterior cingulate (area 25 and some of 32),
insula, medial (14) orbital and lateral (12) orbital cortex, ventromedial wall of the
medial wall of the prefrontal cortex, but only the caudal orbitofrontal and the medial
wall of the prefrontal cortex reciprocate.  The lateral nucleus projects to medial
orbitofrontal cortex area 13 and insula with reciprocation only from the insula.  The
medial and periamygdaloid cortex projects to the insula.
Generally, reciprocation predominates, but several relationships stand out:  the
anterior cingulate innervates only amygdalar nuclei sending efferents to it; the basal
nucleus reciprocates to all four of the dense innervations regions; and the insula
appears to have the greatest number of connections, either afferent or efferent, with
amygdalar nuclei.  In humans undergoing procaine-induced emotional experiences,
the anterior cingulate, insula and amygdala had robust concurrent activation (Ketter et
al., 1996).
The lateral nucleus and some portions of the basal nucleus (Aggleton et al.,
1980) receive projections from the anterior inferotemporal cortex (area TE), a
unimodal visual processing region (Pandya and Yeterian, 1985).   Primary visual and
primary auditory cortices do not seem to directly innervate the amygdala (Aggleton et
al., 1980), however, secondary auditory processing areas, superior temporal gyrus and
association cortex do project to the lateral nucleus (Turner et al., 1980; Van Hoesen,
1981).  Polysensory temporal areas, perirhinal cortex, parahippocampal cortex
(regions TF and TH), project to the lateral, basal, and accessory basal nuclei, with the
heaviest source of efferents coming from the temporal pole region (Turner et al.,
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Figure 7.  Reciprocal Subcortical Connections of the Amygdala.
A convergence of information concerning the internal milieu from widespread
subcortical and brainstem nuclei. Also illustrated is the cholinergic (in bold) and
monaminergic input to the amygdala.  Again, this representation reflects mostly basal
and lateral nuclei innervation, however, other amygdalar nuclei also receive a few
projections.  Abbreviations: ACh, acetylcholine; BNST, bed nucleus of the stria
terminalis; CG, central, grey; DA, dopamine; DR, dorsal raphe; Ch3- HLDB,
cholinergic portion of the horizontal limb of the diagonal band; Ch4-NBM,
cholinergic portion of the nucleus basalis of Meynert; LC, locus coeruleus; MT,
MST: secondary visual processing areas; NACC, n. accumbens; NE, norepinephrine;
NST, n. solitary tract; PAG, periaquaductal grey; PBN, parabrachial n.; OA, OB, OC:
olfactory cortex; OlfB, olfactory bulb; OlfT, olfactory tract; RF, reticular formation;
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Figure 8.  Reciprocal Cortical Connections of the Amygdala.
A convergence of external environmental information from widespread secondary
and polymodal association areas descends onto the amygdala.  The amygdala is
unique in that in most cases it modulates its own afferents.  This representation
reflects mostly basal and lateral nuclei innervation, however, other amygdalar nuclei
also receive a few projections.  Abbreviations:  AC, anterior cingulate; DLPFC,
Dorsolateral prefrontal cortex; MPFC, medial prefrontal cortex; MT, MST: secondary
visual processing areas; OA, OB, OC: olfactory cortex ; OPFC orbitofrontal cortex;
TA, TE, TEO, TG, TH, TPO, TP: temporal regions. After Aggleton and Saunders,
2000.
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In contrast, to the incomplete occipital and temporal efferents to the
amygdala, the amygdala projects to directly all visual areas of temporal and occipital
cortex in primates.  The basal nucleus projects across the cortical mantle from area 17
to the temporal pole with progressively denser innervation in the rostral direction
(Mizuno et al., 1981; Amaral and Price, 1984).  This pattern is replicated in auditory
cortex, although the specific amygdalar nuclei responsible for the projections remain
unknown.  The lateral and accessory basal nuclei projections to polysensory regions
of the temporal lobe are also more dense in the temporal pole, but also increase as
they progress from the lateral to medial perirhinal region (Amaral and Price, 1984).
Projections to areas 35 and 36 are progressively denser along the caudal to rostral axis
of the ventral surface of the temporal lobe; these originate in the basal and accessory
basal nuclei area, but area 35 also receives afferents from the lateral nucleus
(Stefanacci et al., 1996).
The olfactory bulb projects directly to the nucleus of the lateral olfactory tract,
periamygdaloid cortex, and the anterior cortical nucleus, of which the first two nuclei
reciprocate.  In addition, amygdalar afferents from olfactory association cortices, such
as the piriform cortex, terminate in the same amygdala nuclei that receive directly
form the olfactory bulb in the rat (Carmichael and Price, 1996).   Piriform cortex also
projects to the medial and posterior cortical amygdalar nuclei in the rat (Krettek and
Price, 1978; Ottersen, 1982). Olfaction is the only sense with direct connections to
cortical areas, instead of first synapsing in sensory relay nuclei such as the thalamus.
Projections to the hippocampus and associated cortex for the most part follow
other species, such as cat and rat, but there are significant exceptions; the accessory
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basal nucleus sends efferents to the hippocampal formation and related cortices,
entorhinal cortex and subiculum.  There are considerably more amygdalo-
hippocampal efferents than afferents, suggesting that the amygdala has more impact
on the hippocampal processing than the reverse (Amaral et al., 1992).
The entorhinal cortex, as the major interface between the hippocampal
formation and the amygdala (Witter and Amaral, 1991), and poly-modal sensory
cortices (Insauti et al., 1987), receives amygdalar efferents from the lateral, accessory
basal, anterior cortical and medial nuclei, and periamygdaloid cortex (Insauti et al.,
1987; Saunders and Rosene, 1988). The basal nucleus also sends a minor projection
to this area.  Reciprocal projections to lateral nucleus have been questioned as to
whether they consist of only fibers of passage piercing the lateral nucleus, or if they
form en passant connections.  The basal nucleus and periamygdaloid cortex are
innervated by the subiculum and CA1 hippocampal formation (Saunders et al., 1988).
Since the basal forebrain nuclei have been discussed in detail already, a brief
synopsis of the amygdalar connection follows.  The nucleus basalis of Meynert, the
nucleus of the horizontal limb of the diagonal band, and the amygdala have
substantial reciprocal connections (Mesulam et al., 1983; Russchen et al., 1985b).
This most exemplified by the reciprocal projection between the basal nucleus
(parvicellular) of the amygdala and the nucleus basalis in the forebrain (Amaral and
Bassett, 1989).   In addition, the accessory basal and the central nuclei send a major
projection to the magnocellular division of the basal forebrain.   These regions of the
basal forebrain are considered the origination of cholinergic cell bodies that project
across the forebrain.  The magnocellular division of the basal nucleus of the amygdala
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has the highest levels of ChAT of any forebrain regions, suggesting this is the most
substantial cholinergic projection of the basal forebrain (Hellendall et al., 1986).
The amygdalostriatal projection also has substantial efferents of the amygdala,
projecting to both dorsal and ventral striatal structures.  The nucleus accumbens
receive efferents from the basal and accessory nuclei, while the caudate and putamen
receives input from the magnocellular division of the basal nucleus (Parent et al.,
1983; Russchen et al. 1985a).  There also exists a lighter projection to the ventral
pallidum from the (Russchen et al. 1985a).
The thalamus, usually considered a major sensory and motor relay, has
significant innervation from limbic regions, thus midline and mediodorsal thalamic
nuclei are considered limbic thalamus (Vogt et al., 1987).  The central and medial
nuclei of the amygdala project to midline thalamic nuclei, nucleus reunions and
caudal centralis nucleus (Price and Amaral, 1981).  The midline nuclei reciprocate
back to the central, but also project to the basal nucleus of the amygdala (Mehler,
1980).  The posterior thalamus, near the medial geniculate, sends projections to the
lateral, accessory basal, medial and central nuclei (Mehler, 1980).
Mediodorsal thalamus receives projections from almost all amygdalar nuclei,
but mostly from the lateral, basal, and accessory basal nuclei, and periamygdaloid
cortex.  The terminations are primarily in the magnocellular region that projects to the
same orbital and medial prefrontal areas that receive amygdalar efferents (Porrino et
al., 1981; Goldman-Rakic- and Porrino, 1985).  Furthermore, there is a distinct
amygdalo-thalamic topographical pattern (amygdala dorsal cells project to thalamic
ventral cells) that is synaptically connected to the amygdalo-cortical and thalamo-
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cortical topography.  This direct and trans-thalamic amygdalar efferents projecting to
the same orbital cortex region are “registered”, as demonstrated by multiple axonal
tracers that show overlap; i.e., the nuclei of the amygdala that projects to the
orbitofrontal cortex, also projects to mediodorsal region that projects to the identical
orbital cortex area.  Although, the anterior cingulate projections do not have
overlapping mediodorsal regions with the amygdala as seen with orbitofrontal cortex
(Ray and Price, 1990), they may have indirect connections via interneurons to other
thalamic nuclei.
The hypothalamus receives significant, primarily unidirectional, projections
from the amygdala.  The central nucleus has the most substantial efferents of the
amygdaloid complex (Amaral et al., 1982; Price et al., 1987).  The central nucleus
also innervates the para-mammillary nuclei.  The basal nucleus of the amygdala
projects to the lateral tuberal nucleus.  There are two projections from amygdalar
nuclei to the medial hypothalamic nuclei.  These include anterior cortical and medial
nuclei to the anterior hypothalamus (Price et al., 1991), medial and accessory basal
nuclei and the amygdalohippocampal area to the ventromedial and premammillary
nuclei of the hypothalamus (Heimer and Nauta, 1969).  Hypothalamic-amygdalar
projections include the ventromedial and lateral hypothalamic nuclei send fibers back
to the amygdalar central, medial, basal and accessory basal nuclei.  The lateral
hypothalamus has reciprocal projections back to the central and medial nuclei, via the
ventral amygdalofugal pathway.
The central nucleus is the only amygdalar nucleus that projects to the
midbrain, pons and medulla, via the caudal amygdalofugal pathway.  Autonomic
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control by the amygdala may be achieved by innervation of the periaquaductal grey,
the parabrachial nucleus, the dorsal vagal nuclei, and the reticular formation (Price
and Amaral, 1981).  The amygdala receives various monaminergic fibers (Mehler,
1980; Norita and Kawamura, 1980) from the brain stem.
1.2.3.4 Functional Attributes of the Amygdala
The functional role of the amygdala has been the subject of numerous studies
and theories since the discovery of amygdalar lesions in monkeys produce “tame”
animals (Brown and Schäfer, 1888; Klüver and Bucy 1937; Weiskrantz, 1956;
Schreiner and Kling, 1956).  Visually agnosia, hyperorality, and hypersexuality are
also associated with ablation of the amygdala in the cat (Schreiner and Kling, 1953).
Geschwind (1965) hypothesized that sensory information from temporal lobe
processing regions must impinge on the amygdaloid complex in order to be
associated with the appropriate affective or motivational valence.  The basis of this
effect has been traced to the loss of fear conditioning by lesions of the basolateral
complex (basal and lateral nuclei) and central nucleus (Brady et al., 1954; Davis,
1992; LeDoux, 1996), which occurs in conjunction with motoric, autonomic,
hormonal and attentional alterations (Davis, 1995).  Stimulation of the amygdala can
produce complex responses of motor inhibition, autonomic arousal, and EEG changes
that when taken together resemble fear responses (Davis, 1995).
The basolateral - centromedial functional division of the amygdala is
continually being revised.  Swanson and Petrovich (1999) segment the rat amygdala
into four functional units, adding two olfactory systems to the traditional basolateral
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and centromedial divisions: 1) frontotemporal system - basal and lateral nuclei have
reciprocal projections with the frontal, parietal, cingulate, prefrontal, insular,
hippocampal, and olfactory cortices, striatum, nucleus accumbens, and thalamus; 2)
autonomic system - central nucleus projects to the SI, the bed nucleus of the stria
terminalis, hypothalamus, and brainstem autonomic nuclei; 3) main olfactory system -
cortical and basomedial nuclei projecting to SI, central and medial amygdalar nuclei,
medial prefrontal, agranular insular, perirhinal, and hippocampal cortices, thalamus,
striatum, nucleus accumbens, and parabrachial nucleus;  4) accessory olfactory
system - medial, cortical and posterior nuclei project to the SI, central amygdalar
nucleus, main olfactory system, ventral subiculum, medial prefrontal, agranular
insula, and the nucleus accumbens.  There exists discrepancies between this model
based on the rat and what has been summarized in Amaral et al. (1992) with respect
to cholinergic innervation in the monkey, as suggested by Saunders (personal
communication).
In contrast to a segmented approach to amygdalar function, the presence of
extensive intrinsic connections and 40 Hz oscillations (Gault and Coustan, 1965) of
the amygdala suggest that the amygdala functions as relative unit (Aggleton and
Saunders, 2000).  In nonhuman primates and humans, amygdalar activity appears to
have some selectivity to faces, and particularly for facial fear recognition.  Bilateral
amygdala damage in man produced deficits in recognizing facial affect of fear and
anger, while sad, disgust and surprise affects were somewhat impaired, and happy
was unaffected compared to brain-damaged and healthy controls (Adolphs et al.,
1999).  What was striking was the lack of consistency of errors the amygdala-
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damaged subjects made; they did not confuse one emotion for another, but chose
different emotions upon repetition of a trial.  These results suggest a general function
of the amygdala of emotion detection, rather than a specific fear-detector.
In a related study, amygdala-damaged subjects were less able to assess the
trustworthiness and approachability from faces but not verbal description of these
attributes, thus extending the impairment sustained into the social realm (Adolphs et
al., 1998).  These subjects performed as well as controls when assessing these
attributes in the ten most negatively rated faces after slight alterations of facial
features.
In summary, the anatomical connections of the amygdala have been
extensively studied resulting in a large body of literature.  As demonstrated in Figures
7 and 8 the intra-amygdala pathways as well as the projections to other brain regions
are numerous (Aggleton and Saunders, 2000).  Whether the amygdala operates as
relative unit or with functional subdivisions remains to be elucidated.  However, the
functional response of procaine may very well be related to the amygdalar basolateral
- centromedial division.  For example, the anterior paralimbic rCBF activation (Ketter
et al., 1996) may be related to the basolateral system projecting to prefrontal regions,
while endocrine alterations (Kling et al., 1994) could be a function of corticomedial
modulation of hypothalamic nuclei.  It appears that the collective amygdalar nuclei
communicate in such a manner that different aspects of emotional behavior can be
compartmentalized to specific effector pathways and at the same time result in an
orchestrated fashion.  The broad rostral cortical region innervated by the basal
nucleus suggests it may have a significant role in attention, i.e., it may be acting as a
60
general amygdalar switch that brings all the cortical regions “on-line” (activated
together) when emotional processing is required to modulate executive functions.
1.2.4 Thalamic and Striatal Relationships with the Limbic System
Portions of the thalamus and striatum mediate limbic functions and have
neuroanatomical connections with regions classically considered as limbic.  The
midline nuclei of the dorsal thalamus, because of its, often reciprocal, projections to
limbic areas, as well as to sensory and motor areas, has long been hypothesized to be
involved in emotional behavior as a route for sensory information to be accessed.
The mediodorsal thalamus projects to the amygdala, and anterior cingulate areas
24a,b and 25.  As mentioned in the discussion of the amygdala, the amygdala
innervates the orbitofrontal cortex via direct and trans-thalamic connections and the
anterior cingulate through direct and two-step thalamic (via thalamic interneurons)
projections.
The striatum also has considerable connections with motor and limbic regions,
that can be organized into dorsal and ventral striatopallidal pathways, respectively
(Alheid and Heimer, 1996).  Limbic pathways include ventral pallidal and striatal
afferents from the prefrontal cortex, including, anterior cingulate and orbitofrontal
cortex; limbic cortex receives from mediodorsal thalamus, which has reciprocal
connections with the ventral pallidal and striatal structures.  In addition, there are
reciprocal connections of these ventral striatal and pallidal regions with the amygdala,
septum, habenula, subthalamic nucleus, substantia nigra and ventral tegmental area.
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The amygdalo-striatal projection is one of the most substantial efferents of the
amygdala projecting to the nucleus accumbens.
As has been noted throughout this thesis, the involvement of the cholinergic
system in the limbic system is widespread and substantial.  The thalamus and striatum
are no exception.  All the thalamic nuclei express cholinergic activity, but especially
in the mediodorsal, intralaminar nuclei, reuniens nucleus, anterodorsal nucleus, lateral
geniculate and reticular nucleus, by pontine and tegmental cholinergic neurons
(Mesulam, 1995).  There are also cholinergic projections from the magnocellular
basal forebrain nuclei to midline thalamic nuclei, including the nucleus centralis
superior and dorsalis, ventral reunions nucleus, and paraventricular nucleus
(Russchen et al., 1985a).
In the striatum there are high levels of cholinergic markers, most of which are
a result of cholinergic interneurons (Graybiel, 1990), and also from Ch4-NBM
(Mesulam, 1995).  However, the co-existence of NGF receptor immunoreactivity
suggests extrinsic innervation from basal forebrain nuclei.  In addition, there are
known cholinergic projections originating from the pontine and tegmental nuclei to
striatal nuclei.
1.2.5 Neuroanatomical Circuits
Alexander and colleagues (1990) have brought renewed interest in the
construction of neuronal circuits, which are more complex than the earlier work of
Papez (1937), Yakovlev (1948), and McLean (1949, 1952).   These distributed
networks, rather than focalized locus of control, has sought to delineate parallel basal
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ganglia-thalamocortical circuits mediating motor, oculomotor, prefrontal and limbic
functions based on neuroanatomy and neurochemistry.  Both the limbic and prefrontal
loops are implicated in emotional behavior with distinctions being made as to the
division of experiential and executive functioning with respect to these two circuits.
The limbic circuit connects the anterior cingulate and medial orbitofrontal
cortex (MOFC) with ventral striatal and pallidal regions, the olfactory tubercle and
nucleus accumbens and extended amygdala, that project on to the subthalamic
nucleus that project onto limbic thalamic nuclei that returns projects up to the limbic
cortex completing the loop.  As outlined above, cholinergic neurons modulate the
anterior cingulate, which has major outflow to effector regions of the brain.  One
might speculate that repeated passes through these loops could allow for
amplification or reduction, and thus refinement of signals relaying putative
emotionally significant information in an on-going basis.  The functions of the limbic
loop have not been studied as well, but they are hypothesized to be more attuned to
the experience and expression of affect, and motivational processes.
 The prefrontal circuit is more likely to incorporate the emotional valence of
the situation at hand and “adjust” cognitive functions, such as memory and decision-
making.  For example, the dorsolateral prefrontal cortex (DLPFC) is activated during
the Wisconsin Card Sort Test as evidenced by PET in healthy subjects, and less so in
pathological states, such as schizophrenia (Weinberger et al., 1986).
Comparing the limbic and prefrontal circuits, differences between them
mainly stem from the cortical regions involved, but also from the particular striatal
and thalamic components are involved, as well.  The limbic circuit involves the
63
anterior cingulate and medial orbitofrontal cortex, while the prefrontal incorporates
dorsolateral prefrontal and lateral orbitofrontal cortices.   The limbic circuit involves
the ventral striatal structures and mediodorsal thalamus, while the prefrontal
incorporates dorsal striatal region, caudate, and thalamic ventroanterior pars
compacta (VApc).  These differences may represent preferential neurochemistry of
each circuit.  For example, the limbic circuit includes anterior cingulate and MOFC,
cortical regions of the limbic circuit that receive heavy cholinergic input from the
basal forebrain.  Moreover, the limbic and prefrontal circuits differ with respect to the
involvement of the ventral pallidum and the substantia nigra, suggesting a dominance
of acetylcholine or dopamine, respectively.  The limbic circuit is involved in
visceromotor and cholinergic areas, while the prefrontal circuit appears to be
integrating areas more typically thought of as motor or dopaminergic.
1.2.6 Neuroanatomy Summary
Cholinergic cell bodies originating in the basal forebrain send afferents to
numerous targets, but most heavily to the amygdala, the ventral and anterior portions
of the anterior cingulate, the orbitofrontal cortex, and the insula.  In addition, the
majority of the cortex, dorsal striatum, globus pallidus, and hypothalamus receive
significant cholinergic innervation, however, not as heavily as the aforementioned
regions.  The ventral and anterior portions of the anterior cingulate, the orbitofrontal
cortex, and the insula also receive substantial afferents from the amygdala.  Thus,
there exists potential for these cortical regions to receive dual innervation from
cholinergic cell bodies, direct and indirect.  The neuroanatomical diagram in Figure 9
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incorporates cholinergic pathways discovered from several neuroanatomists in a
single model and provides a basis to test hypotheses regarding cholinergic function
and its relationship to emotional behavior.  This model will be referred to as the
AChNet and will be tested in experiment II presented in Chapter 3 and 4.
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Figure 9.  Schematic Summarizing the Cholinergic Influences on the Brain.
Cholinergic innervation, direct and indirect, of the amygdala, anterior cingulate, and
cortex suggests an important role in the limbic system, which implicates a pivotal
function in emotion regulation. This is supported by pattern of cholinergic cell bodies
and their most proximal and heavy targets that overlaps with the anterior paralimbic
activation pattern of procaine. Shading represents density of dual innervation, direct
cholinergic and indirect via the amygdala. Thick arrows indicate heavier innervation.
Numbers in the anterior cingulate indicate Brodmann areas (1909).  Abbreviations:
AC, anterior cingulate; ACh, acetylcholine; DLPFC. Dorsolateral prefrontal cortex;
DMNV, dorsal motor nucleus of the vagus; DR, dorsal raphe; LC, locus coeruleus;
MOFC, medial orbitofrontal cortex; Ch4-NBM, cholinergic portion of the nucleus
basalis of Meynert; NST, n. solitary tract; M1/M2, primary and secondary motor
cortex; PAG, periaquaductal grey; PN, pontine nuclei; RN, red n.; S1/S2, primary and
secondary sensory cortex; CA1, hippocampus; TF, TH, TE, TEO, TA, TPO, temporal
regions designated by Bonin and Bailey (1947); TP, temporal pole; VLPFC,
ventrolateral prefrontal cortex; VTA, ventral tegmental area.
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1.3 Neurobiology of Emotion
Understanding the neurobiology of emotion regulation can be aided by
observing clinical and behavioral changes after lesions occurring in humans and
animals, by examining effects of emotion induction by neuropsychological or
pharmacological challenges, or by comparing normal to pathological emotion states
in humans.  Each method has its associated benefits and caveats.  Therefore, the
information gleaned from each approach can contribute uniquely to understanding the
neurobiology of emotion when keeping their respective qualifications in mind.  Any
one neuromodulatory system is unlikely to be solely responsible for a single
behavioral response, which are more likely related to the subtle interplay of the
various systems.  Excitatory and inhibitory neurotransmission occurs primarily via
the amino acid neurotransmitters, glutamate (GLU) and gamma-amino-butyric acid
(GABA), respectively, while neuromodulators, such as cholinergic, monaminergic,
peptidergic, and chemical (e.g., nitric oxide), fine tune neurotransmission.  A brief
review of these mechanisms from several research perspectives follows.
1.3.1 Lesion Studies
Lesion studies have suggested neural substrates of emotion, e.g., Klüver-Bucy
syndrome (1937, 1939).  Examples of linking different emotions to specific brain
areas include rage induced by septal nuclei lesions and loss of fear conditioning
associated with amygdalar lesions.  Of these, septal rage may be closely associated to
a single neuromodulatory system because it is has a concentration of cholinergic cell
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bodies (Mesulam, 1995), despite the fact that it contains many neuromodulatory
substances (Záborszky et al., 1993).  In contrast, the amygdala also has diverse
neurochemistry, but most likely lacks neuromodulatory cell bodies.
While the ablation technique has been beneficial in isolating potential regions
involved in a behavior, it is unclear whether the lesion effects are direct or indirect
effects, i.e., the resulting behavior may be related to the integral function of the
region, a disruption of its relationships with other regions, or both.  Another problem
is the interpretation of emotional behavior in animals, as this must be, in some cases,
inferred from some measurable parameter, and leads to difficulties in the
extrapolation from animals to humans.
With these caveats in mind, this portion will focus on the relative effects of
lesioning the cholinergic and monaminergic systems to compare how these systems
can interact in arousal and attentional.  Studies of arousal and attentional mechanisms
may serve as a window into in emotional processing of animals.  Indeed, these
general brain functions are not in their own right unrelated to emotional processing,
but are hypothesized to be an essential part of it (LeDoux, 1996).
At first glance, the broad diffuse innervation patterns of the cholinergic and
monaminergic systems appear to lack anatomical specificity.  See Figure 10.   This
does not necessarily mean that the neuroactive substances lack functional specificity.
Intuitively, this is most likely not the case.  With regard to arousal and attentional
mechanisms, Robbins and colleagues (1995, 2002) has done a series of elegant lesion











Figure 10.  Distributions of the Acetylcholine and Monoaminergic Projections
Schematic of putative cholinergic and monoaminergic projections of the human brain.
These drawings are primarily based on the neuroanatomical pathways in the rat.  The
cholinergic system is the only classic neurotransmitter with cell bodies in the
forebrain, as well as the brainstem.  Abbreviations: ACh= acetylcholine;
NE=norepinephrine; DA=dopamine; DR= dorsal raphe; 5-HT=serotonin;
SI=substantia inominata; LC=locus coeruleus; SN=substantia nigra TEG=tegmentum
at the junction of the midbrain and pons.
69
He compared the behavioral responses of rats tested in a five-choice task after
cytotoxic lesions of the respective nuclei containing the cholinergic and
monaminergic cell bodies.  The five choice test is an adaptation of continuous
performance test of attention; rats are trained to detect brief visual stimuli that are
presented randomly at one of five locations in session of 100 trials separated by a 5s
inter-trial interval (ITI).   The animals are tested in four conditions: baseline,
distraction condition (where random bursts of white noise occur just prior to stimulus
presentation), an unpredictable condition (when stimuli are presented randomly), and
drug condition (d-amphetamine injected into n. accumbens which produces increased
locomotor activity, and impulsive and premature responding).
Cholinergic lesions with alpha-amino-3-hydroxy-5-methyl-4-isoxazole
proprionic acid (AMPA) or quisqualate microinjected into the nucleus basalis results
in reduced accuracy performance of 70% from the baseline condition. This effect can
be mimicked with ICV hemicholium, nucleus basalis (NBM) injections of muscimol
(this GABA agonist reduces cortical cholinergic function).  All three of these effects
reversed by physostigmine (Muir et al., 1992a; Muir et al., 1992b).  In this paradigm,
the cholinergic system seems to function to ensure the information acted upon is
accurate and implies the relative saliency of the stimulus with respect to the
environment is mediated by cholinergic mechanisms (Robbins and Everritt, 1995).
This may well have deep roots in adaptive behavior, as it absolutely necessary for
survival to distinguish friend from foe or safety from danger.
These results agree with the long-standing notions that cholinergic system is
involved in arousal, attention, and memory, as well as aggression, sexuality and thirst
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(Goldberg and Hanin, 1976).  Impairment of visual or auditory signal detection can
occur after scopolamine injections (Warburton, 1977).  However, a general role may
be to facilitate focus on the environment and orchestrate an appropriate behavioral
response (Panksepp, 1986) and utilize these functions as part and parcel of emotional
processing (LeDoux, 1996).  Caution is required in interpreting excitotoxic lesions as
these types of lesions also destroy other neurochemicals (Dunnett et al., 1991), thus
may be related more generally to the functions or connections of NBM.  This is
supported by the fact that damage to VLDB does not produce the same effect
(Marston et al., 1994).
Lesions with 6-hydoxydopamine (6-OHDA) into dorsal noradrenergic bundle
produces no gross behavioral deficits and animals can do simple associative tasks,
such as conditioned taste aversion (Robbins and Everitt, 1995).  Performance on 5-
choice test is impaired only in distraction, unpredictable, or drug conditions, but not
at baseline.  This suggests that normal functioning of the norepinephrine (NE) system
acts to preserve attentional mechanisms in stressful situations, and may be increasing
the signal to noise ratio to offset these effects (Foote, 1983).  NE appears to fulfill
many of the properties of the cortical arousing system envisaged by Hebb (1955) and
research supports enhancement of processing especially in the cortex and
hippocampus.
With lesions produced with 6-OHDA injected into the ventral striatum,
performance on the 5-choice task is not impaired in accuracy, but response latency is
increased and overall probability of responding is decreased.  The implications of
reduced motivation with DA lesions concur with the long-standing putative notion of
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reward-punishment functions associated with the dopaminergic system (Wise, 1984).
The DA system’s main functions may be to achieve of activation of behavior in
response to cues that signal availability of incentives or reinforcers.
After dorsal raphe lesions with 5,7-dihydroxytryptamine (5,7-DHT),
performance on the 5-choice task showed there was no impairment of accuracy, but
increased impulsive responding in all conditions was observed (Robbins and Everitt,
1995).  Impulsivity resulting from removal of serotonergic tone agrees with the
overall function of behavioral inhibition that has also long been associated with the
serotonin system (Panksepp, 1986; Robbins and Everitt, 1995).  This can be in the
context of a variety of behaviors that are inhibited by serotonin, such as feeding,
aggression, and play (Vogt, 1982), or induced by serotonin, sleep (Jouvet, 1972).  The
function of the 5-HT system has long been associated with regulation of appetite,
sleep, locomotor activity, and pain response (Panksepp, 1986; Jouvet, 1972; Vogt,
1982).
1.3.2 Normal versus Pathological Psychopharmacology
The neurobiology of emotional processing has relied heavily on
psychopharmacology of affective disorders, where several monaminergic theories
have been generated based on the alleviation of symptoms with antidepressant
medications, such as Prozac.  Pharmacology studies on these mood-altering drugs
have implicated the serotonin (5-HT), norepinephrine (NE) systems, and dopamine
(DA), although more recent studies have shown some efficacy of cholinergic drugs in
the treatment of depression (Burt, 1999).
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Initially, tricyclic antidepressants (TCA) and monoamine oxidase inhibitors
(MAOIs) were identified as successful treatments in depression.  Imipramine, the first
TCA to be identified, blocked the reuptake of NE into presynaptic neurons
(Glowinski and Axelrod, 1966; Glowinski and Iverson, 1966).  These experiments led
to the generation of the catecholamine theory in the pathogenesis of depression
(Prange, 1964; Bunney and Davis, 1965; Schildkraut, 1965).  Indolamines were
added as a potential mediator of mood dysfunction, as these were thought to be
modulating serotonergic neurons (Brogden et al., 1981; Bryant et al., 1982).
Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline,
paroxetine, citalopram, and fluvoxamine, soon followed supplanting NE as the major
neuromodulatory system implicated in depression.  The fact that both NE and 5-HT
systems have consistently showed abnormalities suggests that these systems play a
central role in affective disorders (Garth and Nemeroff, 2002).  The strongest support
for serotonin system dysfunction in mood disorders comes from the alleviation of
depressive symptoms with SSRIs.  The “serotonin hypothesis” (Meltzer and Lowy,
1987; Maes and Meltzer, 1995) was generated in from evidence of pre- and post-
synaptic dysregulation in depression.
Typically the indolamine dopamine is associated with schizophrenia. Despite
this, there is evidence of DA dysregulation and that some antidepressants may act
through a dopaminergic mechanism in mesolimbocortical system (Willner, 1995).
This system projects from the substantia nigra and the ventral tegmental area in the
midbrain to the septum, amygdala, hippocampus, and prefrontal cortex.  Low
cerebrospinal fluid (CSF) homovanillic acid (HVA), the major DA metabolite has
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been reported in patients with depression (Roy et al., 1985 and many others),
Parkinson’s and Alzheimer’s disease (Van Praag et al., 1975; Wolfe et al., 1990),
suggesting either a common etiology of depressed mood or psychomotor symptoms.
Dopaminergic psychostimulants such as amphetamines, cocaine, and
methylphenidate cause transient mood elevation in healthy volunteers and patients
with depressed mood, as well as individuals abusing substances.  This suggests a role
of the DA system in the induction of normal emotions and moods.  Of interest,
scopolamine, a non-specific muscarinic antagonist, diminished self-administration of
cocaine suggesting that cholinergic agents may regulate the release of DA (Ranaldi
and Woolverton, 2002), thus participating emotional responses.
While most tricyclic antidepressants have anti-cholinergic actions that yield
adverse effects (such as dry mouth and difficulty in urination), it is also possible that
relative cholinergic blockade could contribute to their efficacy and increased
proclivity to cause switches in mania compared with less anticholinergic
antidepressants (Peet, 1994; Guille et al., 1999).  On the other hand, donepezil, a
cholinesterase inhibitor, has been reported to be efficacious in treating bipolar
disorder (Burt et al. 1999) and relieves some of the anti-cholinergic adverse effects
with some risk of mania induction (Jacobsen, 1999), indicating that maintaining a
relative cholinergic balance may be instrumental to mood disorders.
1.3.3 Emotion Induction Studies
Pharmacological emotion induction studies have implicated the cholinergic
system in affective processing.  This has originated from the finding that individuals
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with depression are more susceptible to the effects of muscarinic agonists than
healthy volunteers.   For example, physostigmine, a cholinesterase inhibitor, can
reduce manic symptoms and exacerbate depressive symptoms in patients with bipolar
disorder (Janowsky, 1972b).  Furthermore, physostigmine administration results in
relapse of depressive symptoms in bipolar patients successfully treated with lithium,
while healthy controls do not develop depressed mood.  The patients with bipolar
disorder also have concomitant hormonal disturbances and emotional arousal
expressed as dysphoria (a mixed anxiety depression state, with more anxiety than
depression) with physostigmine administration. Procaine also produces similar
emotional and endocrine responses (Kellner et al., 1987; Kling et al., 1994; Ketter et
al., 1996).
Several theories regarding the relative balance of neuromodulators with
acetylcholine, including cholinergic-noradrenergic (Janowsky, 1972a) and
cholinergic-serotonergic (Overstreet et al., 1998), and their interactions have been
suggested.  Arecoline also has been reported to cause dysphoria (Nurnberger et al.,
1989).  Sitaram and colleagues (1987) found enhanced REM latency induced by
arecoline, a general muscarinic agonist, in mood disorder patients whether or not
currently depressed, and in individuals with a family history of depression compared
to those without such history.
1.3.4 Interactions Between the Cholinergic and Other Neurotransmitter Systems
Opportunity for complementary actions between the cholinergic system and
monaminergic systems is supported by the existence of many cortical and subcortical
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brain regions innervated by cholinergic, serotonergic and noradrenergic projection
neurons, however, the dopaminergic system has predominately a subcortical afferent
pattern and limited cortical projections.  With regard to the anterior cingulate, the
cortex serotonergic projections terminate in all layers, but most heavily in layers I, II,
V and VI in area 24 of the anterior cingulate (Crino et al., 1993); thus there is
potential for interaction at layers I and II as cholinergic terminate for the most part in
these layers as well as layer III (Van Hoesen et al., 1993).  Noradrenergic innervation
of the anterior cingulate occurs in all layers of area 24 thus allowing for cholinergic
interaction in layers I, II and III (Crino et al., 1993), and there is also dopaminergic
innervation of the anterior cingulate, layers I, II, V and VI (Crino et al., 1993).
Other potential regions of complementary actions can occur in the ventral and
dorsal striatal and pallidal regions.  Amygdalar (lateral, basal, and central nuclei) co-
localization of ACh with NE may be more restricted than that of 5-HT, with maybe
the major nuclei where interaction can occur is in the central nucleus (Amaral et al.,
1992).  Interaction of the cholinergic system with the DA systems is well documented
in the both the dorsal (Graybiel, 1990, 2000) and ventral striatum (Holt et al., 1997;
Záborszky and Cullinan, 1992), where ACh stimulates dopamine release.  Peptidergic
actions may potentiate this dopamine release.
The monoaminergic systems all project to the basal forebrain nuclei.
Documented interactions between ACh and NE can occur in the basal forebrain
(Záborszky et al., 1991) and 5-HT (Nilsson et al., 1988).  The frontal cortex is only
area with feedback connections to brainstem/midbrain monoaminergic and
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cholinergic cell groups; these connections allows for regulation of its own input
(Goldman-Rakic, 1987).
The basal forebrain area has numerous GABAergic cell bodies that are
projection neurons as well as interneurons.  GABAergic projections from the cortex
synapse on cholinergic cell bodies in the basal forebrain (Sarter and Bruno, 2002).
Within the striatum, cholinergic markers co-localize with GABA and other
neurotransmitters (Graybiel, 1990).  These are just a few examples of sources of most
likely numerous interactions between the cholinergic and GABAergic systems.
This brief assessment touches upon but a few of the multiple potential sources
of complementary actions between the cholinergic and monaminergic systems.  To
summarize the relevant neuropharmacological findings, a balance between
acetylcholine and both serotonin and norepinephrine in the anterior cingulate,
amygdala, and basal forebrain has been documented. There is considerable evidence
indicating the dopamine and cholinergic systems act in complementary ways in the
dorsal (Graybiel, 1990, 2000) and ventral striatum (Holt et al., 1997; Záborszky and
Cullinan, 1992).  In addition, amino acid, peptidergic and unknown neuromodulatory
systems may inhibit or facilitate the actions of ACh and other neurotransmitters.  As
multiple neuromodulatory systems function together, the relative role of any single
system with respect to the emotional processing may be limited.
1.4 Theories of Emotion Regulation
Strongman (1987) loosely categorizes the numerous current theories from
their origins in by physiological constructs, such as motivation and/or arousal
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(Lindsley, 1951, 1970), by behavioral (Watson, 1930; Pavlov, 1938; Skinner, 1953;
Millenson, 1967; Gray, 1995), by psychoanalytic or experiential, or by cognitive
approaches.   There are composite approaches (Plutchik, 1980; Izard, 1993)
incorporating to varying degrees both psychological and physiological aspects.  Some
models have delved into neurophysiology and psychopharmacology, while
incorporating constructs from behaviorists, cognitive scientists and psychopathology
(Panksepp, 1986; LeDoux, 1996).  In addition, examination of neuropsychiatric
conditions has generated medical models (Mayberg, 2002; Davidson, 2002; Damasio,
2001).
Motivational theories consider dimensions of arousal, activation and
pleasantness/unpleasantness as models of emotion.  Lindsley (1970) took into account
attention, sleep, vigilance, and motivation in his model that involved the descending
and ascending reticular systems (ARAS), based on electroencephalogram (EEG)
studies.   Lindsley proposed that the reticular system must be activated in order for
emotional behavior to occur, as opposed to the limbic system, which functions to
organize input into particular expressions.
Arousal has been suggested to be modulated by brainstem the monaminergic
nuclei, ACh, NE, DA, and 5-HT (LeDoux, 1996; Robbins and Everitt, 1995;
Mesulam, 1995).  The relationship of arousal to the cholinergic system may be unique
in that there is the additional major group of cholinergic cell bodies in the basal




There are many investigators that have created composite theories, which take
into account the various perspectives of emotional behavior.  Izard (1993), Panksepp
(1986), and LeDoux (1996) stand out due to their efforts to integrate neurobiological,
cognitive, and psychological concepts that resulted in a comprehensive model of
emotion.  Emotions can be associated to the underlying neural processes, with the
eventual goal of ascribing individual emotions to a particular neural circuit.  For
example, the amygdala is the most likely the pivotal component of the neural system
subserving fear (Davis, 1995; LeDoux, 1996).  Emotion also includes an expressive
component, where affect can be assessed. Motoric aspects, such as facial and vocal
expression, visceral activity, and eye, head and postural movement, help to define
emotions.  This perspective also creates the possibility to identify emotions, and
assess with precise and objective methods, such as research utilizing faces expressing
specific emotions  (Ekman and Friesen, 1978).  Emotions are part of and register in
consciousness.  The words emotion, feeling and emotional experience are often used
interchangeably.  Experiential factors, such as motivation, perception, tendency to
action and feeling state, are not always in the forefront of consciousness, but add to
the gestalt/qualia of emotion.
1.4.2 Izard
Izard recognized the value of examining emotions from various perspectives
and created one of the more comprehensive model of emotion to date (1993).  Izard
proposed that because of the significant role of emotion in evolution and adaptation
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(Darwin, 1859, 1872/1965) several avenues for generating them must have
developed.  Furthermore, redundancy in the nervous system creates the possibility for
different pathways in the genesis of emotion.  Izard (1993) proposed a multi-system
model of emotion activation, where four inter-related systems can generate and
modulate emotion. The four systems are neural, sensorimotor, motivational, and
cognitive processes.  He suggested that these four systems related to each other,
dependently or independently, and had different underlying mechanisms and
processes.  Ultimately, however, generation of emotions relies on neural processing
subserving each system, making neural processing the only system necessary and
sufficient for emotion generation.  Finally, at any time, each system may exert
dominance in terms of driving emotion supplanting the one currently active.  For
example, a sudden sharp pain to the foot may initially induce anger (sensorimotor
induction), but quickly be replaced by sympathy upon appraisal of the accidental
nature of the situation – a child dropping something (cognitive induction).
Izard (1993) argued that evidence from evolution and biology suggested a
hierarchical organization, with neural processing at the basic level, serving
sensorimotor, motivational and cognitive levels to generate emotion, with cognition at
the highest level.  In a developmental sense, neural and sensorimotor systems engage
before motivational (e.g., reproduction) and cognitive (e.g., higher order reasoning)
systems.  Information processing can also be arranged hierarchically.  In general, the




Panksepp (1986) developed a complex multilevel theory that ultimately rests
on neurophysiology, and was based on integration of introspection (or
anthropomorphism) and animal brain research.  At the same time, his theory is
traditional, with the incorporation of evolutionary perspectives that mammals share
emotional circuits in the limbic system, the “obligatory internal dynamics.”  He made
five assumptions: 1) distinct emotion processes are reflected in specific hard-wired
circuits; 2) primitive emotion processes are shared between humans and other
animals; 3) the number of basic emotional circuits are limited, but much can be
contrived through mixtures and social learning; 4) neurotaxonomy may possibly be
considered through introspection; and 5) a scientific understanding of emotion
processes may be gained through the study of brain organization.   He proposed: 1)
genetically hard-wired unconditioned responses are made to life-challenging
circumstances; 2) an adaptive activation or inhibition of classes of related actions
exist; 3) with recurrent feedback, emotion circuits change their sensitivities; 4) neural
activity can go on longer than circumstances that give rise to it; 5) reinforcement can
condition activity in the emotion circuits to environmental stimuli; and 6) interaction
occurs between the emotion circuits and the brain mechanisms of consciousness.
He described four emotion-mediating circuits that connect the midbrain, with
the limbic system and the basal ganglia, subserving expectancy, fear, rage and panic.
Dopamine and ACh mediate the expectancy and rage circuits, while the panic and
fear circuits are mediated by benzodiazepine receptors and endorphins.  Each has
distinct neuroanatomical connections in the common midbrain and limbic system
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regions, of which brain amines, such as serotonin and norepinephrine, may be
involved differentially.
At a psychological level, he draws into his theory ideas of how learning and
reinforcement play a role in shaping emotional responses and their neural substrates.
For example, in the expectancy circuit, learning has been shown to be an intrinsic
property.  “With an emotive state-dependence on memory retrieval, and thus,
emotional experience, higher brain circuits might access lower brain circuits leading
to the cognitive appraisal as an influence on the development of emotions.”
Panksepp, thus, created a model where the brain emotion system forms unique limbic
circuits specialized for each of the four basic emotional/experiential states, which are
initially hard-wired genetically, but through subjective experience can be modulated
and/or combine to result in more complex emotions.
1.4.4 LeDoux
Integrating previously separate concepts from behaviorism, neuroanatomy and
neurochemistry, LeDoux suggested limbic circuits subserving emotion are malleable
by experience.  LeDoux (1996) incorporated current theories of working memory,
consciousness, arousal systems and subjective experience.  Based on his work on
fear-conditioning of the amygdala, he created a model of the general emotion system
in effort to build up core knowledge on one emotion that may eventually be expanded
to other emotions.   He chose to focus on fear as it is pervasive within human
experience, is an important feature of psychopathology, and is expressed similarly
across species.
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According to LeDoux (1996), there are three general principles of emotion.
First, subjective emotional experiences result from becoming consciously aware that
an emotion system is active.  However, the roots are in the unconscious processes.
Emotions are created by the establishment of a conscious representation of the
underlying processing systems, much like other cognitive processes such as working
memory.  Second, working memory may be the cognitive interface between bottom-
up and top-down processing systems. This requires brain systems to have various
short-term buffers of information readily available for different aspects of cognition,
like sensory, spatial, linguistic or emotional aspects of behavior.  For example, the
lateral prefrontal cortex performs general purpose working memory tasks, while
anterior cingulate and orbitofrontal cortex may be specialized as emotion-related
working memory tasks.
Third, by combining the first two principles, emotions come about when the
specialized emotion systems are represented in consciousness through utilizing the
principles of working memory.  The emotion system is dependent on the neural
network subserving it, which heavily relies on the amygdala for species-specific and
experience-specific contextual information, and the anterior cingulate and
orbitofrontal cortex for evaluative processing.
LeDoux’s hypothesized a series of events occurs with activation of the
amygdala.  First, there is direct influence on the cortex via direct connections from
the amygdala to the cortex.  These pathways allow the defense system network of the
amygdala to influence attention, perception and memory in situations where we are
facing danger.  The vast, often reciprocal, connections of the amygdala with sensory
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processing areas, visual and auditory, at multiple levels of the processing allows for
modulation of the same processes generating input into the amygdala.  Amygdalar
connections with hippocampal systems mediate the long-term memory processing.
The most important connections include those with the anterior cingulate modulating
executive functioning and orbitofrontal cortex mediating working memory of reward
and punishment.
A second focus is the nature of the amygdala-triggered arousal – attentional
mechanisms that are dependent on level of arousal.  Cortical and thalamic cells
become unsynchronized upon arousal with selectively driven cells activating more so.
Four arousal systems are each dominated by different forebrain cholinergic or
brainstem nuclei neurotransmitters (ACh, NE, DA and 5-HT).  Together, these
systems mediate arousal level, but each with subtle differences.  However, the basal
forebrain cholinergic system appears to be particularly important.  Damage to nucleus
basalis prevents stimuli that “warn of danger” from eliciting arousal and stimulation
of the amygdala or nucleus basalis elicits cortical arousal.  Moreover, drugs that block
ACh actions on the cortex prevent the effects on arousal of conditioned stimuli,
amygdala stimulation or nucleus basalis stimulation from occurring.  Thus, detection
of a dangerous situation initiates the amygdala to release ACh from the basal
forebrain across the cortex.
Arousal can occur from non-threatening or novel events, but they are not
prolonged as in the case of events with emotional significance and do not involve the
amygdala.  Cortical arousal occurs directly from sensory input and indirectly from
brainstem activation from cortical efferents (Lindsley, 1951, 1970); LeDoux suggests
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that these kinds of arousal quickly habituate.  If there is emotional significance to the
stimulus, the amygdala acts to perpetuate the arousal.  The neurophysiology
underlying sustained activity in a circuit may be achieved by recurrent loops or
bursting activity.   Thus, one might speculate that the anatomical connections of the
anterior cingulate with dual innervation from the NBM and amygdala may subserve
extended arousal and attention in emotional circumstances.
LeDoux hypothesized the core of emotional processing to be the nonspecific
emotional system, which can be triggered by any emotional event, and interaction of
this general emotion system with appraisal and evaluative processing systems that
generate species-specific actions.  Attentional mechanisms and long-term memory of
emotionally significant events are posited to be a result of the anterior cingulate and
orbitofrontal cortex processing.  Additional information from short- and long-term
working memory by lateral prefrontal cortex converges into a representation that has
a precise meaning and consequently a specified course of action.  Attentional
mechanisms also come into play by blocking other ongoing cortical input.
Species-specific visceral and motoric expression is hypothesized to occur via
amygdala connections with hypothalamic and brainstem nuclei, which feedback to
brain.  This allows for a host of neuromodulatory mechanisms to ensue to produce
visceral and motoric aspects of emotional expression, feedback to the brain and result
in modulating the expression. Cannon’s idea that the viscera do not respond with a
specific pattern has been shown not to be the case; galvanic skin response (GSR),
heart rate, skin temperature all show differential expression with the different
emotions.  The visceral reaction is too slow to account for James’ feedback theory,
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however, the striated muscle response is quick enough and has been theorized as a
potential source of feedback (Izard, 1993).
To recapitulate LeDoux’s model, the whole picture is the combined
functioning of the specialized emotion system (amygdala and its connections),
cortical sensory buffers, cortical working memory, cortical arousal and bodily
feedback.  “When all of these systems function together a conscious emotional
experience is inevitable” (LeDoux, 1996).
1) Emotional feelings (of fear) are represented in working memory.
2) Complete feelings (of fear) involve activation of the amygdala.
3) Feelings are sustained by the arousal system keeping attention on the
emotional situation.
4) Emotional experiences are sustained by feedback from the body providing
distinct sensations that make emotions feel different from one another.
5) Emotional feelings can happen without direct cortical projections from the
amygdala, i.e., the working memory of a feeling can be deduced from
indirect sources, however, the emotion will be different.
6) Emotional feelings can happen without being conscious of the eliciting
stimulus – “The emotional responses and the conscious content are both
products of specialized emotions systems that operate unconsciously.”
1.4.5 Damasio
Damasio (2001) proposed that the combination of both visceral and motoric
feedback underlie the “gut feelings” associated with emotion.  When subjects who
86
performed certain facial expressions characteristics of emotions were queried about
how they felt, there was a significant influence by whether the expressions were
associated with positive or negative emotions (Ekman, 1992, 1993; Adelmann and
Zajonc, 1989).
Damasio hypothesized from the work of Valins (1966) that the “as if”
feedback becomes cognitively represented in working memory to thereby influence
feelings and decisions.  In this study, subjects were given false feedback about their
heart rate when viewing pictures (Valins, 1966); the subjects believed that their heart
rate was changing enough to make them feel as though they were emotionally
aroused, and that they like certain pictures more than others. Damasio suggested this
supported the existence feedback could act to influence subjective experience.
1.4.6 Mayberg
The last two models to be discussed in detail have originations in the
pathophysiology of emotion.  Mayberg’s model of emotion regulation originated
from the observation that there is a common affective response to structural deficits
and resulting brain dysfunction in disease states.  Parkinson’s, Huntington’s, and
Alzheimer’s disease (Mayberg, 2002) can cause secondary depression, a depressed
mood in conjunction with the primary motor or memory disorder.  She developed a
model of emotion regulation drawn from examining common functional
neuroanatomical substrates in depressed states observed in primary and secondary
mood disorders, the functional changes associated with antidepressant or
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psychotherapeutic interventions in mood disorders, the remission of symptoms
whether or not on active treatment, and induction of emotions.
She observed that remission of symptoms, whether from antidepressants,
placebo, or psychotherapy, often (but not always) yielded changes in cortical
structures mediating attention and cognition, such as dorsal anterior and posterior
cingulate (24c, 23), dorsolateral prefrontal cortex (9, 10, 46), premotor, and parietal
cortices.  In contrast, antidepressants often (again, but not always) yielded changes in
limbic regions associated with vegetative-circadian functions, such as subgenual
anterior cingulate, insula (anterior and posterior), orbitofrontal cortex, amygdala,
hippocampus and hypothalamus.  The limbic and cortical components are modulated
by the subcortex component including the rostral anterior cingulate (24a; not
subcortex, but activity matches these other subcortical areas), basal ganglia, thalamus,
and brainstem, of which all have been reported to have increased metabolic of blood
flow activity in mood disorders (Ketter et al., 1999; Kimbrell et al., 2002).  Her belief
is that the failure of this regional network to respond to homeostatically in times of
increased stress results in the various symptoms observed in depressed patients, and
may explain the heterogeneity of the disorder depending on the nature of the
network’s dysfunction (Mayberg, 2002).
1.4.7 Davidson
Based on models like Plutchik (1980) and Gray (1995), Davidson (2002)
suggested two essential emotion systems, approach and withdrawal.  Each is
associated with positive or negative affect in the general form of moving towards a
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desired goal or way from aversive stimulation, respectively.  These emotion systems
are subserved by specific neural networks, which often can be distinguished by the
laterality of the regions involved.  For example, the left prefrontal cortex is
considered part of the positive affect system, because focal damage of the dorsolateral
prefrontal cortex results in depressive symptoms, in line with the reasoning that
depression is associated with deficits of positive affect.  Although the method lacks
spatial resolution, electrophysiological (EEG) asymmetries have been shown, with
positive affect to be associated with the left prefrontal cortex and negative affect with
the right prefrontal cortex (Davidson, 1998).  PET studies of emotion induction have
also shown this laterality (George et al., 1995).
1.4.8 Summary
According to Strongman (1987) current emotion theory has evolved such that
several principles have come out of the work on emotion: (1) Emotion can be viewed
as a system that both affects and can be affected by other systems; (2) Emotions can
influence arousal and motivation; they can be energizing or motivating, or they can be
draining and demoralizing; (3) Intricate links exist between cognition and emotion;
(4) Emotional expression is an important component of the emotional experience; (5)
Some form of hierarchy in emotions may exist, some are primary and some are
secondary, indicative of a nature versus nurture division; (6) Similarities and
differences exist between the various emotions, and they can range in intensity, in
which the quality may change upon reaching some vague threshold; and (7) Emotion
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is multi-faceted; this has promoted many avenues for exploration.  These principles
have in some cases continued to develop in a similar vein, however, most theories
have incorporated several of these ideas.
Clearly, the study of emotion is complicated.  However, with techniques to
analyze brain and behavior relationships becoming more sophisticated, the
information gleaned utilizing these newer methods has resulted in the development of
these complex theories.  Of the theories reviewed here, LeDoux has developed an
intriguing theory spanning scientific fields from consciousness to neurochemistry.
The purported involvement of the cholinergic system speculated in his theory
provides strong rationale for this thesis and theoretical background to discuss the
results of the proposed experiments.
1.5 The Muscarinic Cholinergic System Involvement in Emotion Regulation
There appears to be substantial evidence that the cholinergic system plays a
role in emotion and its regulation. For example, lesions of the NBM interferes with
arousal elicited by stimuli that may “warn of danger” and the fear-conditioning
process (LeDoux, 1996), and the reduced accuracy in tests of arousal and attention,
functions closely related to emotional processing (Robbins and Everritt, 1995).  Older
studies have shown that lesions of the septal nuclei, which have high concentrations
of cholinergic cell bodies, induce septal rage.
Connections between cholinergic cell groups and the amygdala and anterior
cingulate regions may subserve novel and sustained attentional mechanisms
necessary for assigning emotional valence to particular situations, and initiate
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appropriate action (LeDoux, 1996).  This is consistent with Panksepp’s theory (1986)
of the rage and expectancy circuits being influenced via ACh and DA
neuromodulatory effects, and agrees with the general arousal system of ARAS
(Mesulam, 1995).  The importance of the cholinergic system in the neurochemistry of
the basal forebrain region, including the cholinergic cell groups, ventral striatal
region, amygdala, and extending to the anterior cingulate, but also projecting across
the cortical mantle, supports Mesulam’s notion that the cholinergic system may be the
most substantial regulatory system.
Challenge studies with known cholinergic activity in man have also supported
a role of this system in emotional processing.  Physostigmine, an ant cholinesterase,
administration in humans yields dysphoria (Janowsky, 1986).  Similar emotional and
endocrine responses occur with procaine hydrochloride  (Novocain) administration,
although the mechanism of the latter remains to be established and is the focus of this
thesis.  Since 1950s, case reports have described emotional and sensory responses to
the antibiotic procaine-penicillin (Araskiewicz and Rybakowski, 1993), where
procaine is tagged onto penicillin to enhance central nervous system (CNS)
penetration.   Anxiety and perceptual disturbances, such as auditory, visual, gustatory
and somatosensory hallucinations, along with autonomic arousal emerge within
seconds following injection of procaine-penicillin, with these responses lasting from
5 to 30 minutes.  Procaine-penicillin has a longer half-life than procaine
hydrochloride due to a different metabolic pathway, and thus yields more prolonged
effects than procaine.
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Similarly profound, but briefer, emotional and sensory experiences occur
upon intravenous administration of procaine hydrochloride, a local anesthetic that has
been used as an investigational tool in humans for probing the limbic system (Ketter
et al., 1996; Parekh et al., 1995; Kling et al., 1994; Kellner et al., 1987;).  A dose of
1.84 mg/kg in healthy individuals produces emotional responses including dysphoria,
euphoria (elation), visual and auditory sensory experiences, hormonal changes such
as increased adrenocorticotropic hormone (ACTH), cortisol, and prolactin (Kellner,
1987) and EEG fast activity increases in the temporal lobes (Parekh, 1995).  The
experiences described by the subjects in these experiments are reminiscent of those
described by Penfield, Gloor and Halgren (Penfield and Jasper, 1954; Halgren et al.,
1978; Gloor et al., 1982) after direct stimulation of limbic cortex during epilepsy
surgery.
With the development of positron emission tomography (PET) and functional
magnetic resonance imaging (fMRI), the neural substrates involved in emotional
processing can be determined at the neuroanatomical level at the same moment that
emotions are experienced.  Measurement of cerebral blood flow (CBF) with H2
15O
PET during procaine administration yielded a 23% increase of global blood flow and
even greater regional increases in anterior paralimbic areas (Ketter et al., 1996).
Furthermore, both euphoria and fear responses correlated with changes in left
amygdala CBF; euphoria had an inverse relationship with changes in left amygdala
CBF, while fear had a positive correlation.  Also, increases in mesial occipital and
global CBF were associated with visual hallucinations.
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Preliminary analysis of the CBF response to procaine in affectively ill patients
compared to healthy volunteers blunted (diminished increases) global CBF and
regional absolute paralimbic CBF activation.  Patients with mood disorders have
blunted rCBF in the “resting” state (when they are asked to monitor their internal
emotional state), suggesting that some of the procaine’s effects on blood flow may be
related to baseline differences.  However, even after subtracting out the baseline
differences blunted anterior paralimbic activation is still seen compared to healthy
controls.  PET studies during self-induced emotional states showed overlapping rCBF
increase in anterior paralimbic regions (George, et al., 1995).   Thus, emotional states
either self-induced or pharmacologically-induced, resulted in activation of
overlapping anterior paralimbic areas.  Taken together, the above data suggests that
procaine may be a useful tool for investigating the neural substrates of emotional and
sensory experiences.
1.5.1 Procaine as a Muscarinic Cholinergic Ligand
Animal studies have linked emotional responses to the actions of procaine and
have implicated the muscarinic cholinergic system.  Procaine administered to animals
selectively activated electrophysiological activity in limbic structures (Wagman et al.,
1967; Racine et al., 1975; Racine et al., 1979; Munson et al., 1970).  Utilizing
deoxyglucose methodology (2-DG), lidocaine, an amide local anesthetic, was shown
to selectively activate limbic metabolism in rats (Post et al., 1984).   Local
anesthetics, including cocaine, lidocaine and procaine, can induce kindled seizures
and aggressive behavior in rodents (Post, 1981).  Cholinomimetics induce kindled
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seizures similar to electrical amygdaloid kindling, which can be blocked by
muscarinic antagonists (Cain, 1981).  Furthermore, atropine inhibits and
physostigmine weakly facilitates procaine induced kindling in rats (Heynen, 1995).
The mechanism of procaine’ s sensory and emotional effects is not known.
Evidence from neuroanatomy, neuropharmacology and neurochemistry suggests
muscarinic M2 receptors might play a role in action of procaine (Mesulam, 1995;
Nieuwenhuys, 1985; Vogt, 1993; Adamec et al., 1985).   The following sections will
detail each of those perspectives.
1.5.2 Neuroanatomy
Since the cholinergic neuroanatomy has been extensively reviewed already, a
brief synopsis of the relevant brain regions and their connections follows. The
reciprocal connections between the amygdala and substantia inominata and further
reciprocation between limbic cortex and thalamus provide an interface between
limbic cortex and visceral hypothalamic areas whereby sensory and cognitive
phenomena influence emotional aspects and autonomic responses.  Of particular
interest are the bi-directional cholinergic pathways between the CH4-NMB and the
amygdala and the anterior cingulate, and projections to medial orbitofrontal cortex
and regions ventral to both of these areas.  Thus, the anterior cingulate appears to
receive direct and indirect via the amygdala cholinergic input (Figure 9).  This dual
innervation may subserve the maintenance of attentional mechanisms described by
LeDoux (1996) required in emotional processing that is adaptively oriented.
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Moreover, it is precisely these regions that are selectively activated with acute
procaine administration in humans (Ketter et al., 1996).
Mesulam (1995) emphasized the importance of the amygdala and limbic basal
ganglia as mediators of emotional behavior.  The cholinergic telencephalic
projections (paralimbic areas) can be classified into two major groups:  1) the anterior
projection group including all regions of the cortex, basolateral amygdala, reticular
nucleus in the thalamus and basal ganglia nuclei or the amygdalocentric portion of the
limbic system suggesting a role for ACh in emotional processing; and 2) The septal
nuclei and the vertical limb of the diagonal band  (VLDB) within the substantia
inominata cholinergic projections innervate the hippocampal complex.  This
population of cholinergic neurons corresponds to the posterior or hippocampocentric
portion of the limbic system that may mediate memory and learning.   Heimer and
Alheid (1991) suggested this septohippocampal system appears to be a separate
functional unit from other basal forebrain systems.  Vogt defined reciprocal cingulate
connections with amygdala, insula, anterior temporal lobe, and basal forebrain in
similar manner (Vogt et al., 1992).  He described the anterior cingulate as ”executive”
mediating affective, attentional, semantic processing and vocal functions, and the
posterior cingulate as “evaluative” being involved in motor and sensory processing.
The pedunculopontine and lateral dorsal tegmental nucleus are the major
groups of cholinergic cell bodies in the brainstem; these areas project to the
intralaminar thalamus and onto the cortex as part of the ascending reticular pathways.
Brainstem cholinergic pathways also project to the lateral hypothalamus and basal
forebrain.   Thus, phylogenetically more recent telencephalic structures mediating
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more sophisticated functions and older brainstem areas contributing to consciousness
and arousal constitute the neuroanatomy of the cholinergic system.
1.5.3 Neuropsychopharmacology
The neuropsychopharmacology of the cholinergic system is divided into two
major receptor systems, nicotinic and muscarinic, originally isolated by their affinity
to nicotine and muscarine, respectively.  Nicotinic receptors are ligand-gated ion
channels with a pentameric structure of subunits that allows passage of potassium
(K+) and sodium (Na+) (Changeux, 1993).  Four muscarinic receptor subtypes(M1-
M4) have been discovered through pharmacological studies, while cloning studies
identified five subtypes (m1-m5), with concordance between the two methods, i.e.,
the M1 corresponds to the m1, etc., although m5 remains unpaired.  The five subtypes
are believed to be comprehensive based on total nonselective agonist binding as
compared with partitioning of selective antagonist binding.
Muscarinic receptors can be divided into two groups, based on coupling to
specific G proteins.  M1, M3 and M5 receptors act via Gq stimulating PI turnover,
while the M2 and M4 couple with Gi inhibiting cyclic adenosine monophosphate
(cAMP) production.  Increase phosphotidylinositol (PI) turnover results in release of
calcium (Ca++) stores from the endoplasmic reticulum and increased phosphorylation
of membrane receptor proteins, K+ and Ca++ channels.  This results in increased
likelihood of channel opening and further increases in Ca++ levels.  Thus, direct and
indirect increases in Ca++ increase neuronal excitability.  cAMP activation also
phosphorylates membrane proteins, increasing the likelihood of K+ or Ca++ channels.
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By inhibiting cAMP production, M2 activation results in reduced phosphorylation of
K+ or Ca++ channels, thereby decreases neuronal excitability.
M1/M3/M5 compared to M2/M4 receptors have more complex transduction
pathways yielding additional opportunities for signal amplification.  Therefore,
M1/M3/M5 class of receptors is believed to have less need for sensitivity to ligands or
of signal transduction within the receptor/ G protein complex.  In contrast, the M2/M4
receptors are thought to need to be more sensitive to signal activation having less
steps in the transduction pathway and less opportunity for amplification.  Besides the
active site, the M2 receptor contains an allosteric site creating the possibility of
potentiation of agonist activity (Lena and Changeux, 1993).
Nicotinic receptors are localized predominately in the nucleus basalis of
Meynert, cortex, thalamus, striatum, hippocampus and cerebellum in humans (Ripoli
et al., 2004).  Four methods for muscarinic receptor localization (competitive binding
curves, direct binding studies with same selective antagonist, immunoprecipitation
and identification of clones through in situ hybridization) yield similar findings.  M1
receptor density increases caudal to rostral with highest densities in hippocampus,
cortex and striatum and lowest densities in the brainstem nuclei.  M2 receptors have
more uniform and low-level distribution with the highest density in brainstem nuclei
and lower levels rostrally.  However, there are some significant exceptions;
intermediate to high M2 receptor density is found in the olfactory bulb, cortical layers
I and II, lateral and medial septum, striatum, hippocampus, and amygdala.  Flynn and
Mash (1993) found the highest levels of M2 receptors in hypothalamic nuclei,
including the lateral hypothalamic area, and the anterior nucleus and other thalamic
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areas.  The non-M1/M2 distributions generally show increases caudal to rostral with
the highest densities in the striatum and cortex and lowest densities in brainstem
nuclei.
1.5.4 Neurochemistry
Acetylcholine has two active moieties, an acetate and a choline, each binding
with one of the cholinergic receptor systems.  The choline portion binds muscarinic
receptor’s active site and the acetate portion binds the nicotinic receptor’s active site.
The binding of a positively charged choline moiety to the active site in the muscarinic
receptors suggests that anionic amino acid residue(s) are involved (Hulme et al.,
1990).  Aspartate (ASP) 105 and 111 provide carboxylic residues with a usual pK
around 3.9.  Depending on the pH and adjacent residues' effect on the active site, the
aspartates may have a negative charge drawing in ACh.  Adjacent to the aspartates
are threonine 234 and tyrosine 506 with hydroxyl residues that may encourage
agonist, but not antagonist binding.  The OH residues may create an oxyanion hole
stabilizing the double bond oxygen in the ester linkage of acetate during transition
states.  Site-directed mutagenesis studies show that the aspartates, threonine and
tyrosine are essential for ACh binding (Brann et al. 1993; Fraser et al., 1989).
Procaine (mw=236) has a similar structure to ACh with respect to the choline-
like ester linkage of a hydrophilic tertiary amine (Figure 11).  It differs with respect to
the acetate end; a lipophilic aromatic replaces the methyl group.  When protonated,
procaine can be viewed as an ACh molecule with an aromatic ring substituted for the
methyl end group.   The positive charge of the choline-like end may bind to the same
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active site as ACh, however, the bulky ring may keep procaine from fitting
completely into the receptor.  The tyrosine and threonine residues cannot confer their
stabilizing effect resulting in partial binding to the active site. The amine portion of
the procaine is thought to bind to residues inside the pore.
The acetate portion of ACh is known to bind to the nicotinic receptor;
procaine’s lipophilic ring may be too bulky to allow significant binding to the
nicotinic receptor’s active site.  However, it is also well known that procaine non-
competitively binds to a high affinity site in the nicotinic receptor pore, blocking ion
conductance (Klobin et al., 1979; Lena and Changeux, 1993; Yost and Dodson,
1993), not blocking the active site.
Procaine’s chemical properties make it very easy to pass the blood brain
barrier (BBB; Table 2).  It has low lipid solubility constant and is protonated at
normal body pH to facilitate membrane passage with the acid/base transporter.
Elimination occurs mostly via butyrylcholinesterases in the plasma and the synapse.
At high concentrations enzyme inhibition may occur (Butterworth and Strichartz,
1990; De Jong, 1994).
Animal studies show that procaine displays a variety of neurochemical
actions.  It blocks voltage-gated sodium, but not potassium channels, in the Torpedo
californica and the Electrophorus electricus by binding in the channel pore and
altering the gating mechanism keeping the channel in an inactive state (Butterworth
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Figure 11.  Structural Comparison Between Procaine and Acetylcholine.
Procaine has an additional moiety of an aromatic ring that may aid its passage
through the blood brain barrier and produce differential binding properties.  The
tertiary, rather than quaternary, amine base of procaine may a more limited
differential effect on passage or binding from acetylcholine.
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Table 2.  Physio-Chemical Properties of Procaine Hydrochloride.
2%  base at pH 7.4
Low protein binding (5.8%)
Low lipid solubility constant
Half-life estimations:
t1/2 = 7.7 minutes in humans
t1/2 = 45 minutes in rhesus monkeys (1st estimation)
Metabolized predominantly by butyrylcholinesterase
[plasma] > [brain]
Only 10-20% of cholinesterases are butyrylcholinesterase
Majority of enzyme concentrations found in synapse
Enzyme inhibition occurs at higher concentrations
CSF concentrations
50% of plasma levels 5 minutes after 1 mg/kg injection
may be as high as 90% on 1st pass
rate of entry estimated to be faster than quinine and slower than pentobarbital
May be passing BBB with acid/base transporter
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 Procaine competitively displaces quinuclidinyl benzilate (QNB) at M2 receptors in
the guinea pig ileum (Hisayama et al., 1989) with a Kd (dissociation constant) of 4
µM and inhibits QNB binding in the rat brain also at low µM concentrations
(Saraswati et al., 1992).The affinity constants for the M1 receptor cited are virtually
identical, however, the tissue used for the assay was rat hippocampal membranes.
Since the approximate levels of muscarinic receptors two thirds M1 and one third M2.
This is a considerable proportion of M2 receptors, thus M1 binding is suspect.  The
affinity constant of procaine for the nicotinic receptor on rat brain membranes is 50 -
100 µM depending on the agonist used (methylcarbachol or
dimethylphenylpipereinium [DMPP]) (Saraswati et al., 1992).  With the exception of
sigma, and 5-HT3 receptors, the affinity constants for virtually every other system is
millimolar or higher (Sharkey et al., 1988; Fan and Weight, 1994). Although the
influence of these receptors with similar affinities to procaine cannot be disregarded,
the distributions of these receptors do not complement the procaine activation pattern
as well as the muscarinic receptor.  Specifically, sigma receptors are mostly found in
hippocampus, striatum, thalamus, cerebellar hemisphere and vermis, and across the
cortex (Elsinga et al., 2004) and 5-HT3 receptors are localized in the layers II-III of
the cortex, hippocampus, and amygdala, caudate putamen, nucleus accumbens, and
within the brainstem, motor nuclei and area postrema in rats (Morales et al., 1998).











































Figure 12.  Relative Affinities of Procaine
Relative affinities of procaine for (A.) various neurotransmitter and neuromodulators
receptors and (B.) muscarinic compounds for the mAChR (muscarinic receptor).  The
receptors with the highest affinity for procaine are the muscarinic M2 and possibly the
M1 , and the sigma receptors.  Procaine has approximately a ten-fold higher affinity
for the acetylcholine receptor than ACh.  Abbreviations: ACh (acetylcholine), AT
(angiotensin), DA (dopamine), ET (endothelin), GABA (gamma-aminobutyric acid),
Gly (glycine), Glu (glutamate), NE (norepinephrine), NPY (neuropeptide Y), QNB
(quinuclidinyl benzilate), SP (substance P), α2 (alpha2 NE), β1 (beta1 NE), σ-1
(sigma 1), 5-HT (serotonin).
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1.5.5 Summary
There are several ways the cholinergic system and its neuroanatomical
connections could participate in procaine’s emotional and sensory experiences, as
well as the selective anterior paralimbic activation.  The widespread cholinergic
innervation across the cortex, basal forebrain and brainstem is consistent with arousal
theories of cholinergic stimulation producing increased global brain activity and may
also explain, in part, the global increase in cerebral blood flow seen with procaine.
However, given the widespread distribution of Na+ channels (Worley and Baraban,
1987) and known procaine bind to them, other mechanisms could contribute to these
global effects.   Cholinergic activation could modulate more regional specific effects,
such as the anterior paralimbic increases in rCBF (Ketter et al., 1996) and temporal
lobe fast EEG activity (Parekh et al., 1995).  Cholinergic mechanisms in arousal-
related low voltage fast EEG activity has been reported in the rat (Steriade et al.,
1990; Stewart et al., 1984), and may be balanced with GABAergic transmission
(Jones, 2004). The regional concentration of cholinergic cell bodies in the basal
forebrain and projections to anterior paralimbic regions is consistent with muscarinic
mechanisms contributing to such regional effects.  The regions most activated by
procaine appear to have heavy cholinergic and amygdalar innervation (Figure 9).
Core limbic areas, amygdala and hippocampus, have the highest density of
cholinergic innervation, both M1 and M2 (Flynn and Mash, 1993; Mesulam, 1995).
Differential distribution of the cholinergic system in sensory - limbic pathways could
play a pivotal role in emotion.  Moreover, cholinergic drugs are known to influence
limbic functions such as emotion, reward and aggression.   Taken together, the
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anterior paralimbic activation pattern with procaine and its effects on M2 muscarinic
cholinergic receptors suggest a role of cholinergic mediation.
In summary, cholinergic modulation could contribute significantly to
procaine-induced emotional and sensory experiences.  This is suggested by
procaine’s: 1) preferential affinity to M2 muscarinic cholinergic receptors in vitro,
which are localized in key limbic areas; 2) ability to selectively activate limbic
structures associated with emotion regulation while producing concomitant clinical
electrophysiological effects; and 3) similarities in action to muscarinic agonists.
Taken together, the anterior paralimbic activation pattern with procaine and its effects
on M2 muscarinic cholinergic receptors suggest a role of cholinergic mediation.
This dissertation explores whether the blood flow and affective changes observed
with procaine are related to binding to muscarinic receptors.
The question at hand has two parts and will be addressed by two experiments
addressed in the next three chapters.   First, does procaine bind to M2 muscarinic
receptors in vivo?  This will be evaluated by examining the binding of [18F]FP-TZTP,
a specific radiotracer for the M2 receptor with agonist activity, in the presence and
absence of procaine in rhesus monkeys (Chapter 2).   Second, what is the relationship
between procaine’s functional response of affective changes and blood flow effects to
the muscarinic system?  Regional cerebral blood flow measured with [15O] PET and
behavioral data collected during procaine administration in humans, healthy controls
and patients with bipolar disorder, will be examined testing the cholinergic model
described above with two-fold methodology.  A preliminary analysis describing any
potential differences in response to procaine administration between the two groups
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will be used to compare and contrast the findings of the second method (Chapter 3).
The two-fold methodology includes: 1) assessing functional connectivity, as defined
as the correlative relationships between brain regions, to confirm modulation of
cholinergic pathways with procaine administration; and 2) multivariate multiple
regression, based on the neuroanatomical model (AChNet) in Figure 9, will assess the
relationships between core cholinergic brain regions and the robust cerebral blood
flow responses that occurs with procaine administration (Chapter 4).
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Chapter 2: A Potential Cholinergic Mechanism of Procaine’s Limbic
Activation
The following is the article as published in full in Neuropsychopharmacology
29, 1239-1250. An afterword discusses the links between this preclinical work and
the clinical work presented in subsequent chapters, and addresses any outstanding
concerns arising since publication.
A Potential Cholinergic Mechanism of Procaine’s Limbic Activation
Brenda E. Benson1, Richard E. Carson2, Dale O. Kiesewetter2, Peter Herscovitch2,
William C. Eckelman2, Robert M. Post1, Terence A. Ketter1, 3
1 Biological Psychiatry Branch, NIMH, NIH, Bethesda, MD
2 Positron Emission Tomography Department, NIH, Bethesda, MD
3 Department of Psychiatry and behavioral Sciences, Stanford University,
Stanford, CA
Key Words:  muscarinic receptors, FP-TZTP, procaine, limbic system, brain imaging,
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The local anesthetic procaine, when administered to humans intravenously
(i.v.), yields brief intense emotional and sensory experiences, and concomitant
increases in anterior paralimbic cerebral blood flow, as measured by positron
emission tomography (PET). Procaine's high muscarinic affinity, together with the
distribution of muscarinic receptors that overlaps with brain regions activated by
procaine, suggests a muscarinic contribution to procaine's emotional and sensory
effects. This study evaluates the effects of procaine on cerebral muscarinic
cholinergic receptors in the anesthetized rhesus monkey. Whole brain and regional
muscarinic receptor binding was measured before and after procaine administration
on the same day in three anesthetized rhesus monkeys with PET and the radiotracer 3-
(3-(3[18F]fluoropropylthio)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-
methylpyridine ([18F]FP-TZTP), a cholinergic ligand that has preferential binding to
muscarinic (M2) receptors. On separate days each animal received six different doses
of i.v. procaine in a randomized fashion. Procaine blocked up to ~90% of [18F]FP-
TZTP specific binding globally in a dose-related manner. There were no regional
differences in procaine's inhibitory concentration for 50% blockade (IC50) for
[18F]FP-TZTP. Tracer delivery, which was highly correlated to cerebral blood flow in
previous monkey studies, was significantly increased at all doses of procaine with the
greatest increases occurring near procaine's IC50 for average cortex. Furthermore,
anterior limbic regions showed greater increases in tracer delivery than nonlimbic
regions. Procaine has high affinity to muscarinic M2 receptors in vivo in the rhesus
monkey. This, as well as a preferential increase of tracer delivery to paralimbic
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regions, suggests that action at these receptors could contribute to i.v. procaine's
emotional and sensory effects in man. These findings are consistent with other
evidence of cholinergic modulation of mood and emotion.
2.2  Introduction
The local anesthetic procaine has unique neuropsychopharmacological
properties that make it useful as a discrete probe of the limbic system and associated
studies of emotion. In this regard, it has been used as an affective challenge in healthy
volunteers (Ketter et al., 1996; Servan-Schreiber et al., 1998), and patients with mood
disorders (Ketter et al., 1993) and panic disorder (George et al., 1993), as well as in
individuals abusing alcohol (George et al., 1990) and cocaine (Adinoff et al., 2001).
Procaine (1.84 mg/kg), when administered intravenously (i.v.) in healthy
volunteers (Kellner et al., 1987), results in brief intense emotional (ranging from
euphoria to dysphoria) and sensory experiences (visual, auditory, and olfactory
illusions/hallucinations) in association with increased relative anterior paralimbic
cerebral blood flow (CBF) as measured with [15O] water positron emission
tomography (PET) (Ketter et al., 1996). In healthy individuals, procaine also induces
the following: hormonal changes such as increased adrenocorticotropic hormone
(ACTH), cortisol, and prolactin (Kling et al., 1994); and increased temporal lobe fast
activity electroencephalogram (EEG) (Parekh et al., 1995). Furthermore, the right
amygdala blood flow correlated with the degree of affective arousal, while the left
amygdala CBF correlated positively with the degree of dysphoria and negatively with
the degree of euphoria (Ketter et al., 1996). The experiences described by the subjects
in these procaine studies are reminiscent of those reported after direct stimulation of
109
limbic cortex during epilepsy surgery (Gloor et al., 1982; Halgren et al., 1978;
Penfield and Jasper, 1954). The emotional and endocrine changes also resemble the
effects of acute challenge with the anticholinesterase drug physostigmine (Janowsky
et al., 1986).
The neurochemical mechanisms of procaine's emotional, sensory, and
endocrine effects could provide valuable insights into the neurobiology of normal and
pathological emotion regulation, but have not been clearly elucidated. Procaine is
classically associated with the blockade of voltage-gated sodium channels producing
the local anesthetic effect for which it was designed and synthesized by Einhorn in
1905. Procaine produces 50% inhibition of the action potential at 1.1 mM in frog and
rat sciatic nerve (Butterworth and Strichartz, 1990), by binding in the channel pore
and altering the gating mechanism to increase the probability of the inactive state,
thereby reducing the likelihood of an action potential (Butterworth and Strichartz,
1990). Site-directed mutations in rat brain sodium channels show reduced use-
dependent blockade, confirming this hypothesis (Scholz, 2002). Procaine is also
hypothesized to have direct effects on the lipid bilayer and hence indirectly influence
components in the neuronal membrane (De Jong, 1994).
Procaine also interacts with many neurochemical systems, but is most potent
at the muscarinic cholinergic receptor. Procaine competitively displaces quinuclidinyl
benzilate (QNB), a nonspecific muscarinic antagonist at putative M2 receptors in the
guinea-pig ileum with a delivery rate constant (Ki) of 4 µM (Hisayama et al., 1989)
and inhibits QNB binding (Ki=4 µM) in rat hippocampal membranes known to have
M1 and M2 receptors (Sharkey et al., 1988). In contrast, the affinity of procaine for
110
M3 receptor was 5 mM in the guinea-pig mesenteric artery (Itoh et al., 1981).
Procaine inhibits methylcarbachol or dimethylphenylpipereinium (DMPP) binding
presumably at nicotinic cholinergic receptors on rat brain membranes at higher
concentrations (Ki=50-100 µM depending on the agonist used) than observed in the
muscarinic system (Saraswati et al., 1992). Sigma receptors are the only other sites at
which procaine binds in the low micromolar range (3.6 µM; Sharkey et al., 1988).
The affinity of procaine for other systems include transporters (dopamine
(DA): 104 mM, norepinephrine (NE): 217 mM, and serotonin (5-HT): 276 mM) and
receptors (serotonin (0.1-10 mM, depending on subtype), neuropeptide Y (5 mM),
angiotensin (5 mM), endothelin (5 mM), adrenergic (α2: 5 mM, β1: 100 mM), glycine
(1 mM), glutamate (1 mM), and gamma-aminobutyric acid (GABA) (1.5-5.4 mM per
subunit); Aoshima et al., 1992; Cunningham and Lakoski, 1988; Fishlock and Parks,
1966; Itoh et al., 1981; Napier, 1992; Ritz et al., 1987; Sharkey et al., 1988; Sugimoto
et al., 2000; Sato et al., 2000). It should be noted that for some ligands affinity
constants were not determined, but stated doses had no biological effects, such as D1
and D2 receptors (Napier, 1992). Thus, based on affinities, procaine would be
expected to have primary actions on the muscarinic cholinergic and sigma receptor
systems that could be important contributors to its clinical effects.
Cholinergic M1 and M2 receptors are present in core limbic areas, such as
amygdala and hippocampus, as well as primary sensory regions. While M1 receptors
have primarily a cortical distribution, M2 receptors have a more uniform distribution
across the brain, cortically and subcortically (Mesulam, 1995; Mesulam et al., 1983;
Flynn and Mash, 1993). Telencephalic cholinergic projections originating in the basal
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forebrain nuclei, such as the nucleus basalis, send efferents to most of the cortex,
including the anterior cingulate, as well as to subcortical regions, the basolateral
amygdala, and hippocampus (Mesulam, 1995; Mesulam et al., 1983). Of particular
interest are the efferents of the basolateral amygdala that heavily innervate the
anterior cingulate and nearby medial orbitofrontal cortex (Russchen et al., 1985a, b).
These anterior paralimbic regions with direct and indirect cholinergic connections are
also the areas that exhibit the most robust activation by procaine in humans (Ketter et
al., 1996). Thus, the distribution and the potential functional consequences of the
cholinergic receptors in limbic pathways could allow cholinergic mechanisms to play
an important role in emotion (Heimer, 2003).
Cholinergic drugs have been shown to influence limbic regions known to
mediate mood, reward, and aggression. For example, neuronal activity in the
dorsolateral prefrontal and orbitofrontal cortex, and the amygdala of monkeys has
been shown to be altered by iontophoretic administration of cholinergic agents (Aou
et al., 1983; Inoue et al., 1983; Lenard et al., 1989). Similar to GABA, procaine
microinjection (6-20 mg) into rat nucleus basalis inhibits frontal cortical neuronal
firing in response to conditioned stimuli (pairing with medial forebrain stimulation)
(Rigdon and Pirch, 1984). Moreover, procaine selectively activates limbic structures
electrophysiologically in rats (Munson et al., 1970; Racine et al., 1975, 1979;
Wagman et al., 1967). Utilizing 2-deoxyglucose methodology, lidocaine, a closely
related amide local anesthetic, selectively activated limbic structures in rats (Post et
al., 1984). Local anesthetics, including cocaine, lidocaine and procaine, can produce
kindled seizures and aggressive behavior in rodents (Post, 1981). Intra-amygdalar
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injection of cholinomimetics also induces kindled seizures (similar in appearance to
those evoked by electrical amygdaloid kindling), which can be blocked by muscarinic
antagonists (Cain, 1981). Furthermore, atropine, a muscarinic antagonist, inhibits and
physostigmine weakly facilitates procaine-induced kindling in rats (Heynen et al.,
1995).
In summary, cholinergic modulation could contribute significantly to
procaine-induced emotional and sensory experiences. This is suggested by procaine's:
(1) preferential affinity to M2 muscarinic cholinergic receptors that are localized in
key limbic areas; (2) ability to selectively activate limbic structures associated with
emotion regulation while producing concomitant clinical electrophysiological effects;
and (3) similarities in action to muscarinic agonists. In this study, we specifically
explore the potential role of the muscarinic system in procaine's effects by measuring
muscarinic receptor binding in anesthetized rhesus monkeys with the PET radioligand
[18F]FP-TZTP, 3-(3-(3[18F]fluoropropylthio)-1,2,5-thiadiazol-4-yl)-1,2,5,6-
tetrahydro-1-methylpyridine (Kiesewetter et al., 1995) before and after procaine
administration.
We hypothesized that the binding of [18F]FP-TZTP would be reduced by
procaine as a function of the dose administered. In addition, we hypothesized that the
K1 of the ligand, which correlates strongly with CBF (Carson et al., 1998), would
have a pattern of specific limbic increases similar to those observed with CBF in





Four adult male rhesus monkeys (Macaca mulatta) weighing 11.7, 8.8, 8.0,
and 7.1 kg were studied with brain imaging techniques while receiving general
anesthesia during the entire procedure. One animal was unable to complete the whole
series of studies due to arterial port failure, and thus was not included in the analysis.
All studies were performed under a protocol approved by the NIH Clinical Center
Animal Care and Use Committee. The monkeys were routinely monitored by
veterinary staff, housed according to American Association for Laboratory Animal
Care (AALAC) standards in individual cages, allowed ample feed and were provided
with psychological enrichment.
2.3.2 Experimental Design
Animals underwent PET with the radiopharmaceutical 3-(3-
(3[18F]fluoropropyl)thio)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine
([18F]FP-TZTP) while anesthetized with isoflurane. A total of 18 experiments, six
with each animal, were conducted on separate days with each experiment separated
by 20-180 days. On each study day, two dynamic PET scan sessions were collected,
including an initial baseline scanning session with saline administration followed by a
second with continuous infusion of procaine, at one of six doses, ranging from zero,
0.01562, 0.03125, 0.0625, 0.125, to 0.5 mg/kg/min (active drug doses referred to as
dose 1 to dose 5, respectively). The order of procaine doses was randomized. These
doses were chosen based on self-administration studies (Ford and Balster, 1976;
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Hammerbeck and Mitchell, 1978), while being safely under the seizure-inducing
levels (Babb et al., 1979). These infusion rates were determined from procaine
infusion rates from self-administration studies of 1 mg/kg per injection at an average
rate of 24 injections per hour (Ford and Balster, 1976) and 4 mg/kg per injection at an
average rate of nine injections per hour (Hammerbeck and Mitchell, 1978).
2.3.3 Radiopharmaceutical
[18F]FP-TZTP (Kiesewetter et al., 1995, 1999) was developed as an extension
of the structural class of M2 agonists made available by Nova Nordisk (Sauerberg et
al., 1992). FP-TZTP exhibits modest selectivity for M2 (2.2 nM) over M1 (7 nM)
receptors. Studies of cross reactivity with other neurotransmitter systems showed low
affinity for all biogenic amine systems evaluated. FP-TZTP exhibited affinity for
sigma-1 (62 nM) and 5-HT1 receptor (2 µM) (Kiesewetter et al., 1995). The uniform
uptake of [18F]FP-TZTP across the brain resembles the distribution of M2 receptors,
which is consistent with M2 selective binding. In rats, [
18F]FP-TZTP displays high
uptake and high specific binding as determined by ex vivo autoradiography
(Kiesewetter et al., 1999). In muscarinic knockout mice, the M2 knockout mouse is
the only one that shows significantly reduced [18F]FP-TZTP uptake in all brain tissues
regions (Jagoda et al., 2003). Taken together, these data support [18F]FP-TZTP
preferential M2 binding in vivo. Tracer kinetic modeling for [
18F]FP-TZTP has been
developed by Carson et al. (1998), so that PET data can be converted into parametric
images of total binding (V, volume of distribution) and radioligand delivery (K1). The
binding of [18F]FP-TZTP has been shown to be decreased by administration of
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physostigmine, and thus the binding was sensitive to endogenous acetylcholine
(Carson et al., 1998). While other potential ligands, such as the nonselective
muscarinic agonist CI-979 (milameline; Hartvig et al., 1997) or nonselective
muscarinic antagonist [11C]-scopolamine (Frey et al., 1992), and [11C]NMPB ([11C]N-
methyl-4-piperidyl benzilate; Zubieta et al., 2003) could contribute additional
information pertaining to the profile of in vivo actions of potential agents on
muscarinic receptors, [18F]FP-TZTP was chosen over others due to its preferential
binding to M2 receptors. Furthermore, the study design was conducive to using an 
18F
compound, particularly because a single synthesis generated the total radiotracer
required for both phases of each study day.
2.3.4 Procedure
On the morning of the each procedure, the fasted animal was initially given
0.5 mg ketamine and 5 cc of 2.5% sodium pentathol intramuscularly to produce
quasi-anesthesia (light anesthesia) for the placement of three i.v. lines, usually in both
radial veins and a femoral vein, and intubation for eventual general anesthesia. The
animal was transported to the PET suite and placed in the PET scanner and general
anesthesia was induced with inhalation of 1-2% isoflurane using a Stevens-Johnson
anesthesia machine.
The head was positioned in a stereotactic headholder for coronal image
acquisition. An arterial line was attached to a permanent subcutaneous arterial port
(Model 21-Y036, Sims Deltec, St Paul, MN) implanted in the femoral artery, a
temperature probe was inserted into the rectum, and cardiopulmonary monitoring
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equipment leads were placed on the animal to monitor their cardiovascular,
pulmonary, and thermoregulatory functions throughout the entire procedure
(electrocardiogram (EKG), blood pressure, respiration rate, end-tidal pCO2, and
temperature). Once cardiopulmonary measures were stable under anesthesia, the
experimental procedures began.
After a transmission scan, two [18F]FP-TZTP dynamic scan sessions were
acquired. First, a series of dynamic scans were collected over 180 min with saline
infusion. After the primary data collection period of 90 min, procaine administration
began and continued for the remainder of the experimental procedure. Sterile 10%
procaine hydrochloride solution (Sanofi Winthrop Pharmaceuticals) was diluted with
saline to desired concentrations on each experimental day and kept in the dark until
experiments began, as procaine is light sensitive.
Procaine was administered i.v. in a continuous fashion with a Harvard pump.
The syringe and i.v. lines were wrapped with aluminum foil to limit light exposure.
The procaine dosing strategy involved a two-step infusion rate; a loading dose, which
was double the target dose, was administered for 40 min and was followed by the
target or maintenance dose for the remainder of the scanning session. At 40 min after
beginning the target dose, the second set of dynamic scans was acquired over 90 min,
while the constant procaine infusion continued (mean interval between scans 185±2
min). Upon completion of the experiment, the intravenous and arterial lines and
monitoring equipment were removed, the animal was taken out of the PET scanner,
returned to its home cage and allowed to recover from anesthesia.
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[18F]FP-TZTP was synthesized for each study day according to previously
published methods (Kiesewetter et al., 1995, 1999). The product from a single
radiosynthesis was split for two injections. The mean activity injected was 1.0±0.1
mCi for the first injection (saline scan) and 3.5±1.6 mCi for the second injection
(procaine scan); mean [18F]FP-TZTP mass was 0.4±0.2 nmol for the first injection
and 4.5±2.1 nmol for the second injection; mean specific activity injected was
2700±1000 mCi/mol for the first injection and 840±310 mCi/mol for the second
injection. More radioactivity was given for the second injection to attenuate the effect
of the residual radioactivity from the first injection.
Arterial blood samples were drawn from the indwelling arterial port
throughout the scanning procedure. A total of 29 blood samples (0.5 ml) taken over
the scanning period were centrifuged and 0.1 ml plasma aliquots were counted in a
calibrated gamma counter to generate time activity curves. Seven 1 ml blood samples
were obtained at 0,3,8,15,30,50 and 90 min after injection for determination of the
unmetabolized radiotracer fractions by thin layer chromatography (TLC) according to
methods previously described (Carson et al., 1998).
Procaine levels were determined from three 2 ml blood samples taken at 0, 15,
and 45 min after the second injection of the radiotracer (40, 55, and 85 min after
maintenance dose was initiated); two drops of sodium arsenite per milliliter blood
were added immediately to inhibit procaine metabolism by butyrylcholinesterases in
blood. The samples were assayed for procaine levels by gas chromatography
measuring the free procaine level in plasma (National Medical Services, Inc., Willow
Grove, PA). Steady-state plasma concentrations were achieved through the
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loading/maintenance dose strategy, with procaine concentrations having a coefficient
of variation of 9%. No trends were observed over time among the three procaine
samples. The mean plasma concentrations achieved are presented in Table 3.
2.3.5 Imaging Data Collection and Analysis
Image collection and analysis followed the methods of Carson et al. (1998).
Images were acquired with the General Electric (GE) Advance tomograph (DeGrado
et al., 1994) in three- dimensional mode, which collects 35 slices simultaneously with
a 4.25 mm interslice distance and a 6 mm isotropic reconstructed resolution.
Reconstructed scans were corrected for attenuation, scatter, random emissions, and
deadtime, and calibrated in nCi/ml.
[18F]FP-TZTP functional images of delivery rate from the plasma (K1 (ml
plasma/min/ml tissue)) and equilibrium volume of distribution (V (ml plasma/ml
tissue)) or total binding were computed from the dynamic scans collected over the
initial 45 min, utilizing a kinetic model with an arterial input function that has been
corrected for metabolites (Carson et al., 1998). Initially, the time delay between brain
and blood sampling (t) was determined by a one-compartment model fitting three
parameters (t, V, K1). Functional images of V and K1 were created by first generating
a pixel by pixel time activity curve adjusting for the global t, and then fitting to a two-
parameter (K1 and V) model.
For the second injection, the data were adjusted for residual radioactivity and
residual metabolites remaining from the first injection (baseline scanning). Images
were corrected for residual activity and metabolites from the first injection with
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identical methodology as that of Carson et al. (1998). Briefly, the model equation for
the second injection was modified to include a nonzero initial radioactivity
concentration (C0), which clears exponentially (exp(-k2t)), where k2 is the clearance
rate constant of the second injection. For each pixel, C0 was estimated by averaging
the pixel value for the 30 min preceding the second injection (corrected for decay).
This extrapolated background radioactivity amounted to less than 10% of total
activity for the second injection. The magnitude of metabolites remaining from the
first injection was estimated in a similar manner, and affected the early portion of the
input function for the second injection.
Regions of interest (ROIs) were defined on coronal magnetic resonance
imaging scans (MRIs) using the rhesus monkey atlas of Paxinos et al. (2000). T1
weighted images were acquired on a GE Signa (1.5 Tesla), with a sequence 3D SPGR
(X=1 mm, Y=1 mm, Z=0.39 mm), while sedated with ketamine and robinol on a
separate day from the PET studies. The V and K1 images were coregistered to the
structural MRIs using the Automated Image Registration (AIR) algorithm (Woods et
al., 1998) that transformed and resliced the functional images into the coordinate
system of the MRIs. Primary ROIs were anterior cingulate, amygdala, and basal
forebrain structures ventral striatal and pallidal nuclei that were particularly activated
in the human blood flow studies. Additional ROIs were defined in prefrontal, parietal,
occipital, temporal cortices, thalamus, striatum, posterior cingulate, hippocampus,
cerebellum, and brainstem. Primary sensory (V1 [visual], A1[auditory] and
S1[somatosensory]) and motor cortex (M1) were also measured, but not included into
statistical inference testing as they were encompassed in some of the previously
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mentioned regions. The mean V and K1 levels were calculated from baseline and
procaine scans for each ROI and a cortical average (prefrontal, anterior cingulate,
posterior cingulate, parietal, occipital, and temporal cortices) was obtained.
The V values measured at baseline (Vbase) and with procaine (Vproc)
administration were corrected for nonspecific binding by subtracting a uniform value
of 7 mL/mL (rationale explained below) taken from preblocking studies with [18F]FP-
TZTP (Carson et al., 1998), yielding binding potential (BP) values for each scan
(BP1=Vbase-7; BP2=Vproc-7). Percent blockade was calculated by
∆BP = 100((BP1 – BP2) / BP1).
The relationship of average cortical blockade (BP) to procaine dose was
evaluated with repeated measure ANOVA with procaine dose as the one within
factor, (SuperAnova, v1.11, Abacus Concepts, Berkeley, CA).
IC50 (inhibitory concentration for 50% blockade) values were calculated by
two methods using Graphpad Prism software (v3.0a for Macintosh, Graphpad
Software, Inc., San Diego, CA), and were compared for best fit. The first method
determined IC50 from the percent blockade measures (BP) with the two-parameter
model equation:
∆BP = ∆BPmax [L] /  (IC50 + [L])
where ∆BPmax is the maximum percent blockade achievable with procaine. Ligand
concentrations [L] were based on mean procaine plasma levels acquired during each
scanning period. The second fitting method used a sigmoidal dose-response model
fitting three parameters to the equation
BP2 = BPmax (1- (∆BPmax /100) [L] /  (IC50 + [L]) )
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where BPmax is the binding potential in the absence of procaine. These models differ
in that the three-parameter model only used data from the second scan of each day
and assumed a fixed value for BPmax on all days for all animals. The two-parameter
model used the baseline results (BP1) measured for each animal on each experimental
day to directly calculate BP. The three-parameter model also included the second-
scan information on the zero-dose experimental day. Regional variations of IC50
values were assessed with repeated measure ANOVA with two within factors, region
and procaine dose.
The statistical inferential methods for K1 values were essentially identical to
those described to assess BP measures. K1 ROI values (without any corrections)
measured at baseline (K1-base) and with procaine (K1-proc) administration were used to
calculate percent change by
∆K1 = 100((K1-proc – K1-base ) / K1-base).
The relationship of average cortical change of K1 to procaine dose was
evaluated with repeated measure ANOVA with one within factor, procaine dose.
Regional variations of K1 change were assessed with repeated measure ANOVA with
two within factors, region and dose. When appropriate post hoc means comparisons
were conducted, as in the case of testing the a priori hypothesis of selective anterior
paralimbic, K1 increases. Variability of peripheral measures was also examined with
repeated measures ANOVA, with two within factors of dose and times.
Owing to the relative uniformity of muscarinic M2 receptor distribution across
the brain, nonspecific binding measures were estimated in the following way. Since
individual values were not available, a constant value for the nonspecific distribution
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of volume was used. Several constants were evaluated (6, 7, 8, and 8.7 ml/ml (the
mean cortex value reported in Carson et al. (1998) from preblocking studies)), but the
IC50 estimates, regardless of constant value, remained essentially identical. For
example, for the mean cortex IC50, a value of 1.34 µM was obtained when using a
constant value of 8.7 ml/ml as compared to 1.31 µM obtained with 7 ml/ml for
nonspecific distribution volume estimates. The constant value of 7 ml/ml,
approximately the mean value of the cerebellum from preblocking studies was chosen
for the analyses, under the assumption that nonspecific binding is uniform across the
brain. Note that the underestimation of nonspecific binding in this study would have
the effect of underestimating the maximum percent blockade. Again using the cortex
average as an example region, the BPmax using 8.7 ml/ml was 100.1%, while 7
ml/ml produced a value of 88.4%.
2.4 Results
2.4.1 Control Values
On one day, each animal received saline administration during the second
scanning period, in lieu of procaine, to establish test-retest reliability. Cortical
[18F]FP-TZTP BP did not differ significantly on retest (mean±SD saline1, 21.4±2.9
ml/ml; saline2, 23.1±3.4; F=1.48, df=1,2, p=ns). However, there was a slight
tendency for regional [18F]FP-TZTP BP changes from saline1 to saline2, as indicated
by a region X scan interaction (F=2.28, df=12,24, p=0.04). Most regions increased
slightly 1.0-2.4 ml/ml (average change 5.9%), but the thalamus, cerebellum, and the
brainstem remained at the same level (<0.8 ml/ml change). This slight trend of BP
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with time on anesthesia was also seen in the work of Carson et al. (1998) and will
tend to result in an underestimation of BP.
Cortical values for K1 also showed a slight, but nonsignificant increase (5.7%)
from saline1 to saline2, a nonsignificant increase (mean±SD saline1, 0.42±0.09;
saline2, 0.45±0.13; F=0.53, df=1,2, p=ns). Again there was significant regional
variation (F=2.32, df=12,24, p=0.04) from saline1 to saline 2. Most regions increased
0.02-0.133 ml/min/ml (average change 11.2%), but parietal and occipital cortex
remained at the same level. These increases in K1 are consistent with the work of
Carson et al. (1998) and most likely reflects time-related CBF increases associated
with isoflurane administration (McPherson et al., 1994). These small increases in K1
measures indicate that any procaine-induced flow increases may be slightly
overestimated.
2.4.2 Peripheral Measures
There was no significant effect of procaine administration dose on heart rate
(HR: F=1.21, df=5,10, p=ns), systolic or diastolic blood pressure (SYS: F=0.90,
df=5,10, p=ns; DIA: F=1.04, df=5,10, p=ns;), respiration rate (RR: F=1.26, df=5,10,
p=ns), or pCO2 (pCO2: F=1.46, df=5,10, p=ns). Although most measures significantly
decreased with time (HR: F=11.27, df=5,10, p=0.000; SYS: F=6.47, df=5,10,
p=0.000; DIA: F=2.45, df=5,10, p=0.030; RR: F=6.64, df=5,10, p=0.000; pCO2:
F=8.37, df=5,10, p=0.000), a drug X time interaction was only observed with pCO2
which was significantly increased on the highest dose (0.500 mg/kg/min) after
procaine administration and returned to baseline levels after cessation of the loading
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phase (HR: F=0.51, df=5,10, p=ns; SYS: F=0.64, df=5,10, p=ns; DIA: F=0.94,
df=5,10, p=ns; RR: F=0.83, df=5,10, p=ns; pCO2: F=1.59, df=5,10, p=0.016).
2.4.3 Global Effects
The IC50 values generated by the two fitting methods (two-parameter and
three-parameter) differed by approximately a factor of 2. For example, the average
cortical ROI IC50 values were 1.31 µM and 0.75 µM for the two- and three-parameter
models, respectively. The percent coefficient of variation of IC50 from the fits was
comparable at ~30%, thus model selection could not be performed based on
goodness-of-fit. In subsequent results, the two-parameter results were chosen over the
three-parameter results, because the former model directly accounted for day-to-day
and animal-to-animal variability of baseline [18F]FP-TZTP binding potential (Table
3).
Table 3.  The Effects of Procaine Administration on the Functional Response of the
Cortex
Procaine [18F]FP-TZTP Specific Binding Tracer Delivery
Dose Plasma Level BP (ml/ml) K1 (ml/min/ml)
(mg/kg/min) (µM) Baseline Procaine % Decrease Baseline Procaine
%
Increase
0.000 0.00 20.7 ± 3.5 22.4 ± 3.9 -8.5 0.42 ± 0.09 0.45 ± 0.13 5.7
0.016 0.65 20.9 ± 6.2 13.2 ± 2.5 35.1 0.40 ± 0.17 0.62 ± 0.31 51.7
0.031 1.19 16.9 ± 1.8 10.3 ± 0.8 39.1 0.48 ± 0.09 0.62 ± 0.13 31.5
0.063 2.92 16.3 ± 4.5 7.7 ± 2.1 52.5 0.38 ± 0.11 0.48 ± 0.20 22.6
0.250 12.24 12.6 ± 0.6 2.7 ± 0.8 78.1 0.36 ± 0.04 0.43 ± 0.10 17.9
0.500 21.37 20.1 ± 9.7 2.3 ± 1.0 88.6 0.36 ± 0.05 0.42 ± 0.02 19.5
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Figure 13.  Effects of Procaine on [18F]TZTP Binding and Flow
(A.) Coronal slice presentation of volume of distribution images (V) from a single animal
displaying the significant reduction in specific binding of [18F]FP-TZTP by procaine. Global
reduction in specific binding in this subject was 86.9%. Upper panel: baseline binding is
fairly uniform; lower panel: procaine administration (0.5 mg/kg/min) is essentially identical
to preblocking studies with FP-TZTP (Carson et al., 1998). (B.) Procaine increased K1
measures the greatest in the anterior cingulate, striatum, and basal forebrain nuclei. Data
represents a subtraction image in a single monkey (0.016 mg/kg/min procaine minus
baseline). The PET images were registered to the animal's MR images; coordinates are mm




















Figure 14.  Dose-Response Relationship of Procaine and Global [18F]FP-TZTP
Binding
Procaine blocks cortical [18F]FP-TZTP binding potential in a dose-related fashion that
follows the saturation binding curve (solid line) with an IC50 of 1.31 µM with an
estimated accuracy of ±0.41 µM. The maximum blockade was 87% and minimum
was 23%.
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Figure 13 depicts (top and middle panels) representative [18F]FP-TZTP V
images with and without procaine co-administration in a single animal at the highest
dose of 0.5 mg/kg/min. Baseline and procaine global [18F]FP-TZTP specific binding
is reported in Table 3. Procaine, in a dose-related manner, blocked average cortical
[18F]FP-TZTP total specific binding (F=51.45, df=5,10, p=0.0001; Figure 14).
Procaine significantly increased average cortical [18F]FP-TZTP K1 values
(F=6.23, df=2,10, p=0.0071), however, not in a sigmoidal dose-related manner (Table
3). The peak change (52%) in K1 occurred at the low dose of 0.016 mg/kg/ml (mean
procaine plasma level=0.65 mM; see Figure 13 bottom panel) and had successively
smaller increases with each higher dose, although still increased by 20% at the
highest dose of 0.5 mg/kg/min. The post hoc analysis of dose revealed all doses
combined resulted in significantly higher K1 values compared to the baseline study
(baseline: 5.7±17.0%; procaine: 28.6±17.3; F=11.28, df=1, 10, p=0.007). This effect
was attributable primarily to 0.016 mg/kg/min dose with a 51.7% increase (dose 1 vs
baseline: F=27.16, df=1, 10, p=0.002) and also to the 0.031 mg/kg/min dose with a
31.5% increase (dose 2 vs baseline: F=23.54, df=1, 10, p=0.02).
2.4.4 Regional Effects
The dose-response relationship of [18F]FP-TZTP specific binding across the
regions mirrored the global findings (Table 4). The regional IC50 did not vary
significantly across the areas measured and ranged from 1.00 to 2.25 µM (F=0.88;
df=12,24; p=ns).
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[18F]FP-TZTP K1 (Table 4) varied significantly across ROIs (F=5.58; df=2,12;
p=0.0001) and across procaine doses (F=5.61; df=4,8; p=0.02); however, there was
no interaction of region X dose (F=0.79; df=60,120; p=ns). In the regional post hoc
analysis, the K1 of the anterior paralimbic areas (including the amygdala, anterior
cingulate, basal forebrain nuclei, hippocampus, and prefrontal cortex, mean
K1=34.7%) was significantly increased compared with other regions (including
posterior cingulate, occipital cortex, parietal cortex, cerebellum, and brainstem; mean
K1=21.0%, F=29.05, df=1,24, p=0.0001).
Table 4. Regional [18F]FP-TZTP Parameter Values
Specific Binding Delivery Rate
Baseline BP IC50 ∆BPmax Baseline K1 K1 Increase
Region (ml/ml) (µM) (ml/min/ml) (Maximal)
Cortex Average 17.9 ± 5.4 1.31 88.4 0.40 ± 0.09 51.7
Striatum 19.5 ± 5.8 1.48 88.9 0.48 ± 0.12 73.6
Basal Nuclei 17.4 ± 5.2 1.51 93.2 0.47 ± 0.11 72.6
Ant Cingulate 21.4 ± 6.7 1.00 85.4 0.43 ± 0.10 68.4
Hippocampus 17.0 ± 5.1 1.65 92.0 0.46 ± 0.11 57.5
Amygdala 15.2 ± 5.0 1.74 94.2 0.43 ± 0.10 55.9
Thalamus 15.6 ± 5.0 1.72 83.9 0.46 ± 0.12 55.1
Prefrontal 17.0 ± 5.1 1.11 88.5 0.36 ± 0.09 54.8
Temporal 17.4 ± 5.4 1.48 91.5 0.41 ± 0.10 54.2
Brainstem 9.2 ± 3.3 2.25 97.7 0.41 ± 0.12 51.6
Post Cingulate 19.1 ± 5.7 1.36 85.2 0.40 ± 0.09 50.0
Cerebellum 8.9 ± 2.9 2.12 100.4 0.62 ± 0.17 49.4
Parietal 18.8 ± 5.8 1.24 84.9 0.35 ± 0.07 40.3
Occipital 14.9 ± 4.4 1.52 93.3 0.38 ± 0.11 34.4
Primary Sensory (V1) 14.9 ± 4.5 1.51 92.7 0.41 ± 0.12 37.5
                          (A1) 21.6 ± 6.2 1.37 87.6 0.48 ± 0.11 61.8
                         (S1) 15.2 ± 4.8 1.45 91.4 0.33 ± 0.07 52.1
Primary Motor   (M1) 16.7 ± 5.5 1.19 89.9 0.34 ± 0.07 66.6
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2.5 Discussion
In this PET study of anesthetized monkeys, procaine blocked the binding of a
muscarinic ligand in a dose-related manner, globally and uniformly across the primate
brain. The IC50 for the cortex was estimated to be 1.31 µM, which corresponds to
plasma levels achieved between infusion doses 0.0312 and 0.0625 mg/kg/min
procaine. This is in the proximity of in vitro assessments of M2 muscarinic receptor
Kd of 4 µM as determined in rat hippocampal slices and guinea-pig ileum (Hisayama
et al., 1989; Sharkey et al., 1988). Given the nearly 100% blockade achieved, these
results support a direct interaction of procaine with the same muscarinic receptors to
which [18F]FP-TZTP is binding. Furthermore, the V images of procaine
administration at the maximal dose in this study were essentially identical to the V
images obtained during the preblocking experiments with [18F]FP-TZTP studies
(Carson et al., 1998).
Although procaine is known to selectively increase limbic
electrophysiological activity in animals and anterior paralimbic perfusion in humans
(Heynen et al., 1995; Ketter et al., 1996; Munson et al., 1970; Parekh et al., 1995;
Post, 1981; Post et al., 1984; Racine et al., 1975, 1979; Wagman et al., 1967), the lack
of regional variation in IC50 values suggests that the competition of procaine with
[18F]FP-TZTP binding sites is similar across the brain. Furthermore, these data
suggest that procaine's limbic selectivity is most likely not a result of limbic
muscarinic receptors having enhanced regional sensitivity to procaine over that of
other brain regions.
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Nonetheless, the selective activation of paralimbic structures by procaine
could still involve cholinergic mechanisms. Amygdalar neurons via muscarinic
mediation have been associated with bursting phenomena (Yajeya et al., 1997),
postsynaptically (Washburn and Moises, 1992) and presynaptically (Sugita et al.,
1991). Bursting activity was further tied to a complement of presynaptic muscarinic
receptors that were estimated to be comprised of 50% M3, 30% M2, and 20% or less
M1, but most likely not due to the well characterized M-current (Yajeya et al., 1997).
Moreover, similar neuronal depolarization responses due to cholinergic mechanisms
have been implicated in other paralimbic structures such as hippocampus, entorhinal,
and piriform cortices and anterior cingulate (Benson et al., 1988; Colino and
Halliwell, 1993; Hasselmo and Bower, 1992; Klink and Alonso, 1997; McCormick
and Prince, 1986), as well as septum, basal forebrain, striatum, thalamus, and
neocortical structures (Hasuo et al., 1988; Hsu et al., 1995; McCormick and Prince,
1987; Szerb et al., 1994). Thus, it is possible that procaine acting on M2 receptors
could initiate bursting activity and enhance firing in limbic regions. These results
suggest that the interaction of muscarinic receptors with the local neuronal
environment could contribute to procaine's limbic effects.
It is likely that procaine is acting as an agonist since: cholinomimetics induce
kindling similar to procaine (Wasterlain et al., 1981); and physostigmine weakly
facilitates procaine-induced kindling while atropine substantially slows this process
(Heynen et al., 1995). Moreover, the clinical effects of physostigmine share
similarities to procaine (Janowsky et al., 1986).
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Conversely, however, antagonist activity is suggested by procaine
competitively inhibiting acetylcholine-induced contraction (Ishii and Shimo, 1984) of
guinea-pig cecum. Furthermore, procaine inhibits opening of cation channels on
guinea-pig ileal smooth muscle cells thus affecting the acetylcholine-induced cationic
currents; GTPγS currents are inhibited in a similar manner (Chen et al., 1993). Lastly,
procaine is known to have a biphasic effect on neuronal excitation with
anticonvulsant activity at lower concentrations and proconvulsant activity at higher
concentrations (De Jong, 1994; Foldes et al., 1960, 1965), which could reflect both
agonist and antagonist cholinergic activity.
Cerebral blood flow, as measured by K1, significantly increased globally and
regionally in the anterior paralimbic regions with all procaine doses, but the
relationship of procaine dose and K1 increase appears to be more complex than that
observed with the binding data. The most robust increase was observed at the lowest
dose of procaine and all subsequent higher doses resulted in less of an increase above
baseline saline condition. The largest K1 changes occurred at plasma levels near the
IC50. This suggests that the K1 effects associated with the lower doses could possibly
be related to M2 muscarinic blockade. However, the apparent reduction of the K1
increase at the subsequently higher doses might be explained by procaine's effects on
sigma or other receptors, or be a direct effect of the M2 receptors yielding a biphasic
relationship of procaine dose on K1. Allosteric modulation of the muscarinic receptor
has been documented with cocaine (Flynn et al., 1992), and given the structural
similarities between procaine and cocaine, such modulation could account for a
smaller change in K1 at higher doses. Another potential contributor to the complex K1
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changes observed in this study could be the reduced ability of the model to fit K1 with
higher receptor occupancy (Carson et al., 1998), resulting in an underestimation of
K1. This would yield lower flow changes than would be expected with a direct
receptor blockade to flow relationship.
While it would be enticing to suggest that these K1 changes reflect actual
blood flow alterations, caution should be exercised. Despite the strong correlation of
cerebral blood flow and K1 (r=0.85; Carson et al., 1998), the relationship of blood
flow changes to procaine administration in this study can only be inferred. However,
the regional pattern of K1 increases in this study is similar to the blood flow increases
observed in humans (Ketter et al., 1996). The K1 data indicate that procaine binding
to cholinergic M2 receptors may contribute to the overall activation of anterior
paralimbic regions. This suggestion is supported by preferential reductions in
prefrontal cortex blood flow after scopolamine injection in humans in xenon-133 PET
studies (Honer et al., 1988), which are reversed by physostigmine (Prohovnik et al.,
1997). Also, carbachol injection into the substantia inominata increases blood flow
globally and in many limbic areas in rats (Barbelivien et al., 1999).
Procaine can have autonomic effects, such as increases or decreases in heart
rate or blood pressure, when administered i.v. in humans (Foldes et al., 1965, 1960;
Haasio et al., 1988; Scott, 1975). In this study, the minimal autonomic decreases
observed are consistent with known effects related to time on anesthesia. It is notable
that significant cerebral effects occurred while the peripheral effects were minimal.
There are several limitations to this study. Few animals were studied; despite
this, the dose-response relationship of procaine blockade of [18F]FP-TZTP was robust
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and consistent across each monkey (Figure 14). Further, the use of only rhesus
monkeys suggest caution in extrapolation to man.
General anesthesia precluded the collection of behavioral measures during
procaine administration restricting the scope of the study; the ability to relate the
degree of blockade to behavioral measures would be a key element in determining a
clearer role of the muscarinic system in the emotional and sensory effects of procaine.
The general anesthesia (Durieux, 1996) may have confounded the K1 changes
observed, or interacted with procaine to alter the muscarinic activity (Brett et al.,
1988; Dilger et al., 1992, 1993). Ketamine-muscarinic interactions (Durieux, 1995)
may have also confounded the binding changes observed, but these effects would be
present at baseline and with procaine. Anesthesia may have also limited the
physiological changes potentially induced by procaine, either directly or indirectly.
Finally, different methods from those used in the human studies were
necessary for the acquisition of the binding potential data, including the [18F]FP-
TZTP measurement after plasma procaine levels had leveled off, as well as the use of
a constant infusion paradigm rather than a bolus administration. This may have
resulted in assessing the procaine-flow relationship under different physiological
conditions than in the human studies, limiting the ability to extrapolate from this
study to the human studies.
With these caveats in mind, considerable evidence suggests a role for the
cholinergic system in normal and pathological emotions. An enhanced ratio of
cholinergic to adrenergic function has been hypothesized to play a role in mania and
depression (Fritze, 1993; Janowsky et al., 1972a). Cholinergic challenge studies lend
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support to this theory. For example, physostigmine can reduce manic symptoms and
exacerbate depressive symptoms in bipolar patients (Janowsky et al., 1972b).
Furthermore, physostigmine administration results in relapse of depressive symptoms
in bipolar patients successfully treated with lithium, while healthy controls do not
develop depressed mood. These patients have concomitant hormonal disturbances and
emotional arousal expressed as dysphoria (Janowsky et al., 1986).
Arecoline, a nonselective muscarinic agonist, has also induced dysphoria in
mood disorder patients whether or not they were currently depressed; this was greater
in individuals with a family history of depression compared to those without such
history (Gillin et al., 1991; Nurnberger et al., 1989). Both arecoline (Sitaram et al.,
1980) and donepezil, a cholinesterase inhibitor (Perlis et al., 2002) decrease REM
latency in patients with major depression, but not in healthy controls.
In a [15O] blood flow study analyzing the functional associativity of
cholinergic forebrain regions with and without procaine administration, some
abnormalities were found to normalize with procaine (Benson et al., unpublished
data). At baseline, patients with mood disorders compared to healthy controls show
significantly weaker positive relationships among the cholinergic forebrain regions,
which became stronger and similar to controls with procaine. Thus, commonly
reported alterations in prefrontal, anterior cingulate, temporal, striatal, and cerebellar
brain regions in mood disorders (see reviews; Dougherty and Rauch, 1997; Ketter et
al., 1997; Drevets, 1998) may have a cholinergic component to their dysregulation.
In conclusion, these data demonstrate that intravenous procaine administration
in anesthetized monkeys was associated with a dose-related blockade of the M2
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muscarinic ligand, [18F]FP-TZTP. This is the first demonstration of muscarinic
cholinergic binding of procaine in primates, in vivo. In addition, cerebral blood flow
(K1) was significantly increased in limbic regions of the brain. If significant receptor
occupancy occurs at comparable plasma levels in humans, these data suggest a
possible cholinergic contribution to the robust emotional and sensory effects of
procaine and its ability to selectively activate amygdala and closely related anterior
paralimbic structures. Thus, based on the binding and flow data presented here,
procaine could prove to be another way of assessing muscarinic receptor tone in
limbic areas in patients compared to healthy volunteers. Further studies to explore the
relationship of muscarinic receptor activity with behavioral assessments, and use of
agonist and antagonist ligands could delineate a clearer role of the cholinergic system
in the effects of procaine on emotion.
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2.6 Afterword: Linking Preclinical and Clinical Data
To recapitulate the major findings of this study, procaine blocked the
muscarinic PET ligand in a dose-related manner that suggests direct binding with the
same M2 site.  Moreover, the flow of the ligand was increased with procaine
administration most with the dose closest to the in vivo IC50 and in the same areas as
demonstrated in humans (Ketter et al., 1996).
The potential for interaction between muscarinic receptors and the anesthetics
used in this study needs clarification.  Sodium pentathol does not modulate
muscarinic receptor activity (Weber et al., 2004), but more likely will affect nicotinic,
glutamate and GABA receptors.  However, the findings in the control studies support
two notions concerning general anesthesia effects.  First, on the zero dose of procaine
[18FP]-TZTP binding was higher with the second scan, possibly indicating an
interaction with time on anesthesia.  These results agree with the work of Durieux
(1996); he suggests that isoflurane decreases the dissociation rate from muscarinic
receptors, which results in increased binding of muscarinic agents with muscarinic
receptors.  As noted in the paper, increased binding with time on anesthesia would
have the effect of under-estimating the difference in binding between baseline and
procaine scans on all non-zero doses.  Second, it is well-known that cerebral blood
flow increases with general anesthesia.  This was also observed in the control studies,
and would have the effect of over-estimating the difference in the flow of the ligand
between baseline and procaine scans.
An outstanding question centers on whether the IC50 determined here
corresponds to a clinically relevant dose of procaine.  However, two potential
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confounds limit the successful extrapolation of doses used in this study to those used
in the human studies.  The classic approach of allometry (Chappell and Mordenti,
1991) assumes faster drug metabolism in species smaller than in humans, which is not
the case for procaine; rhesus monkeys (t1/2= 45 minutes; Reidenberg, 1972)
metabolize procaine at least four times slower than humans (t1/2= 7.69 minutes; Seifen
et al., 1979).  Further complications arise from the conversion from bolus to constant
infusion administration methods, and the resulting difference in the physiologic
response to the two administration styles.  With these caveats in mind, inter-species
scaling of doses could be as follows.  Assuming a conversion factor from monkey to
human dose is 4.5 (Reidenberg, 1972) and converting a constant infusion rate back to
a bolus injection by reversing the method applied to establish the doses tested in this
study, the IC50 of procaine in humans could be equivalent to a dose between 0.71 and
1.94 mg/kg procaine, depending on the rate of injections. If the conversion from bolus
administration dosing in the self-administration studies to constant infusion doses in
this study produced somewhat equivalent plasma procaine levels, then the doses used
in this study could be behaviorally or physiologically relevant.
Procaine levels of 0.11 µg/ml were obtained with an bolus dose of 1.84 mg/kg
in the study of Ketter et al. (1996), however, the plasma samples were collected 5
minutes post-injection. Given the short half-life of procaine, these levels most likely
do not reflect the procaine concentrations at the time of peak intensity of emotional
and sensory experiences. Green and colleagues (1974) reported plasma levels of 3.6-
11 µg/ml, equivalently 15-47 µM, with injections of procaine-penicillin that were
associated with panic attacks.  The procaine levels in these studies are in the same
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range as the IC50 determined in this study.  Taken together, these findings suggest that
procaine binding to muscarinic receptors is viable explanation for the emotional and
sensory experiences induced by procaine administration.
The question remains as to the relationship of the muscarinic system to the
functional response of procaine, i.e., is muscarinic modulation contributing in the
emotional and sensory experiences that procaine induces. This study will adopt an
exploratory approach to confirm cholinergic pathways and potential relationships
between the blood flow and emotional responses to procaine.  Functional
connectivity, as defined as the correlative strengths between regions of interest
(ROIs), will serve as a method to confirm cholinergic pathways.  The relationship
between rCBF and emotional responses will be examined with multivariate multiple
regression methods as outlined by the cholinergic model in Figure 9.   Regional blood
flow in core cholinergic brain regions will be measured utilizing an existing CBF
PET data from patients with mood disorders and healthy volunteers who participated
in the procaine study.  Multivariate multiple regression can describe the strength,
direction and nature of the relationships between brain regions and behavioral
outcome.
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Chapter 3: Alterations of Regional Cerebral Blood Flow with
Procaine Administration in Bipolar Illness
3.1 Introduction
The local anesthetic procaine has unique neuropsychopharmacological
properties that make it useful as a discrete probe of the limbic system and its
relationship to emotion modulation.   Procaine and related local anesthetics are
known to selectively increase limbic perfusion, metabolism and electrophysiological
activity in animals (Benson et al. 2004; Heynen et al. 1995; Munson et al. 1970; Post
1981; Post et al. 1984; Racine et al. 1975; Racine et al. 1979; Wagman et al. 1967).
Furthermore, procaine has been used as an affective challenge in healthy controls
(Ketter et al., 1996; Servan-Schreiber et al., 1998), and patients with mood disorders
(Ketter et al., 1993) and panic disorder (George et al., 1993), as well as individuals
abusing alcohol (George et al., 1990) and cocaine (Adinoff et al., 2001).
Procaine, when administered intravenously (i.v.) in healthy controls, results in
brief intense emotional and sensory experiences in association with increased global
and regional anterior paralimbic cerebral blood flow (CBF) as measured with [15O]
water PET (Ketter et al. 1996); the amygdala, insula and anterior cingulate are
particularly activated.  In healthy individuals, 1.84 mg/kg procaine induces the
following: an array of brief intense emotional responses ranging from dysphoria (fear
and anxiety) to euphoria; visual and auditory sensory illusions/hallucinations (Kellner
et al. 1987); hormonal changes such as increased ACTH, cortisol, and prolactin
secretion (Kling et al. 1994); and increased temporal lobe fast activity EEG (Parekh et
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al. 1995). Furthermore, the degree of right amygdala activity on PET correlated with
the degree of affective arousal, while the left amygdala CBF correlated positively
with the degree of dysphoria and inversely with the degree of euphoria (Ketter et al.
1996).   Increases in the mesial occipital CBF were associated with the occurrence of
visual hallucinations.
Although classically associated with the blockade of voltage-gated sodium
channels, procaine also interacts with many neurochemical systems.  However, it has
high affinity to the muscarinic cholinergic receptor.  In vitro studies have shown
procaine competitively displaces the non – specific muscarinic antagonist, QNB
(quinuclidinyl benzilate), at putative M2 receptors (Ki = 4 µM; Hisayama et al. 1989)
on guinea pig ileum and M1 and M2 receptors (Ki = 4 µM; Sharkey et al. 1988) in rat
hippocampal membranes.
Moreover, procaine has recently been shown to have in vivo action on
muscarinic M2 receptors in the anesthetized rhesus monkey utilizing a radiotracer
with preferential binding to these receptors (Benson et al., 2004).  In that study,
procaine blocked the M2 ligand (TZTP) in a dose-related manner with an in vivo IC50
(1.31 µM) that mirrored estimates determined from in vitro studies (Sharkey et al.,
1988; Hisayama et al. 1989). Furthermore, peak increases in the flow of the
muscarinic radiotracer were near this IC50.  These results suggest that the binding of
procaine to muscarinic receptors may contribute to the emotional and sensory effects
observed in man (Ketter et al., 1996).
Such a cholinergic effect would be consistent with the work of Janowsky, et
al. (1972a, 1972b, 1986), in which they proposed that there exists an imbalance of
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cholinergic-adrenergic activity in patients with mood disorders. Indirect and direct
cholinergic agonists, such as physostigmine and arecoline, can produce dysphoria in
manic patients (Janowsky et al., 1972b).  The patients have concomitant hormonal
disturbances with this emotional arousal (Janowsky et al., 1986).  These findings have
led Janowsky to hypothesize that the cholinergic-noradrenergic balance is shifted
towards cholinergic activity with depression and with noradrenergic activity with
mania (Janowsky et al., 1972a).   More recently, Overstreet and colleagues (1998)
have suggested a cholinergic-serotonergic imbalance in mood disorders in which they
argue that a cholinergic overactivity predisposes one to depression and serotonergic
mechanisms induce depressive episodes.
Procaine studies have not included patients with bipolar disorder despite the
putative role of amygdala and cholinergic substrates in this disorder.  This study was
undertaken to assess the CBF response to procaine in a group in which emotion
dysregulation is one of the hallmark symptoms.  Bipolar disorder is characterized by
baseline hyper-metabolism in several subcortical limbic regions, including the
amygdala, and striatum and hypo-metabolism in cortical limbic structures such as the
dorsolateral prefrontal cortex and anterior cingulate at baseline (Ketter et al., 2001).
Preliminary results suggest patients with mood disorders (unipolar and bipolar)
exhibit blunted anterior paralimbic CBF response to procaine compared to healthy
controls (Ketter et al., 1993).  This study postulates that a blunted response to
procaine in bipolar disorder will be confirmed in this larger and diagnostically more
pure sample.  In addition, with patients primarily in the depressed phase of the illness,
cholinergic regions may be overactive compared to controls.  More specific
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hypotheses relating changes in cholinergic activity to other brain regions are
examined in a companion paper on functional connectivity of the basal forebrain
cholinergic region in patients and controls before and after procaine.
3.2 Methods
3.2.1 Subjects
Healthy controls (HC; n=32; 17 men, 15 women; mean ± SD age, 30.1 ± 7.5;
range 18 to 45 years) and patients with bipolar illness (BPD; n=15; 7 men, 8 women;
gender χ2 = 0.17, p = ns, df =1; mean ± SD age, 39.2 ± 10.4; range 24 to 53 years;
between groups age comparison: t = 9.2, df = 45, p = 0.001) participated in PET study
using H2
15O water after obtaining written informed consent (Ketter et al., 1996).  The
subjects were informed that procaine had various transient emotional and sensory
effects, ranging from minimal to intense and from pleasant to unpleasant.  They were
told they could stop the procedure at any time, and that diazepam was available if
needed.  All subjects were determined to be physically healthy by history and
physical examination, including neurological exam, electrocardiogram (EKG),
routine serum chemistry studies (with HIV), comprehensive drug screening, and
magnetic resonance imaging (MRI).
Diagnosis of Bipolar Disorder was confirmed with Schedule for Affective
Disorders and Schizophrenia – Lifetime Anxiety Version (Mannuzza et al., 1986) by
trained physician.  Except for one BPI patient (at some point experienced moderate to
sever mania), all were BPII (n=14; at some point experienced hypo-mania or mild
mania), most with a confirmed history of rapid cycling (n=11; defined as
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experiencing 4 or more cycles of mania and depression).  A fuller description of the
illness characteristics was derived from data on the prior course of each patient’s
illness gathered from retrospective life charts from 12 patients (Leverich and Post,
1996, 1998).  Age of onset and number of hospitalizations for depression or mania
were directly transcribed, while, number of episodes for depression or mania,
episodes per year, number of weeks ill, percent of life ill for entire life and since age
of onset, and duration of illness (current age minus age of onset) were determined
using prescribed criteria.  Previous successful and unsuccessful medication trials were
also examined in 12 patients, from whom a refractoriness index was computed on a 0
to 100 scale.  A failed trial of each anti-depressant of a different class was assigned a
rating of 10, ECT a 30, adjunctive treatments such as thyroid a 5, and other treatments
a 2.5 (Post et al. 2001, unpublished rating scale, available upon request).
3.2.2 Procaine Procedure and Behavioral Measures
Regional cerebral blood flow (rCBF) was measured using H2
15O PET during
intravenous saline and procaine administration in a single-blind design, where they
were instructed to expect saline, low-dose or high-dose procaine.  Subjects were
injected with saline (sham scan), saline (baseline scan; BL), low-dose procaine (0.46
mg/kg), high-dose procaine (1.84 mg/kg; PR) and saline (recovery of baseline scan)
in the same order.  This order was chosen to ensure progressing to the higher dose
was safe and to remove possible artifacts from high-dose exposure to subsequent
scans.  There was twenty minutes between each scan allowing for time to return to
baseline.  Analysis of low-dose procaine in previous studies of healthy controls and
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preliminary analysis in patients revealed little to no effect on blood flow or behavioral
ratings; for these reasons, only high dose procaine results will be presented.
Baseline behavioral measures of mood, including clinician and self-ratings,
were collected before the scanning session began (Table 5).  Clinician ratings
included Hamilton Depression Rating scale (Hamilton, 1960; [HDRS]), Young Mania
Rating Scale (Young et al., 1978; [YMRS]), and Spielberger State Anxiety Scale
(Spielberger et al., 1970; [SSAS]), and self-ratings included Beck Depression
Inventory (Beck, et al., 1961; [BDI]).  These assessments, as well as the life chart
variable measures, indicate that the patients were moderately depressed (mean HDRS
= 16.9), predominately not manic (two subjects YMRS > 10), and treatment-
refractory (multiple medication trials). Likert-based ratings of emotional and sensory
experiences were collected at baseline and immediately after each scan.
Demographic, clinician and self-ratings data were analyzed using paired (within
group drug comparisons) and unpaired t-tests (between-group comparisons) or
repeated measures ANOVA with between and within group factors, as deemed
appropriate.
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Table 5. Subjects Demographics and Illness Characteristics
Variable N Mean SD Range
Healthy Controls
   Gender (17 M / 15 F)
   Age (years) 32 30.0 7.5 18-45
Hamilton Depression Rating Score 32 1.0 1.4 0-5
Patients with Bipolar Disorder
   Gender (7 M / 8 F)
Age (years) 15 39.5 14.2 20-65
Hamilton Depression Rating Score 15 16.9 9.6 0-33
 Spielberger Anxiety Scale 14 44.5 11.7 25-69
Beck Depression Score 15 14.8 9.8 0-37
Young Mania Rating 13 4.1 5.1 0-17
Age of Onset (years) 12 18.8 8.1 6-30
Duration of Illness (years) 12 20.4 10.7 8-43
Number of Hospitalizations 12 2.6 3.0 0-10
Number of Episodes (depression) 12 208.9 562 3-1983
Number of Episodes (mania) 12 186.3 565 1-1981
Number of Weeks Depressed 12 246.8 276.6 42.7-988.5
Number of Weeks Manic 12 84.9 152.5 1.3-457.9
Number of Failed Medication Trials 12 9.2 4.1 1-13
Refractory Index Score (0-100) 12 14.1 28.9 1.75-55.5
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3.2.3 PET Acquisition and Data Analysis
After placement of an arterial-line in the radial artery and an intravenous line
placed in the opposite arm, the subjects were taken to the PET suite and asked to lie
supine on the bed of the PET scanner.  A thermoplastic mask with openings for the
eyes, ears, nose, and mouth placed over the face and fastened to the scanner bed
restricted head movement (Smith and Nephew, Madison, WI).  A transmission scan
from a germanium 68 / gallium-68rotating pin source was obtained to allow
correction for attenuation by the skull and cerebrum, and to ensure optimal placement
in the scanner. This was followed by the series (saline / procaine) of scan acquisitions
described above.  The subjects were instructed to lie quietly with eyes closed and
monitor their sensory and emotional experiences during the scans.  Upon completion
of the scan, emotional and sensory ratings, as well as reports of any unusual
cognitions or somatic / visceral sensations, were collected.
As a preventative measure, each subject’s heart rate, blood pressure and
chemistry were monitored during the entire procedure.  To correct for pCO2 effects
on CBF, the pixel values were adjusted for pCO2 levels at baseline and with procaine
with the following formula suggested by Grubb et al. (1974):
rCBFadj = 1.8 (40 - rCBF).
All results reported in this study incorporate this adjustment.
Brain images were collected on a Scanditronix tomograph (PC2048-15B,
Scanditronix Inc, Uppsala, Sweden) with 6.9-mm in-plane and 5- to 6-mm axial-full-
width-half maximum resolution over a four minute period.  Fifteen seconds after
procaine/saline administration, the radiotracer consisting of 1110-MBq bolus of
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15O water was injected.  Emission data were collected in 15 planes spaced 6.5 mm
apart beginning at the canthomeatal line and started when the radiotracer bolus
reached the head.  Continuous radial arterial blood sampling for blood radioactivity
levels was used to generate radiotracer time-activity curves.  Regional CBF was
calculated from the dynamic tracer-kinetic modeling of the PET scan data and the
time-activity curve using least-squares method (Herscovitch et al. 1983; Raichle et al.
1983).
Image processing was performed on a Unix workstation (SUN Ultra 10 Sparc
station, SUN Microsystems Inc, Mountain View, CA) and statistical analysis was
performed on a Macintosh G3 and Windows 2000™ personal computers.  Image
display and region definition were performed using Analyze imaging software
(Biomedical Imaging Resource, Mayo Foundation, Rochester, MN).
After CBF scans were visually inspected for image quality and artifacts,
automated image processing was performed using SPM99 (statistical parametric
mapping; Friston et al., 1994).  Images were first co-registered across conditions.
This was followed by reorientation parallel to intercommissural plane, and resizing,
reslicing and rescaling to yield sterotatically normalized images (Friston et al., 1989,
1995) corresponding to the human brain atlas of Talairach and Tourneaux (1988).
Images were then smoothed to a resolution of 10-mm transaxial and 6-mm axial
yielding a final reconstructed resolution of 12 mm isotropic.
Global cerebral blood flow (gCBF) was calculated as the mean of all grey-
matter voxels.  For grey-matter determination, the background noise threshold (above
which a voxel is presumed to be in-brain) was set at one-eighth of the mean of the
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entire image space, and the whole-brain mean was calculated using only these
suprathreshold voxels.  Voxels exceeding 70% of the whole-brain mean were
assumed to be in grey matter.
Statistical inference testing on absolute and globally normalized rCBF data
was performed to examine potential differences between groups, conditions and their
interaction using SPM 99 (Friston et al., 1990).  The relationship between mood and
procaine-induced blood flow response was assessed by correlating HDRS scores with
change in blood flow.
The resulting Z-maps correspond to the raw probabilities in each voxel of the
null hypothesis (H0: Z=0).  To correct for multiple comparisons, these Z-maps were
then submitted to cluster analysis within SPM99 (Friston et al. 1994).  Cluster
analysis considers the smoothness of the Z-map, arising from the low-pass filtering
applied to the input images, as well as inherent spatial autocorrelation in the
underlying brain function, in determining the effective independence of the multiple
comparisons contained in the total brain volume analyzed.   A spatial extent threshold
is generated from this smoothness estimate and the Z threshold specified.  A voxel is
retained as significant only if it falls within a cluster of contiguous suprathreshold
voxels that is larger that this extent, which should occur by chance only 5% of the
time (for a cluster probability threshold set at .05) in a Z-map of that smoothness.
The cluster analysis corrects for multiple comparisons by dropping voxels that
are not robustly represented. Thus, the final cluster size is a combination of spatial
extent and significance level. For purposes of depicting topography of the findings in
the figures, raw p-values are displayed for all voxels falling in clusters deemed
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significant by this analysis.  Regions with significant findings, as well as the local
maxima, were identified according to the atlas of Talairach and Tourneaux (1988).
When possible, Brodmann's areas are also indicated.
3.3 Results
3.3.1 Emotional and Sensory Response to Procaine
Despite the expected significant baseline differences between the groups in
ratings of depression, fear, anxiety, anger, calmness, and overall bad/good feeling, the
brief emotional and sensory responses were generally equivalent in the procaine
condition, exhibiting a simple main effect of procaine (Table 6 and Figures 15-19).
This included emotional ratings of euphoria, anxiety, calmness, tiredness, and sensory
ratings for visual and auditory changes.  Anger and overall feeling of bad/good did
not significantly increase with procaine in either group.
The remainder of the emotion ratings changed in more complex ways.
Depression exhibited a significant drug x group interaction, due to the significantly
greater baseline depression ratings in the patients (HC: 0.0 ± 0.0; BPD: 1.73 ± 1.5; t=-
4.38, p=0.001, df=14; unequal variances: F=114.07, p=0.000, df=1, 45), which
became nonsignificant with procaine (HC: 0.63 ± 1.7; BPD: 1.27 ± 1.7; t=-1.20, p =
ns, df=45).  Patients rated fear significantly higher than controls at baseline and with
procaine, and each group rated fear higher with procaine compared to baseline, such
that there was an overall main group and drug effect respectively, but no significant
drug x group (DXG) interaction.
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In both groups, ratings of anger at baseline, with procaine or delta-condition
were not normally distributed.  In addition, only patient ratings of depression at
baseline or with procaine were normally distributed.  Thus, correlations involving
anger and depression (baseline, procaine, or delta) should be viewed with caution,
and delta-ratings were not included in the results of the multivariate analyses
described below.
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test Repeated Measures ANOVA
Rating Drug Group Mean SD  t p  Source F P Wilk'sλ
Depression Saline HC 0.00 0.00 * -4.38 0.001 Drug 0.11 ns 0.998
BPD 1.73 1.53 Group 11.92 0.001
Procaine HC 0.63 1.70 -1.20 ns D X G 5.01 0.030
BPD 1.27 1.71
Anger Saline HC 0.00 0.00 * -2.36 0.033 Drug 3.45 ns 0.929
BPD 0.60 0.99 Group 1.86 ns
Procaine HC 0.66 1.60 -0.30 ns D X G 0.98 ns
BPD 0.80 1.32
Euphoria Saline HC 0.44 0.98 0.35 ns Drug 34.07 0.000 0.569
BPD 0.33 0.90 Group 0.35 ns
Procaine HC 2.34 2.57 -0.81 ns D X G 0.94 ns
BPD 3.00 2.59
Bad/Good Saline HC 3.13 0.71 3.58 0.001 Drug 0.14 ns 0.997
BPD 2.27 0.88 Group 2.00 ns
Procaine HC 2.66 2.18 0.28 ns D X G 0.86 ns
BPD 2.47 2.26
Fear Saline HC 0.13 0.42 * -2.77 0.013 Drug 49.07 0.000 0.478
BPD 0.73 0.80 Group 7.20 0.010
Procaine HC 2.25 2.49 -2.06 0.045 D X G 1.61 ns
BPD 3.80 2.21
Anxiety Saline HC 0.69 1.06 -2.11 0.041 Drug 65.64 0.000 0.407
BPD 1.40 1.12 Group 1.07 ns
Procaine HC 3.63 2.18 -0.26 ns D X G 0.67 ns
BPD 3.80 2.21
Calmness Saline HC 3.72 1.40 2.29 0.027 Drug 13.34 0.001 0.771
BPD 2.73 1.34 Group 1.01 ns
Procaine HC 1.78 2.06 -0.23 ns D X G 2.30 ns
BPD 1.93 2.25
Tiredness Saline HC 1.44 1.46 0.24 ns Drug 9.45 0.004 0.826
BPD 1.33 1.23 Group 0.72 ns
Procaine HC 0.41 0.80 * -1.57 ns D X G 3.28 ns
BPD 1.07 1.53
Visual Saline HC 0.31 0.74 0.17 ns Drug 29.00 0.000 0.608
BPD 0.27 1.03 Group 0.36 ns
Procaine HC 2.72 2.52 0.58 ns D X G 0.25 ns
BPD 2.27 2.43
Auditory Saline HC 0.06 0.35 0.68 ns Drug 322.72 0.000 0.122
BPD 0.00 0.00 Group 0.07 ns
Procaine HC 4.66 1.83 -0.40 ns D X G 0.27 ns
BPD 4.87 1.36














































df = 1, 45
Healthy Controls (n=32)
Patients (n=15)
Figure 15. Procaine-Induced Emotions:  Fear and Anxiety
At baseline, patients with bipolar disorder have significantly higher fear and anxiety
ratings than healthy controls.  Procaine-induced increases in these ratings were the
same on average and in distribution in both groups.
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Figure 16. Procaine-Induced Emotions: Depression and Anger
At baseline, patients with bipolar disorder have significantly higher depression and
anger ratings than healthy controls.  There was a significant interaction of drug and
group in ratings of depression, suggesting that the patients depressed mood at
baseline did not change with procaine, as seen in the controls.  Procaine-induced
increases in anger ratings were the same on average and in distribution in both
groups.  Neither depression nor anger ratings exhibited a normal distribution, as most
were scored as zero.
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df = 1, 45
Healthy Controls (n=32)
Patients (n=15)
Figure 17.  Procaine-Induced Emotions: Euphoria and Good-Bad Feeling
At baseline, patients with bipolar disorder and healthy controls have similar euphoria
and overall feeling of good or bad ratings than healthy controls.  Procaine-induced
increases in these ratings were the same on average and in distribution in both groups.
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df = 1, 45
Healthy Controls (n=32)
Patients (n=15)
Figure 18.  Procaine-Induced Emotions: Calmness and Tiredness
At baseline, patients with bipolar disorder and healthy controls have similar calmness
and tiredness ratings than healthy controls.  Procaine-induced increases in these

























df = 1, 45
























Figure 19.  Procaine-Induced Sensations: Visual and Auditory
At baseline, patients with bipolar disorder and healthy controls have similar visual
and auditory sensory ratings than healthy controls.  Procaine-induced increases in




Since the CBF response to procaine administration in healthy controls has
been published (Ketter et al., 1996), only a short synopsis of those results follows.  A
robust global and relative blood flow increase is associated with procaine
administration (Figure 20).  Procaine increased gCBF by 20.3% (baseline [BL]: 42.2
mL/min/100g; procaine [PR]: 50.8 mL/min/100g; t = 8.57, p = .0004, df = 31).  In an
analysis of absolute rCBF with procaine compared to baseline, all regions of the brain
are affected, such that the resultant cluster of significant increases with procaine
compared to baseline encompassed the entire brain with a maximal difference in the
anterior cingulate (Figure 21; Table 7).  There were no significant absolute decreases
in rCBF with procaine compared to baseline.
Normalized rCBF increases occur in the anterior paralimbic structures, with a
large cluster including the anterior cingulate, anterior insula, medial (amygdala) and
anterior temporal lobe, the basal forebrain cholinergic area, the dorsal and ventral
striatum, and the medial orbitofrontal cortex (Figure 21).  Significant decreases in
rCBF with procaine compared to baseline were observed in mostly posterior regions
of the brain, including bilateral cerebellum, inferior parietal, fusiform cortex, and
posterior temporal cortex.  However, significant decreases were also observed in the
left DLPFC (BA 46), which may encompass Broca’s area.  Due to the data
normalization process, the normalized decreases reported in both the healthy controls
and patients are relative to the average blood flow of the brain.  In both groups,
procaine robustly increased rCBF globally and no area exhibited decreased blood
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flow. Therefore, any significant decreases in rCBF represent less robust increases
than significant rCBF increases.
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Table 7. Significant Findings in Regional CBF Identified by Comparative Analyses
Talairach Cluster
Location Size
Analysis Region X Y Z (k) Z
Healthy Controls (HC)
Procaine vs Baseline
Absolute ↑ L Pregenual AC -2 +22 +20 46610 5.56
↓ none
Normalized ↑ L Pregenual AC -2 22 16 10798 5.87
↑ R Supragenual AC +8 +12 +28 5.67
↑ L SI/Hypothalamus -2 -2 0 5.56
↑ R Middle Temporal +58 -40 +4 76 3.40
↑ L Somatosensory -54 0 +8 20 3.22
↑ R Somatosensory +56 -4 +16 86 4.00
↓ L Cerebellum -12 -78 -16 9148 4.57
↓ R Cerebellum 34 -62 -12 4.91
↓ L Inferior Parietal -42 -36 38 262 3.59
↓ R Inferior Parietal 46 -26 36 302 3.59
↓ L DLPFC (BA44) -32 14 28 159 3.53
↓ L Cuneus -14 -52 8 60 3.45
Bipolar Disorder (BPD)
Procaine vs Baseline
Absolute ↑ L Pregenual AC -4 28 +12 52855 3.69
↑ R Supragenual AC +2 +10 +12 3.44
↑ L Amygdala +22 0 -20 3.69
↑ R Amygdala -18 +6 -20 3.55
↑ L SI/Hypothalamus -2 +4 0 3.38
↓ none
Normalized ↑ R Supragenual AC +2 +4 +36 1515 4.37
↑ R Pregenual +6 +28 +16 4.25
↑ SI/Hypothalamus 0 2 0 3.25
↑ R Anterior Insula +28 +8 -8 22 3.44
↑ L Amygdala 20 0 -16 4422 4.42
↑ R Amygdala -16 6 -20 5.08
↑ L Parahippocampal -18 -42 +4 143 3.20
↑ L Occipital -10 -84 +28 48 3.26
↓ L Cerebellum -40 -62 -28 2075 3.52
↓ R Cerebellum 2 -56 -24 363 4.87
↓ Medulla 2 -28 -28 148 3.76
↓ R Inferior Parietal 46 -38 40 513 3.37





Analysis Region X Y Z k Z
15 BPDs vs 32 HCs - Baseline
Absolute ↑ none
↓ none
Normalized ↑ R Medial Frontal 16 48 8 315 3.35
↑ R Amygdala / Hippocampus 26 -12 -20 143 3.89
↑ L Posterior Temporal -36 -50 20 120 4.25
↑ R Posterior Temporal 34 -50 20 351 3.37
↑ L Cerebellum -54 -8 -12 43 3.48
↓ R Subgenual AC / SI 2 8 -12 94 3.16
↓ L DLPFC -38 24 32 514 2.97
15 BPDs vs 32 HCs - Procaine
Absolute ↑ none
↓ none
Normalized ↑ L Posterior Temporal -36 -48 16 73 2.99
↑ R Posterior Temporal 36 -36 24 135 3.02
↑ L Occipital -32 -84 4 413 3.08
↑ L Cerebellum -10 -66 -4 1752 3.41
↑ R Cerebellum 14 -58 -24 1752 3.22
↓ L DLPFC -28 26 40 94 3.03
↓ R GP/Putamen/Insula 30 -10 4 400 3.01
↓ L Posterior Temporal -54 -30 0 225 3.37
↓ L Inferior Parietal -50 -52 28 80 3.17
15 BPDs vs 32 HCs - Drug X Group
Absolute ↑ none
↓ none
Normalized ↑ L Cerebellum -16 -52 -16 1912 3.15
↑ R Cerebellum +18 -76 -24 621 3.11
↑ L Parahippocampal Gyrus -16 -48 4 1912 3.68
↓ R Amygdala +14 -18 -20 139 3.85
↓ R Dorsal AC +10 -26 +36 45 3.42
↓ R Supragenual AC +14 +24 +40 61 3.15
↓ R Temporal Pole +38 +8 -20 199 2.97
For Z > 2.97 p<0.001; for Z > 3.89 p<0.0001
161
Figure 20.  Effects of Procaine on rCBF in 32 Healthy Controls
Mean regional cerebral blood flow (rCBF) at baseline (top) and with procaine
(bottom) in 32 healthy controls. Procaine increases rCBF throughout the brain with
the most robust increase (indicated in red) in anterior paralimbic regions, such as the
anterior cingulate, amygdala, insula, medial orbitofrontal and prefrontal cortex, and
ventral and dorsal striatum.  Transverse sections through the human brain displayed
from left to right moving from ventral to dorsal aspect. Abbreviations: numbers
indicate Talairach Z plane; L=left. Note: the sagittal views illustrate the limits of the
data collection range, i.e., the extreme dorsal and ventral areas of the brain were not
in the imaging space.
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Figure 21.  Procaine Increases Anterior Paralimbic rCBF in 32 Healthy Controls
Procaine significantly increases anterior paralimbic rCBF compared to baseline in
both absolute and normalized statistical comparisons.  Transverse sections through
the human brain displayed from left to right moving from ventral to dorsal aspect.
Abbreviations: L=left; Zthresh=Z threshold; k=number of voxels; numbers indicate
Talairach Z plane. Note: the sagittal views illustrate the limits of the data collection
range, i.e., the extreme dorsal and ventral areas of the brain were not in the imaging
space.
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3.3.2.2 Patients with Bipolar Disorder
In these moderately depressed (mean HDRS = 16.9) patients with bipolar
disorder, gCBF significantly increased by 27.4% (BL: 43.4 mL/min/100g; PR: 55.2
mL/min/100g; t = 2.91, p = .01, df=14) with procaine compared to baseline (Figure
22).  These increases were not significantly different from healthy controls (Group: F
= 0.74, p= ns, df = 1, 45; Drug: F = 23.71, p < .0001, df = 1, 45; DXG: F = 0.62, p=
ns, df = 1, 45).  As seen in healthy controls, only significant increases in absolute
rCBF with procaine compared to baseline occurred in the patients (Figure 23; Table
7).  However, the significance level was diminished, most likely due to the smaller
sample size.  Absolute CBF was significantly increased across the entire imaging
space, with maxima centering in the anterior cingulate, amygdala and basal forebrain
cholinergic area.
In the normalized rCBF analysis, procaine yielded anterior paralimbic
increases, and posterior cortical and cerebellar decreases compared to baseline.  This
pattern was similar to that observed in the healthy controls, however, the spatial
extent of the changes was somewhat diminished.  Regions that were significantly
increased with procaine compared to baseline included bilateral anterior cingulate,
amygdala, the basal forebrain cholinergic area, anterior insula, and right medial
orbitofrontal cortex.  Significant decreases in rCBF with procaine compared to
baseline occurred in bilateral cerebellum, inferior parietal, and right DLPFC.
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Figure 22.  Effects of Procaine on rCBF in 15 Patients with Bipolar Disorder
Mean regional cerebral blood flow (rCBF) at baseline (top) and with procaine
(bottom) in 15 patients with bipolar disorder. Procaine increases rCBF throughout the
brain with the most robust increase (indicated in red) in anterior paralimbic regions,
such as the anterior cingulate, amygdala, insula, medial orbitofrontal and prefrontal
cortex, and ventral and dorsal striatum.  Transverse sections through the human brain
displayed from left to right moving from ventral to dorsal aspect. Abbreviations:
numbers indicate Talairach Z plane; L=left. Note: the sagittal views illustrate the
limits of the data collection range, i.e., the extreme dorsal and ventral areas of the
brain were not in the imaging space.
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Figure 23.  Procaine Increases Anterior Paralimbic rCBF in 15 Patients with Bipolar
Disorder
Procaine significantly increases anterior paralimbic rCBF compared to baseline in
both absolute and normalized statistical comparisons.  Transverse sections through
the human brain displayed from left to right moving from ventral to dorsal aspect.
Abbreviations: L=left; Zthresh=Z threshold; k=number of voxels; numbers indicate
Talairach Z plane. Note: the sagittal views illustrate the limits of the data collection
range, i.e., the extreme dorsal and ventral areas of the brain were not in the imaging
space.
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3.2.3.3 Patient versus Controls Comparisons
There were no significant differences between the patients and controls at
baseline in gCBF (HC: 42.2 mL/min/100g; BPD: 43.4 mL/min/100g; t = 1.40, p = ns,
df = 45) or in the absolute analysis (not shown).  At baseline, in the normalized
analysis compared to controls, rCBF in the patients was higher in the right peri-
amygdalar region, and bilateral MOFC and MPFC, posterior temporal cortex and
cerebellum (Figure 24; Table 7).  The DLPFC and VLPFC, and right subgenual and
left pregenual anterior cingulate were significantly decreased in the patient compared
to the controls.  The subgenual cluster extended into the basal forebrain substantia
inominata area.
With procaine, gCBF (HC: 50.8 mL/min/100g; BPD: 55.2 mL/min/100g; t =
1.40, p = ns, df = 45) and absolute rCBF were not significantly different between
patients and controls (not shown).  In the normalized analysis, many posterior areas
elevated at baseline in patients versus controls remained after procaine, such as in
bilateral posterior temporal, occipital, parietal cortex, and cerebellum.  Patients
showed significant normalized rCBF decreases (less rCBF increases) than controls in
bilateral DLPFC (BA 10), the left supragenual anterior cingulate cortex, right
putamen/insula, right anterior temporal, and left medial temporal cortices, as well as
left inferior parietal cortex (Figure 24; Table 7).
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Figure 24.  Group Differences in Normalized rCBF at Baseline and with Procaine
Patients with Bipolar Disorder exhibit hypoperfusion in the DLPFC and pregenual
anterior cingulate (PGAC), and hyperperfusion in the subgenual anterior cingulate
(SGAC) compared to healthy controls at baseline.  The baseline abnormalities in the
DLPFC and PGAC persist while the SGAC activity normalizes.  Transverse sections
through the human brain displayed from left to right moving from ventral to dorsal
aspect. Abbreviations: L=left; Zthresh=Z threshold; k=number of voxels; numbers
indicate Talairach Z plane.
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Regions showing a significant group x drug interaction were distributed
throughout the brain (Figure 25; Table 7), but revealed a general pattern of attenuated
anterior paralimbic and enhanced posterior-cerebellar CBF responses to procaine in
patients compared to controls.  Specifically, the right subgenual and pregenual
anterior cingulate, right medial and anterior temporal, and left inferior parietal
cortices were significantly less activated by procaine in the patients than in the
controls.  In contrast, regions significantly more activated by procaine in the patients
compared to controls included the left fusiform / posterior parahippocampal region,
and, occipital, and cerebellum. However, this pattern was not completely uniform; the
anterior regions bilateral DLPFC (BA 46) and left pregenual anterior cingulate were
also significantly more activated by procaine in the patients compared to controls.
3.3.3 Mood and Change in CBF Correlations in Patients
Hamilton depressions ratings (HDRS) significantly correlated positively with
the change blood flow (procaine-baseline) in the right amygdala and left substantia
inominata, and bilateral medial orbitofrontal, hippocampus, posterior temporal,
occipital, parietal and cerebellar cortices in patients (Figure 26).  Also, significant
negative correlations were observed in bilateral subgenual and pregenual anterior
cingulate, VLPFC and MPFC, and right DLPFC.
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Figure 25.  Group / Drug Interaction: 15 Patients vs 32 Controls, Procaine vs Baseline
The DLPFC and cerebellum activated significantly more in the patients than in
controls, while the pregenual anterior cingulate activated significantly less so.
Transverse sections through the human brain displayed from left to right moving from
ventral to dorsal aspect. Abbreviations: L=left; Zthresh=Z threshold; k=number of
voxels; numbers indicate Talairach Z plane.
Figure 26.  Mood Correlation with Change in rCBF in 15 Patients
Worsening of mood was associated with procaine-induced increased right amygdala,
left ventral striatum, MOFC, left DLPFC, and posterior rCBF, and decreased in
anterior cingulate, VLPFC and MPFC rCBF.
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  3.4 Discussion
As in healthy controls (Ketter et al., 1996), moderately depressed treatment-
refractory patients with bipolar disorder showed regional CBF increases in the
amygdala, anterior cingulate, basal forebrain, ventral striatum, and insula with
procaine compared to baseline.  However, this anterior paralimbic activation was less
robust compared to controls.  Moreover, regions previously implicated in the
pathophysiology of bipolar illness, including DLPFC and subgenual anterior
cingulate, exhibited a differential CBF response in patients and controls with procaine
compared to baseline.
Despite similar robust global cerebral blood flow responses to procaine in
patients and healthy controls, differences in normalized rCBF exhibited many of the
expected differences at baseline and with procaine.  At baseline compared to controls,
patients with bipolar disorder exhibited hypoperfusion in the DLPFC and anterior
cingulate, while orbitofrontal, temporal lobe and cerebellar regions showed hyper-
perfusion.  Of note, the basal forebrain region was hypo-perfusional in patients
compared to controls at baseline. The DLPFC and anterior cingulate hypoperfusion
and posterior hyperperfusion persisted during the procaine condition, suggesting
abnormal functional activity of the anterior paralimbic regions in these patients across
different states of emotional arousal (at baseline and during procaine-induced
emotional experiences).  These alterations in these regions may be trait markers for
bipolar disorder.  That is, they occur across mood states as well as across emotional
states.  However, reversal of hypo-frontality, but not cerebellar and striatal hyper-
activity, is associated with euthymia (Ketter et al., 2001).  The lack of significant
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changes in the depression ratings from baseline to procaine conditions suggests the
level of moderately depressed mood in the patients at the time of the study remained
relatively unchanged and is supported by depression ratings collected during the
study.  This may help explain the persistent hypo-frontality at baseline and with
procaine in this study.  In addition, the procaine challenge yields primarily affective,
rather than cognitive activation, consistent with less expected effects on DLPFC
activity.
Some areas of baseline abnormalities in the patients were corrected
(normalized) by procaine, such as the increase in MOFC activity, while accompanied
by an equivalent emotional response as seen in controls.  This contrasts with the
response of the DLPFC, and implies the function of this region may be dependent on
some facet of the current emotional state.  Modulation of the MOFC, a cortical region
with heavy direct cholinergic innervation, could reflect procaine’s muscarinic
cholinergic actions.
Further analysis revealed DLPFC and several other regions exhibited
differential normalized CBF responses in the patients compared to the healthy
controls with procaine-induced changes.  Some parts of the DLPFC (mostly BA 9/10;
X=-40, Y=55, Z=12) remained hypo-perfusional in both conditions, while BA 46 (X=
-45, Y=32, Z=20) within the DLPFC exhibited blood flow increases that were
significantly greater in the patients compared to controls.  A second area of
interaction occurred in the subgenual and pregenual anterior cingulate region; this
area activated significantly less in the patients than in the controls.  DLPFC and the
anterior cingulate, which have been implicated in the pathophysiology of bipolar
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disorder (see reviews, Ketter et al., 1997: Drevets, 1998; Dougherty and Rauch,
1997), thus exhibited differential blood flow responses to procaine in patients
compared to controls, although these groups experienced generally similar levels of
affective arousal.  These findings extend the current understanding of the
(dys)function of the DLPFC and anterior cingulate in mood disorders by suggesting
that a functional adjustment, hyper- or hypo-activity, respectively, assisted in the
attainment of an emotional experience similar to controls.
According to Davidson (2002), both the anterior cingulate and the DLPFC
may function in the resolution of conflicts between the internal state and external
information, and often these regions act reciprocally (Benson et al., 2000).  In this
context, a study paradigm in which strong emotional and sensory experiences are
occurring in a laboratory environment may raise considerable emotional/cognitive
conflicts and re-appraisals, and thus, the expectation would be increased activity in
both regions.  Relative to controls, hypo-activation in DLPFC converted to hyper-
activation and the pregenual AC activation showed further hypo-activation during a
chemically driven emotional experience.  These differences under procaine activation
may represent functional adjustments in patients with bipolar illness during conflict
resolution, and further reveal dysregulation of these substrates in bipolar disorder
compared to controls.  Moreover, the lack of activation of the subgenual AC could
reflect the neural and glial abnormalities reported in this region in those with bipolar
illness (Öngur et al., 1998, Drevets et al., 1997; Rajkowska et al., 1999; Rajkowska,
2000).
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 Another region of group/drug interaction occurred in the cerebellum, where
elevated rCBF observed at baseline remained higher in the patients compared to the
controls during procaine.  This differential baseline and functional response to
procaine in patients compared to controls with concomitant emotional responses
further implicates the cerebellum in mood dysregulation, although causal
relationships remain to be determined.  Although, historically the cerebellum has
been associated with motor activity and movement disorders, recently Schmahmann
(1998) has described the cerebellar-mood dysregulation.  Several investigators have
shown increased activity in the cerebellum in bipolar (Ketter et al., 2001) and
unipolar (Kimbrell et al., 2002) disorder.
The cholinergic forebrain regional CBF was significantly reduced at baseline
in the patients compared to the controls, and both groups showed increased blood
flow in this area with procaine without a significant drug X group interaction.  These
results suggests that despite the region’s reduced blood flow at baseline in the patients
compared to controls, the region seems to activate similarly with procaine, and
supports a cholinergic mechanism of procaine’s actions.
Arecoline, a nonselective muscarinic agonist, has also induced dysphoria in
mood disorder patients whether or not they were currently depressed; this was greater
in individuals with a family history of depression compared to those without such
history (Gillin et al. 1991; Nurnberger et al. 1989).   Procaine’s ability to induce
dysphoria and sensory responses could be more directly related to its cholinergic
properties, while euphoria may occur through cholinergic interactions with other
neuromodulatory systems, such as dopamine (Graybiel et al., 2000).  Other
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mechanisms cannot be excluded as procaine binds with sigma and serotonin receptors
with similar affinities.
This study has several limitations.  As noted above, the sample in this study
was relatively small group of patients with bipolar illness, primarily BPII subtype
experiencing rapid-cycling, and considered treatment resistant.  At the time of the
study most of the patients were not severely depressed, manic or euthymic, but
mostly mildly depressed.  However, despite the small cross-section of bipolar illness
in this sample, the regional abnormalities observed at baseline were similar to that
reported in the literature (see reviews, Dougherty and Rauch, 1997; Ketter et al.,
1997; Drevets, 1998).  In any case, examination of the functional response to procaine
in patients with bipolar illness during different phases (euthymic, severe depression,
or mania) of the illness could provide a more complete picture of limbic and
cholinergic dysregulation in bipolar disorder.
No attempt was made to correlate emotional response with the functional
response to procaine.  These were explored in the next chapter, where the emotional
and sensory ratings were correlated with many ROIs.  However, the relationship of
baseline mood ratings of depression (HDRS) to change in CBF was evaluated.  In this
analysis, change (procaine – baseline) in anterior cingulate and parts of DLPFC CBF
negatively correlated with HDRS scores indicating the more depressed the subjects
showed the least change in CBF in these anterior paralimbic regions.  These results
parallel the notion that patients with bipolar illness showed a blunted CBF response to
procaine in anterior paralimbic areas.  Additionally, change in blood flow in a small
cluster in the cholinergic forebrain area and amygdala positively correlated with
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HDRS, suggesting that depressed mood was associated with increased activity in
these regions that have significant cholinergic innervation.
3.5 Conclusion
In conclusion, patients with bipolar disorder exhibit blunted anterior
paralimbic CBF response to procaine compared to healthy controls.  In addition,
differential activation in the DLPFC, subgenual and pregenual anterior cingulate, and
cerebellum occurred in conjunction with a generally similar range of affective
responses to procaine in the groups.  These regions have repeatedly been reported as
abnormal in this disorder.  Procaine-induced blood flow increases in regions believed
to have significant cholinergic innervations (amygdala, MOFC and ventral striatum)
were associated with worsening of mood.  This is consistent with the work of
Janowsky and colleagues (1972).  Further studies with other affective challenges
(pharmacological or self-induced) and in patients with bipolar disorder with more
diverse symptomatology may provide a clearer picture of the dysfunction experienced
in bipolar illness.
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Chapter 4: Alterations in Functional Connectivity With Procaine
Administration in Humans
4.1 Introduction
Procaine has been used as an affective challenge in healthy controls (Ketter et
al., 1996; Servan-Schreiber et al., 1998), and patients with mood disorders (Ketter et
al., 1993) and panic disorder (George et al., 1993), as well as individuals abusing
alcohol (George et al., 1990) and cocaine (Adinoff et al., 2001).  Procaine, when
administered intravenously (i.v.) in healthy controls results in brief intense emotional
and sensory experiences in association with increased global and regional anterior
paralimbic cerebral blood flow (CBF) as measured with [15O] water PET (Ketter et al.
1996); the amygdala, insula and anterior cingulate are particularly activated.  In
healthy individuals, 1.84 mg/kg procaine induces the following: an array of brief
intense emotional responses ranging from dysphoria (fear and anxiety) to euphoria;
visual and auditory sensory illusions/hallucinations (Kellner et al. 1987); hormonal
changes such as increased ACTH, cortisol, and prolactin secretion (Kling et al. 1994);
and increased temporal lobe fast activity EEG (Parekh et al. 1995).
In patients with bipolar disorder compared to healthy controls, the procaine-
induced anterior paralimbic activation was blunted (see previous chapter).  Moreover,
the severity of depression ratings correlates inversely with the procaine-induced
change in blood flow the anterior cingulate and DLPFC and directly in ventral limbic
structures, such as the amygdala and basal forebrain cholinergic regions.
177
Furthermore, a differential CBF response of the DLPFC and subgenual and pregenual
anterior cingulate during procaine compared to baseline.
The mechanism of procaine’s limbic activation is unknown.  Although
classically associated with the blockade of voltage-gated sodium channels, procaine
has recently been shown to have in vivo action on muscarinic M2 receptors in the
anesthetized rhesus monkey utilizing a radiotracer with preferential binding to these
receptors (Benson et al., 2004).  In that study, procaine blocked the M2 ligand (TZTP)
in a dose-related manner with an in vivo IC50 (1.31 µM) that mirrored estimates
determined from in vitro studies (Sharkey et al., 1988; Hisayama et al. 1989).
Furthermore, peak increases in the flow of the muscarinic radiotracer were near the
estimated IC50.  These results suggest that the binding of procaine to muscarinic
receptors may contribute to the emotional and sensory effects observed in humans if
comparable receptor occupancy occurs (Ketter et al., 1996).
Indirect and direct cholinergic agonists, such as physostigmine and arecoline,
can produce dysphoria in manic patients and normal controls  (Janowsky, 1972b).
The patients have concomitant hormonal disturbances with this emotional arousal
(Janowsky et al. 1986).  These findings have led Janowsky to hypothesize that the
cholinergic system is favored over noradrenergic activity during the depressive phase
of bipolar illness.  Arecoline, a nonselective muscarinic agonist, has also induced
dysphoria in mood disorder patients whether or not they were currently depressed;
this was greater in individuals with a family history of depression compared to those
without such history (Gillin et al. 1991; Nurnberger et al. 1989).   These effects are
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similar to components of the response induced by procaine administration in patients
and healthy controls (Ketter et al., 1996; Ketter et al., 1993).
Several other theories relating the cholinergic system have been suggested
more recently.  Overstreet and colleagues (1998) have suggested a cholinergic-
serotonergic interactions in mood disorders in which they argue that a cholinergic
overactivity predisposes one to depression and serotonergic mechanisms induce
depressive episodes.  Another theory relating the cholinergic system to emotional
processing lies in the work of LeDoux (1996).  In his model of the general emotion
system, amygdala triggered arousal systems interface with basal forebrain cholinergic
activity to mediate fear responses; the basal forebrain cholinergic system activates
prefrontal cortex when stimulated by the amygdala during emotionally significant
events.  In addition, this activity can be sustained to maintain attention on emotional
stimuli.  Damage to NBM interrupts this process.
In summary, cholinergic modulation could contribute significantly to
procaine-induced emotional and sensory experiences.  This is suggested by procaine’s
ability to: 1) induce emotions and endocrine changes; 2) most robustly activate
anterior paralimbic regions in a pattern similar to the most dense muscarinic
cholinergic innervation; and 3) in vivo action on M2 muscarinic cholinergic receptors.
The purpose of this study was to explore any potential contribution of cholinergic
brain regions to procaine-induced emotional and sensory experiences in patients with
bipolar disorder and healthy controls.  Several methods were employed to assess
these potential relationships.
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In this study, functional connectivity and multivariate techniques were used to
examine a cholinergic model using procaine challenge data in patients with mood
disorders and healthy controls.  Functional connectivity, defined as the correlative
strengths between two ROIs, offers an alternative perspective to activation studies (t-
tests) by providing additional information regarding the relationships between ROIs
rather than differences between groups or conditions.  rCBF activation with procaine
was examined in patients with bipolar disorder compared to healthy controls in a
companion paper for comparing and contrasting purposes.
Multivariate multiple regression tested a cholinergic model derived from what
is known about the neuroanatomy of the basal forebrain cholinergic system.  In this
model, the heaviest cholinergic regions, cell bodies and targets (Mesulam, 1995;
Amaral et al., 1992), are depicted in Figure 9.  The main hypothesis tested in this
experiment is that the correlation strengths between regions with cholinergic input
would be greater than non-cholinergic pathways, and the former would be enhanced
following procaine administration.  Following the hypothesis of Janowsky, these
correlational strengths will be greater in the patients than in the healthy controls.
Additionally, anxiety experiences will be related to enhanced cholinergic drive in the
network according the work of LeDoux (1996).  Although the study was hypothesis-
driven, due to the methods employed here and the retrospective nature of the study




The subjects, procedure, behavioral measures, PET acquisition and
preliminary image processing methods were explained in detail in the previous
chapter.  Briefly, 32 healthy controls and 15 otherwise medically healthy patients
with bipolar disorder underwent PET studies with and without procaine
administration after informed consent was obtained.  The subjects were informed that
procaine had various transient emotional and sensory effects, ranging from minimal
to intense and from pleasant to unpleasant, and they were told they could stop the
procedure at any time, and that diazepam was available at all times.   Diagnosis of
Bipolar Disorder was confirmed with Schedule for Affective Disorders and
Schizophrenia – Lifetime Anxiety Version (Mannuzza et al., 1986) by trained
physician.  The majority of the fifteen patients with bipolar disorder were type BPII
(n=14) experiencing rapid cycling (n=11; 3 were undetermined due to lack of life
chart information).
4.2.2 Procaine Procedure and Behavioral Measures
Regional cerebral blood flow (rCBF) was measured using H2
15O PET during
intravenous saline and procaine administration in a single-blind design, where they
were instructed to expect saline, low-dose or high-dose procaine.  Subjects were
injected with saline (sham scan), saline (baseline scan), low-dose procaine (0.46
mg/kg), high-dose procaine (1.84 mg/kg) and saline (recovery of baseline scan) in the
same order.
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Baseline behavioral measures of mood, including clinician and self-ratings,
were collected before the scanning session began (Table 5).  Clinician ratings
included Hamilton Depression Rating scale (Hamilton, 1960; [HDRS]), Young Mania
Rating Scale (Young et al., 1978), and Spielberger State Anxiety Scale (Spielberger
et al., 1970; [SSAS]), and self-ratings included Beck Depression Inventory (Beck, et
al., 1961; [BDI]).  Likert-based ratings of emotional and sensory experiences were
collected at baseline and immediately after each scan.  Demographic, clinician and
self-ratings data were analyzed using paired (within group drug comparisons) and
unpaired t-tests (between-group comparisons) or repeated measures ANOVA with
between and within group factors, as deemed appropriate.
4.2.3 PET Acquisition and Data Analysis
The procedure and preliminary data analysis was described previously in the
previous chapter.  Statistical inference testing on absolute and globally normalized
rCBF data (Friston et al., 1990) was performed with a two-fold purpose, thus two
methodological approaches were used: 1) functional connectivity studies examined
the relationships of the cholinergic ROIs to themselves and a number of other ROIs
located across the brain; and 2) multivariate multiple regression explored the
relationship of procaine-induced changes in emotional responses to rCBF.  Each of
these methods is detailed below.
Functional connectivity was assessed using regional correlation matrices
generated in Statview (SAS Institute, Cary, NC) and SPSS (SPSS Inc., Evanston, IL).
Correlations presented herein are restricted to those between the four bilateral
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cholinergic ROIs (hindbrain and forebrain) and the remaining 26 bilateral ROIs and
three hindbrain ROIs as depicted in Figure 27.  This resulted in 481 distinct
relationships.
Small regions (mean number of pixels = 172.2 ± 136.7; range = 71-609;
values exclude cerebellar and temporal ROIs) were defined on the magnetic
resonance imaging (MRI) supplied with SPM99 by one of two tracing methods or a
center of mass approach, depending on the region.  With tracing methods, the area
chosen for the ROI was considered to be the most central portion of the region.
Based on the MRI, the basal forebrain cholinergic area was divided into two ROIs
representing the substantia inominata (SI) and the septal area (SEP).  A third
forebrain ROI was defined as the conglomerate of the basal forebrain cholinergic
region (BF), which included the SI and SEP regions, and some extended amygdala,
but not the amygdala proper.  Due to the indistinct boundaries of the basal forebrain
regions and limits of the resolution of the PET scanning technique, the substantia
inominata and the septal region were drawn in an inclusive manner, yielding regions
that encompassed what was thought to be the heaviest cholinergic innervation area.
The brainstem ROI representing the cholinergic cell bodies in the tegmentum (TEG)
was also defined on the MRI supplied by SPM 99.
For some areas of cortex, a center of mass was chosen based on coordinates
reported in the literature where significant findings occurred.  This method was
applied to: 1) the region anterior to the genu with Talairach coordinates X = ±6, Y =
42, and Z=10 corresponds the region described by Mayberg and colleagues (1997)
that has differential responsiveness with effective antidepressant treatment; 2) a
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region near the subgenual anterior cingulate reported to be hypo-metabolic
(coordinates X = ±6, Y = 38, and Z=-6; Drevets, et al., 1997) in depressed mood
disorder patients; and 3) the dorsolateral prefrontal cortex (DLPFC; coordinates X =
±40, Y = 22, and Z=22) and anterior insula (coordinates X = ±36, Y = 14, and Z=4)
where patients with Bipolar Disorder exhibit hypo-metabolism or hyper-metabolism,
respectively, at baseline compared to controls (Ketter et al., 1999).
Other cortical regions were defined by placing a spherical mass in the center
of the region guided by the atlas of Talairach and Tourneaux (1988); this method was
used for ventrolateral prefrontal (VLPFC), lateral (LOFC) and medial (MOFC)
orbitofrontal, inferior parietal, anterior and posterior temporal cortices, and the
temporal pole.  The anterior cingulate was subdivided into subgenual, pregenual,
supragenual and dorsal regions (Benson et al., 2000).
Nuclei regions were manually traced from the MRI supplied by SPM 99, such
as the amygdala, hippocampus, caudate, putamen, globus pallidus, medial nucleus of
the dorsal thalamus, midbrain, pons, and medulla.  The cerebellar folia and nuclei
were defined based on the atlas of Schmahmann et al. (2000).  The temporal and
cerebellar ROIs were the only regions for which there was no rationale for a small
targeted region, thus the entire region was included in the ROI.
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Figure 27.  Location of Regions of Interest (ROIs)
Representation of ROI placements on MRI supplied by SPM. Transverse sections
through the human brain displayed from left to right moving from ventral to dorsal
aspect. Abbreviations: L=left; numbers indicate Talairach Z plane.
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Significant differences between groups or drug conditions in functional
connectivity were determined by two methods, due to the smaller sample size of the
patient group, thus the potential for Type II error.  The first method used either
statistical comparison across groups by Fisher’s r-to-z transformed r values or the
methods of Steiger (1980) for comparison across conditions that incorporates within-
subject dependence of the conditions.  The alpha level for significant correlations and
differences between drugs or groups was set at α=0.05.  With Steiger’s method, the
comparisons between conditions in the patient group (n=15) showed few significant
differences.  This is in sharp contrast to the control group (n=32), where numerous
significant differences were found.  Given the null hypothesis of no differences
between the groups (rcontrols = rpatients), the chances of the numerous differences
between the groups was suspect and indicated that the likelihood of a Type-II error in
the patient group comparisons was high. Tables summarizing the first method can be
found in Appendices A and B.
The second method attempted to establish significance less dependent on
sample size, while remaining rigorous.  This method used the cut-off of r>0.43 or r<-
0.43 (critical r for n=15) to determine whether correlations were significantly
different from zero in either group or condition.  To compare across groups or drugs,
the root mean square difference (∆r) was calculated in each case,
∆r = √ rbd 2 – rhc 2, or
∆r = √rp2 – rc2,
while keeping the sign of correlations intact.  The cut-off for significance in the
comparison was set r>0.50 or r<-0.50. This second method showed that indeed, in the
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healthy control group, the significant differences between conditions were for the
most part the same as the first method.  However, in the patient group there were
many differences between the drug conditions not detected by the first method, and
more similar to that observed in the controls.  Thus, the results presented in this study
refer to this second method.
Due to the retrospective design, the number of regions examined and at times
the segmentation of regions close to the resolution of the PET scanning technique,
this study is viewed in an exploratory analysis of potential relationships between the
cholinergic regions and the remainder of the brain.  Owing to the significant age
difference between the two groups, regional correlations with and without partialling
out age were compared, and none were found not to be significantly different using
the methods as outlined below for comparing correlations.  No significant differences
in the regional correlations were observed when baseline mood, as measured by
HDRS, was partialled out.   No attempt was made to partial out HDRS in the controls,
as controlling for a covariate with no variance is not statistically valid.  Thus, the
results reported here are correlations without age or HDRS partialled out.
No attempt to correct for multiple comparisons was made with either method
in that the aim of the study was to examine the regional patterns of significant
changes rather than the depending on any one correlational difference as meaningful.
Specific hypotheses in this regard were limited to confirmation in each group of three
known neuroanatomical pathways between the cholinergic ROIs and the rest of the
brain, i.e., 1) the substantia inominata projection pattern to the amygdala, subgenual
and pregenual anterior cingulate, anterior insula, and MOFC; 2) septo-hippocampal
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pathway; and 3) tegemental – brainstem pathway.  More generally, alterations in the
correlative relationships of the cholinergic ROIs with brain regions shown to be
hyper- or hypo-active in patients compared to controls would extend and support
potential differences in activation studies.
4.2.4 Relationships Between Emotional Responses and rCBF
Two approaches were employed to delineate relationships between procaine-
induced emotional and sensory changes and rCBF.  First, a focused assessment of the
correlations between the change in rCBF in the cholinergic ROIs and the change in
emotional and sensory ratings (delta-delta correlations) directly evaluated the
cholinergic relationships to emotion and sensory regulation.  This was followed by
multivariate multiple regression analyses examining the ability of delta CBF
cholinergic network (AChNet), as described by Figure 9, to predict the change in
emotional and sensory responses, which is detailed below.
Multivariate multiple regression analysis was used to evaluate the degree of
associativity between emotional experiences and rCBF activation.  Delta ratings were
predicted from delta-rCBF according to the cholinergic model in Figure 9 (AChNet).
The six ROIs (SI, amygdala, subgenual AC, pregenual AC, anterior insula, and
MOFC) with the heaviest cholinergic innervation were chosen to predict positive
(euphoria, calmness) and negative (anxiety, fear) emotional responses.  Due to sample
size limitations, separate analyses were performed for each group and laterality (right
and left).  A reduced model, which explained the most variance without loosing more
than 20% of the total variance, was the result of an elimination process whereby
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variables were removed from the full model one by one (similar to stepwise
regression, although the automated software function was not used).  First, the one
emotion with the least variance explained was eliminated; this was followed by
elimination of a ROI based on the lowest partial correlation.  In most cases, the model
was reduced to two to three regions that explained a majority of the variance in the
complete model ∆R2 > 0.20.  Subsequently, substitutions in the model were made in
an effort to improve the fit of the model.  Either singly or in combinations, exchanges
included BF for SI, Drevets ROI for subgenual AC, Mayberg ROI for pregenual AC,
and DLPFC for MOFC.  A significant model was considered to be R2 > 0.25, and
significant improvement after substitutions in a model was ∆R2 > 0.20.  Significant
differences in models between groups was set at ∆R2 > 0.10.
4.3 Results
4.3.1 Emotional and Sensory Response to Procaine
Emotional and sensory responses to procaine were reported in the previous
chapter, and will only be briefly described.  Baseline ratings of depression, fear,
anxiety, anger, calmness and overall bad/good feeling were significantly different
between the groups.  Ratings of euphoria, anxiety, calmness, tiredness, and sensory
ratings for visual and auditory changes were essentially identical in the procaine
condition.  There was a significant group X drug interaction in depression ratings, due
to greater depression ratings of the patients at baseline, which became nonsignificant
with procaine.  Also, Patients rated fear significantly greater in both conditions.
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Ratings of anger and depression were generally not normally distributed (mostly zero
scores), with the exception of depression ratings by the patients at baseline.
4.3.2 Functional Connectivity Studies
The correlational matrices for each condition (saline or procaine) in the
healthy controls and patients are displayed in Tables 8 and 9, respectively.  The
regions in these tables are listed in the general order from rostral to caudal orientation
across the brain, with the cholinergic ROIs heading the table.  This method of
organization revealed clusters of significant positive and negative correlations across
the ROIs, often indicating strong correlative relationships between adjacent or
anatomically related regions with the cholinergic ROIs.  An example would be the
cluster of positive correlations between the forebrain septal area ROI with dorsal
thalamus and striatum.  The right-hand panel illustrates where there was a significant
change in the correlation coefficients across conditions, with red indicating
significantly more positive correlation and blue indicating significantly less positive
correlation.  The color-coding along the right edge of the tables corresponds to three
cholinergic pathways, tegemental-midbrain, substantia inominata-forebrain, and the
septo-hippocampal pathways.
 4.3.2.1 Healthy Controls at Baseline
All of the forebrain cholinergic ROIs were significantly positively inter-
correlated in healthy controls at baseline (Tabele 8).  However, the tegemental ROI
did not always correlate significantly with the forebrain cholinergic ROIs.  The
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brainstem, including the medulla, pons, midbrain, and cerebellum, ROIs were all
significantly positively correlated with bilateral tegmental ROI, but not all the
cholinergic forebrain ROIs.  Of the cholinergic forebrain ROIs, the septal area (and
thus the BF mean ROIs) was positively correlated with the midbrain and hindbrain,
while the SI ROIs were not.
Many of the forebrain nuclei, such as the amygdala, hippocampus, striatum
and thalamus, exhibited positive correlations with predominately the forebrain, but
few of the tegmental cholinergic ROIs.   Again, the majority of the forebrain
significant correlations were with the septal area ROI, as seen in the hindbrain and
midbrain.
Cortical regions displayed both positive and negative correlations with the
cholinergic ROIs, although few of the negative correlations were significant.  Almost
all of the subdivisions of the anterior cingulate ROIs were significantly positively
correlated with the SI ROI (mostly on the right), but relatively few were significantly
correlated with the septal ROI.  The subgenual subdivision correlated with both SI
and SEP ROIs.
The temporal pole significantly positively correlated with the forebrain
cholinergic ROIs.  In contrast, the posterior temporal cortex generally was not
correlated with the forebrain cholinergic ROIs, but in a few cases was significantly
negatively correlated.  None of the temporal cortex ROIs were significantly correlated
with the tegemental ROI.  In general, the insula was not significantly correlated with
the cholinergic ROIs, either forebrain or tegmental; the exceptions were the right
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Table 8. Correlative Relationships Between Cholinergic Brain Regions and ROIs



















































































































L Tegementum 0.51 0.31 0.27 0.56 0.57 0.52 0.50 0.67 -0.34 -0.23 -0.21 -0.18 -0.21 -0.16 0 0 0 ↓ ↓ ↓ ↓
R Tegmentum 0.51 0.05 0.03 0.44 0.37 0.31 0.30 0.67 -0.28 -0.04 -0.04 0.02 -0.12 -0.01 0 0 0 0 0 0 0
L SI 0.31 0.05 0.61 0.64 0.59 0.81 0.60 -0.34 -0.28 0.80 0.87 0.71 0.95 0.79 0 0 ↑ ↑ 0 0 ↑
R SI 0.27 0.03 0.61 0.43 0.67 0.57 0.76 -0.23 -0.04 0.80 0.74 0.81 0.81 0.94 0 0 ↑ ↑ 0 ↑ ↑
L Septal n 0.56 0.44 0.64 0.43 0.85 0.88 0.81 -0.21 -0.04 0.87 0.74 0.86 0.91 0.81 ↓ 0 ↑ ↑ 0 0 0
R Septal n 0.57 0.37 0.59 0.67 0.85 0.77 0.91 -0.18 0.02 0.71 0.81 0.86 0.76 0.90 ↓ 0 0 0 0 0 0
L BF 0.52 0.31 0.81 0.57 0.88 0.77 0.83 -0.21 -0.12 0.95 0.81 0.91 0.76 0.84 ↓ 0 0 ↑ 0 0 0
R BF 0.50 0.30 0.60 0.76 0.81 0.91 0.83 -0.16 -0.01 0.79 0.94 0.81 0.90 0.84 ↓ 0 ↑ ↑ 0 0 0
Medulla 0.56 0.67 0.39 0.34 0.64 0.61 0.59 0.56 0.78 0.57 -0.15 -0.10 -0.02 -0.13 0.00 -0.02 ↑ 0 0 0 ↓ ↓ ↓ ↓
Pons 0.75 0.77 0.29 0.01 0.63 0.53 0.53 0.42 0.67 0.85 0.00 0.18 0.21 0.24 0.15 0.24 0 0 0 0 ↓ 0 ↓ 0
Midbrain 0.80 0.49 0.41 0.20 0.72 0.62 0.73 0.62 0.31 0.40 0.47 0.50 0.53 0.56 0.61 0.59 ↓ 0 0 0 0 0 0 0
L Cerebellum 0.58 0.63 0.18 0.03 0.45 0.33 0.30 0.30 0.77 0.61 -0.40 -0.28 -0.38 -0.41 -0.29 -0.28 ↑ 0 0 0 ↓ ↓ 0 0
R Cerebellum 0.61 0.69 0.23 0.00 0.43 0.30 0.31 0.25 0.72 0.56 -0.32 -0.24 -0.33 -0.40 -0.22 -0.23 0 0 0 0 ↓ ↓ 0 0
L Cerebellum n 0.54 0.59 0.29 0.14 0.46 0.32 0.42 0.36 0.75 0.52 -0.12 -0.02 -0.17 -0.22 -0.03 -0.03 ↑ 0 0 0 0 0 0 0
R Cerebellum n 0.49 0.62 0.22 -0.01 0.40 0.23 0.34 0.27 0.62 0.40 0.25 0.22 0.19 0.05 0.35 0.23 0 0 0 0 0 0 0 0
L m Thalamus 0.52 0.44 0.46 0.28 0.69 0.49 0.74 0.59 0.07 0.08 0.58 0.59 0.61 0.60 0.67 0.65 ↓ 0 0 ↑ 0 0 0 0
R m Thalamus 0.42 0.40 0.29 0.24 0.66 0.56 0.62 0.63 0.12 0.09 0.50 0.58 0.51 0.60 0.53 0.66 0 0 0 ↑ 0 0 0 0
L Caudate 0.46 0.03 0.60 0.49 0.60 0.56 0.81 0.67 -0.22 -0.11 0.77 0.75 0.75 0.72 0.78 0.77 ↓ 0 0 ↑ 0 0 0 0
R Caudate 0.32 0.19 0.32 0.57 0.52 0.57 0.61 0.72 0.01 0.06 0.54 0.70 0.63 0.70 0.60 0.74 0 0 0 0 0 0 0 0
L Putamen 0.06 -0.17 0.31 0.57 0.26 0.37 0.38 0.50 -0.20 -0.18 0.85 0.77 0.75 0.67 0.82 0.77 0 0 ↑ ↑ ↑ ↑ ↑ ↑
R Putamen 0.04 -0.03 0.45 0.59 0.17 0.28 0.39 0.50 -0.19 -0.13 0.75 0.83 0.66 0.65 0.73 0.83 0 0 ↑ ↑ ↑ ↑ ↑ ↑
L Globus Pallidus 0.27 0.21 0.18 0.08 0.47 0.38 0.49 0.44 -0.46 -0.42 0.67 0.48 0.58 0.43 0.65 0.47 ↓ ↓ ↑ 0 0 0 0 0
R Globus Pallidus 0.15 0.21 0.37 0.36 0.59 0.50 0.58 0.62 -0.25 -0.20 0.64 0.66 0.62 0.65 0.65 0.74 0 0 ↑ ↑ 0 0 0 0
L Hippocampus 0.36 0.39 0.38 0.45 0.57 0.52 0.57 0.55 0.24 0.24 0.02 0.05 0.07 -0.09 0.14 0.07 0 0 0 0 ↓ ↓ ↓ ↓
R Hippocampus 0.41 0.34 0.28 0.39 0.53 0.66 0.52 0.62 0.50 0.49 -0.41 -0.34 -0.24 -0.23 -0.30 -0.24 0 0 ↓ ↓ ↓ ↓ ↓ ↓
L Amygdala 0.54 0.37 0.45 0.30 0.69 0.57 0.67 0.60 -0.05 -0.16 0.50 0.34 0.53 0.41 0.55 0.46 ↓ 0 0 0 0 0 0 0
R Amygdala 0.34 0.19 0.28 0.14 0.55 0.47 0.49 0.54 0.00 0.18 0.35 0.48 0.46 0.54 0.41 0.62 0 0 0 0 0 0 0 0
L Ant Insula -0.35 -0.46 0.26 0.08 -0.35 -0.32 -0.15 -0.25 -0.32 -0.28 0.72 0.73 0.63 0.62 0.66 0.67 0 0 ↑ ↑ ↑ ↑ ↑ ↑
R Ant Insula -0.04 -0.17 0.24 0.46 0.06 0.17 0.12 0.24 -0.25 -0.14 0.60 0.74 0.49 0.63 0.50 0.71 0 0 ↑ ↑ 0 ↑ 0 ↑
L Post Insula 0.03 -0.07 0.25 0.22 0.07 0.09 0.20 0.24 -0.16 -0.17 0.64 0.55 0.57 0.47 0.60 0.56 0 0 ↑ ↑ ↑ 0 ↑ ↑
R Post Insula 0.07 -0.09 0.04 -0.05 0.01 -0.06 0.19 0.08 -0.33 -0.20 0.69 0.76 0.62 0.68 0.67 0.78 0 0 ↑ ↑ ↑ ↑ ↑ ↑
L Subgenual AC 0.03 -0.12 0.66 0.56 0.36 0.30 0.52 0.37 -0.06 -0.07 0.64 0.54 0.58 0.49 0.69 0.51 0 0 0 0 0 0 0 0
R Subgenual AC 0.20 0.06 0.48 0.66 0.54 0.62 0.50 0.67 0.09 0.14 0.35 0.45 0.43 0.42 0.43 0.45 0 0 0 0 0 0 0 ↓
L Drevet -0.03 -0.31 0.42 0.51 0.16 0.28 0.19 0.26 -0.31 -0.26 0.69 0.48 0.49 0.30 0.63 0.40 0 0 ↑ 0 0 0 ↑ 0
R Drevet 0.00 -0.18 0.36 0.61 0.19 0.36 0.19 0.40 -0.03 -0.07 0.53 0.61 0.40 0.42 0.45 0.52 0 0 0 0 0 0 0 0
L Pregenual AC -0.07 -0.37 0.42 0.68 0.23 0.40 0.30 0.43 -0.36 -0.28 0.66 0.74 0.60 0.63 0.58 0.73 0 0 ↑ 0 ↑ 0 0 ↑
R Pregenual AC -0.12 -0.41 0.25 0.66 0.03 0.25 0.09 0.33 -0.22 -0.31 0.67 0.64 0.53 0.55 0.57 0.59 0 0 ↑ 0 ↑ 0 ↑ 0
L Mayberg -0.01 -0.45 0.48 0.68 0.19 0.36 0.31 0.40 -0.28 -0.20 0.61 0.72 0.57 0.64 0.55 0.74 0 0 0 0 ↑ ↑ 0 ↑
R Mayberg -0.11 -0.45 0.22 0.62 -0.02 0.19 0.07 0.27 -0.24 -0.30 0.66 0.66 0.53 0.58 0.56 0.62 0 0 ↑ 0 ↑ ↑ ↑ ↑
L Supragenual AC -0.04 -0.48 0.55 0.62 0.23 0.34 0.31 0.40 -0.45 -0.53 0.71 0.62 0.55 0.54 0.60 0.61 ↓ 0 0 0 ↑ 0 ↑ 0
R Supragenual AC 0.02 -0.43 0.45 0.69 0.12 0.33 0.27 0.43 -0.46 -0.46 0.76 0.68 0.61 0.60 0.67 0.61 ↓ 0 ↑ 0 ↑ ↑ ↑ 0
L Dorsal AC -0.02 -0.38 0.26 0.65 0.15 0.27 0.33 0.44 -0.23 -0.31 0.63 0.69 0.58 0.68 0.62 0.72 0 0 ↑ 0 ↑ ↑ ↑ ↑
R Dorsal AC -0.05 -0.41 0.27 0.56 0.04 0.13 0.26 0.33 -0.22 -0.36 0.62 0.73 0.55 0.69 0.61 0.69 0 0 ↑ 0 ↑ ↑ ↑ ↑
L Post AC -0.24 -0.10 0.36 0.19 0.00 0.06 0.20 0.16 0.04 -0.11 0.25 0.25 0.16 0.22 0.32 0.37 0 0 0 0 0 0 0 0
R Post AC -0.13 -0.30 0.46 0.33 0.11 0.23 0.26 0.31 -0.02 -0.18 0.16 0.19 0.20 0.33 0.25 0.33 0 0 0 0 0 0 0 0
L Ant Tenporal 0.00 -0.05 0.30 0.20 0.35 0.40 0.24 0.22 0.02 0.17 -0.14 -0.22 -0.06 -0.14 -0.11 -0.21 0 0 0 0 0 0 0 0
R Ant Temporal -0.03 0.02 0.22 0.40 0.07 0.37 0.03 0.28 0.23 0.16 -0.10 -0.02 -0.08 -0.10 -0.07 0.02 0 0 0 0 0 0 0 0
L Post Temporal 0.16 0.01 0.03 -0.40 0.04 -0.07 -0.01 -0.18 0.15 0.23 -0.08 -0.26 -0.13 -0.32 -0.10 -0.29 0 0 0 0 0 0 0 0
R Post Temporal -0.10 0.06 -0.47 -0.47 -0.31 -0.23 -0.43 -0.29 0.15 0.33 -0.31 -0.28 -0.28 -0.27 -0.31 -0.27 0 0 0 0 0 0 0 0
L TP 0.09 -0.01 0.69 0.62 0.54 0.55 0.63 0.57 0.18 0.12 0.12 0.21 0.15 0.07 0.23 0.21 0 0 ↓ ↓ ↓ ↓ ↓ ↓
R TP 0.04 0.13 0.36 0.47 0.35 0.50 0.33 0.46 0.23 0.28 -0.02 0.17 -0.01 0.01 0.04 0.20 0 0 0 0 ↓ 0 0 0
L Inf Parietal -0.04 -0.10 0.20 0.19 0.06 0.05 0.13 -0.08 -0.20 -0.23 0.49 0.34 0.34 0.24 0.40 0.21 0 0 0 0 0 0 0 0
R Inf Parietal -0.18 -0.06 -0.21 0.05 -0.17 0.00 -0.17 -0.10 -0.26 -0.08 -0.01 0.01 0.02 0.07 -0.05 -0.04 0 0 0 0 0 0 0 0
L Occipital -0.12 0.17 0.07 -0.21 -0.12 -0.23 -0.06 -0.25 0.22 0.15 -0.04 -0.13 0.05 0.02 -0.07 -0.08 0 0 0 0 0 0 0 0
R Occipital -0.24 -0.29 0.07 -0.30 -0.32 -0.38 -0.16 -0.32 -0.01 -0.14 0.07 -0.04 0.04 0.07 0.00 0.03 0 0 0 0 0 0 0 0
L DLPFC -0.25 -0.49 0.17 0.00 -0.06 -0.02 -0.02 -0.06 -0.30 -0.32 0.34 0.18 0.21 0.14 0.16 0.14 0 0 0 0 0 0 0 0
R DLPFC -0.35 -0.57 -0.11 -0.16 -0.39 -0.32 -0.33 -0.31 -0.49 -0.38 0.34 0.42 0.22 0.34 0.18 0.34 0 0 0 0 0 0 0 0
L VLPFC 0.12 -0.27 0.45 0.47 0.13 0.24 0.31 0.32 -0.34 -0.35 0.61 0.37 0.41 0.24 0.51 0.31 0 0 0 0 0 0 0 0
R VLPFC 0.23 0.01 0.29 0.52 0.32 0.57 0.28 0.56 -0.13 -0.07 0.40 0.44 0.33 0.32 0.37 0.41 0 0 0 0 0 0 0 0
L MOFC 0.08 -0.18 0.43 0.45 0.16 0.25 0.21 0.24 0.11 0.14 0.28 0.32 0.25 0.16 0.28 0.27 0 0 0 0 0 0 0 0
R MOFC 0.15 -0.03 0.40 0.60 0.25 0.41 0.26 0.44 0.22 0.19 0.20 0.36 0.14 0.14 0.22 0.28 0 0 0 0 0 0 0 0
L LOFC 0.40 0.29 0.22 0.35 0.50 0.46 0.46 0.60 0.31 0.25 0.10 0.24 0.01 0.00 0.17 0.21 0 0 0 0 ↓ 0 0 ↓
R LOFC 0.18 0.22 -0.12 0.18 0.30 0.30 0.18 0.40 Totals 0.13 0.17 -0.13 0.08 -0.17 -0.09 -0.07 0.05 Totals 0 0 0 0 0 0 0 0
# r > .45 15 8 17 26 22 23 23 24 158 8 7 32 30 30 27 31 30 195 0 0 0 0 0 0 0 0
# r < -.45 0 4 1 1 0 0 0 0 6 4 2 0 0 0 0 0 0 6 0 0 0 0 0 0 0 0
Total 15 12 18 27 22 23 23 24 164 12 9 32 30 30 27 31 30 201 0 0 0 0 0 0 0 0
Cholinergic System
# Positive corrs 40 33 58 55 54 54 54 53 401 26 27 47 49 49 50 47 50 345 r ∆r Tegmental-Midbrain
# Negative corrs 22 29 4 7 8 8 8 9 95 36 35 15 13 13 12 15 12 151 >.50 ↑ >.50 Substantia Inominata
Total 62 62 62 62 62 62 62 62 496 62 62 62 62 62 62 62 62 496 <-.50 ↓ <-.50 Septo-Hippocampal
Legend
Procaine vs Saline
BF MeanBasal ForebrainBrainstemBasal ForebrainBrainstem
Saline Procaine
BF MeanBasal ForebrainBrainstemBF Mean
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 anterior insula was positively correlated with right SI ROI, and the left anterior
insula correlated negatively with the left septal and tegmental ROIs.
Significant correlations, of either valence, were generally not observed
between prefrontal cortex regions with the cholinergic ROIs.  Bilateral VLPFC cortex
was generally positively correlated with the forebrain cholinergic ROIs, whereas
bilateral DLPFC was negatively correlated with the midbrain tegmental ROI.
Regions lacking significant relationships with any of the cholinergic ROIs
were the bilateral posterior insular, lateral orbitofrontal cortex, inferior parietal and
occipital cortices, and right anterior and left posterior temporal cortex.
4.3.2.2 Healthy Controls with Procaine
Three major organizational themes emerged in the procaine condition.  First, a
striking pattern of clustering of positive correlations in the forebrain ROIs was
observed with themselves, the anterior cingulate, the insula, and the striatum. This
was primarily a result of the addition of the anterior cingulate and the anterior and
posterior insula, which were significantly more positive with procaine than at
baseline. There were few correlations apart from these clusters.  Regions with
significantly more positive correlations in the procaine condition than at baseline
included the anterior cingulate, anterior and posterior insula, and the putamen.
Second, some correlations were no longer significant resulting in significantly
less positive correlations. The correlations with the temporal pole and the
hippocampus were either weak and/or negative with procaine, resulting in a
significant reduction in correlational strength with the forebrain cholinergic ROIs.
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The only significant change in correlative relationships of cholinergic ROIs with the
amygdala was a loss of a significant positive correlation between the bilateral
tegmental and the left amygdala ROIs.
 Third, more often than not, the forebrain and tegmental ROIs exhibited a
differential pattern of correlations or significant changes in correlations with procaine
compared to baseline with the other ROIs, depending on whether the cholinergic
source was brainstem or forebrain.  For example, within the cholinergic ROIs, the
correlations between forebrain ROIs, whether between contralateral pairs or amongst
forebrain ROIs, remained or became significantly more positive with procaine
compared to baseline.  In contrast, a significant reduction in correlational strength
between the left tegmental and cholinergic forebrain ROIs from the baseline
condition were observed (Table 8; middle and right sections).
This differential pattern was also observed in the hindbrain, where the
medulla, pons and cerebellum lacked significant correlations with the forebrain ROIs
while the tegmental ROIs were significantly positively correlated; the pattern in the
midbrain was reversed, where the forebrain ROI correlations were significantly
positive and the tegmental ROIs were not significant.  Significant changes in the
correlations with procaine from baseline occurred in the opposite manner also.  The
correlations of the forebrain ROIs, specifically the septal area ROI, became
significantly more negative with the medulla, caudal pons, and cerebellum, while the
correlations of the tegmental ROIs were significantly more positive in the medulla,
and left cerebellum folia and nuclei; again, the exception is the midbrain.  This
194
differential pattern of significant changes with procaine from baseline also occurred
with the caudate, globus pallidus, and supragenual AC.
4.3.2.3 Patients at Baseline
In general, the patients displayed the same overall pattern of significant
correlations between the cholinergic and other ROIs as compared to the healthy
controls, however, with some significant variations.  In some cases, weaker
correlations were observed leaving “holes” in the significance pattern (Table 9; left
panel).  The positive correlations amongst the cholinergic ROIs were for the most part
significant, as well as the correlations between the contralateral pairs, with the
exception of the SI pair.   These positive correlations were in some cases,
significantly less positive in the patients compared to the controls (Table 9; left
panel).  In contrast, the contralateral tegmental correlation was significantly more
positive in the patient compared to the controls.
Although some of the correlational patterns appeared somewhat different from
the controls, upon assessment of significant differences, often there were few (Table
10).  This occurred in correlations between the cholinergic and the brainstem, the
dorsal thalamus and striatum ROIs.
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Table 9. Correlative Relationships Between Cholinergic Brain Regions and ROIs




















































































































L Tegementum 0.69 0.36 0.16 0.28 0.55 0.35 0.28 0.62 0.05 -0.11 0.28 0.44 0.27 0.10 0 0 0 0 0 0 0
R Tegmentum 0.69 0.19 0.12 0.27 0.54 0.17 0.33 0.62 -0.18 -0.13 0.06 0.15 0.03 0.16 0 0 0 0 ↓ 0 0
L SI 0.36 0.19 0.31 0.89 0.46 0.82 0.36 0.05 -0.18 0.75 0.80 0.73 0.82 0.75 0 0 ↑ 0 ↑ 0 ↑
R SI 0.16 0.12 0.31 0.19 0.57 0.54 0.95 -0.11 -0.13 0.75 0.76 0.64 0.83 0.93 0 0 ↑ ↑ 0 ↑ 0
L Septal n 0.28 0.27 0.89 0.19 0.52 0.82 0.33 0.28 0.06 0.80 0.76 0.87 0.96 0.80 0 0 0 ↑ ↑ ↑ ↑
R Septal n 0.55 0.54 0.46 0.57 0.52 0.50 0.73 0.44 0.15 0.73 0.64 0.87 0.83 0.77 0 ↓ ↑ 0 ↑ ↑ 0
L BF 0.35 0.17 0.82 0.54 0.82 0.50 0.59 0.27 0.03 0.82 0.83 0.96 0.83 0.85 0 0 0 ↑ ↑ ↑ ↑
R BF 0.28 0.33 0.36 0.95 0.33 0.73 0.59 0.10 0.16 0.75 0.93 0.80 0.77 0.85 0 0 ↑ 0 ↑ 0 ↑
Medulla 0.34 0.75 0.02 0.14 0.22 0.37 0.23 0.30 0.27 0.68 -0.34 -0.13 -0.06 0.13 -0.14 0.10 0 0 0 0 0 0 0 0
Pons 0.80 0.85 0.49 0.20 0.58 0.73 0.50 0.40 0.88 0.64 0.34 0.07 0.40 0.55 0.41 0.30 0 ↓ 0 0 0 0 0 0
Midbrain 0.60 0.70 0.54 0.23 0.65 0.69 0.62 0.44 0.59 0.23 0.79 0.48 0.72 0.84 0.73 0.63 0 ↓ ↑ 0 0 0 0 0
L Cerebellum 0.61 0.79 0.15 0.33 0.27 0.57 0.27 0.48 0.68 0.55 -0.21 -0.30 -0.13 0.03 -0.12 -0.12 0 ↓ 0 0 0 ↓ 0 0
R Cerebellum 0.67 0.78 0.24 0.14 0.35 0.72 0.23 0.36 0.57 0.61 -0.18 -0.26 -0.15 0.12 -0.17 0.01 0 ↓ 0 0 0 ↓ 0 0
L Cerebellum n 0.66 0.48 0.51 0.41 0.36 0.70 0.41 0.53 0.31 0.36 0.24 0.12 0.24 0.33 0.25 0.33 ↓ 0 0 0 0 ↓ 0 0
R Cerebellum n 0.43 0.68 0.38 0.36 0.32 0.66 0.25 0.51 0.05 0.35 0.27 0.26 0.16 0.23 0.16 0.46 0 ↓ 0 0 0 ↓ 0 0
L m Thalamus 0.39 0.50 0.59 0.38 0.66 0.53 0.72 0.48 0.36 0.25 0.64 0.42 0.63 0.80 0.66 0.63 0 0 0 0 0 ↑ 0 0
R m Thalamus 0.66 0.51 0.64 0.35 0.57 0.69 0.63 0.45 0.36 0.31 0.81 0.63 0.80 0.85 0.80 0.79 ↓ 0 ↑ ↑ ↑ 0 0 ↑
L Caudate 0.19 -0.14 0.56 0.24 0.61 0.18 0.75 0.27 0.23 -0.25 0.58 0.49 0.66 0.43 0.74 0.42 0 0 0 0 0 0 0 0
R Caudate 0.43 0.01 -0.04 0.50 -0.14 0.29 0.28 0.44 0.35 -0.31 0.51 0.34 0.57 0.53 0.62 0.29 0 0 ↑ 0 ↑ 0 ↑ 0
L Putamen 0.50 0.21 0.60 0.44 0.49 0.43 0.69 0.49 0.41 0.13 0.77 0.42 0.67 0.77 0.66 0.58 0 0 0 0 0 ↑ 0 0
R Putamen 0.02 -0.06 0.10 0.79 -0.11 0.35 0.12 0.72 0.16 -0.04 0.66 0.60 0.55 0.73 0.60 0.71 0 0 ↑ ↓ ↑ ↑ ↑ 0
L Globus Pallidus 0.38 0.27 0.16 0.51 0.19 0.40 0.43 0.56 0.29 -0.03 0.56 0.37 0.61 0.44 0.66 0.42 0 0 ↑ 0 ↑ 0 ↑ 0
R Globus Pallidus 0.54 0.46 -0.14 0.33 -0.10 0.42 0.07 0.43 0.04 -0.08 0.62 0.65 0.73 0.69 0.69 0.71 ↓ 0 ↑ ↑ ↑ ↑ ↑ ↑
L Hippocampus -0.15 0.08 -0.01 0.34 0.13 0.22 0.25 0.40 0.34 0.34 0.44 0.26 0.35 0.15 0.33 0.29 0 0 0 0 0 0 0 0
R Hippocampus -0.03 -0.46 0.33 0.10 0.18 0.06 0.28 0.07 -0.13 0.10 0.18 0.00 -0.20 -0.02 -0.22 0.06 0 0 0 0 0 0 0 0
L Amygdala 0.36 0.53 0.46 0.56 0.41 0.75 0.40 0.67 0.38 0.58 0.55 0.55 0.50 0.56 0.53 0.73 0 0 0 0 0 ↓ 0 0
R Amygdala -0.01 0.20 0.68 -0.09 0.76 0.28 0.41 0.06 0.01 0.26 0.55 0.40 0.30 0.40 0.28 0.54 0 0 0 0 ↓ 0 0 ↑
L Ant Insula 0.21 0.53 0.23 -0.19 0.43 0.19 0.19 -0.01 0.37 0.31 -0.24 -0.42 -0.14 0.01 -0.27 -0.27 0 0 0 0 0 0 0 0
R Ant Insula 0.17 0.30 0.22 -0.32 0.22 -0.25 0.06 -0.26 0.29 0.22 -0.14 -0.46 -0.10 -0.07 -0.20 -0.31 0 0 0 0 0 0 0 0
L Post Insula 0.30 0.24 0.65 0.18 0.51 0.43 0.39 0.28 0.25 0.31 0.40 0.28 0.25 0.37 0.23 0.45 0 0 ↓ 0 0 0 0 0
R Post Insula 0.09 0.08 0.64 0.12 0.47 0.24 0.29 0.16 0.17 0.05 0.70 0.43 0.46 0.57 0.43 0.52 0 0 0 0 0 ↑ 0 ↑
L Subgenual AC 0.14 -0.10 0.11 0.17 0.09 -0.01 0.31 0.07 0.36 -0.12 0.01 0.21 0.37 0.46 0.38 0.18 0 0 0 0 0 0 0 0
R Subgenual AC 0.12 -0.06 -0.16 0.78 -0.22 0.33 0.22 0.68 -0.09 -0.09 0.25 0.63 0.43 0.26 0.56 0.59 0 0 0 0 0 0 ↑ 0
L Drevet 0.45 0.39 0.56 0.41 0.55 0.47 0.61 0.47 0.00 -0.13 0.82 0.75 0.70 0.78 0.71 0.80 0 0 ↑ ↑ 0 ↑ 0 ↑
R Drevet 0.29 0.20 0.54 0.77 0.49 0.75 0.56 0.81 0.06 0.11 0.76 0.83 0.65 0.58 0.74 0.86 0 0 ↑ 0 0 0 0 0
L Pregenual AC 0.50 0.14 0.39 0.68 0.23 0.47 0.55 0.68 -0.10 -0.16 0.79 0.90 0.72 0.71 0.75 0.90 ↓ 0 ↑ ↑ ↑ ↑ ↑ ↑
R Pregenual AC 0.34 0.14 0.55 0.72 0.49 0.53 0.76 0.72 -0.04 0.06 0.74 0.76 0.53 0.60 0.65 0.84 0 0 0 0 0 0 0 0
L Mayberg 0.48 0.03 0.56 0.58 0.42 0.49 0.69 0.58 -0.02 -0.15 0.80 0.91 0.82 0.79 0.84 0.91 0 0 ↑ ↑ ↑ ↑ 0 ↑
R Mayberg 0.33 0.05 0.60 0.54 0.51 0.36 0.76 0.53 0.04 0.04 0.72 0.75 0.59 0.72 0.68 0.85 0 0 0 ↑ 0 ↑ 0 ↑
L Supragenual AC 0.14 -0.23 0.24 0.10 0.13 -0.03 0.42 0.06 0.06 -0.09 0.72 0.78 0.78 0.72 0.74 0.78 0 0 ↑ ↑ ↑ ↑ ↑ ↑
R Supragenual AC 0.41 -0.06 0.51 0.15 0.35 0.30 0.45 0.17 0.27 -0.10 0.64 0.59 0.68 0.70 0.73 0.67 0 0 0 ↑ ↑ ↑ ↑ ↑
L Dorsal AC 0.18 -0.18 0.64 0.25 0.50 0.40 0.48 0.27 0.44 0.18 0.50 0.45 0.48 0.56 0.53 0.57 0 0 0 0 0 0 0 0
R Dorsal AC -0.05 -0.17 0.42 0.15 0.40 0.21 0.38 0.20 0.25 0.18 0.53 0.45 0.53 0.61 0.55 0.62 0 0 0 0 0 ↑ 0 ↑
L Post AC 0.18 0.24 0.11 0.54 0.03 0.27 0.15 0.54 -0.21 0.08 0.21 0.49 0.01 -0.03 0.14 0.47 0 0 0 0 0 0 0 0
R Post AC 0.32 0.19 0.09 0.46 -0.04 0.24 0.18 0.40 0.02 0.10 0.06 0.37 0.16 0.07 0.30 0.36 0 0 0 0 0 0 0 0
L Ant Tenporal -0.26 -0.10 -0.52 -0.41 -0.38 -0.34 -0.38 -0.37 0.09 -0.05 -0.70 -0.36 -0.43 -0.46 -0.42 -0.44 0 0 0 0 0 0 0 0
R Ant Temporal -0.18 0.09 -0.38 -0.16 -0.28 -0.20 -0.22 -0.14 0.11 0.17 -0.59 -0.40 -0.43 -0.39 -0.50 -0.39 0 0 0 0 0 0 0 0
L Post Temporal -0.52 -0.57 -0.59 -0.48 -0.42 -0.41 -0.54 -0.49 0.06 0.09 -0.88 -0.72 -0.68 -0.60 -0.72 -0.73 ↑ ↑ ↓ ↓ ↓ 0 0 ↓
R Post Temporal -0.67 -0.32 -0.19 -0.21 0.05 -0.13 -0.30 -0.16 -0.30 -0.04 -0.64 -0.54 -0.69 -0.59 -0.73 -0.54 ↑ 0 ↓ 0 ↓ ↓ ↓ ↓
L TP 0.22 0.55 0.26 -0.17 0.43 0.21 0.22 -0.04 0.33 0.42 0.12 0.20 0.22 0.35 0.17 0.34 0 0 0 0 0 0 0 0
R TP -0.08 0.36 0.18 -0.29 0.41 0.09 0.16 -0.17 0.33 0.50 0.08 0.17 0.20 0.30 0.15 0.32 0 0 0 0 0 0 0 0
L Inf Parietal 0.00 -0.14 0.10 -0.16 0.03 -0.02 -0.01 -0.16 0.05 0.06 0.57 0.31 0.39 0.43 0.30 0.37 0 0 ↑ 0 0 0 0 0
R Inf Parietal 0.11 -0.31 0.60 0.48 0.29 0.11 0.51 0.35 0.08 0.23 0.71 0.57 0.46 0.48 0.53 0.72 0 0 0 0 0 0 0 ↑
L Occipital -0.09 0.26 -0.07 -0.44 -0.12 -0.25 -0.44 -0.36 -0.42 -0.29 -0.04 -0.21 -0.47 -0.49 -0.36 -0.25 0 0 0 0 0 0 0 0
R Occipital 0.36 0.39 0.14 -0.44 0.18 0.02 -0.16 -0.33 0.02 -0.12 0.31 -0.10 -0.13 0.03 -0.04 -0.05 0 0 0 0 0 0 0 0
L DLPFC 0.22 -0.11 0.28 -0.15 0.23 0.02 0.16 -0.18 -0.03 -0.34 0.55 0.56 0.60 0.53 0.61 0.46 0 0 0 ↑ ↑ ↑ ↑ 0
R DLPFC -0.27 -0.22 0.11 -0.05 0.10 0.07 -0.11 -0.11 -0.14 -0.40 0.77 0.66 0.55 0.60 0.55 0.57 0 0 ↑ ↑ ↑ ↑ ↑ ↑
L VLPFC 0.19 -0.33 -0.01 0.39 -0.12 0.15 0.27 0.30 -0.04 -0.46 0.48 0.57 0.64 0.54 0.66 0.44 0 0 0 0 ↑ ↑ ↑ 0
R VLPFC -0.19 -0.38 0.41 0.42 0.34 0.19 0.36 0.31 -0.05 -0.08 0.45 0.25 0.21 0.45 0.20 0.35 0 0 0 0 0 0 0 0
L MOFC 0.12 0.36 0.09 0.09 0.26 0.22 0.19 0.16 -0.10 -0.24 0.57 0.68 0.64 0.66 0.55 0.61 0 0 ↑ ↑ ↑ ↑ ↑ ↑
R MOFC 0.09 0.20 0.14 0.66 0.21 0.65 0.25 0.69 -0.18 0.10 0.50 0.85 0.55 0.46 0.58 0.81 0 0 0 ↑ ↑ 0 ↑ 0
L LOFC -0.18 -0.21 -0.40 0.31 -0.38 -0.10 -0.17 0.20 -0.04 0.11 -0.37 0.04 -0.05 -0.09 -0.01 0.01 0 0 0 0 0 0 0 0
R LOFC -0.44 -0.58 -0.57 0.09 -0.60 -0.31 -0.44 -0.09 Total 0.06 0.18 -0.56 -0.17 -0.25 -0.28 -0.25 -0.19 Total 0 ↑ 0 0 ↑ 0 0 0
# r > .45 12 15 22 17 17 22 20 20 145 5 7 35 27 32 33 32 32 203 0 0 0 0 0 0 0 0
# r < -.45 2 3 3 1 1 0 1 1 12 0 1 5 3 3 4 3 2 21 0 0 0 0 0 0 0 0
Total 14 18 25 18 18 22 21 21 157 5 8 40 30 35 37 35 34 224 0 0 0 0 0 0 0 0
Legend Cholinergic System
# Positive corrs 48 42 50 48 50 51 52 48 389 45 39 49 48 48 52 48 52 381 r ∆r Tegmental-Midbrain
# Negative corrs 14 20 12 14 12 11 10 14 107 17 23 13 14 14 10 14 10 115 >.50 ↑ >.50 Substantia Inominata
Total 62 62 62 62 62 62 62 62 496 62 62 62 62 62 62 62 62 496 <-.50 ↓ <-.50 Septo-Hippocampal
BrainstemBrainstemBF Mean
Saline
BF MeanBrainstem Basal Forebrain
Procaine Procaine vs Saline
Basal ForebrainBasal Forebrain BF Mean
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Table 10. Correlative Relationships Between Cholinergic Brain Regions and




















































































































L Tegementum 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ↓ 0 0 ↑ ↑ ↑ 0
R Tegmentum 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ↓ 0 0 0 0 0 0
L SI 0 0 ↓ ↑ 0 0 0 0 0 0 0 0 0 0 0 0 0 ↓ 0 0 0
R SI 0 0 ↓ 0 0 0 ↑ 0 0 0 0 0 0 0 0 0 0 0 0 0 ↓
L Septal n 0 0 ↑ 0 ↓ 0 ↓ 0 0 0 0 0 0 0 ↑ 0 ↓ 0 ↑ 0 ↑
R Septal n 0 0 0 0 ↓ ↓ ↓ 0 0 0 0 0 0 0 ↑ 0 0 0 ↑ ↑ 0
L BF 0 0 0 0 0 ↓ ↓ 0 0 0 0 0 0 0 ↑ 0 0 0 0 ↑ ↑
R BF 0 0 0 ↑ ↓ ↓ ↓ 0 0 0 0 0 0 0 0 0 0 ↓ ↑ 0 ↑
Medulla 0 0 0 0 ↓ 0 ↓ 0 ↓ 0 0 0 0 0 0 0 ↓ 0 0 0 ↑ ↑ ↑ 0
Pons 0 0 0 0 0 0 0 0 ↑ ↓ 0 0 0 0 0 0 ↑ ↓ 0 0 0 0 0 0
Midbrain ↓ ↑ 0 0 0 0 0 0 ↑ 0 ↑ 0 0 ↑ 0 0 ↑ ↓ ↑ 0 ↑ ↑ ↑ 0
L Cerebellum 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ↓ 0 0 ↑ 0 0 0
R Cerebellum 0 0 0 0 0 ↑ 0 0 0 0 0 0 0 0 0 0 ↓ 0 0 0 0 ↓ 0 0
L Cerebellum n 0 0 0 0 0 ↑ 0 0 ↓ 0 0 0 0 0 0 0 ↓ 0 0 0 0 0 0 0
R Cerebellum n 0 0 0 0 0 ↑ 0 0 ↓ 0 0 0 0 0 0 0 ↓ 0 0 0 0 ↓ 0 0
L m Thalamus 0 0 0 0 0 0 0 0 0 0 0 0 0 ↑ 0 0 0 0 0 ↓ 0 0 0 0
R m Thalamus ↑ 0 ↑ 0 0 0 0 0 0 0 ↑ 0 ↑ ↑ ↑ 0 0 0 0 0 ↑ 0 ↑ ↑
L Caudate 0 0 0 0 0 ↓ 0 ↓ 0 0 ↓ ↓ 0 ↓ 0 ↓ ↑ 0 0 0 0 0 0 0
R Caudate 0 0 0 0 ↓ 0 ↓ ↓ 0 0 0 ↓ 0 0 0 ↓ 0 0 0 ↓ 0 0 ↑ 0
L Putamen ↑ 0 ↑ 0 0 0 ↑ 0 0 0 0 ↓ 0 0 0 ↓ 0 0 ↓ ↓ ↓ 0 ↓ ↓
R Putamen 0 0 0 ↑ 0 0 0 ↑ 0 0 0 ↓ 0 0 0 0 0 0 0 ↓ 0 0 0 ↓
L Globus Pallidus 0 0 0 ↑ 0 0 0 0 ↑ 0 0 0 0 0 0 0 0 0 0 ↓ 0 0 0 0
R Globus Pallidus ↑ 0 0 0 ↓ 0 ↓ 0 0 0 0 0 0 0 0 0 0 0 0 0 ↑ 0 ↑ 0
L Hippocampus 0 0 0 0 ↓ 0 ↓ 0 0 0 0 0 0 0 0 0 0 0 ↑ 0 ↑ ↑ ↑ 0
R Hippocampus 0 ↓ 0 0 ↓ ↓ 0 ↓ ↓ 0 0 0 0 0 0 0 0 0 0 ↑ ↑ ↑ 0 ↑
L Amygdala 0 0 0 0 ↓ ↑ ↓ 0 0 ↑ 0 0 0 0 0 ↑ ↑ 0 0 0 ↑ 0 ↑ ↑
R Amygdala 0 0 ↑ 0 ↑ 0 0 ↓ 0 0 0 0 0 0 0 0 0 0 0 0 ↓ 0 0 0
L Ant Insula 0 ↑ 0 0 ↑ 0 0 0 0 0 ↓ ↓ ↓ ↓ ↓ ↓ 0 ↓ ↓ ↓ ↓ ↓ ↓ ↓
R Ant Insula 0 0 0 ↓ 0 0 0 0 0 0 ↓ ↓ ↓ ↓ ↓ ↓ 0 0 ↓ ↓ ↓ ↓ ↓ ↓
L Post Insula 0 0 ↑ 0 ↑ 0 0 0 0 0 0 0 ↓ 0 ↓ 0 0 0 ↓ 0 ↓ ↓ ↓ 0
R Post Insula 0 0 ↑ 0 0 0 0 0 0 0 0 ↓ 0 0 ↓ ↓ 0 0 ↓ ↓ ↓ 0 ↓ ↓
L Subgenual AC 0 0 ↓ ↓ 0 0 0 0 0 0 ↓ ↓ 0 0 ↓ 0 0 0 0 0 0 0 0 0
R Subgenual AC 0 0 ↓ 0 ↓ ↓ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ↑ 0 ↑ 0
L Drevet 0 0 0 0 ↑ 0 ↑ 0 0 0 0 ↑ ↑ ↑ 0 ↑ 0 0 0 ↑ 0 ↑ 0 ↑
R Drevet 0 0 0 0 0 ↑ ↑ ↑ 0 0 ↑ ↑ ↑ 0 ↑ ↑ 0 0 0 0 0 ↓ 0 0
L Pregenual AC ↑ 0 0 0 0 0 0 ↑ 0 0 0 ↑ 0 0 0 ↑ 0 0 0 ↑ 0 0 0 0
R Pregenual AC 0 0 0 0 0 0 ↑ ↑ 0 0 0 0 0 0 0 ↑ 0 0 0 0 ↓ 0 ↓ 0
L Mayberg 0 0 0 0 0 0 ↑ 0 0 0 ↑ ↑ ↑ 0 ↑ ↑ 0 0 0 ↑ 0 0 0 0
R Mayberg 0 0 ↑ 0 ↑ 0 ↑ 0 0 0 0 0 0 0 0 ↑ 0 0 0 0 0 0 ↓ 0
L Supragenual AC 0 0 0 ↓ 0 0 0 0 0 ↑ 0 0 ↑ 0 0 0 0 0 ↑ ↑ ↑ ↑ 0 ↑
R Supragenual AC 0 0 0 ↓ 0 0 0 0 ↑ 0 0 0 0 0 0 0 0 0 0 ↑ 0 0 0 0
L Dorsal AC 0 0 ↑ ↓ 0 0 0 0 ↑ 0 0 ↓ 0 0 0 0 0 0 ↓ 0 ↓ 0 0 0
R Dorsal AC 0 0 0 ↓ 0 0 0 0 0 0 0 ↓ 0 0 0 0 0 0 0 0 0 0 0 0
L Post AC 0 0 0 ↑ 0 0 0 ↑ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
R Post AC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L Ant Tenporal 0 0 ↓ 0 ↓ ↓ 0 0 0 0 ↓ 0 0 0 0 0 0 0 0 0 0 0 0 0
R Ant Temporal 0 0 0 0 0 0 0 0 0 0 ↓ 0 0 0 ↓ 0 0 0 0 0 0 0 0 0
L Post Temporal ↓ ↓ ↓ 0 0 0 ↓ 0 0 0 ↓ ↓ ↓ ↓ ↓ ↓ ↑ ↑ ↓ ↓ ↓ 0 0 0
R Post Temporal ↓ 0 0 0 ↑ 0 0 0 0 0 ↓ 0 ↓ ↓ ↓ 0 ↑ 0 ↓ ↓ ↓ ↓ ↓ ↓
L TP 0 ↑ ↓ ↓ 0 ↓ ↓ ↓ 0 0 0 0 0 0 0 0 0 0 ↑ ↑ 0 ↑ ↑ ↑
R TP 0 0 0 ↓ 0 ↓ 0 0 0 0 0 0 0 0 0 0 0 0 0 ↑ 0 ↑ 0 ↑
L Inf Parietal 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
R Inf Parietal 0 0 ↑ 0 0 0 ↑ 0 0 0 ↑ ↑ 0 0 ↑ ↑ 0 0 0 0 0 0 0 ↑
L Occipital 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
R Occipital 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
L DLPFC 0 0 0 0 0 0 0 0 0 0 0 ↑ ↑ ↑ ↑ 0 0 0 0 ↑ ↑ ↑ ↑ 0
R DLPFC 0 ↑ 0 0 0 0 0 0 0 0 ↑ ↑ ↑ 0 ↑ 0 0 ↓ ↑ 0 0 0 0 0
L VLPFC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ↑ ↑ ↑ 0 0
R VLPFC 0 0 0 0 0 ↓ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ↑ 0 0
L MOFC 0 0 0 0 0 0 0 0 0 0 0 ↑ ↑ ↑ 0 ↑ 0 0 ↑ ↑ ↑ ↑ 0 ↑
R MOFC 0 0 0 0 0 ↑ 0 ↑ 0 0 0 ↑ ↑ 0 ↑ ↑ 0 0 ↑ ↑ ↑ 0 ↑ ↑
L LOFC 0 0 0 0 ↓ 0 0 ↓ 0 0 0 0 0 0 0 0 0 0 0 0 ↑ 0 0 ↑
R LOFC 0 ↓ ↓ 0 ↓ 0 0 0 Total 0 0 ↓ 0 0 0 0 0 Total 0 ↑ 0 0 ↑ 0 0 0
# r > .5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
# r < -.5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cholinergic System
r ∆r Tegmental-Midbrain
>.50 ↑ >.50 Substantia Inominata







Brainstem Basal Forebrain BF Mean
Procaine
Brainstem Basal Forebrain BF Mean
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In the cortex, the pattern of the correlations between the forebrain cholinergic
and the anterior cingulate ROIs in the patients also appeared different from the
controls, and in this case many were found to be significantly different.  For example,
forebrain cholinergic ROIs, as a whole, were significantly positively correlated with
ROIs in the pregenual, Mayberg, and Drevets subdivisions of the anterior cingulate,
while the remainder of the cingulate, in general, was not; significantly more positive
correlations were observed in patients compared to controls in these subdivisions
(pregenual, Mayberg, and Drevets) most uniformly with bilateral BF ROI.  The
correlations between cholinergic forebrain and the subgenual and supragenual
subdivision ROIs (SI only) had few significant correlations in either direction in the
patients, but when compared to controls, they were significantly less positively
correlated.
With the exception of the anterior cingulate, few cortical ROIs were
significantly correlated with the most of the cholinergic ROIs.  Despite this, there
were several cortical areas where significant differences from controls were found in
the correlations.  The correlations with the anterior temporal cortex and temporal pole
ROIs were significantly less positively correlated in the patients compared to the
controls.  The LOFC ROIs were significantly negatively correlated with the
cholinergic ROIs, and were significantly more negatively correlated in the patients
compared to the controls.
Some correlational patterns did not look that different and upon significance
testing few differences were found between the groups at baseline.   The regions that
did not have any significant differences between the patients and controls at baseline
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were the left thalamus, inferior parietal, and occipital, and right posterior cingulate,
posterior temporal, and MOFC.  The DLPFC (more positive with right tegmental
ROI) and VLPFC (less positive with right septal ROI) only had one correlation
significantly between the groups.
4.3.2.4 Patients with Procaine
At first glance, the correlational patterns occurring with procaine in each
group appeared more similar than observed at baseline, although this was not always
the case.  The major organizational themes as described in the controls with procaine
were also evident in the patient correlations.
The appearance of clusters of positive correlations in the procaine condition
also occurred in the patients. This was similar to controls, albeit not as consistent, and
with some meaningful differences (Table 9; middle and right panels).  The
similarities in the patterns occurred between the forebrain cholinergic ROIs and
themselves, the striatum, and anterior cingulate.  Most ROIs in these areas showed
significantly more positive correlations with procaine compared to baseline.
Nonetheless, when comparing across groups in the procaine condition, often
the correlations of the cholinergic ROIs with the caudate and putamen, subgenual
subdivision ROIs were significantly less positive, and Drevets, Mayberg, and
supragenual ROIs were significantly more positive in the patients compared to the
controls.  Thus, despite the initial pattern similarities in the striatum and anterior
cingulate subdivisions in the procaine condition, the correlational relationships
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between the cholinergic ROIs and these regions are changing significantly differently
with procaine in the patients compared to the controls.
In the cortex, group differences of the correlational patterns occurred with the
bilateral hippocampus, insula, and DLPFC, and left posterior temporal, temporal pole,
and VLPFC.  In general, there were no significant correlations between any
cholinergic ROI and the hippocampal ROIs in either condition, which was
significantly different from controls.   In most cases, the correlations of the forebrain
cholinergic ROIs with the insula were not significantly positively correlated, and in
one case it was significantly negatively correlated (right SI ROI).  These correlations
were significantly less positive in the patients compared to the controls (Table 9; right
panel).  There were additional clusters between the forebrain cholinergic ROIs and
the DLPFC, VLPFC, posterior temporal (left only) and temporal pole ROIs in the
patients, which were not observed in the controls.  The prefrontal and temporal cortex
correlations were significantly more and less, respectively, positively correlated in the
patients compared to the controls.
In summary, the correlational strengths were significantly more positive with
procaine compared to baseline between the cholinergic ROIs and the anterior
cingulate, anterior and posterior insula, the putamen and themselves in the controls.
In the patients, significantly more positive correlations were observed with the
cholinergic ROIs, the anterior cingulate, DLPFC, VLPFC, MOFC, and striatum with
procaine compared to baseline.  At baseline, the cholinergic areas were significantly
less positively correlated with themselves in the patients compared to controls.  In
addition, numerous significant correlations, both positive and negative, between the
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groups occurred mostly in subcortical forebrain structures, anterior cingulate and
temporal cortical area, but not prefrontal cortical areas.  With procaine, significantly
more positive correlations in the patients compared to the controls occurred between
the cholinergic ROIs and the thalamic, pregenual anterior cingulate, DLPFC, and
MOFC ROIs.  Also observed in the procaine condition, significantly less positive
correlations in patients compared to controls occurred between cholinergic ROIs and
the striatal nuclei, insula, subgenual anterior cingulate, and temporal cortex ROIs.
4.3.3 Multivariate Analysis of Behavioral and Cerebral Blood Flow Relationships
4.3.3.1 Behavioral and Regional CBF Relationships
In the controls, none of the cholinergic ROIs correlated significantly with any
of the emotional or sensory ratings at baseline or with procaine (Appendices C, D).
However, in the patients, significant positive correlations occurred between
depression ratings and the bilateral BF ROI (Appendix F), and between auditory
sensations and right tegemental ROI at baseline.  With procaine, all forebrain
cholinergic ROIs correlated positively with calmness ratings (Appendix G).
Examination of the delta-delta correlations revealed opposite relationships
between cholinergic ROIs and ratings of euphoria and anxiety in both groups in
different ways.  Specifically, delta anxiety ratings correlated negatively with left BF
delta-CBF (r=-0.55) in the patients and non-significantly in the controls (r=.20).
Delta euphoria ratings correlated positively with right tegemental delta-CBF(r=.65) in
the patients and negatively in the patients (r=-.50). In both cases, the correlations
201
observed in the patients were significantly different from the controls (Figures 28 and
29).
In addition, significant delta-delta positive correlations occurring only in the
patients were observed between calmness and left BF and septal ROIs, overall
bad/good and left BF ROI.  Also occurring only in the patients, delta auditory
sensations and delta bilateral tegmental ROIs were significantly positively correlated.
Regarding non-cholinergic ROIs, significant correlative relationships were
sparse in any condition in the controls.  In contrast, there were numerous significant
correlations in the patients at baseline, with procaine and delta-delta.  Examination of
these relationships is outside the scope of this study, however, the disparity of the
number of CBF/emotion correlations between the two groups is notable.
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Figure 28.  Differential Relationships of Forebrain vs Brainstem rCBF with Anxiety
Response to Procaine in Patients vs Controls
rCBF in the BF region correlates inversely with anxiety ratings in patients with
bipolar disorder, while this correlation is direct in controls (Fisher’s R-to-Z = 2.39).
The brainstem relationships were similar in both groups (Fisher’s R-to-Z = 0.06).
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Figure 29. Differential Relationships of Forebrain vs Brainstem rCBF with Euphoria
Response to Procaine in Patients vs Controls
rCBF in the tegmentum region correlates directly with anxiety ratings in patients with
bipolar disorder, while this correlation is inverse in controls (Fisher’s R-to-Z = 3.86).
The forebrain relationships were similar in both groups (Fisher’s R-to-Z = 0.66).
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4.3.3.2 Multivariate Emotion and Cholinergic CBF Network Analysis
The relationship between procaine-induced changes in CBF in the AChNet
and changes in ratings, i.e., delta-CBF/delta-rating relationships, was analyzed using
multivariate multiple regression separately by group and laterality (Appendix I).
Negative emotions were limited to anxiety and fear, due to the non-normal
distribution  of the depression and anger ratings, and positive emotions included
euphoria and calmness ratings.  Regions were eliminated one by one to find the core
regions responsible for explaining the most variance in the ratings.
In the controls, negative emotions were explained by change in AChNet CBF,
as a whole, to a modest degree (HC-L: R2=0.41; HC-R: R2=0.42).  This was mostly
due to anxiety ratings (HC-L: R2=0.27; HC-R: R2=0.38), rather than fear ratings (HC-
L: R2=0.18; HC-R: R2=0.21).  Within a reduced AChNet, the variance of delta-
anxiety ratings was best explained by delta-rCBF in the amygdala and SI (R2=0.24)
and the amygdala and MOFC (R2=0.25) in the left and right networks, respectively,
in the control group.
Several competing models were tested (in both groups) by substituting BF
ROI for SI, Drevets ROI for subgenual AC, Mayberg ROI for pregenual AC, or
DLPFC for MOFC, either singly or in combinations. In the controls, the substitution
of BF, Drevets, Mayberg and DLPFC ROIs in combination in the network as a whole
resulted in the greatest increase in the variance explained in the delta-negative
emotions (R2=0.52), and in delta-anxiety ratings (R2=0.43).  The reduced model of
the left BF, Drevets and DLPFC resulted in a significant increase in the variance of
the delta-anxiety ratings (R2=0.41) over the best model with no exchanges (AM and
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SI: R2=0.27; see Figure 30).  Exchanges of any combination in the left network did
not increase the variance explained in delta-fear ratings in the controls.  In addition, in
examination of the right network in the controls, none of the substitutions resulted in
a significant increase of the variance explained in delta-negative emotions combined
or separately.
Turning to the examination of the change of positive emotions, the same
methods as outlined with the negative emotions were employed.  In the controls, the
network in any form, right or left, full or reduced, substitutions or not, did not explain
the variance of delta-positive ratings (Figure 31).
In the patients, both left and right networks delta-CBF explained a substantial
portion of the variance of the delta-negative emotion ratings (BPD-L: R2=0.59; BPD-
R: R2=0.61) in the network as a whole, which was significantly more than the
controls (∆R2 close to .20).  Of the negative emotion ratings, further analysis revealed
that it was also primarily the delta-anxiety ratings that were explained by the delta-
rCBF (BPD-L: R2=0.29; BPD-R: R2=0.61) rather than the delta-fear ratings (BPD-L:
R2=0.13; BPD-R: R2=0.26) as observed in the controls.  However, in contrast to the
controls, the addition of the pregenual AC ROI along with the amygdala and SI in the
left reduced model was needed to explain the most possible variance in the delta-
anxiety (R2=0.23) in the patients.  Delta-rCBF in the right AChNet included the same
ROIs as in the controls, the subgenual AC and MOFC, to explain 45% of the variance
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Figure 30.  Testing the AChNet Model: Relationship to Anxiety Ratings
Anxiety ratings were explained by rCBF in the left BF, Drevets and DLPFC ROIs
slightly more so in the patients compared to the controls. In addition, rCBF in the BF
and Drevets ROIs, but not DLPFC, were significantly more negatively related to
anxiety ratings in the patients compared to controls (BF: t=-2.94, p=.005, df=45;
Drevets: t=2.92, p=.006, df=45; DLPFC: t=-0.35, p=ns, df=45). Abbreviations:
AINS= anterior insula; AM=amygdala; BF=basal forebrain cholinergic region;
DLPFC= dorsolateral prefrontal cortex; MOFC=medial orbitofrontal cortex; PGAC=































Figure 31.  Testing the AChNet Model: Relationship to Euphoria Ratings
Euphoria ratings were explained significantly in the patients but not controls by rCBF
in the left BF, AM, PGAC and AINS ROIs . In addition, rCBF in the BF was
significantly more positively related to euphoria ratings in the patients compared to
controls (BF: t=2.58, p=.01; AM: t=-1.79, p=ns; PGAC: t=0.34, p=ns; AINS: t=-1.72,
p=ns). Abbreviations: AINS= anterior insula; AM=amygdala; BF=basal forebrain
cholinergic region; DLPFC= dorsolateral prefrontal cortex; MOFC=medial
orbitofrontal cortex; PGAC= pregenual anterior cingulate; SGAC = subgenual
anterior cingulate.
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In the examination of AChNet substitutions in the patients, the exchange of
left BF, Drevets, and DLPFC together explained significantly more variance of delta-
negative emotions (R2=0.83) than the basic model (R2=0.58), and of delta-anxiety
ratings (R2=0.58) than the basic model (R2=0.29).  The left reduced network model
explaining the most variance in patient delta-anxiety ratings included the BF, Drevets
and DLPFC ROIs (R2=0.53).  Thus, the same substitutions as seen in the controls also
resulted in the most increase in the variance explained in the patients.  However, the
beta weight for the BF ROI was significantly different between the groups (HC:
B=.05; BPD: B=.51; t=-2,94, p=.005, df = 45).  The variance explained in the delta-
fear ratings was improved by substituting DLPFC in the left network as a whole
(R2=0.43), and by the reduced model including the SI, pregenual AC, anterior insula
and DLPFC predominately explained (R2=0.34).
With respect to the right network in the patients, the substitution of Drevets
for subgenual AC resulted in the largest increase in the variance explained (R2=0.79)
of delta-negative emotions, while in the reduced model, Drevets and pregenual AC
explained 59% of the delta-anxiety rating variance.  The variance explained in delta-
fear ratings in the patients was best modeled by Drevets, Mayberg and DLPFC
substitutions in the complete network (R2=0.42), however, only 21% of the delta-fear
rating variance was explained by those regions alone.
The variance in delta-positive emotions (R2=0.64) was explained by change in
the left AChNet in the patients, which was significantly more than in the controls
(R2=0.25).  This was primarily due to delta-euphoria ratings in the whole model
(R2=0.63), and to the left subgenual AC, pregenual AC, anterior insula, and the
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MOFC (R2=0.49) in a reduced model.  Substitution of left BF for SI resulted in the
greatest increase in the variance explained in delta-positive emotions (R2=0.84)
compared to other alterations of the basic model.  The variance in the change in delta-
euphoria ratings was explained best by the inclusion of left amygdala, BF, pregenual
AC and anterior insula (R2=0.71) in the model.  With substitutions, the variance in the
change in delta-calmness ratings was explained best by the inclusion of left BF,
subgenual AC, and pregenual AC (R2=0.44) in the model.
 In the right AChNet, 41% of the variance in delta-positive emotions was
explained by the original network as whole in the patients, of which, both delta-
euphoria ratings (R2=0.34) and delta-calmness (R2=0.50) were explained.  The best
reduced model explaining the variance in delta-euphoria ratings before substitutions
included the right subgenual AC, pregenual AC and the MOFC (R2=0.30).  After
substitutions, although using Drevets, Mayberg and DLPFC ROI resulted in the
greatest increase in the explained variance (R2=0.69) in delta-positive emotions in a
full model, the best reduced model explaining the most variance (R2=0.45) of the
delta-euphoria ratings included BF, Mayberg, and DLPFC CBF.  The explained
variance in calmness ratings of the patients was by right SI, Drevets, anterior insula
and MOFC rCBF (R2=0.48).
4.4 Discussion
There are two principle findings from this study.  First, procaine enhanced the
associativity between regions with known neuroanatomical connections via
cholinergic pathways in controls.  This was replicated in patients, although with
210
subtle, but meaningful differences.  Second, regions of cholinergic cell bodies and
their targets were associated with emotional experiences of anxiety in controls.  In
contrast, anxiety ratings were related to the same cholinergic regions but in an
opposite manner in patients.  Moreover, feelings of euphoria were positively
associated with cholinergic brain regions in patients, as well.
4.4.1 Cholinergic Pathway Confirmation
The functional connectivity analysis of cholinergic brain regions in patients
and healthy controls at baseline and with procaine will be discussed in the context of
a two-fold purpose: 1) to confirm cholinergic pathways are measurable at baseline
and are modulated by procaine administration; 2) to support and extend the activation
study findings by providing alternative perspectives from traditional brain imaging
methods through examination of associative relationships of the cholinergic regions
of the brain with those previously identified by the procaine activation studies.
The main findings of the functional connectivity analysis were that CBF in
many of the cholinergic ROIs significantly correlated with CBF in parts of the brain
(both brainstem and forebrain) with known cholinergic pathways at baseline in
healthy controls and patients.  Moreover, when challenged by procaine (an agent that
blocks a cholinergic radiotracer; Benson et al., 2004), the functional connectivity of
these cholinergic ROIs increased significantly in most of areas with known
neuroanatomical connections.  For example, in the controls at baseline the SI CBF
correlated significantly with CBF in most of the anterior cingulate subdivisions,
amygdala, and MOFC, but not the anterior insula.  With procaine, significant
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increases in correlations were observed between the SI and anterior cingulate and
insula CBF.  Both at baseline and with procaine, SI functional connectivity reflected a
substantial portion of the pattern of what is believed to be the heaviest cholinergic
innervation of the forebrain (Amaral et al., 1992; Russchen et al., 1985; Mesulam,
1995).  Regions, such as anterior temporal cortex or DLPFC, with less robust or
direct (lacking monosynaptic links) cholinergic innervation did not show significant
changes in CBF correlative strengths.
In the patients, the SI cholinergic pathways were partially confirmed at
baseline, however, they were more so with procaine.  At baseline, SI CBF correlated
significantly with CBF in the amygdala, most anterior cingulate subdivisions and
MOFC, but not with CBF in the anterior insula.  With procaine, significantly more
positive correlations of CBF in the forebrain cholinergic ROIs occurred for most
anterior cbingulate subdivisions, and MOFC.   While CBF in the amygdala became
significantly less positively correlated with septal CBF, the correlations with SI CBF
remained unchanged.
The activity in the septo-hippocampal pathway is reflected by significant
positive correlation between CBF in these two ROIs in the controls.  The procaine-
induced significant reduction in correlational strength between septal CBF and
hippocampal CBF suggests this pathway may be modulated during intense emotional
experiences.  These results are interesting in light of the poor memory recall during
strong emotional events and are consistent with septo-hippocampal pathway
disruption during such times (Dudar, 1975; Smith, 1972).  The modulation of
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hippocampal systems during emotional processing also is supported by theories of
encoding of facial affect and emotional stimuli (Adolphs et al., 1999).
In the patients, hippocampal CBF was not significantly correlated with CBF in
any of the cholinergic ROIs at baseline or with procaine, and did not show significant
changes in the correlative relationships.  Thus, septo-hippocampal function may be
disrupted or not revealed by these methods in patients.  The significant interaction of
group and drug suggests that with procaine the correlative relationships of septal and
hippocampal CBF become more positive in patients, while the controls become more
negative.  This discrepancy is interesting in light the complaints about memory
function often expressed by patients.  Reduced hippocampal volumes have been
reported not only in bipolar disorder (Noga et al., 2001), but also in major depression
(Sheline, 1999), post-traumatic stress disorder (PTSD; Bremner et al., 1995), which in
some disorders may be a result of hypercortisolemia (Sheline, 2000).  These changes
in functional connectivity complement the abnormalities reported in traditional brain
imaging studies, where hippocampal activity correlated with severity of depression
(previous chapter) and metabolism was increased in moderately depressed patients
(Ketter et al., 2001).
The temporal pole, a region with an intermediate degree of cholinergic
innervation exhibited a reduction in functional connectivity in controls.  This
complements the hippocampal findings, and is not surprising given the intimate
connections of the entorhinal and perirhinal cortex with the hippocampus.  However,
these changes were not observed in the patients.
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Tegmental CBF was predominately positively correlated with brainstem CBF,
while having few significant negative correlations with forebrain CBF in the controls.
In patients, tegmental CBF correlated with CBF in other brainstem regions, thalamus,
globus pallidus, as well as the posterior temporal cortex.  The cholinergic tegmental
nuclei innervate the medulla, pons, midbrain and globus pallidus (Carpenter, 1991;
Krnjevic, 1975).  Thus, the predominance of significant changes between the
tegmental CBF and CBF in adjacent hindbrain, thalamus, and globus pallidus is
consistent with the cholinergic projections traveling in the central, dorsal, and ventral
tegmental tract innervating the hindbrain, thalamus, and globus pallidus, respectively.
Discrepancies from known neuroanatomical pathways, however, included the
lack of significant changes in correlations of cholinergic ROIs with amygdala and
MOFC CBF in controls, and with anterior insula CBF in patients.  The amygdala is a
small cluster of nuclei, and partial volume effects, scanner resolution, and image
processing could contribute to the attenuation of amygdalar signals.  Although rCBF
in MOFC was significantly increased with procaine in controls in the activation
analysis, the lack of change in correlative relationships between MOFC and
cholinergic forebrain CBF was not expected.  MOFC and SI CBF significantly
correlated at baseline, as expected from known pathways, but not with procaine;
however, this change was too limited to establish a significant difference in
correlations across conditions.   Although MOFC receives direct cholinergic
innervation from the basal forebrain area, competing influences of different
neurotransmitter systems could override the cholinergic input to attenuate the change.
Whether cholinergic influences in MOFC are excitatory or inhibitory are unknown,
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and furthermore it is not clear whether these influences will result in hyper- or hypo-
perfusion.
The presence of significant positive correlations between the cholinergic ROIs
and prefrontal ROIs, such as DLPFC, VLPFC, and MOFC in patients provides
support for cholinergic dysregulation in bipolar disorder.  These correlations were
significantly more positive in the patients compared to controls, where significant
correlations between cholinergic ROIs and prefrontal cortex were not observed.  This
suggests that the procaine-induced increases in blood flow in prefrontal cortex may be
in some way associated with increased activity in the cholinergic forebrain area in the
patients but not the controls.  This is consistent with Janowsky’s notion of
exaggerated responses to cholinergic stimulation in affective disorders compared to
healthy controls (1994).
The observed changes in correlative relationships between CBF in cholinergic
ROIs and CBF occurred in regions with the heaviest cholinergic innervation; this
reinforces the hypothesis that the neuroanatomical distribution of the cholinergic
system in limbic structures overlaps with the pattern of selective limbic activation
induced by procaine (Ketter et al., 1996).  Telencephalic cholinergic projections
originate in the basal forebrain nuclei, such as the substantia inominata and nucleus
basalis, and send efferents to most of the cortex as well as to the basolateral amygdala
and anterior cbingulate (Mesulam 1995; Mesulam et al. 1983).  Both the amygdala and
the anterior cbingulate send efferents to the basal forebrain cholinergic nuclei,
suggesting feedback modulation of their own afferents (Mesulam, 1995; Heimer,
1994; Záborszky, 1993).  These reciprocal connections create an opportunity for
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enhancement, diminution, or refinement of neuronal activity related to the valence
and saliency of environmental stimuli, thus affecting potential behavioral outcome.
The cholinergic drive to the amygdala has been hypothesized to an essential
component of the “general emotion system” (LeDoux, 1996).  The cholinergic basal
forebrain, anterior cbingulate, insula, and MOFC may well be other structures integral
to emotion regulation.
Cholinergic M1 and M2 receptors are present in core limbic areas, such as
amygdala and hippocampus, as well as in primary sensory regions.  While M1
receptors have primarily cortical distribution, M2 receptors have more uniform
cortical and subcortical distribution across the brain, (Mesulam 1995; Mesulam et al.
1983).  Thus, the distribution of both subtypes of cholinergic receptors in sensory –
limbic pathways could allow cholinergic mechanisms to play an important role in
emotion.
Two other perspectives cannot be dismissed.  Procaine is known to have
similar affinities with sigma (Sharkey, 1988), 5-HT3 (Fan and Weight, 1994), and
most recently reported 5-HT1A (Kalipatnapu and Chattopadhyay, 2004).  While the
distributions of both sigma and 5-HT3 receptors do not overlap well with the pattern
of procaine activation (Ketter et al., 1996), 5-HT1A are distributed in many limbic
areas.  These receptors do not have any preference for anterior versus posterior
cingulate (Neumeister et al., 2004), and PET studies show the highest binding of 5-
HT1A antagonists in the hippocampus (Drevets et al., 1999).  Neither the posterior
cingulate nor the hippocampus were selectively activated with procaine (Ketter et al.,
1996).
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A second area of consideration is that the cholinergic system is known to
interact with many other neurotransmitter systems in the amygdala, hippocampus,
ventral and dorsal striatum, and the cortex for starters.  For example, GABAergic-
cholinergic influences on neural activity in the basal forebrain  (Jones, 2004) and the
thalamus (Steriade, 2004) may mediate complementary role in arousal and slow wave
sleep.  Dopaminergic-cholinergic interactions in the dorsal and ventral striatum most
likely participate in pleasure / rewards systems (Koob and Nestler, 1997).
Cholinergic-serotonergic interactions in the cortex and hippocampus may regulate
mood (Overstreet et al., 1998).  Thus, considering the functional response of procaine
to be solely a cholinergic action would be remiss.
4.4.2 Alternative Perspective of Activation Study Findings
Many of the regions shown to be abnormal in patients in the activation study
also exhibited differential functional connectivity as evidenced by significant
alterations in the correlative relationships between the cholinergic ROIs and other
brain regions.  Each of these will be discussed in the context of pertinent findings in
the literature.
The functional connectivity of three prefrontal cortical areas, DLPFC, VLPFC
and MOFC was significantly altered with procaine in patients, as evidenced by
significant increases in positive CBF correlations with the forebrain cholinergic ROIs
compared to controls.  Furthermore, all three areas exhibited differential responses to
procaine in the patients versus the controls in the activation analysis.  As mentioned
in the previous chapter, baseline DLPFC hypo-activity changed to hyper-activity and
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baseline MOFC hyper-activity converted to hypo-activity in patients compared to
controls with procaine.  Taking the results of the two methods together, the findings
suggest that the procaine-induced hyper- or hypo-activity in the DLPFC and MOFC,
respectively, may be an expression of altered functional connectivity of the
cholinergic forebrain region in patients.  Studies of neuronal and glial cell
histopathology support prefrontal cortex dysfunction.  For example, Rajkowska
(2000) has found that a neuronal cell density reduction of 16-22% in layer III,
pyramidal cell reduction of 17-30% in layers III and V, and a glial cell reduction of
19% in DLPFC.
In patients compared to controls, CBF in the subgenual anterior cingulate
region had distinctly different relationships with CBF in cholinergic ROIs.  CBF in
bilateral SI and left subgenual ROIs were significantly less positively correlated in the
patients compared to the controls, both at baseline and with procaine.  Persistent
discrepancies could indicate a trait marker.  Indeed, the neuronal and glial cell loss of
the subgenual region in mood disorder patients compared to controls (Drevets et al.,
1997; Öngur et al., 1998; Rajkowska, 2000) is considered one of the first clear-cut
documented neuroanatomical abnormalities described at a neuronal level in a
psychiatric disease; nerve growth factor (NGF) is known to be co-localized with
acetylcholine in basal forebrain neurons (Mesulam, 1995).  The observed neuronal
and glial cell loss of the subgenual cbingulate region could be a result in both loss of
these growth factors and cholinergic dysregulation as revealed by altered functional
connectivity between the basal forebrain cholinergic and the subgenual cbingulate
observed in this study.
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The anterior insula was one of the few regions in which the CBF correlations
changed in opposite directions with procaine in the two subject groups, rather than
moving in the same direction.  In the healthy controls, the CBF correlations became
significantly more positive, while in patients, CBF correlations with the anterior
insula moved in a negative direction, although not always significantly.  These often
non-significant changes in opposite directions in the two groups resulted in a
significant interaction between all forebrain ROIs and bilateral anterior insula.  This
region has been associated with differential treatment response in patients with
bipolar disorder (Ketter et al., 1999).  Baseline hyper-metabolism especially in the
left insula was predictive of eventual response to the anti-convulsant carbamazepine,
while baseline hypo-metabolism was predictive of the response to the calcium-
channel blocker nimodipine.  Although neither of these drugs has a primary
cholinergic mechanism action, cholinergic innervation may well influence the activity
of this region.
4.4.3 Emotion and CBF Relationships
The most noteworthy finding of the examination of blood flow and emotional-
sensory experiences induced by procaine was that CBF changes in regions containing
cholinergic cell bodies and their targets explained a substantial portion of the variance
of anxiety and euphoria ratings, although in different ways in patients and controls.
As such, these changes in associations between emotional experiences and rCBF may
indicate a abnormalities in the neural networks subserving emotion in patients
compared to controls.
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The procaine-induced anxiety ratings were explained to a fair degree in both
groups by the same (left) or similar (right) cholinergic model, but in a different
manner.  For example, while changes in the same regions on the left (BF, subgenual
AC, DLPFC) were associated with changes in anxiety ratings in both groups, the
relationships of BF and subgenual AC CBF changes to changes in anxiety were in
opposite directions in patients and controls.  This was not the case, however, with
DLPFC, where changes in rCBF had similar relationship to changes in anxiety ratings
in both groups.  In addition, while CBF changes in identical ROIs on the right (BF,
subgenual AC, DLPFC) explained the most variance in anxiety ratings in controls, the
patients differed in that changes in the right pregenual AC and Drevets CBF were
associated with changes in anxiety.
Although similar degrees of euphoria ratings were endorsed in both groups,
only changes in AChNet CBF in patients were associated with changes in euphoria
ratings.  In the controls, changes in caudate CBF were significantly correlated with
changes in euphoria ratings.  This is expected, as changes in caudate and nucleus
accumbens are integral to pleasure-reward systems (Koob and Nestler, 1997;
Salamone et al., 1997).
These findings suggest there may be alterations in the neural networks
subserving the functional response of euphoria in patients.  There is considerable
evidence indicating the dopamine activity influences cholinergic activity and vice
versa in the dorsal (Graybiel, 1990, 2000) and ventral striatum (Holt et al., 1997;
Záborszky and Cullinan, 1992).   Procaine can directly modulate cholinergic activity
(Benson, 2004), thus could yield indirect modulation of dopamine systems in ventral
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regions.  Moreover, dopamine may regulate cortically projecting basal forebrain
neurons (Day and Fibiger, 1992, 1993), as well as septohippocampal projections (Day
and Fibiger, 1994).  Taken together, if the cholinergic system is altered in the
patients, dopamine function may be affected such that shifts in the neural networks
subserving the pleasure-reward functions.
On a different level, changes in euphoria ratings were associated with CBF
changes in the right DPLFC CBF changes, while anxiety was associated with the left
DLPFC CBF changes in the patients.  This data follows what has been accepted in
lesion data from human prefrontal cortex lesions, where stroke occurring on the left
prefrontal cortex usually results in depression, while right-side damage is associated
with mania (Robinson, 2003).  Davidson and colleagues (2002) hypothesize that left-
sided prefrontal cortex functions to regulate “approach-related appetitive goals” and
dysfunction of DLPFC may result in “deficits in pre-goal attainment forms of positive
affect,” i.e., depressive symptoms.   Right-sided functions may modulate inhibition,
and disruption would result in excessive behavioral inhibition (Davidson, et al.,
2002).  The data in this study suggest that right DLPFC hypo-activity could cause
loss of inhibition in the form of mania.
4.4.4 Consolidation of Findings
Consolidating the findings from the three different methodological approaches
gives support to the hypothesis that the cholinergic system is contributing to the
emotional-sensory response induced by procaine.  Patients compared to controls had
BF hypo-perfusion at baseline, positive correlations between HDRS and procaine-
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induced change in BF CBF, and increased strength of correlations between BF and
the CBF in multiple ROIs at baseline and with procaine.  In conjunction with the
direct relationship between increased BF blood flow and increased anxiety ratings in
patients, these results suggest increased activity in the BF region in patients may be
dysfunctional at rest and that depending on the cholinergic target, during emotional
situations the influence may become over- (DLPFC, MOFC, supragenual AC,
hippocampus) and under-driven (anterior insula).
The relationship of DLPFC blood flow and experiential effects of procaine
appears to be complex.  In patients, procaine induced hyper-perfusion ion the DLPFC
and hyper-association to CBF in cholinergic cell body regions compared to healthy
controls, while the associations between change in DLPFC CBF and anxiety ratings
was fairly similar in patients and controls.  A possible explanation could be that
cholinergic influence on the DLPFC may be enhanced (functional connectivity) in
patients compared to controls resulting in increased perfusion (activation response),
and an equivalent anxiety response.
Combining the results across the three methods employed in the study, the
association of changes in emotion ratings with differential CBF changes in BF and
subgenual AC (or Drevets region) extends the understanding of the regional
neurochemistry and physiology of bipolar illness.  Although serotonin,
norepinephrine and dopamine systems have been most commonly implicated in
affective disorders, an enhanced ratio of cholinergic to adrenergic function has also
been hypothesized to play a role in mania and depression (Fritze 1993; Janowsky et
al. 1972b).  In this theory, when the balance shifts to favor noradrenergic
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predominance manic symptoms emerge, and cholinergic dominance is associated
with depressive symptoms.  While, depression ratings did not change significantly
during the study, anxiety is commonly present during and often covaries with
depression.  Cholinergic overdrive in patients is supported by the direct relationship
between BF rCBF and anxiety ratings.
Cholinergic challenge studies lend support to Janowsky’s theory.  For
example, physostigmine can reduce manic symptoms and exacerbate depressive
symptoms in bipolar patients (Janowsky et al. 1972a).  Furthermore, physostigmine
administration results in relapse of depressive symptoms in bipolar patients
successfully treated with lithium, while healthy controls do not develop depressed
mood.  These patients have concomitant hormonal disturbances and emotional
arousal expressed as dysphoria (Janowsky et al. 1986) that overlap those seen with
procaine.
Arecoline, a nonselective muscarinic agonist, has also induced dysphoria in
mood disorder patients whether or not they were currently depressed and in
individuals with a family history of depression compared to those without such
history (Gillin et al. 1991; Nurnberger et al. 1989).  Decreased REM latency in
patients with major depression, but not in healthy controls, was observed with i.v.
arecoline (Sitaram et al. 1980) and donepezil, a cholinesterase inhibitor (Perlis et al.
2002).
While most tricyclic antidepressants are known to have anti-cholinergic
adverse effects (such as dry mouth and urinary retention), it is also possible that
relative cholinergic blockade could contribute to their efficacy and increased
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proclivity to cause switches in mania compared with less anticholinergic
antidepressants (Guille et al. 1999; Peet 1994).  On the other hand, donepezil has
been reported to be efficacious in treating bipolar disorder (Burt et al. 1999) and
relieves some of the anti-cholinergic adverse effects with some risk of mania
induction (Jacobsen and Comas-Diaz 1999), suggesting that maintaining cholinergic
balance may be important to mood disorders.
The predominance of positive CBF correlations between regions with
cholinergic neurons and other areas at baseline and with procaine in both patients and
controls suggest that, in general, cholinergic neurotransmission may be associated
with cortical activation.  However, an interesting dichotomy in how the relationships
changed from baseline to procaine between CBF in the cholinergic and other brain
ROIs was revealed for the brainstem and forebrain cholinergic ROIs.  Significant
changes from baseline to procaine in brainstem cholinergic (tegmentum) CBF
relationships moved from positive to negative associations. This could reflect
differences in procaine’s effects in cholinergic cell body and terminal regions.
In contrast, the forebrain cholinergic ROI relationships with other brain
regions were more variable after procaine.  The ROI differential relationships in
brainstem vs forebrain cholinergic areas may indicate a basic difference in the
functional connectivity of these two cholinergic systems.  The cholinergic brainstem
system has been associated with the ascending reticular activating system (ARAS).
These tegmental pathways are part of the ARAS.  The function of this system is
hypothesized to activate the basal forebrain nuclei involved in mediating arousal
level.  The direct relationships observed in this study are consistent with this view. In
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contrast, the basal forebrain nuclei may play a crucial role in attention, emotional
learning, and memory given their strategic amygdala, hippocampal and paralimbic
connections.
4.4.5 Limitations
This study has several limitations.  Most importantly, it depends on post-hoc
data analyses.  Although the hypothesis were, in part, developed by some of the
preliminary data incorporated in this analysis, the most significant aspect of the study,
the alteration of cholinergic functional connectivity in the patient group, had not been
previously explored in this manner.   These findings need to be replicated in a study
where procaine and/or other cholinergic agents are used to modulate brain activity to
test the apriori hypothesis that the cholinergic regions contribute to the processing of
emotional experiences.
The sample size in this study was relatively small for the statistical methods
employed.  Functional connectivity and regression analyses require large sample sizes
to minimize Type II error that can potentially occur from random or atypical
sampling.  The potential for Type II error, in this case falsely rejecting the null
hypothesis of equivalent correlations, is noteworthy when the sample size falls under
20 (Stevens, 1996), thus reaching significance in this smaller group may be more a
function of power than true differences between the groups.  Fluctuations in
correlations are routine with insufficient sample sizes.  Also, these methods do not
address issues of multiple comparisons.  The functional connectivity in the patients
with bipolar disorder often displayed a similar pattern as seen in the healthy controls
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at baseline, providing some internal replication, but not always. Therefore, these
results in this exploratory study should be viewed with caution and require
replication.
The demographics of the sample limit the extrapolation to bipolar illness, in
general.  These patients were predominately rapid-cycling, treatment-refractory BPII
sub-type.  They also had previous medication trials and were significantly older than
the control group (which was statistically controlled when appropriate).  Thus, the
possibility of medication effects or the existence of significant alterations in brain
neurochemistry due to the aging process in this disease versus healthy controls
remains to be ruled out.
A third limitation is the inability to segment regions that are solely
cholinergic, given the lack of cholinergic specificity of the basal forebrain neurons.  It
is well known that the cholinergic neurons are interspersed with other non-cholinergic
neurons, most notably GABAergic projections, thus regional CBF is related to
diverse neuronal influences beyond cholinergic activity.  Despite this, the cholinergic
functional attributes of the basal forebrain are of major significance and deserve
further more specific dissection in the study of emotion and memory.
Lastly, with respect to amygdala findings, results reported here may differ
slightly from the work of Ketter et al. (1996), due to different methodology.  Whereas
Ketter et al. (1996) explored small regions of interest in the center of the amygdala
(determined by PET images co-registered MRIs) on the unfiltered original PET
images not processed, the current study used highly processed PET CBF images that
had undergone reorientation, stereotactic normalization and substantial filtering for
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signal-to-noise enhancement purposes.  The amygdala as whole was markedly
activated by procaine and the lack of significant correlations of its global blood flow
could reflect a failure to distinguish among its many clusters of small nuclei.
4.4.6 Conclusion
In conclusion, procaine appeared to modify cholinergic pathways as
evidenced by alterations in the functional connectivity between cholinergic regions
and their targets in healthy controls.  The functional connectivity of cholinergic brain
regions in patients with bipolar disorder revealed alterations from the pattern
observed in healthy controls with procaine administration.  These findings
supplement those in the literature regarding absolute or relative CBF changes from
controls in prefrontal cortex, anterior cingulate, insular cortex, temporal cortex and
basal forebrain regions in patients.  Moreover, cholinergic regions and their primary
targets were differentially associated with emotional responses in patients and healthy
controls, suggesting abnormalities in the function of cholinergic networks in patients.
This study provides further support for cholinergic involvement in mood disorders as
summarized decades ago by Janowsky and coworkers (1972) and more recently by
Overstreet and colleagues (1998).  Further studies are required to replicate this
finding as well as to examine cholinergic function in mood disorders with other
cholinergic agents that modify brain activity.
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Chapter 5: Conclusions and Implications
5.1 Overall Summary
The major findings in both clinical and preclinical studies support the notion
of cholinergic involvement in emotion regulation.  This is suggested by the binding of
procaine to muscarinic M2 receptors in vivo in the preclinical experiment and the
association of blood flow changes in cholinergic basal forebrain areas with brief
intense emotional responses induced by procaine in the clinical experiment.  Procaine
blocked the binding of a muscarinic ligand in a dose-related manner (IC50 = 1.31
µM), globally and uniformly across the primate brain, suggesting direct binding with
M2 muscarinic receptors.  In addition to the muscarinic binding, the cerebral blood
flow, as measured by K1, significantly increased globally and regionally in the
anterior paralimbic regions on all doses. The largest K1 changes occurred at plasma
levels near the IC50.  This suggests that the K1 effects associated with the lower doses
could possibly be related to M2 muscarinic blockade.  Moreover, the pattern of K1
increases in this study is similar to the blood flow increases seen globally and
regionally in anterior paralimbic areas observed in humans (Ketter et al. 1996).  If
comparable occupancy occurs in humans as in this study with monkeys, a cholinergic
mechanism of procaine’s limbic activation is viable.
It cannot be determined from this study whether procaine is acting as an
agonist or antagonist on the muscarinic receptors.  Agonist activity is supported by
the following results: cholinomimetics induce kindling similar to procaine
(Wasterlain et al. 1981); physostigmine weakly facilitates procaine-induced kindling
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while atropine slows this process (Heynen et al. 1995); and procaine induces
membrane voltage changes that are short acting and reversible (Isreal, 1979).
Moreover, the clinical effects of physostigmine share similarities to procaine
(Janowsky et al. 1986).
Conversely, antagonist activity is suggested by procaine competitively
inhibiting acetylcholine-induced contraction (Ishii and Shimo, 1984) of guinea pig
cecum.  Furthermore, procaine inhibits opening of cation channels on guinea pig ileal
smooth muscle cells thus affecting the acetylcholine induced cationic currents;
GTPγS currents are inhibited in a similar manner (Chen et al. 1993).  Lastly, procaine
is known to have a biphasic effect on neuronal excitation with anticonvulsant activity
at lower concentrations and pro-convulsant activity at higher concentrations (De Jong
1994; Foldes et al. 1965; Foldes et al. 1960).  It is possible that procaine could also
have biphasic effects on cholinergic neurotransmission yielding both agonist and
antagonist activity.
The biphasic actions could stem from numerous sources.  Procaine may
initiate its effects by preferential affinity to cholinergic, sigma, and serotonergic
receptors, but their interactions among these and with other neurotransmitter systems,
could yield opposing effects.  In addition, with regard to cholinergic receptors,
activation may be coupled to inhibitory (M2) or excitatory (M1) neuronal effects.
Procaine, as a limbic selective probe that binds to cholinergic M2 receptors,
appears to be a useful way of assessing emotion regulation in healthy individuals and
patients with psychiatric disease.  The second experiment examined emotion
regulation using several approaches based on a cholinergic model that resulted in
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three principle findings:  1) with traditional brain imaging activation methodology,
treatment-refractory patients with bipolar illness exhibited equivalent emotional
responses, but blunted anterior paralimbic rCBF increases to procaine administration;
2) analysis of the functional associatively of cholinergic forebrain regions with and
without procaine administration demonstrated cholinergic pathway modulation as
evidenced by enhanced associative relationships on procaine between regions
believed to be connected via cholinergic neuronal pathways in patients and controls;
and 3) blood flow changes in core regions of cholinergic cell bodies and their targets
were correlated with changes in ratings of anxiety and euphoria.  However, these
associations differed in patients and controls. Cholinergic basal forebrain (NBM and
septal area) ROI was directly related to anxiety in controls and inversely related in
patients. Only the bipolar patients showed any associative relationships between
euphoria ratings and the cholinergic regions in the model.
With regard to the second main clinical finding, in the healthy control group
procaine increased the positive associations of cholinergic regions with the anterior
cingulate, anterior insula, and striatum, and negative relationships of the
hippocampus, temporal pole, and cerebellum.  These changes could reflect known
cholinergic pathways, including the substantia inominata to prefrontal area, septo-
hippocampal and tegmental-midbrain pathways.  These results suggest a minor
alteration in the proposed AChNet model and are depicted in Figure 32.   The MOFC
did not show increased associativity with procaine compared to baseline in the
controls.  This may be a function of the complexity of the neuromodulatory
influences on this cortical region.
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Figure 32.  Cholinergic Model in Healthy Controls
The functional connectivity data suggest a modification of the proposed model in
Figure 9 in healthy controls.  The contribution of the cholinergic innervation of the
MOFC appears to be less substantial than the implied by cholinergic pathway analysis
in this procaine-infusion paradigm. Shading represents density of dual innervation,
direct cholinergic and indirect via the amygdala. Numbers in the anterior cingulate
indicate Brodmann areas (1909).  Abbreviations:  AC, anterior cingulate; ACh,
acetylcholine; DLPFC. Dorsolateral prefrontal cortex; DMNV, dorsal motor nucleus
of the vagus; DR, dorsal raphe; LC, locus coeruleus; MOFC, medial orbitofrontal
cortex; Ch4-NBM, cholinergic portion of the nucleus basalis of Meynert; NST, n.
solitary tract; M1/M2, primary and secondary motor cortex; PAG, periaquaductal
grey; PN, pontine nuclei; RN, red n.; S1/S2, primary and secondary sensory cortex;
CA1, hippocampus; TF, TH, TE, TEO, TA, TPO, temporal regions designated by
Bonin and Bailey (1947); TP, temporal pole; VLPFC, ventrolateral prefrontal cortex;
VTA, ventral tegmental area.
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Patients with mood disorders compared to healthy controls show significantly weaker
positive relationships amongst the cholinergic forebrain regions at baseline, which
became stronger and similar to controls with procaine.  Procaine increased the
strength of positive relationships of these cholinergic regions with anterior cingulate,
amygdala, MOFC, DLPFC, posterior temporal cortex, thalamus, and striatum
compared to baseline in patients.  This pattern in the patients reflects most of the
cholinergic pathways, but some discrepancies appear.  Specifically, the anterior
insula, hippocampus, and temporal pole changes in correlative relationships with
cholinergic regions were not observed in the patients.  Also, some additional changes
in the cholinergic correlative relationships, the amygdala, MOFC, DLPFC, posterior
temporal cortex, and thalamus were observed that were not present in healthy
controls.  These changes form the AChNet are depicted in Figure 33.
These findings are of interest because many of the regions with altered
functional connectivity between patients with bipolar illness and controls are also
regions found to be hyper-metabolic or hypo-metabolic at baseline in patients
compared to controls (Ketter et al., 2001).  For example, the anterior cingulate and
prefrontal areas are hyper-metabolic in patients in the depressed phase of their illness
compared to controls, while the cerebellum and basal forebrain structures, such as the
striatum and thalamus, are hyper-metabolic irrespective of mood state in patients
compared to controls.  Thus, commonly reported alterations in activity in prefrontal,
insular, temporal, striatal, thalamic, and cerebellar brain regions in mood disorders
(see reviews; Dougherty and Rauch, 1997; Ketter et al., 1997; Drevets, 1998) may
have a cholinergic component to their dysregulation.
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Figure 33.  Cholinergic Model in Patients with Bipolar Disorder
The functional connectivity data suggest a different modification of the proposed
model in Figure 9 for the patients with bipolar disorder than in the healthy controls.
The contribution of the cholinergic innervation of the DLPFC, and VLPFC appears to
be more substantial than the implied by cholinergic pathway analysis in this procaine-
infusion paradigm. In contrast, the cholinergic innervation of the insula may be less
influential than thought based on neuroanatomy.  Shading represents density of dual
innervation, direct cholinergic and indirect via the amygdala. Numbers in the anterior
cingulate indicate Brodmann areas (1909).  Abbreviations:  AC, anterior cingulate;
ACh, acetylcholine; DLPFC. Dorsolateral prefrontal cortex; DMNV, dorsal motor
nucleus of the vagus; DR, dorsal raphe; LC, locus coeruleus; MOFC, medial
orbitofrontal cortex; Ch4-NBM, cholinergic portion of the nucleus basalis of
Meynert; NST, n. solitary tract; M1/M2, primary and secondary motor cortex; PAG,
periaquaductal grey; PN, pontine nuclei; RN, red n.; S1/S2, primary and secondary
sensory cortex; CA1, hippocampus; TF, TH, TE, TEO, TA, TPO, temporal regions
designated by Bonin and Bailey (1947); TP, temporal pole; VLPFC, ventrolateral
prefrontal cortex; VTA, ventral tegmental area.
233
The blunted blood flow response in the anterior cingulate and the increased
functional connectivity of the prefrontal cortex could be directly related to M2
receptors.  Recently, significant reductions in M2 receptor levels, as measured with
[18F]FP-TZTP, was observed in the anterior cingulate, as well as in whole brain,
striatum and occipital cortex at rest in medication-free patients with bipolar disorder
(D. Cannon, personal communication).  Notably, blood flow in the hippocampus and
posterior cingulate were not reduced.  These changes were not observed in patients
with major depression.  Exacerbated functional connectivity could be a direct result
of loss of muscarinic inhibition of excitatory processes.  This is further supported by
increased functional connectivity of other brain regions, such as the thalamus and the
insula, with widespread brain regions (B. Benson, unpublished data).  An emerging
hypothesis could be that the M2 receptors play a critical role in the inhibition of
excitatory processes in normal cholinergic function, supporting a system of balance in
emotion and mood regulation.  M2 receptor loss in patients with bipolar disorder may
alter the cholinergic networks such that the normal cholinergic inhibition is no longer
in place, and thus creates an imbalance between the cholinergic and excitatory
systems.  An example at the cellular would be in amygdalar neurons, where a
complement of muscarinic receptors (M1-M4) mediate the excitatory actions of
glutamate (Yajeya et al., 2000), and may contribute to the spontaneous firing of fast-
firing neurons that may belong to a population of intrinsic inhibitory neurons
(Washburn and Moises, 1993).  Loss of M2 receptors would alter this inhibitory
balance.  The ideas presented here suggest another mechanism of cholinergic
imbalance in mood disorders as proposed by others, e.g., cholinergic / noradrenergic
234
(Janowsky et al., 1972a, 1972b, 1986), and cholinergic / serotonergic systems
(Overstreet et al., 1998), that may be contributing to the emotion and mood
dysregulation these patients experience.
The neuroanatomical distribution of the cholinergic system in limbic
structures overlaps with the pattern of selective limbic activation induced by procaine
(Ketter et al., 1996).  Telencephalic cholinergic projections originate in the basal
forebrain nuclei, such as the substantia inominata and nucleus basalis, and send
efferents to most of the cortex as well as to the basolateral amygdala and anterior
cingulate (Mesulam 1995; Mesulam et al. 1983).  Both the amygdala and the anterior
cingulate send efferents to the basal forebrain cholinergic nuclei, suggesting feedback
modulation of their own afferents (Russchen et al., 1985a, 1985b; Amaral et al., 1984,
1989, 1992).  These reciprocal connections create an opportunity for enhancement,
diminution, or refinement of neuronal activity related to the valence and saliency of
the environment stimuli, thus affecting potential behavioral outcome (Mesulam,
1995; Heimer and Alheid, 1991, Záborszky, 1993).  The cholinergic drive to the
amygdala has been hypothesized to an essential component of the “general emotion
system” (LeDoux, 1996).
The anterior cingulate may well be another structure integral to emotion
regulation. The pregenual and subgenual regions of the anterior cingulate activate less
so in the patients compared to controls with procaine compared to baseline.  In
addition, the subgenual / Drevets region of the anterior cingulate was one of the three
regions of the core cholinergic model were associated with anxiety ratings in both
patients and controls.  This region is reported to have reduced glial and neuronal cell
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numbers in bipolar and unipolar illness (Drevets et al., 1997, Öngur et al., 1998;
Rajkowska, et al., 1999; Rajkowska, 2000) that may be a function of altered
cholinergic and NGF influences from the basal forebrain.  In addition, the pregenual
anterior cingulate was associated with euphoria ratings in patients only.  These
relationships are in agreement with the literature of emotion induction studies, where
the anterior cingulate was one of the regions most often activated (Ketter et al., 2003).
In addition to the anterior cingulate, the functional response of the DLPFC in
patients with bipolar illness compared to healthy controls exhibited differential
responses: 1) DLPFC is hypo-perfusional at baseline in patients compared to controls;
2) DLPFC activity increases more so in patients compared to controls with procaine
(interaction results); and 3) there is increased correlative strength between DLPFC
and BF cholinergic ROIs with procaine in patients compared to controls, yet similar
relationship of change in DLPFC activity with anxiety response in both patients and
controls.  Combined, these differences suggest that the DLPFC of the patients maybe
be under-functioning at rest, and with procaine activity is over-driven possibly via
cholinergic mechanisms to yield equivalent (to controls) emotional response of
anxiety.  The DLPFC is one of the components mediating working memory as part of
the general emotion system put forth by LeDoux (1996).  Thus, all three regions of
the final model explaining the variance in anxiety ratings generated by the
multivariate multiple regression were integral components to his theory.
The basal forebrain ROI exhibited differential responses in the patients and
controls with respect to the associations with anxiety and euphoria ratings induced by
procaine. The subcortical region (BF) exhibited inverse relationships with emotion
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ratings of anxiety, while DLPFC remained similar in patients and controls according
to the multivariate multiple regression model. This is suggestive of alterations in the
neural networks subserving emotion in patients with bipolar illness.  The amygdala-
triggered arousal-attentional mechanisms are sustained by basal forebrain ACh
release that influences the anterior cingulate and DLPFC (LeDoux, 1996).  Thus, in
patients the basal forebrain portion of the system seems to be under-active with
anxiety responses and over-active with euphoria responses to procaine compared to
controls.
The results of the two experiments combined is consistent with the notion that
procaine acting preferentially on M2 muscarinic receptors may participate in the
modulation of anxiety in patients and controls, and in euphoria in patients.  Since the
majority of the patients were moderately depressed in this study, the expectation is
the cholinergic-noradrenergic balance would favor cholinergic over-activity in
patients according to Janowsky and colleagues (1972).  From this perspective, the
differential relationship of the cholinergic BF region with emotion ratings in patients
compared to controls is consistent with their work.  The enhanced strength of the
euphoria – BF strong relationship in patients supports these ideas well.  However, the
opposite relationship of anxiety ratings with BF rCBF in patients and controls is only
indirectly supportive in that differences exist from controls.  Additional support
comes from the correlation of increased blood flow in the amygdala, MOFC, and a
small region in the cholinergic forebrain area with severity of mood (HDRS).
For the most part the emotional responses were predominately dichotomous –
categorized as euphoria or dysphoria.  This was true for both patients and controls.
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Although changes in basal forebrain blood flow was associated with a change in
anxiety ratings in an opposite manner in patients and controls, eventual procaine-
induced emotional response was not predicted by any baseline clinician or self-ratings
in the patients.  For example, in the patients HDRS scores were correlated with
SSAS, baseline depression and anxiety ratings, and depression ratings with procaine.
SSAS scores correlated with baseline depression, fear and anxiety ratings, but not
with ratings collected during procaine administration.  Spielberger self-ratings
correlated with baseline depression, fear and anxiety ratings, and depression ratings
with procaine.  Thus, current mood state did not “predict” a euphoric or dysphoric
response.  These results were similar in the controls.  While the controls would not
have sufficient range in the clinical and self-ratings collected at baseline for
predictive power, the baseline likert-based ratings of emotions were not predictive of
eventual procaine-induced emotion response (T. Ketter, personal communication).
The basis for this apparent lack of prediction remains to be determined.  Most
likely, the procaine-induced emotional and sensory experiences are a result of a
combination of factors that could not measured during this study.  Possible
explanations could include the following.  Analogous to context-dependent (either
environmental or conditioning) differential drug response, the relative neurochemical
equilibrium at the time of infusion, as well as how procaine affects these
neurochemical systems may provide different “starting points” that would result in
either euphoria or dysphoria.  In a related manner, it might be feasible that the recent
history of these systems may be influencing responses in the near future.  A second
possibility is the relative complement of muscarinic receptor subtypes and/or balance
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of muscarinic receptors with other receptors, such as GABA, may influence a
response in either direction.  Additionally, the respective complements of other
receptors with similar high affinity to procaine, such as sigma-1, 5-HT3, and 5-HT1A
receptors, could produce these differential effects.  However, in the controls, repeated
administrations of procaine with subsequently higher doses show that within minutes
on the same day in an individual can have either response (R. Post, personal
communication).  This would argue in favor of the relative equilibrium of the affected
neurochemistry shifts over time.
5.2 Implications
5.2.1 Basal Forebrain Arousal Mechanisms
The findings in this study suggest that procaine-induced emotional
experiences are associated with blood flow increases in basal forebrain, the amygdala
and prefrontal cortical regions, including the anterior cingulate and DLPFC.  Exactly
how procaine, which binds to muscarinic receptors, could produce blood flow
activation may be explained by procaine acting as an agonist on both M1 and M2
receptors.  Procaine was shown to bind to M2 receptors in vivo in the first experiment
presented herein.  However, procaine has been shown to bind to M1 receptors in vitro
(Sharkey et al., 1988).
First, as would be expected, agonist activity on M1 receptors would increase
cortical excitability.  The binding of procaine to M1 receptors results in an
intracellular response to increase PI turnover and phosphorlylation of Ca++ and K+
channels to have an overall effect of neuronal excitation.  Activation of M1 receptors
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on cortical pyramidal cells would initiate the release of the excitatory amino acid
glutamate, and subsequent downstream arousal.  This would occur in conjunction
with M1 activation on the amygdala, as well, which may cause the release of ACh
from the basal forebrain.
The basal forebrain, including the NBM and the amygdala, has been
implicated in cortical arousal mechanisms. NBM activity and the associated release of
ACh correlated with elevated behavioral arousal (Buzasáki and Gage, 1989), with
anticipation of highly predictable reward (Inglis et al., 1994), with induction of slow-
wave sleep (Nuñez, 1996) and during production of low-voltage fast EEG activity
(Celesia and Jasper, 1966).  Ch4-NBM lesions may inhibit the cortex to attend and
process brief, highly salient sensory stimuli (Robbins and Everitt, 1995).  Thus, for
the most part, acetylcholine release appears to stimulate the brain.
A second route to cortical arousal from muscarinic receptor activation may
occur via agonist activity on M2 receptors.  M2 receptor activation results in a
decreases in cAMP and a subsequent decrease in the phosphorlylation of Ca++ and K+
channels; the overall effect of M2 activation is that of inhibition.  Activation of M2
receptors on GABAergic neurons could inhibit the inhibitory effects of GABA on the
cortical pyramidal cells, i.e., a release of inhibition would occur.  Thus, activation of
M2 receptors could also result in glutamatergic release from cortical pyramidal cells
and amygdalar-basal forebrain activation as described with M1 binding.
Stimulation of the NBM in vivo results in EEG activation originating from the
cortex, depolarizes cortical neurons, and changes large-amplitude, slow oscillations
into low-amplitude, fast oscillations (Metherate et al., 1992).  Furthermore,
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endogenous ACh applied to the cortex in vitro was associated with the replacement of
slow, rhythmic discharges to higher-frequency, single spike discharges, and facilitates
the appearance and magnitude of intrinsic membrane potential oscillations.
Modulation of these cholinergically mediated cortical oscillations may be counter-
balanced by GABA (Jones, 2004).
Záborszky hypothesizes that these fast cortical oscillations (20-40 Hz) are part
of a basal forebrain-prefrontal cortical loop.  The basal forebrain exhibits
topographical organization of prefrontal cortex efferents that are positioned to
coordinate cortical oscillations with other cortical loops, thus building larger
functional networks.  Moreover, they may work concurrently with cortico-thalami-
cortical or brain stem-thalamic oscillators (Steriade, 1990). Oscillations in the basal
forebrain regions maintained by cholinergic cells (Metherate et al., 1992), which rely
on NGF to sustain their viability, but also have intrinsic pacemaker qualities (Khateb
et al., 1992).  Muscarinic cholinergic synapses on modules of pyramidal cells in the
cortex may serve as an integral component.
Cholinergic mechanisms in mediating amygdalar neuronal activity (Yajeya et
al. 1997) have been identified postsynaptically (Washburn and Moises 1992) and
presynaptically (Sugita et al. 1991).  Moreover, similar neuronal depolarization
responses due to cholinergic mechanisms have been implicated in other paralimbic
structures such as hippocampus, entorhinal and piriform cortices and anterior
cingulate (Benson et al. 1988; Colino and Halliwell 1993; Hasselmo and Bower 1992;
Klink and Alonso 1997; McCormick and Prince 1986), as well as septum, basal
forebrain, striatum, thalamus and neocortical structures (Hasuo et al. 1988; Hsu et al.
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1995; McCormick and Prince 1987; Szerb et al. 1994). Thus, it is possible that
procaine acting on M2 receptors could initiate bursting activity and enhance firing in
limbic regions.  These results suggest that the interaction of muscarinic receptors with
the local neuronal environment could contribute to procaine’s limbic effects.
The amygdala may also participate in oscillation systems.  A majority of
amygdala projections are reciprocal, suggesting an anatomical basis for affective
processing phenomena described over 40 years ago.  The amygdala has intrinsic 40
Hz oscillations that are hypothesized to be a source of binding emotional memory
(Gault and Coustan, 1965). The broad rostral cortical region innervated by the basal
nucleus suggests it may have a significant role in attention, i.e., it may be acting as a
general amygdalar switch that brings all the cortical regions “on-line” (activated
online) when emotional processing is required to modulate executive functions.  The
other amygdalar nuclei may contribute more specifics about the relevance of the
ongoing experience.  The amygdala is considered an integral component of the neural
network subserving emotion, encompassing the assessment of emotional valence and
the expression of emotion.
Cholinergic innervation from the basal forebrain of the amygdala and
prefrontal cortex may contribute to oscillations associated with emotional memories
as well as the conscious experience of emotions.  Pelletier and Pare (2004) outline a
detailed method how oscillations in the amygdala may contribute to the consolidation
of memory with emotional contexts.  The basolateral amygdala increases its discharge
rate in fear conditioning paradigms and directly affects cortical activity.  The short
recurring time windows between these phase-locked oscillations may facilitate of
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synaptic plasticity.  As the basolateral amygdala recruits the cholinergic basal
forebrain to release ACh to cortical structures, the anterior cingulate and DLPFC, to
initiate and maintain attention during emotional situations (LeDoux, 1996), a scenario
involving muscarinic and glutamatergic receptors could be envisioned.  Cortical
synaptic plasticity could involve muscarinic and glutamatergic activation of cortical
pyramidal cells, which stimulate glutamate release onto NMDA receptors to encode
the new memories.  This could serve as a basis for working memory in the DLPFC.
These associations may be enhanced via a second phase of  “replay” in sleep or
through continued oscillations resulting in long-term synaptic changes of prefrontal
networks.
The findings in this study suggest that the basal forebrain, the amygdala and
prefrontal cortical regions, including the anterior cingulate and DLPFC, are
associated with the emotional response induced by procaine.  These same regions are
integral to LeDoux’s theory of a “general emotion system.”  Cholinergic modulation
of prefrontal cortex is essential to modulate the attentional systems required to
maintain emotional processing in working memory.  An emerging hypothesis
regarding emotion could be as follows.  Utilizing the circuitry outlined by Záborszky,
the loops through the amygdala and prefrontal cortex are modulated by basal
forebrain activity.  Oscillations in the basal forebrain regions maintained by
cholinergic cells (Metherate et al., 1992), which rely on NGF to sustain their viability,
also have intrinsic pacemaker qualities (Khateb et al., 1992).  Muscarinic cholinergic
synapses on modules of pyramidal cells in the cortex may serve as an integral
component.  This muscarinic modulation may build intracellular coherence and
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collapse of microtubules consisting of MAP-2 proteins that are regulated by
cholinergic mechanisms (Woolf, 1997, 1999). These processes, occurring in a
timeframe of 250 msec, are hypothesized to be a basis of consciousness.  Moreover,
Robbins and colleagues (1995, 2002) hypothesize that cholinergic mechanisms are
essential to the maintenance of selective attention.  It is an easy progression to extend
these ideas to emotion regulation.  Indeed, MAP-2 levels in the subgenual anterior
cingulate have been shown to be decreased (29.5%) in bipolar disorder (Bouras et al.,
2001).  The muscarinic modulation of oscillations in the specific prefrontal,
amygdalar, basal forebrain loops may support the coherence and self-collapse of the
microtubules.  Thus, it is the ebb and flow of these intracellular infrastructures in
these limbic areas that may sustain attention on emotional experiences.  The influence
of cholinergic receptor activation on synaptic plasticity leading to the formation of
emotional memories and intracellular mechanisms linked to the timing of conscious
thoughts suggest that the muscarinic cholinergic system may be tied to emotional
processing more intimately than previously believed.
5.2.2 Clinical Applications
Historically, procaine has been used in geriatric depression (De Jong, 1994),
but has fallen out of favor in preference to tricyclic antidepressants and SSRIs.  A
case study showed that procaine can reduce depressive symptoms (Ketter, personal
communication). However, tolerance develops quickly and successively higher doses
are required to achieve the same benefit.  This, as well as the potential for developing
seizures at higher doses, makes procaine an unlikely candidate for the treatment of
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major depression or bipolar disorder.  However, these limited results suggest that the
cholinergic system may be another avenue for the treatment of depression to be
modulated in conjunction with the serotonergic and noradrenergic mediation.
SSRIs have recently been identified as having cholinergic effects in addition
to their primary serotonergic mechanisms of action.  The anticholinergic effects of
tricyclic antidepressants and SSRIs have been traditionally thought as side effects,
such as dry mouth and difficulty in urination.  However, recent data have been
showing that cholinergic effects may be contributing to alleviating symptoms of
depression (Burt et al., 1999).   In a small cohort of patients with bipolar disorder, 6
of 11 (54.5%) showed marked improvement with an open trial of donepezil.  Others
have shown there is an increased proclivity to cause mood switches into mania
compared with less anticholinergic antidepressants (Guille et al. 1999; Peet 1994).
On the other hand, donepezil relieves some of the anti-cholinergic adverse effects
with some risk of mania induction (Jacobsen and Comas-Diaz 1999), indicating that
maintaining cholinergic balance may be important to mood disorders.  These studies
suggest that controlled clinical trials are indicated to explore the efficacy of
cholinergic agents in mood disorders.
The cholinergic system most likely works in concert with many other
neurotransmitters and neuromodulators to produce its effects on emotion regulation
and the brain.  Presumably these influences work in an integrated fashion such that a
change in one system modifies other systems in turn.  In this regard, the cholinergic
system may be just one avenue for modulating other systems, for instance
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serotonergic, noradrenergic, or dopaminergic, that together contribute to emotion
regulation.
5.2.3 The Cholinergic System from an Evolutionary Perspective.
If one accepts the view that the basal forebrain cholinergic system is involved
in emotion regulation, then the question emerges of how and when this connection
may have occurred with respect to phylogenetic development.  From a behavioral
perspective, basic survival needs underlie the motivation and emotions, which are
inextricably related.  The clustering of cell bodies in the basal forebrain and
brainstem, regions that are relatively newer and older phylogenetically, indicate that
this system has been developing over time. The cholinergic basal forebrain system is
considered to be a conserved system, emerging with tetrapods, but also may have
originated independently in teleosts (Semba, 2004).
Moreover, the phylogenetic development in terms of size and complexity of
the BF region and it projections parallel the evolution of the brain.  The number of
neurons and complexity of the innervation is relatively small in fishes, with the
exception of teleosts, compared to humans and cetaceans (Semba, 2004).  The
increase in the size of the cortical mantle from fishes to humans predicates neuronal
systems for integration and support of the neural processing therein.  At some point in
evolution, presumably with the emergence of bony fishes, the creation of a second
locus of cholinergic cell bodies in the basal forebrain was apparently adaptive.
Semba (2004) hypothesizes that this increase in size and complexity may be an
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evolutionary adaption to support “higher” functions associated with a more complex
cortex.
Several outstanding questions remain.  1) Why did this occur? Semba (2004)
hypothesizes that this increase in size and complexity may be an evolutionary
adaption to support “higher functions” associated with a more complex cortex.   2)
Why was it the cholinergic system, and not some other system?  3) Why was it only
the cholinergic system?  4) What advantage does the cholinergic system have that
made it the candidate to emerge with a forebrain system?  One answer to all these
questions may be that the cholinergic system is considered to be activating, a
behavioral response that is in agreement with the notion of survival; when challenged
with a threatening or an approachable situation, appropriate activation may serve the
individual well.  For example, a threatening situation requires a fear response and the
appropriate behavioral reaction to ensure safety.  An approachable situation may be
the presentation of another individual to engage in bonding.  In both situations,
successful emotion regulation serves to engender social and personal success of the
individual while maintaining safety and integrity.
While the focus has been on the cholinergic system, it most likely works in
concert with many other neurotransmitters and neuromodulators to produce its effects
on emotion regulation and the brain.  The brainstem monaminergic and cholinergic
nuclei emerged much earlier than the cholinergic forebrain nuclei.  Presumably these
influences work in an integrated fashion such that a change in the cholinergic system
modifies these other systems in a complementary manner.
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5.3 Explanation of Anomalous Results
The first experiment demonstrated, as hypothesized, that procaine blocks the
muscarinic receptors in vivo while increasing blood flow in limbic areas.  The second
experiment showed that procaine increased the functional connectivity between core
cholinergic forebrain regions and its primary targets in healthy controls and patients
with mood disorders.  In addition, the core cholinergic regions were associated with
anxiety in healthy controls and patients with mood disorders, and varied with
euphoria only in the patients.  There was a lack of the expected strong relationship of
anxiety ratings with rCBF in MOFC in healthy controls.  Sarter and Bruno (2002)
argue that the cholinergic and GABAergic inputs to the cortex give rise to a complex
mixture of excitatory and inhibitory influences.  Instead, rCBF in DLPFC in
conjunction with the BF and amygdala increased with increasing anxiety ratings.
These results are not entirely unexpected, as abnormal activity in DLPFC has been
implicated in mood disorders.  However, it is primarily the amygdala and anterior
cingulate that are most commonly activated in emotion induction studies (Ketter et
al., 2003).  Kimbrell and colleagues reported increased MOFC CBF with induction of
anxiety (1999).  The differences between their work and this study may lie in the
different method of emotion induction (self-induced vs pharmacological), but also in
the mixture of emotions generated by procaine.
Correlations between the amygdala and the cholinergic ROIs did not increase
with procaine as one might have expected based on the heavy cholinergic innervation
of the amygdala.  In addition, when examining relationships between procaine-
induced emotion ratings and the cholinergic model, changes in the amygdala were not
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implicated.  Although initially associated with anxiety ratings in both patients and
controls, the amygdala was not part of the final model.  The methodology employed
for this study may have occluded any potential relationships.  The utilization of stereo
normalization may have over-processed the data such that smaller regions like the
amygdala may have lost their “signal.”   Co-registration of subjects’s MRI to their
PET data would significantly improve the ability to measure amygdala activity.  This
method was not chosen because of the number of regions and subjects included in the
study.  Each measurement is time-intensive; with 47 subjects and 63 regions, the
amount of time required to complete the measurements was prohibitive.  The
alternative of using MRI-directed measurement of non-stereo normalized amygdala in
conjunction with the remainder of the regions measured with stereo normalized data
was considered and rejected as this type of mixing methodologies is generally not
recommended.
With the stated goal of relating the emotional response of procaine to specific
brain regions, the multivariate multiple regression deliberately limited the regions
assessed to test a cholinergic hypothesis.  This may have resulted in altered
associative relationships that might be incomplete, because of masked or missed
important relationships with other brain regions.  Future studies designed to test other
hypotheses regarding functional connectivity with other ligands will help provide a
more complete picture of how the brain processes emotion.
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5.4 Study Refinement and Future Directions
This work could be improved in several ways.  The first experiment for the
most part yielded the desired outcome, however, there are three areas in particular
that could be enhanced.  First, the data showed significant blockade at the lowest dose
tested that had a sight hint of evidence of differential binding for low and high
receptor affinity states.  Additional procaine doses below the lowest tested could tease
out the likelihood of this case, beyond just completing the binding curve.  There is
evidence that suggests the muscarinic receptors have high and low affinity states
mediated by allosteric binding (Krejci et al., 2004).
Second, the cerebral blood flow (CBF) measures were taken from a non-
traditional method.  Although, the flow of any radiotracer can be related to the true
cerebral blood flow (best measured with H2
15O studies), how highly they correlate
can range from poor to quite well.  In the case of [18F]FP-TZTP, the correlation
between H2
15O CBF studies and flow measured from [18F]FP-TZTP proved to be
sufficiently high (r=0.85; Carson et al., 1998), yielding good confidence in the
[18F]FP-TZTP flow measures.  However, utilizing the standard method of measuring
CBF would leave less to question.  On each study day, the performance of H2
15O
studies with each dose before the [18F]FP-TZTP study would have given the
additional information with respect to the effects of procaine on cerebral blood flow
(the CBF studies would have to be before the binding studies because the half-life of
the [18F]FP-TZTP ligand is fairly long (180 minutes), while H2
15O (t1/2 = 2 minutes)
could be cleared well before the onset of the binding study).  However, since the
primary goal was to measure muscarinic receptor occupancy, the experiment was
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designed and executed as reported in the first experiment.  Altering the study to
include CBF studies could significantly weaken the strength of the binding
experiment.  It is very possible that the first application of procaine for CBF
measurement could alter the binding profile attained during the [18F]FP-TZTP
experiment.
Third, another way to improve the first experiment would have been to add
more subjects. Although the three subjects were very close in dose response,
additional subjects would result in greater confidence in the results.  The number of
subjects was limited due to pilot work indicating strong effect size, to reduce the cost
of the study, and the desire to limit the unnecessary use of animals in research.
The second experiment also could be improved in several ways.  First, the
most serious problem was the retrospective and exploratory nature of the study.
Utilizing data already collected to test the cholinergic hypothesis of emotion
regulation limits the potential questions that can be asked and thus in turn the
conclusions and implications that can be reliably drawn.  Specifically, hypotheses
related to potential cholinergic or anticholinergic effects of procaine would be
beneficial in explaining the role of cholinergic modulation of emotion and mood.
An improved study design would have been to examine the psychological
effects of procaine with and without procaine administration while measuring
muscarinic receptor occupancy with FP-TZTP.   The degree of receptor occupancy
would be correlated with degree of psychological effects induced with procaine.  A
prospective study was not possible because of the provocative nature of a procaine
challenge.  Studies of agents that potentially induce strong psychological effects
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require a very strong scientific rationale and receive high scrutiny by Institutional
Review Board (IRB) for ethical and scientific soundness.  This type of study is also is
time-intensive, taking years to enroll subjects and collect the data.
The ability to extrapolate these findings extrapolate to bipolar illness, in
general, is another area for improvement.  The patients in this study were primarily
treatment-refractory and rapid-cycling BPII subtype.  Therefore, the findings in this
study apply only to this sub-group.  The demographics of the sample limit the
extrapolation to bipolar illness, in general.  These patients were predominately rapid-
cycling, treatment-refractory BPII sub-type.  They also had previous medication trials
and were significantly older than the control group (which was statistically controlled
when appropriate).  Thus, the possibility remains that medication effects or the aging
process on the brain in this disease is different than normal has significantly altered
brain neurochemistry.  Including a broader range of patients with bipolar disorder
would benefit the understanding of this heterogeneous illness.
Several studies would be useful to further explore the role of the cholinergic
system in emotion regulation. 1) Increase the sample size and sub-types of patients
and controls to apply more sophisticated analysis methods, such as path analysis. 2)
Using PET and FP-TZTP, measure simultaneously muscarinic receptor occupancy
and rCBF responses to procaine in healthy controls and patients with mood disorders
with the goal of directly correlating the degree of occupancy with emotional
responses, as mentioned above.  3) Compare the muscarinic receptor occupancy with
other known muscarinic agents, such as arecoline, in healthy controls and patients
with mood disorders.  This would expand the understanding of cholinergic agents
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effects on emotions. 4) Examine receptor occupancy with other radioligands, such as
WAY10035 (binds to 5-HT1A receptors) or raclopride (binds to D2 receptors), during
procaine administration.  This could yield comparative data of how the potential
binding of procaine to cholinergic, serotonergic and dopaminergic systems may
contribute to its effects on cerebral blood flow and emotional and sensory
experiences.
5.5 Conclusion
Intravenous procaine binds to muscarinic M2 receptors in vivo while
selectively increasing blood flow in anterior paralimbic brain regions in anesthetized
monkeys.  Procaine selectively increased anterior paralimbic blood flow in
conjunction with strong emotional and sensory experiences to a lesser degree in
patients with bipolar disorder compared to healthy controls.  Procaine increased
functional connectivity between core cholinergic forebrain regions and their targets in
healthy controls and patients.  Group differences in associativity between core
cholinergic regions and prefrontal cortex implicate cholinergic involvement in the
dysfunction of prefrontal regions that are commonly reported to be abnormal in
patients compared to controls.  Procaine-induced anxiety was associated with
increased blood flow in cholinergic forebrain region in controls and decreased blood
flow in the same region in patients.  Moreover, procaine-induced euphoria was
directly related to core cholinergic regions in patients, but not in controls.  These
findings are consistent with the notion that the cholinergic system is intimately
involved in emotion regulation, and moreover, its modulatory effects are altered in
patients compared to controls.
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Appendix A.  O-15 Emotion and Mood Questionnaire
Name: IV:    L      R
Date: Art Line:   L      R
Hospital #:
Date:
Rating Scale:    0 1 2 3 4 5    6
         None  v. slight    slight     mild        mod     severe      v. severe
1.) What is your mood?  How do you feel?  (0 – 100):  ________________________________
2.) Please rate each of the following:
    a. depression 0 1 2 3 4 5 6
    b. euphoria 0 1 2 3 4 5 6
    c. fear 0 1 2 3 4 5 6
    d. anxiety 0 1 2 3 4 5 6
    e. anger 0 1 2 3 4 5 6
    f. calmness 0 1 2 3 4 5 6
    g. tiredness 0 1 2 3 4 5 6
3.) Overall, please rate how "good" or "bad" you feel using 0 = worst ever; 6 = best ever.
0 1 2 3 4 5 6
4.) Have you noticed any unusual physical sensations in the following body areas?
         Please describe and rate.
    a. Head: 0 1 2 3 4 5 6
    b.Chest, Back or Abdomen: 0 1 2 3 4 5 6
    c. Arms or Legs: 0 1 2 3 4 5 6
    d. Groin 0 1 2 3 4 5 6
5.) Have you noticed anything unusual with your hearing?  If so, please describe and rate.
0 1 2 3 4 5 6
6.) Have you noticed anything unusual with your vision?  Describe and rate.   
0 1 2 3 4 5 6
7.) Have you noticed anything unusual with your sense of taste?  Describe and rate.  
0 1 2 3 4 5 6
8.) Have you noticed anything unusual with your sense of smell?  Describe and rate.  
0 1 2 3 4 5 6
9.) Have you noticed anything unusual about your thoughts or thinking?  Describe and rate.
a. Racing thoughts?  Yes / No
0 1 2 3 4 5 6
b. Slowed thoughts?  Yes /No
0 1 2 3 4 5 6
c. Preoccupation with a particular thought or type of thought?  No/ Yes _________
0 1 2 3 4 5 6
10.) Do you have other comments about what you have been experiencing or thinking?
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Appendix B.  Extended Hamilton Psychiatric Rating for Depression
Name: ______________________
Date:______________________
For each item, select the "cue" which best characterizes the
patient. Record the answer in the space provided.
_______1. DEPRESSED MOOD (Sadness, hopeless, helpless, worthless)
0.  Absent.
1.  These feeling states indicated only on questioning.
2.  These feelings spontaneously reported verbally.
3.  Communicates feeling states non-verbally, i.e., through facial expression, posture, voice, and
tendency to weep.
4.  Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non-verbal
communications.
_______2. FEELINGS OF GUILT
  0.  Absent.
  1.  Self reproach; feels he has let people down.
  2.  Ideas of guilt or rumination over past errors or sinful deeds.
  3.  Present illness is a punishment. Delusions of guilt.
  4.  Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations.
_______3. SUICIDE
  0.  Absent.
  1.  Feels life is not worth living.
  2.  Wishes he were dead or any thought of possible death to self.
  3.  Suicidal ideas or gesture.
  4.  Attempts of suicide (any serious attempt rates 4).
_______4. INSOMNIA, EARLY
  0.  No difficulty falling asleep.
  1.  Complains of occasional difficulty falling asleep i.e., more than 1/2 hour.
  2.  Complains of nightly difficulty falling asleep.
_______5. INSOMNIA, MIDDLE
  0.  No difficulty.
  1.  Patient complains of being restless and disturbed during the night.
  2.  Waking during the night- any getting out of bed rates 2 (except for purposes of voiding).
_______6. INSOMNIA, LATE
  0.  No difficulty.
  1.  Waking in early hours of the morning but goes back to sleep.
  2.  Unable to fall asleep again if gets out of bed.
_______7. WORK AND ACTIVITIES
0.  No difficulty.
1.  Thoughts and feelings of incapacity, fatigue or weakness related to activities, work or hobbies.
2.  Loss of interest in activity, hobbies or work- either directly reported by patient or indirect in
listlessness, indecision and vacillation (feels he has to push self to work or activities).
3. Decrease in actual time spent in activities or decrease in productivity. In hospital, rate 3 if
patient does not spend at least three hours a day in activities (hospital job or hobbies)
exclusive of ward chores.
4. Stopped working because of present illness. In hospital, rate 4 if patient engages in no
 activities except ward chores, or if patient fails to perform ward chores unassisted.
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_______8. RETARDATION (Slowness of thought and speech; impaired ability to concentrate; decreased motor
activity)
  0.  Normal speech and thought.
  1.  Slight retardation at interview.
  2.  Obvious retardation at interview.
  3.  Interview difficult.
  4.  Complete stupor.
______9. AGITATION
  0.  None.
  1.  "Playing with" hands, hair, etc.
  2.  Hand-wringing, nail-biting, hair-pulling, biting of lips.
______10. ANXIETY, PSYCHIC
  0.  No difficulty.
  1.  Subjective tensions and irritability.
  2.  Worrying about minor matters.
  3.  Apprehensive attitude apparent in face or speech.
  4.  Fears expressed without questioning.
______11. ANXIETY, SOMATIC (Physiological concomitants of anxiety, such as: Urinary frequency; sweating;
Gastro-intestinal-dry mouth, wind, indigestion, diarrhea, cramps, belching; Cardio-vascular-
palpitations, headaches; Respiratory-hyperventilation, sighing)
  0.  Absent.
  1.  Mild.
  2.  Moderate.
  3.  Severe.
  4.  Incapacitating.
______12. SOMATIC SYMPTOMS, GASTROINTESTINAL
  0.  None.
  1.  Loss of appetite but eating without staff encouragement. Heavy feelings in abdomen.
2. Difficulty eating without staff urging. Requests or requires laxatives or medication for bowels
or medication for G.I. symptoms.
______13. SOMATIC SYMPTOMS, GENERAL
  0.  None.
1. Heaviness in limbs, back, or head. Backaches, headaches, muscle aches. Loss of energy and
fatigability.
  2.  Any clear cut symptom rates 2.
______14. GENITAL SYMPTOMS (Symptoms such as loss of libido, menstrual disturbances)
  0.  Absent.
  1.  Mild.
  2.  Severe.
______15. HYPOCHONDRIASIS
  0.  Not present.
  1.  Self-absorption (bodily).
  2.  Preoccupation with health.
  3.  Frequent complaints, requests for help, etc.
  4.  Hypochondriacal delusions.
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REMINDER: PLEASE COMPLETE ONLY PART ONE OR PART TWO OF QUESTION #16.
______16. LOSS OF WEIGHT
When rating by history:
  0.  No weight loss.
  1.  Probable weight loss associated with present illness.
  2.  Definite (according to patient) weight loss.
On weekly ratings by ward psychiatrist, when actual weight changes are measured:
 0.  Less than 1 lb. weight loss in week.
  1.  Greater than 1 lb. weight loss in week.
  2.  Greater than 2 lb. weight loss in week.
______17. INSIGHT
  0.  Acknowledges being depressed and ill.
1. Acknowledges illness but attributes cause to bad food, climate, overwork, virus, need for rest,
etc.
  2.  Denies being depressed and ill.
______18. DIURNAL VARIATION
A. Note whether symptoms are worse in morning or evening. If no diurnal variation, mark none.
  0.  No variation.
  1.  Worse in A.M.
  2.  Worse in P.M.
______ B. When present, mark the severity of the variation. Mark "none" if no variation.
  0.  None.
  1.  Mild.
  2.  Severe.
______19. DEPERSONALIZATION AND DEREALIZATION: Such as feelings of unreality, nihilistic ideas.
  0.  Absent.
  1.  Mild.
  2.  Moderate.
  3.  Severe.
  4.  Incapacitating.
______20. PARANOID SYMPTOMS
  0.  None.
  1.  Suspicious.
  2.  Ideas of reference.
  3.  Delusions of reference and persecution.
  4.  Incapacitating.
______21. OBSESSIONAL AND COMPULSIVE
  0.  Absent.
  1.  Mild.
  2.  Severe.
______22. FATIGABILITY (Low energy level, feeling heavy, leaden, weighed down)
0.  Does not feel more fatigued than usual.
1.  Feels more fatigued than usual, but this has not impaired function significantly; less
frequently than in (2).
2.  More fatigued than usual; at least one hour a day; at least three days a week.
3.  Fatigued much of the time most days.
4.  Fatigued almost all the time.
______23. SOCIAL WITHDRAWAL
  0.  Interacts with other people as usual.
  1.  Less interested in socializing with others but continues to do so.
  2.  Interacting less with other people in social (optional) situations.
  3.  Interacting less with other people in work or family (necessary) situations.
  4.  Marked withdrawal from others in work or family (necessary) situations.
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______24. APPETITE INCREASE
  0.  No increase in appetite.
  1.  Wants to eat a little more than usual.
  2.  Wants to eat somewhat more than usual.
  3.  Wants to eat much more than usual.
______25. INCREASED EATING
  0.  Is not eating more than usual.
  1.  Is eating a little more than usual.
  2.  Is eating somewhat more than usual.
  3.  Is eating much more than usual.
______26. CARBOHYDRATE CRAVING (In relation to total amount of food desired or eaten)
  0.  No change in food preference.
  1.  Eating more carbohydrates (starches or sugars) than before.
  2.  Eating much more carbohydrates (starches or sugars) than before.
  3.  Irresistible craving for sweets or starches.
______27. WEIGHT GAIN
  0.  No weight gain.
  1.  Probable weight gain associated with present illness.
  2.  Definite (according to patient) weight gain.
______28. HYPERSOMNIA
 Compare sleep length to euthymic and not to hypomanic sleep length. If this cannot be established, use
8 hours.
  0.  No increase in sleep length.
  1.  At least 1 hour increase in sleep length.
  2.  Greater than 2 hour increase in sleep length.
  3.  Greater than 3 hour increase in sleep length.
  4.  Greater than 4 hour increase in sleep length.
 Was euthymic sleep length used?  YES____ NO____
 Was 8 hour sleep length used?    YES____ NO____
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Appendix C.  Young Mania Rating Scale
Patient Name: ______________________
Date:____________________
______ 1. ELEVATED MOOD
0 = Absent
1 = Mildly or possibly increased on questioning
2 = Definite subjective elevation; optimistic, self-confident; cheerful;
appropriate to content
3 = Elevated, inappropriate to content; humorous
4 = Euphoric; inappropriate laughter; singing
______ 2. INCREASED MOTOR ACTIVITY-ENERGY
0 = Absent
1 = Subjectively increased
2 = Animated; gestures increased
3 = Excessive energy; hyperactive at times; restless (can be calmed)
4 = Motor excitement; continuous hyperactivity (cannot be calmed)
______ 3. SEXUAL INTEREST
0 = Normal; not increased
1 = Mildly or possibly increased
2 = Definite subjective increase on questioning
3 = Spontaneous sexual content; elaborates on sexual matters;  hyper-
sexual by self-report.
4 = Overt sexual acts (towards patients, staff, or interviewer)
______ 4. SLEEP
0 = Reports no decrease in sleep
1 = Sleeping less than normal amount by up to one hour
2 = Sleeping less than normal by more than one hour
3 = Reports decreased need for sleep
4 = Denies need for sleep
______ 5. IRRITABILITY
0 = Absent
2 = Subjectively increased
4 = Irritable at times during interview; recent episodes of anger or
annoyance on ward
6 = Frequently irritable during interview; short, curt throughout
8 = Hostile, uncooperative; interview impossible
______ 6. SPEECH (RATE AND AMOUNT)
0 = No increase
2 = Feels talkative
4 = Increased rate or amount at times, verbose at times
6 = Push; consistently increased rate and amount; difficult to interrupt
8 = Pressured; un-interruptible, continuous speech
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______ 7. LANGUAGE-THOUGHT DISORDER
0 = Absent
1 = Circumstantial; mild distractibility; quick thoughts
2 = Distractible; loses goal of thought; changes topics frequently; racing
thoughts
3 = Flight of ideas; tangentiality; difficult to follow; rhyming, echolalia
4 = Incoherent; communication impossible
______ 8. CONTENT
0 = Normal
2 = Questionable plans, new interests
4 = Special project(s); hyper-religious
6 = Grandiose or paranoid ideas; ideas of reference
8 = Delusions; hallucinations
______ 9. DISRUPTIVE-AGGRESSIVE BEHAVIOR
0 = Absent; cooperative
2 = Sarcastic; loud at times, guarded
4 = Demanding; threats on ward, etc
6 = Threatens interviewer; shouting; interview difficult
8 = Assaultive; destructive; interview impossible
_______10. APPEARANCE
0 = Appropriate dress and grooming
1 = Minimally unkempt
2 = Poorly groomed; moderately disheveled; overdressed
3 = Disheveled; partly clothed; garish make-up
4 = Completely unkempt; decorated; bizarre garb
_______11. INSIGHT
0 = Present; admits illness; agree with need for treatment
1 = Possibly ill
2 = Admits behavior change, but denies illness
3 = Admits possible change in behavior, but denies illness
4 = Denies any behavior change
OTHER ITEMS
1. Distractibility (i.e., attention too easily drawn to unimportant or irrelevant external
stimuli)
2. Increase in goal-directed activity (either socially, at work or school, or sexually).
3. Excessive involvement in pleasurable activities which have a high potential for painful
consequences (i.e., the person engages in unrestrained buying sprees, sexual indiscretions, or
foolish business investments)
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Appendix D.  Beck Depression Inventory
Name:____________________ Date: ________________
On this questionnaire are groups of statements. Please read each group of statements carefully.
Then pick out the one statement in each group which best describes the way you have been
feeling the PAST WEEK, INCLUDING TODAY. Circle the number beside the statement you
picked. If several statements in the group seem to apply equally well, circle each one. Be sure to
read all the statements in each group before making your choice.
1. 0    I do not feel sad.
1    I feel sad.
2    I am sad all the time and I can't snap out of it.
3    I am so sad or unhappy that I can't stand it.
2. 0    I am not particularly discouraged about the future.
1    I feel discouraged about the future.
2    I feel I have nothing to look forward to.
3    I feel that the future is hopeless and that things cannot improve.
3. 0    I do not feel like a failure.
1    I feel I have failed more than the average person.
2    As I look back on my life, all I can see is a lot of failures.
3    I feel I am a complete failure as a person.
4. 0    I get as much satisfaction out of things as I used to.
1    I don't enjoy things the way I used to.
2    I don't get real satisfaction out of anything anymore.
3    I am dissatisfied or bored with everything.
5. 0    I don't feel particularly guilty.
1    I feel guilty a good part of the time.
2    I feel quite guilty most of the time.
3    I feel guilty all of the time.
6. 0    I don't feel I am being punished.
1    I feel I may be punished.
2    I expect to be punished.
3    I feel I am being punished.
7. 0    I don't feel disappointed in myself.
1    I am disappointed in myself.
2    I am disgusted with myself.
3    I hate myself.
8. 0    I don't feel I am worse than anybody else.
1    I am critical of myself for my weaknesses or mistakes.
2    I blame myself all the time for my faults.
3    I blame myself for everything bad that happens.
9. 0    I don't have any thoughts of killing myself.
1    I have thoughts of killing myself, but I would not carry them out.
2    I would like to kill myself.
3    I would kill myself if I had the chance.
263
Appendix D. Cont’d.
10. 0    I don't cry any more than usual.
1    I cry more now than I used to.
2    I cry all the time now.
3    I used to be able to cry, but now I can't cry even though I want to.
11. 0    I am no more irritated than I ever am.
1    I get annoyed or irritated more easily than I used to.
2    I feel irritated all the time now.
3    I don't get irritated at all the things that used to irritate me.
12. 0    I have not lost interest in other people.
1    I am less interested in other people than I used to be.
2    I have lost most of my interest in other people.
3    I have lost all of my interest in other people.
13. 0    I make decisions about as well as I ever could.
1    I put off making decisions more than I used to.
2    I have greater difficulty in making decisions than before.
3    I can't make decisions at all anymore.
14. 0    I don't feel I look any worse than I used to.
1    I am worried that I am looking old or unattractive.
2    I feel that there are permanent changes in my appearance that make me look unattractive.
3    I believe that I look ugly.
15. 0    I can work about as well as before.
1    It takes an extra effort to get started at doing something.
2    I have to push myself very hard to do anything.
3    I can't do any work at all.
16. 0    I can sleep as well as usual.
1    I don't sleep as well as I used to.
2    I wake up 1-2 hours earlier than usual and find it hard to get back to sleep.
3    I wake up several hours earlier than I used to and cannot get back to sleep.
17. 0    I don't get more tired than usual.
1    I get tired more easily than usual.
2    I get tired from doing almost anything.
3    I am too tired to do anything.
18. 0    My appetite is no worse than usual.
1    My appetite is not as good as it used to be.
2    My appetite is much worse now.
3    I have no appetite at all anymore.
19. 0    I haven't lost much weight, if any, lately.
1    I have lost more than 5 pounds.
2    I have lost more than 10 pounds.
3    I have lost more than 15 pounds.
I am purposely trying to lose weight by eating less.
.yes_____    no_____
20. 0    I am no more worried about my health than usual.
1    I am worried about physical problems such as aches and pains; or upset stomach, or constipation.
2    I am very worried about physical problems and it's hard to think of much else.
3    I am so worried about my physical problems that I cannot think of anything else.
21. 0    I have not noticed any recent change in my interest in sex.
1    I am less interested in sex than I used to be.
2    I am much less interested in sex now.
3    I have lost interest in sex completely.
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Appendix E.  Spielberger State-Anxiety
Name: ________________________
Date: _______________
A number of statements which people have used to describe themselves are given
below. Read each statement and then circle the appropriate number to the right of
the statement to indicate how you feel right now, that is, at this moment. There are
no right or wrong answers. Do not spend too much time on any one statement but











1. I feel calm 1 2 3 4
2. I feel secure 1 2 3 4
3. I am tense 1 2 3 4
4. I am regretful 1 2 3 4
5. I feel at ease 1 2 3 4
6. I feel upset 1 2 3 4
7. I am presently worrying over possible
misfortunes 1 2 3 4
8. I feel rested 1 2 3 4
9. I feel anxious 1 2 3 4
10. I feel  comfortable 1 2 3 4
11. I feel self-confident 1 2 3 4
12. I feel nervous 1 2 3 4
13. I am jittery 1 2 3 4
14. I feel high-strung 1 2 3 4
15. I am relaxed 1 2 3 4
16. I am content 1 2 3 4
17. I am worried 1 2 3 4
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18. I feel overexcited and rattled 1 2 3 4
19. I feel joyful 1 2 3 4
20. I feel pleasant 1 2 3 4
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Appendix F. Correlative Relationships Between Cholinergic Brain Regions and ROIs




















































































































L Tegementum 0.51 0.31 0.27 0.56 0.57 0.52 0.50 0.67 -0.34 -0.23 -0.21 -0.18 -0.21 -0.16 0 ↓ 0 ↓ ↓ ↓ ↓
R Tegmentum 0.51 0.05 0.03 0.44 0.37 0.31 0.30 0.67 -0.28 -0.04 -0.04 0.02 -0.12 -0.01 0 0 0 0 0 0 0
L SI 0.31 0.05 0.61 0.64 0.59 0.81 0.60 -0.34 -0.28 0.80 0.87 0.71 0.95 0.79 ↓ 0 0 ↑ 0 ↑ 0
R SI 0.27 0.03 0.61 0.43 0.67 0.57 0.76 -0.23 -0.04 0.80 0.74 0.81 0.81 0.94 0 0 0 0 0 0 ↑
L Septal n 0.56 0.44 0.64 0.43 0.85 0.88 0.81 -0.21 -0.04 0.87 0.74 0.86 0.91 0.81 ↓ 0 ↑ 0 0 0 0
R Septal n 0.57 0.37 0.59 0.67 0.85 0.77 0.91 -0.18 0.02 0.71 0.81 0.86 0.76 0.90 ↓ 0 0 0 0 0 0
L BF 0.52 0.31 0.81 0.57 0.88 0.77 0.83 -0.21 -0.12 0.95 0.81 0.91 0.76 0.84 ↓ 0 ↑ 0 0 0 0
R BF 0.50 0.30 0.60 0.76 0.81 0.91 0.83 -0.16 -0.01 0.79 0.94 0.81 0.90 0.84 ↓ 0 0 ↑ 0 0 0
Medulla 0.56 0.67 0.39 0.34 0.64 0.61 0.59 0.56 0.78 0.57 -0.15 -0.10 -0.02 -0.13 0.00 -0.02 0 0 ↓ 0 ↓ ↓ ↓ ↓
Pons 0.75 0.77 0.29 0.01 0.63 0.53 0.53 0.42 0.67 0.85 0.00 0.18 0.21 0.24 0.15 0.24 0 0 0 0 ↓ 0 0 0
Midbrain 0.80 0.49 0.41 0.20 0.72 0.62 0.73 0.62 0.31 0.40 0.47 0.50 0.53 0.56 0.61 0.59 ↓ 0 0 0 0 0 0 0
L Cerebellum 0.58 0.63 0.18 0.03 0.45 0.33 0.30 0.30 0.77 0.61 -0.40 -0.28 -0.38 -0.41 -0.29 -0.28 0 0 ↓ 0 ↓ ↓ ↓ ↓
R Cerebellum 0.61 0.69 0.23 0.00 0.43 0.30 0.31 0.25 0.72 0.56 -0.32 -0.24 -0.33 -0.40 -0.22 -0.23 0 0 ↓ 0 ↓ ↓ ↓ 0
L Cerebellum n 0.54 0.59 0.29 0.14 0.46 0.32 0.42 0.36 0.75 0.52 -0.12 -0.02 -0.17 -0.22 -0.03 -0.03 0 0 0 0 ↓ ↓ 0 0
R Cerebellum n 0.49 0.62 0.22 -0.01 0.40 0.23 0.34 0.27 0.62 0.40 0.25 0.22 0.19 0.05 0.35 0.23 0 0 0 0 0 0 0 0
L m Thalamus 0.52 0.44 0.46 0.28 0.69 0.49 0.74 0.59 0.07 0.08 0.58 0.59 0.61 0.60 0.67 0.65 0 0 0 0 0 0 0 0
R m Thalamus 0.42 0.40 0.29 0.24 0.66 0.56 0.62 0.63 0.12 0.09 0.50 0.58 0.51 0.60 0.53 0.66 0 0 0 0 0 0 0 0
L Caudate 0.46 0.03 0.60 0.49 0.60 0.56 0.81 0.67 -0.22 -0.11 0.77 0.75 0.75 0.72 0.78 0.77 ↓ 0 0 0 0 0 0 0
R Caudate 0.32 0.19 0.32 0.57 0.52 0.57 0.61 0.72 0.01 0.06 0.54 0.70 0.63 0.70 0.60 0.74 0 0 0 0 0 0 0 0
L Putamen 0.06 -0.17 0.31 0.57 0.26 0.37 0.38 0.50 -0.20 -0.18 0.85 0.77 0.75 0.67 0.82 0.77 0 0 ↑ 0 ↑ 0 ↑ 0
R Putamen 0.04 -0.03 0.45 0.59 0.17 0.28 0.39 0.50 -0.19 -0.13 0.75 0.83 0.66 0.65 0.73 0.83 0 0 0 ↑ ↑ 0 0 ↑
L Globus Pallidus 0.27 0.21 0.18 0.08 0.47 0.38 0.49 0.44 -0.46 -0.42 0.67 0.48 0.58 0.43 0.65 0.47 ↓ ↓ ↑ 0 0 0 0 0
R Globus Pallidus 0.15 0.21 0.37 0.36 0.59 0.50 0.58 0.62 -0.25 -0.20 0.64 0.66 0.62 0.65 0.65 0.74 0 0 0 0 0 0 0 0
L Hippocampus 0.36 0.39 0.38 0.45 0.57 0.52 0.57 0.55 0.24 0.24 0.02 0.05 0.07 -0.09 0.14 0.07 0 0 0 0 ↓ ↓ 0 ↓
R Hippocampus 0.41 0.34 0.28 0.39 0.53 0.66 0.52 0.62 0.50 0.49 -0.41 -0.34 -0.24 -0.23 -0.30 -0.24 0 0 ↓ ↓ ↓ ↓ ↓ ↓
L Amygdala 0.54 0.37 0.45 0.30 0.69 0.57 0.67 0.60 -0.05 -0.16 0.50 0.34 0.53 0.41 0.55 0.46 ↓ ↓ 0 0 0 0 0 0
R Amygdala 0.34 0.19 0.28 0.14 0.55 0.47 0.49 0.54 0.00 0.18 0.35 0.48 0.46 0.54 0.41 0.62 0 0 0 0 0 0 0 0
L Ant Insula -0.35 -0.46 0.26 0.08 -0.35 -0.32 -0.15 -0.25 -0.32 -0.28 0.72 0.73 0.63 0.62 0.66 0.67 0 0 ↑ ↑ ↑ ↑ ↑ ↑
R Ant Insula -0.04 -0.17 0.24 0.46 0.06 0.17 0.12 0.24 -0.25 -0.14 0.60 0.74 0.49 0.63 0.50 0.71 0 0 0 0 0 ↑ 0 ↑
L Post Insula 0.03 -0.07 0.25 0.22 0.07 0.09 0.20 0.24 -0.16 -0.17 0.64 0.55 0.57 0.47 0.60 0.56 0 0 0 0 ↑ 0 0 0
R Post Insula 0.07 -0.09 0.04 -0.05 0.01 -0.06 0.19 0.08 -0.33 -0.20 0.69 0.76 0.62 0.68 0.67 0.78 0 0 ↑ ↑ ↑ ↑ ↑ ↑
L Subgenual AC 0.03 -0.12 0.66 0.56 0.36 0.30 0.52 0.37 -0.06 -0.07 0.64 0.54 0.58 0.49 0.69 0.51 0 0 0 0 0 0 0 0
R Subgenual AC 0.20 0.06 0.48 0.66 0.54 0.62 0.50 0.67 0.09 0.14 0.35 0.45 0.43 0.42 0.43 0.45 0 0 0 0 0 0 0 0
L Drevet -0.03 -0.31 0.42 0.51 0.16 0.28 0.19 0.26 -0.31 -0.26 0.69 0.48 0.49 0.30 0.63 0.40 0 0 0 0 0 0 ↑ 0
R Drevet 0.00 -0.18 0.36 0.61 0.19 0.36 0.19 0.40 -0.03 -0.07 0.53 0.61 0.40 0.42 0.45 0.52 0 0 0 0 0 0 0 0
L Pregenual AC -0.07 -0.37 0.42 0.68 0.23 0.40 0.30 0.43 -0.36 -0.28 0.66 0.74 0.60 0.63 0.58 0.73 0 0 0 0 0 0 0 0
R Pregenual AC -0.12 -0.41 0.25 0.66 0.03 0.25 0.09 0.33 -0.22 -0.31 0.67 0.64 0.53 0.55 0.57 0.59 0 0 ↑ 0 ↑ 0 ↑ 0
L Mayberg -0.01 -0.45 0.48 0.68 0.19 0.36 0.31 0.40 -0.28 -0.20 0.61 0.72 0.57 0.64 0.55 0.74 0 0 0 0 0 0 0 ↑
R Mayberg -0.11 -0.45 0.22 0.62 -0.02 0.19 0.07 0.27 -0.24 -0.30 0.66 0.66 0.53 0.58 0.56 0.62 0 0 ↑ 0 ↑ 0 ↑ 0
L Supragenual AC -0.04 -0.48 0.55 0.62 0.23 0.34 0.31 0.40 -0.45 -0.53 0.71 0.62 0.55 0.54 0.60 0.61 0 0 0 0 0 0 0 0
R Supragenual AC 0.02 -0.43 0.45 0.69 0.12 0.33 0.27 0.43 -0.46 -0.46 0.76 0.68 0.61 0.60 0.67 0.61 ↓ 0 0 0 ↑ 0 ↑ 0
L Dorsal AC -0.02 -0.38 0.26 0.65 0.15 0.27 0.33 0.44 -0.23 -0.31 0.63 0.69 0.58 0.68 0.62 0.72 0 0 0 0 0 ↑ 0 0
R Dorsal AC -0.05 -0.41 0.27 0.56 0.04 0.13 0.26 0.33 -0.22 -0.36 0.62 0.73 0.55 0.69 0.61 0.69 0 0 0 0 ↑ ↑ 0 0
L Post AC -0.24 -0.10 0.36 0.19 0.00 0.06 0.20 0.16 0.04 -0.11 0.25 0.25 0.16 0.22 0.32 0.37 0 0 0 0 0 0 0 0
R Post AC -0.13 -0.30 0.46 0.33 0.11 0.23 0.26 0.31 -0.02 -0.18 0.16 0.19 0.20 0.33 0.25 0.33 0 0 0 0 0 0 0 0
L Ant Tenporal 0.00 -0.05 0.30 0.20 0.35 0.40 0.24 0.22 0.02 0.17 -0.14 -0.22 -0.06 -0.14 -0.11 -0.21 0 0 0 0 0 ↓ 0 0
R Ant Temporal -0.03 0.02 0.22 0.40 0.07 0.37 0.03 0.28 0.23 0.16 -0.10 -0.02 -0.08 -0.10 -0.07 0.02 0 0 0 0 0 0 0 0
L Post Temporal 0.16 0.01 0.03 -0.40 0.04 -0.07 -0.01 -0.18 0.15 0.23 -0.08 -0.26 -0.13 -0.32 -0.10 -0.29 0 0 0 0 0 0 0 0
R Post Temporal -0.10 0.06 -0.47 -0.47 -0.31 -0.23 -0.43 -0.29 0.15 0.33 -0.31 -0.28 -0.28 -0.27 -0.31 -0.27 0 0 0 0 0 0 0 0
L TP 0.09 -0.01 0.69 0.62 0.54 0.55 0.63 0.57 0.18 0.12 0.12 0.21 0.15 0.07 0.23 0.21 0 0 ↓ 0 0 ↓ 0 0
R TP 0.04 0.13 0.36 0.47 0.35 0.50 0.33 0.46 0.23 0.28 -0.02 0.17 -0.01 0.01 0.04 0.20 0 0 0 0 0 ↓ 0 0
L Inf Parietal -0.04 -0.10 0.20 0.19 0.06 0.05 0.13 -0.08 -0.20 -0.23 0.49 0.34 0.34 0.24 0.40 0.21 0 0 0 0 0 0 0 0
R Inf Parietal -0.18 -0.06 -0.21 0.05 -0.17 0.00 -0.17 -0.10 -0.26 -0.08 -0.01 0.01 0.02 0.07 -0.05 -0.04 0 0 0 0 0 0 0 0
L Occipital -0.12 0.17 0.07 -0.21 -0.12 -0.23 -0.06 -0.25 0.22 0.15 -0.04 -0.13 0.05 0.02 -0.07 -0.08 0 0 0 0 0 0 0 0
R Occipital -0.24 -0.29 0.07 -0.30 -0.32 -0.38 -0.16 -0.32 -0.01 -0.14 0.07 -0.04 0.04 0.07 0.00 0.03 0 0 0 0 0 0 0 0
L DLPFC -0.25 -0.49 0.17 0.00 -0.06 -0.02 -0.02 -0.06 -0.30 -0.32 0.34 0.18 0.21 0.14 0.16 0.14 0 0 0 0 0 0 0 0
R DLPFC -0.35 -0.57 -0.11 -0.16 -0.39 -0.32 -0.33 -0.31 -0.49 -0.38 0.34 0.42 0.22 0.34 0.18 0.34 0 0 0 ↑ ↑ ↑ ↑ ↑
L VLPFC 0.12 -0.27 0.45 0.47 0.13 0.24 0.31 0.32 -0.34 -0.35 0.61 0.37 0.41 0.24 0.51 0.31 0 0 0 0 0 0 0 0
R VLPFC 0.23 0.01 0.29 0.52 0.32 0.57 0.28 0.56 -0.13 -0.07 0.40 0.44 0.33 0.32 0.37 0.41 0 0 0 0 0 0 0 0
L MOFC 0.08 -0.18 0.43 0.45 0.16 0.25 0.21 0.24 0.11 0.14 0.28 0.32 0.25 0.16 0.28 0.27 0 0 0 0 0 0 0 0
R MOFC 0.15 -0.03 0.40 0.60 0.25 0.41 0.26 0.44 0.22 0.19 0.20 0.36 0.14 0.14 0.22 0.28 0 0 0 0 0 0 0 0
L LOFC 0.40 0.29 0.22 0.35 0.50 0.46 0.46 0.60 0.31 0.25 0.10 0.24 0.01 0.00 0.17 0.21 0 0 0 0 0 ↓ 0 0
R LOFC 0.18 0.22 -0.12 0.18 0.30 0.30 0.18 0.40 Totals 0.13 0.17 -0.13 0.08 -0.17 -0.09 -0.07 0.05 Totals 0 0 0 0 0 0 0 0
# r > .45 15 8 17 26 22 23 23 24 158 8 7 32 30 30 27 31 30 195 0 0 0 0 0 0 0 0
# r < -.45 0 4 1 1 0 0 0 0 6 4 2 0 0 0 0 0 0 6 0 0 0 0 0 0 0 0
Total 15 12 18 27 22 23 23 24 164 12 9 32 30 30 27 31 30 201 0 0 0 0 0 0 0 0
Cholinergic System
# Positive corrs 40 33 58 55 54 54 54 53 401 26 27 47 49 49 50 47 50 345 r ∆r Tegmental-Midbrain
# Negative corrs 22 29 4 7 8 8 8 9 95 36 35 15 13 13 12 15 12 151 >.50 ↑ >.50 Substantia Inominata
Total 62 62 62 62 62 62 62 62 496 62 62 62 62 62 62 62 62 496 <-.50 ↓ <-.50 Septo-Hippocampal
Basal ForebrainBrainstem
Saline Procaine





Appendix G. Correlative Relationships Between Cholinergic Brain Regions and ROIs





















































































































L Tegementum 0.69 0.36 0.16 0.28 0.55 0.35 0.28 0.62 0.05 -0.11 0.28 0.44 0.27 0.10 0 0 0 0 0 0 0
R Tegmentum 0.69 0.19 0.12 0.27 0.54 0.17 0.33 0.62 -0.18 -0.13 0.06 0.15 0.03 0.16 0 0 0 0 0 0 0
L SI 0.36 0.19 0.31 0.89 0.46 0.82 0.36 0.05 -0.18 0.75 0.80 0.73 0.82 0.75 0 0 0 0 0 0 0
R SI 0.16 0.12 0.31 0.19 0.57 0.54 0.95 -0.11 -0.13 0.75 0.76 0.64 0.83 0.93 0 0 0 0 0 0 0
L Septal n 0.28 0.27 0.89 0.19 0.52 0.82 0.33 0.28 0.06 0.80 0.76 0.87 0.96 0.80 0 0 0 0 0 0 0
R Septal n 0.55 0.54 0.46 0.57 0.52 0.50 0.73 0.44 0.15 0.73 0.64 0.87 0.83 0.77 0 0 0 0 0 0 0
L BF 0.35 0.17 0.82 0.54 0.82 0.50 0.59 0.27 0.03 0.82 0.83 0.96 0.83 0.85 0 0 0 0 0 0 0
R BF 0.28 0.33 0.36 0.95 0.33 0.73 0.59 0.10 0.16 0.75 0.93 0.80 0.77 0.85 0 0 0 0 0 0 0
Medulla 0.34 0.75 0.02 0.14 0.22 0.37 0.23 0.30 0.27 0.68 -0.34 -0.13 -0.06 0.13 -0.14 0.10 0 0 0 0 0 0 0 0
Pons 0.80 0.85 0.49 0.20 0.58 0.73 0.50 0.40 0.88 0.64 0.34 0.07 0.40 0.55 0.41 0.30 0 0 0 0 0 0 0 0
Midbrain 0.60 0.70 0.54 0.23 0.65 0.69 0.62 0.44 0.59 0.23 0.79 0.48 0.72 0.84 0.73 0.63 0 0 0 0 0 0 0 0
L Cerebellum 0.61 0.79 0.15 0.33 0.27 0.57 0.27 0.48 0.68 0.55 -0.21 -0.30 -0.13 0.03 -0.12 -0.12 0 0 ↓ 0 ↓ 0 ↓ 0
R Cerebellum 0.67 0.78 0.24 0.14 0.35 0.72 0.23 0.36 0.57 0.61 -0.18 -0.26 -0.15 0.12 -0.17 0.01 ↓ ↓ 0 0 0 0 0 0
L Cerebellum n 0.66 0.48 0.51 0.41 0.36 0.70 0.41 0.53 0.31 0.36 0.24 0.12 0.24 0.33 0.25 0.33 0 0 0 0 0 0 0 0
R Cerebellum n 0.43 0.68 0.38 0.36 0.32 0.66 0.25 0.51 0.05 0.35 0.27 0.26 0.16 0.23 0.16 0.46 0 0 0 0 0 0 0 0
L m Thalamus 0.39 0.50 0.59 0.38 0.66 0.53 0.72 0.48 0.36 0.25 0.64 0.42 0.63 0.80 0.66 0.63 0 0 0 0 0 0 0 0
R m Thalamus 0.66 0.51 0.64 0.35 0.57 0.69 0.63 0.45 0.36 0.31 0.81 0.63 0.80 0.85 0.80 0.79 0 0 0 0 0 0 0 0
L Caudate 0.19 -0.14 0.56 0.24 0.61 0.18 0.75 0.27 0.23 -0.25 0.58 0.49 0.66 0.43 0.74 0.42 0 0 0 0 0 0 0 0
R Caudate 0.43 0.01 -0.04 0.50 -0.14 0.29 0.28 0.44 0.35 -0.31 0.51 0.34 0.57 0.53 0.62 0.29 0 0 0 0 0 0 0 0
L Putamen 0.50 0.21 0.60 0.44 0.49 0.43 0.69 0.49 0.41 0.13 0.77 0.42 0.67 0.77 0.66 0.58 0 0 0 0 0 0 0 0
R Putamen 0.02 -0.06 0.10 0.79 -0.11 0.35 0.12 0.72 0.16 -0.04 0.66 0.60 0.55 0.73 0.60 0.71 0 0 0 0 0 0 0 0
L Globus Pallidus 0.38 0.27 0.16 0.51 0.19 0.40 0.43 0.56 0.29 -0.03 0.56 0.37 0.61 0.44 0.66 0.42 0 0 0 0 0 0 0 0
R Globus Pallidus 0.54 0.46 -0.14 0.33 -0.10 0.42 0.07 0.43 0.04 -0.08 0.62 0.65 0.73 0.69 0.69 0.71 0 0 0 0 0 0 0 0
L Hippocampus -0.15 0.08 -0.01 0.34 0.13 0.22 0.25 0.40 0.34 0.34 0.44 0.26 0.35 0.15 0.33 0.29 0 0 0 0 0 0 0 0
R Hippocampus -0.03 -0.46 0.33 0.10 0.18 0.06 0.28 0.07 -0.13 0.10 0.18 0.00 -0.20 -0.02 -0.22 0.06 0 0 0 0 0 0 0 0
L Amygdala 0.36 0.53 0.46 0.56 0.41 0.75 0.40 0.67 0.38 0.58 0.55 0.55 0.50 0.56 0.53 0.73 0 0 0 0 0 0 0 0
R Amygdala -0.01 0.20 0.68 -0.09 0.76 0.28 0.41 0.06 0.01 0.26 0.55 0.40 0.30 0.40 0.28 0.54 0 0 0 0 0 0 0 0
L Ant Insula 0.21 0.53 0.23 -0.19 0.43 0.19 0.19 -0.01 0.37 0.31 -0.24 -0.42 -0.14 0.01 -0.27 -0.27 0 0 0 0 0 0 0 0
R Ant Insula 0.17 0.30 0.22 -0.32 0.22 -0.25 0.06 -0.26 0.29 0.22 -0.14 -0.46 -0.10 -0.07 -0.20 -0.31 0 0 0 0 0 0 0 0
L Post Insula 0.30 0.24 0.65 0.18 0.51 0.43 0.39 0.28 0.25 0.31 0.40 0.28 0.25 0.37 0.23 0.45 0 0 0 0 0 0 0 0
R Post Insula 0.09 0.08 0.64 0.12 0.47 0.24 0.29 0.16 0.17 0.05 0.70 0.43 0.46 0.57 0.43 0.52 0 0 0 0 0 0 0 0
L Subgenual AC 0.14 -0.10 0.11 0.17 0.09 -0.01 0.31 0.07 0.36 -0.12 0.01 0.21 0.37 0.46 0.38 0.18 0 0 0 0 0 0 0 0
R Subgenual AC 0.12 -0.06 -0.16 0.78 -0.22 0.33 0.22 0.68 -0.09 -0.09 0.25 0.63 0.43 0.26 0.56 0.59 0 0 0 0 0 0 0 0
L Drevet 0.45 0.39 0.56 0.41 0.55 0.47 0.61 0.47 0.00 -0.13 0.82 0.75 0.70 0.78 0.71 0.80 0 0 0 0 0 0 0 0
R Drevet 0.29 0.20 0.54 0.77 0.49 0.75 0.56 0.81 0.06 0.11 0.76 0.83 0.65 0.58 0.74 0.86 0 0 0 0 0 0 0 0
L Pregenual AC 0.50 0.14 0.39 0.68 0.23 0.47 0.55 0.68 -0.10 -0.16 0.79 0.90 0.72 0.71 0.75 0.90 0 0 0 0 0 0 0 0
R Pregenual AC 0.34 0.14 0.55 0.72 0.49 0.53 0.76 0.72 -0.04 0.06 0.74 0.76 0.53 0.60 0.65 0.84 0 0 0 0 0 0 0 0
L Mayberg 0.48 0.03 0.56 0.58 0.42 0.49 0.69 0.58 -0.02 -0.15 0.80 0.91 0.82 0.79 0.84 0.91 0 0 0 0 0 0 0 0
R Mayberg 0.33 0.05 0.60 0.54 0.51 0.36 0.76 0.53 0.04 0.04 0.72 0.75 0.59 0.72 0.68 0.85 0 0 0 0 0 0 0 0
L Supragenual AC 0.14 -0.23 0.24 0.10 0.13 -0.03 0.42 0.06 0.06 -0.09 0.72 0.78 0.78 0.72 0.74 0.78 0 0 0 0 0 0 0 0
R Supragenual AC 0.41 -0.06 0.51 0.15 0.35 0.30 0.45 0.17 0.27 -0.10 0.64 0.59 0.68 0.70 0.73 0.67 0 0 0 0 0 0 0 0
L Dorsal AC 0.18 -0.18 0.64 0.25 0.50 0.40 0.48 0.27 0.44 0.18 0.50 0.45 0.48 0.56 0.53 0.57 0 0 0 0 0 0 0 0
R Dorsal AC -0.05 -0.17 0.42 0.15 0.40 0.21 0.38 0.20 0.25 0.18 0.53 0.45 0.53 0.61 0.55 0.62 0 0 0 0 0 0 0 0
L Post AC 0.18 0.24 0.11 0.54 0.03 0.27 0.15 0.54 -0.21 0.08 0.21 0.49 0.01 -0.03 0.14 0.47 0 0 0 0 0 0 0 0
R Post AC 0.32 0.19 0.09 0.46 -0.04 0.24 0.18 0.40 0.02 0.10 0.06 0.37 0.16 0.07 0.30 0.36 0 0 0 0 0 0 0 0
L Ant Tenporal -0.26 -0.10 -0.52 -0.41 -0.38 -0.34 -0.38 -0.37 0.09 -0.05 -0.70 -0.36 -0.43 -0.46 -0.42 -0.44 0 0 0 0 0 0 0 0
R Ant Temporal -0.18 0.09 -0.38 -0.16 -0.28 -0.20 -0.22 -0.14 0.11 0.17 -0.59 -0.40 -0.43 -0.39 -0.50 -0.39 0 0 0 0 0 0 0 0
L Post Temporal -0.52 -0.57 -0.59 -0.48 -0.42 -0.41 -0.54 -0.49 0.06 0.09 -0.88 -0.72 -0.68 -0.60 -0.72 -0.73 0 0 0 0 0 0 0 0
R Post Temporal -0.67 -0.32 -0.19 -0.21 0.05 -0.13 -0.30 -0.16 -0.30 -0.04 -0.64 -0.54 -0.69 -0.59 -0.73 -0.54 0 0 0 0 0 0 0 0
L TP 0.22 0.55 0.26 -0.17 0.43 0.21 0.22 -0.04 0.33 0.42 0.12 0.20 0.22 0.35 0.17 0.34 0 0 0 0 0 0 0 0
R TP -0.08 0.36 0.18 -0.29 0.41 0.09 0.16 -0.17 0.33 0.50 0.08 0.17 0.20 0.30 0.15 0.32 0 0 0 0 0 0 0 0
L Inf Parietal 0.00 -0.14 0.10 -0.16 0.03 -0.02 -0.01 -0.16 0.05 0.06 0.57 0.31 0.39 0.43 0.30 0.37 0 0 0 ↓ 0 0 0 0
R Inf Parietal 0.11 -0.31 0.60 0.48 0.29 0.11 0.51 0.35 0.08 0.23 0.71 0.57 0.46 0.48 0.53 0.72 0 ↑ 0 0 0 0 0 0
L Occipital -0.09 0.26 -0.07 -0.44 -0.12 -0.25 -0.44 -0.36 -0.42 -0.29 -0.04 -0.21 -0.47 -0.49 -0.36 -0.25 0 0 0 0 0 0 0 0
R Occipital 0.36 0.39 0.14 -0.44 0.18 0.02 -0.16 -0.33 0.02 -0.12 0.31 -0.10 -0.13 0.03 -0.04 -0.05 0 0 0 0 0 0 0 0
L DLPFC 0.22 -0.11 0.28 -0.15 0.23 0.02 0.16 -0.18 -0.03 -0.34 0.55 0.56 0.60 0.53 0.61 0.46 0 0 0 0 0 0 0 0
R DLPFC -0.27 -0.22 0.11 -0.05 0.10 0.07 -0.11 -0.11 -0.14 -0.40 0.77 0.66 0.55 0.60 0.55 0.57 0 0 0 0 0 0 0 0
L VLPFC 0.19 -0.33 -0.01 0.39 -0.12 0.15 0.27 0.30 -0.04 -0.46 0.48 0.57 0.64 0.54 0.66 0.44 0 0 0 ↓ 0 0 0 0
R VLPFC -0.19 -0.38 0.41 0.42 0.34 0.19 0.36 0.31 -0.05 -0.08 0.45 0.25 0.21 0.45 0.20 0.35 0 0 0 0 0 0 0 0
L MOFC 0.12 0.36 0.09 0.09 0.26 0.22 0.19 0.16 -0.10 -0.24 0.57 0.68 0.64 0.66 0.55 0.61 0 0 0 0 0 0 0 0
R MOFC 0.09 0.20 0.14 0.66 0.21 0.65 0.25 0.69 -0.18 0.10 0.50 0.85 0.55 0.46 0.58 0.81 0 0 0 0 0 0 0 0
L LOFC -0.18 -0.21 -0.40 0.31 -0.38 -0.10 -0.17 0.20 -0.04 0.11 -0.37 0.04 -0.05 -0.09 -0.01 0.01 0 0 0 0 0 0 0 0
R LOFC -0.44 -0.58 -0.57 0.09 -0.60 -0.31 -0.44 -0.09 Total 0.06 0.18 -0.56 -0.17 -0.25 -0.28 -0.25 -0.19 Total 0 0 0 0 0 0 0 0
# r > .45 12 15 22 17 17 22 20 20 145 5 7 35 27 32 33 32 32 203 0 0 0 0 0 0 0 0
# r < -.45 2 3 3 1 1 0 1 1 12 0 1 5 3 3 4 3 2 21 0 0 0 0 0 0 0 0
Total 14 18 25 18 18 22 21 21 157 5 8 40 30 35 37 35 34 224 0 0 0 0 0 0 0 0
Legend Cholinergic System
# Positive corrs 48 42 50 48 50 51 52 48 389 45 39 49 48 48 52 48 52 381 r ∆r Tegmental-Midbrain
# Negative corrs 14 20 12 14 12 11 10 14 107 17 23 13 14 14 10 14 10 115 >.50 ↑ >.50 Substantia Inominata
Total 62 62 62 62 62 62 62 62 496 62 62 62 62 62 62 62 62 496 <-.50 ↓ <-.50 Septo-Hippocampal
BrainstemBrainstemBF Mean
Saline
BF MeanBrainstem Basal Forebrain
Procaine Procaine vs Saline
Basal ForebrainBasal Forebrain BF Mean
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Appendix H.  Correlations Between Brain ROIs and Emotional and Sensory












































Global -0.02 0.15 -0.28 . -0.16 -0.19 . 0.25 -0.18 -0.30
L Tegmentum 0.03 -0.08 -0.08 . 0.14 0.28 . 0.06 0.25 0.03
R Tegmentum -0.09 0.22 0.10 . -0.07 0.18 . 0.05 -0.16 -0.22
L SI 0.00 -0.12 0.04 . 0.31 0.40 . -0.30 0.24 0.24
R SI -0.03 -0.14 -0.31 . 0.45 0.31 . 0.08 0.36 0.26
L Septal n -0.03 -0.06 -0.06 . 0.17 0.30 . -0.26 0.21 0.06
R Septal n -0.07 -0.10 -0.18 . 0.25 0.18 . -0.04 0.30 0.06
L BF 0.06 -0.05 -0.06 . 0.28 0.44 . -0.13 0.20 0.18
R BF -0.01 -0.12 -0.22 . 0.33 0.25 . 0.05 0.31 0.15
Medulla -0.10 -0.01 -0.02 . 0.10 0.30 . -0.14 0.03 -0.13
Caudal Pons 0.06 0.17 0.25 . -0.08 0.14 . -0.08 -0.07 -0.14
Rostral Pons 0.20 0.00 0.04 . 0.17 0.33 . -0.02 0.22 0.04
L Cerebellum 0.04 0.05 0.16 . 0.23 0.22 . -0.29 0.17 0.03
R Cerebellum -0.07 0.08 0.22 . 0.20 0.26 . -0.26 0.18 -0.04
L Cerebellum n 0.14 -0.07 0.07 . 0.27 0.37 . -0.32 0.17 0.14
R Cerebellum n -0.09 -0.05 0.17 . 0.31 0.34 . -0.26 0.21 0.02
L M Thalamus 0.02 0.03 -0.05 . 0.20 0.37 . -0.25 0.04 0.16
R M Thalamus -0.01 0.10 -0.02 . 0.26 0.26 . -0.13 0.18 0.11
L Caudate 0.18 -0.07 -0.09 . 0.21 0.35 . 0.00 0.11 0.23
R Caudate 0.03 -0.18 -0.39 . 0.16 0.27 . 0.04 0.12 0.12
L Putamen -0.20 -0.15 -0.27 . 0.14 0.06 . 0.27 0.22 0.04
R Putamen -0.05 -0.07 -0.07 . 0.19 0.09 . 0.01 0.05 0.10
L Globus Pallidus 0.37 -0.04 0.06 . -0.05 0.11 . 0.18 -0.05 -0.15
R Globus Pallidus -0.07 -0.05 -0.02 . -0.06 -0.03 . 0.05 -0.08 -0.10
L Hippocampus 0.14 0.08 -0.05 . 0.06 0.28 . -0.12 -0.02 -0.06
R Hippocampus 0.06 -0.03 -0.25 . 0.17 0.34 . 0.07 0.10 0.08
L Amygdala 0.03 -0.06 0.08 . 0.23 0.22 . -0.01 0.27 0.05
R Amygdala -0.12 -0.11 0.09 . 0.13 0.17 . -0.21 0.10 0.08
L Ant Insula -0.12 0.02 0.16 . 0.25 -0.01 . -0.11 0.25 0.25
R Ant Insula -0.07 -0.15 -0.24 . 0.49 0.14 . -0.09 0.51 0.26
L Post Insula 0.00 -0.12 0.26 . 0.20 0.07 . 0.20 0.30 0.16
R Post Insula 0.63 0.04 0.21 . 0.10 0.11 . 0.22 0.07 0.09
L Subgenual AC 0.12 0.04 0.01 . 0.33 0.29 . -0.19 0.13 0.14
R Subgenual AC -0.03 -0.16 -0.12 . 0.34 0.18 . -0.24 0.19 0.32
L Drevets 0.09 0.04 0.01 . 0.29 -0.03 . -0.26 0.23 0.24
R Drevets 0.02 0.02 -0.07 . 0.28 -0.08 . -0.29 0.22 0.22
L Pregenual AC 0.00 -0.09 -0.28 . 0.47 0.19 . -0.17 0.28 0.22
R Pregenual AC -0.05 -0.16 -0.26 . 0.48 -0.01 . -0.08 0.50 0.29
L Mayberg -0.02 -0.11 -0.26 . 0.54 0.24 . -0.13 0.40 0.30
R Mayberg -0.06 -0.12 -0.26 . 0.52 0.03 . -0.02 0.48 0.34
L Supragenual AC -0.13 -0.22 -0.10 . 0.30 0.06 . -0.29 0.32 0.24
R Supragenual AC 0.02 -0.30 -0.23 . 0.49 0.16 . -0.17 0.46 0.46
L Dorsal AC 0.08 -0.22 -0.36 . 0.33 0.26 . 0.08 0.29 0.45
R Dorsal AC 0.09 -0.21 -0.45 . 0.30 0.23 . 0.05 0.22 0.43
L Post AC -0.03 0.29 0.19 . -0.20 -0.14 . 0.16 -0.21 -0.18














































L Ant Temporal -0.24 -0.01 0.15 . -0.10 -0.06 . -0.09 -0.04 -0.23
R Ant Temporal -0.15 0.19 0.03 . 0.16 -0.15 . 0.10 0.01 -0.02
L Post Temporal -0.24 0.04 0.43 . -0.30 -0.17 . -0.17 -0.21 -0.14
R Post Temporal -0.14 0.10 0.11 . -0.40 -0.37 . 0.15 -0.30 -0.29
L TP 0.16 -0.01 -0.07 . 0.21 0.19 . -0.20 0.09 0.03
R TP 0.05 0.12 -0.03 . 0.05 -0.05 . -0.11 0.00 0.04
L Inf Parietal 0.03 0.05 -0.16 . 0.32 0.24 . -0.15 0.19 0.29
R Inf Parietal -0.08 -0.06 -0.38 . 0.11 -0.01 . 0.19 0.00 -0.04
L Occipital -0.09 0.21 0.10 . -0.12 0.22 . -0.03 -0.16 -0.19
R Occipital -0.03 0.14 0.23 . -0.13 -0.16 . 0.12 -0.08 -0.24
L DLPFC -0.23 -0.37 -0.01 . -0.07 -0.23 . -0.24 0.18 0.09
R DLPFC 0.17 -0.25 -0.06 . 0.25 -0.01 . -0.15 0.27 0.21
L VLPFC -0.19 -0.18 0.00 . 0.29 0.07 . -0.26 0.25 0.33
R VLPFC 0.04 -0.29 -0.19 . 0.46 0.10 . -0.16 0.40 0.24
L MOFC 0.12 0.18 0.07 . 0.23 -0.06 . -0.22 0.16 0.17
R MOFC 0.08 0.09 -0.03 . 0.21 -0.06 . -0.24 0.08 0.16
L LOFC 0.00 0.01 -0.01 . 0.21 0.05 . -0.06 0.18 0.14
R LOFC 0.01 -0.03 -0.11 . 0.21 0.05 . 0.03 0.09 0.01
# r > .45 1 0 0 0 8 0 0 0 4 1 14
# r < -.45 0 0 0 0 0 0 0 0 0 0 0
Total 1 0 0 0 8 0 0 0 4 1 14
 
# r > .5 1 0 0 0 2 0 0 0 1 0 4
# r < -.5 0 0 0 0 0 0 0 0 0 0 0
Total 1 0 0 0 2 0 0 0 1 0 4
 
# Positive corrs 29 24 25 0 52 45 0 21 50 48 294
# Negative corrs 34 39 38 0 11 18 0 42 13 15 210
Total 63 63 63 0 63 63 0 63 63 63 504
Euphoria  0.05 0.24 . -0.06 0.07 . 0.04 -0.08 0.07
Calmness 0.05  0.33 . -0.32 -0.37 . 0.30 -0.49 -0.35
Good/Bad 0.24 0.33  . -0.27 -0.29 . -0.15 -0.29 -0.08
Depression . . .  . . . . . .
Fear -0.06 -0.32 -0.27 .  0.60 . -0.04 0.81 0.49
Anxiety 0.07 -0.37 -0.29 . 0.60  . -0.18 0.40 0.38
Anger . . . . . .  . . .
Tiredness 0.04 0.30 -0.15 . -0.04 -0.18 .  -0.06 -0.31
Auditory -0.08 -0.49 -0.29 . 0.81 0.40 . -0.06  0.42
Visual 0.07 -0.35 -0.08 . 0.49 0.38 . -0.31 0.42  
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Global 0.10 -0.08 -0.10 0.21 -0.01 0.05 0.11 0.16 0.11 0.09
L Tegmentum -0.22 -0.20 -0.41 -0.10 0.42 0.25 0.48 0.04 0.04 0.16
R Tegmentum -0.23 -0.13 -0.30 -0.17 0.33 0.29 0.21 0.00 -0.11 0.00
L SI 0.14 -0.07 0.15 -0.20 -0.17 0.17 -0.26 -0.35 0.37 0.16
R SI 0.10 -0.12 0.17 -0.23 -0.17 0.09 -0.24 -0.23 0.26 -0.13
L Septal n 0.11 -0.10 0.05 -0.20 -0.02 0.30 -0.38 -0.40 0.42 0.13
R Septal n 0.01 -0.08 0.08 -0.27 -0.10 0.17 -0.41 -0.31 0.44 0.00
L BF 0.08 -0.16 0.08 -0.23 0.00 0.30 -0.27 -0.26 0.30 0.07
R BF 0.04 -0.07 0.18 -0.32 -0.11 0.10 -0.31 -0.16 0.32 -0.12
Medulla -0.19 -0.22 -0.36 -0.01 0.47 0.45 0.34 0.16 -0.11 0.11
Caudal Pons -0.23 -0.19 -0.36 -0.19 0.34 0.32 0.17 -0.15 0.18 0.07
Rostral Pons -0.17 -0.10 -0.17 -0.28 0.22 0.28 -0.01 -0.14 0.36 0.09
L Cerebellum -0.18 -0.13 -0.37 0.04 0.43 0.16 0.48 0.17 -0.22 0.08
R Cerebellum -0.12 -0.07 -0.25 0.00 0.32 0.03 0.42 0.18 -0.28 -0.03
L Cerebellum n 0.02 -0.22 -0.14 -0.26 0.26 0.13 0.49 0.08 -0.10 0.10
R Cerebellum n -0.05 -0.24 -0.20 -0.17 0.26 0.18 0.27 -0.10 0.03 0.04
L M Thalamus -0.02 0.00 -0.01 -0.30 -0.03 0.11 -0.12 -0.14 0.36 -0.01
R M Thalamus -0.19 0.04 -0.09 -0.24 -0.01 -0.08 -0.14 -0.11 0.39 -0.04
L Caudate 0.26 -0.03 0.30 -0.23 -0.21 0.16 -0.32 -0.30 0.36 0.06
R Caudate 0.11 -0.20 0.12 -0.23 0.09 0.25 -0.23 -0.24 0.33 -0.02
L Putamen 0.19 0.02 0.26 -0.31 -0.20 0.11 -0.21 -0.36 0.41 0.08
R Putamen 0.16 0.05 0.33 -0.36 -0.27 -0.07 -0.23 -0.22 0.29 -0.05
L Globus Pallidus 0.37 0.28 0.40 -0.12 -0.39 -0.16 -0.53 -0.29 0.14 -0.16
R Globus Pallidus 0.27 0.27 0.37 -0.35 -0.14 -0.05 -0.25 -0.09 0.41 0.13
L Hippocampus -0.21 -0.26 -0.17 0.03 0.23 0.34 -0.05 0.12 -0.26 -0.21
R Hippocampus -0.28 -0.31 -0.38 -0.03 0.40 0.43 0.37 0.34 -0.23 0.02
L Amygdala -0.14 -0.26 -0.07 -0.25 0.17 0.41 -0.11 -0.25 0.28 0.17
R Amygdala -0.19 -0.23 -0.07 -0.38 -0.03 0.19 -0.03 0.06 0.15 -0.12
L Ant Insula 0.03 0.00 0.13 -0.26 -0.28 -0.03 -0.18 -0.44 0.44 0.06
R Ant Insula 0.16 0.15 0.30 -0.25 -0.35 -0.23 -0.22 -0.31 0.41 -0.04
L Post Insula 0.10 0.10 0.25 -0.13 -0.20 -0.22 -0.32 -0.22 0.16 -0.14
R Post Insula 0.06 -0.06 0.20 -0.27 -0.32 -0.02 -0.23 -0.08 0.21 -0.10
L Subgenual AC 0.05 -0.26 -0.05 -0.15 -0.02 0.33 -0.04 -0.16 0.20 0.18
R Subgenual AC 0.08 -0.22 0.01 -0.25 0.01 0.23 0.00 -0.09 0.04 0.02
L Drevets 0.17 0.04 0.16 -0.17 -0.25 -0.09 -0.09 -0.25 0.15 0.11
R Drevets 0.05 -0.19 -0.09 -0.21 -0.05 0.05 0.20 -0.32 0.41 0.13
L Pregenual AC 0.06 -0.03 0.18 -0.07 -0.25 -0.13 -0.21 -0.30 0.28 -0.09
R Pregenual AC 0.12 -0.11 0.12 -0.19 -0.20 -0.03 -0.05 -0.41 0.44 0.09
L Mayberg 0.00 -0.05 0.16 -0.14 -0.25 -0.09 -0.19 -0.26 0.33 -0.06
R Mayberg 0.17 -0.08 0.20 -0.26 -0.20 -0.05 -0.08 -0.44 0.46 0.11
L Supragenual AC 0.14 -0.05 0.25 -0.07 -0.34 -0.17 -0.29 -0.36 0.42 -0.02
R Supragenual AC 0.25 -0.08 0.29 -0.24 -0.28 -0.04 -0.16 -0.40 0.42 0.06
L Dorsal AC 0.05 -0.08 0.20 -0.08 -0.16 0.09 -0.19 -0.17 0.32 0.00
R Dorsal AC 0.16 -0.16 0.20 -0.22 -0.18 0.10 -0.14 -0.21 0.35 -0.02
L Post AC -0.27 -0.23 -0.02 -0.19 -0.13 -0.12 -0.04 0.30 0.12 -0.21














































L Ant Temporal -0.04 -0.17 -0.06 -0.14 0.16 -0.02 0.31 -0.30 -0.39 -0.10
R Ant Temporal -0.20 -0.15 -0.15 0.03 0.34 0.18 0.13 -0.22 -0.23 0.13
L Post Temporal -0.07 -0.09 -0.18 0.14 0.25 0.16 0.23 -0.22 -0.13 0.17
R Post Temporal 0.09 0.06 -0.06 0.14 0.22 -0.07 0.27 -0.01 -0.13 -0.04
L TP -0.17 -0.33 -0.27 -0.11 0.41 0.33 0.17 0.26 -0.15 -0.02
R TP -0.22 -0.29 -0.22 -0.17 0.27 0.10 0.22 0.38 -0.19 -0.09
L Inf Parietal 0.00 0.04 -0.06 0.00 -0.11 0.04 0.04 -0.29 0.22 0.22
R Inf Parietal 0.15 0.12 0.07 -0.02 0.00 0.01 0.10 -0.09 0.12 0.11
L Occipital -0.17 -0.10 -0.17 0.06 -0.05 -0.07 -0.09 0.04 0.06 -0.03
R Occipital -0.13 0.14 -0.09 -0.14 -0.05 -0.27 0.05 -0.03 0.23 0.05
L DLPFC 0.05 0.14 0.20 0.10 -0.18 -0.20 -0.25 -0.44 0.24 0.13
R DLPFC 0.13 0.08 0.26 -0.15 -0.36 -0.44 -0.14 -0.29 0.23 -0.18
L VLPFC 0.02 -0.17 0.04 0.03 0.05 0.19 -0.04 -0.55 0.30 0.17
R VLPFC -0.08 -0.21 -0.08 0.13 0.01 0.00 0.03 -0.11 0.16 -0.11
L MOFC -0.09 -0.22 -0.27 -0.21 0.08 0.23 0.25 -0.03 0.13 0.15
R MOFC -0.07 -0.28 -0.25 -0.20 0.09 0.25 0.37 -0.02 0.13 0.13
L LOFC -0.08 -0.26 -0.15 -0.07 0.29 0.30 0.20 0.06 -0.01 0.11
R LOFC 0.08 -0.21 0.07 0.00 0.16 0.10 0.19 0.15 -0.16 -0.16
# r > .45 0 0 0 0 1 0 3 0 1 0 5
# r < -.45 0 0 0 0 0 0 1 1 0 0 2
Total 0 0 0 0 1 0 4 1 1 0 7
 
# r > .5 0 0 0 0 0 0 0 0 0 0 0
# r < -.5 0 0 0 0 0 0 1 1 0 0 2
Total 0 0 0 0 0 0 1 1 0 0 2
 
# Positive corrs 36 16 32 13 26 41 24 17 47 36 288
# Negative corrs 27 47 31 50 37 22 39 46 16 27 342
Total 63 63 63 63 63 63 63 63 63 63 630
Euphoria  0.40 0.74 -0.32 -0.39 -0.25 -0.07 -0.12 0.05 -0.05
Calmness 0.40  0.54 -0.14 -0.39 -0.58 -0.33 0.00 -0.05 -0.11
Good/Bad 0.74 0.54  -0.46 -0.64 -0.54 -0.41 0.05 -0.15 -0.31
Depression -0.32 -0.14 -0.46  0.28 0.12 0.03 0.00 -0.07 -0.06
Fear -0.39 -0.39 -0.64 0.28  0.68 0.41 0.01 0.11 0.28
Anxiety -0.25 -0.58 -0.54 0.12 0.68  0.31 -0.08 0.19 0.46
Anger -0.07 -0.33 -0.41 0.03 0.41 0.31  0.19 0.00 0.33
Tiredness -0.12 0.00 0.05 0.00 0.01 -0.08 0.19  -0.48 -0.34
Auditory 0.05 -0.05 -0.15 -0.07 0.11 0.19 0.00 -0.48  0.55
Visual -0.05 -0.11 -0.31 -0.06 0.28 0.46 0.33 -0.34 0.55  
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Global -0.20 0.06 -0.14 0.16 -0.10 -0.03 0.09 0.11 0.08 0.34
L Tegmentum -0.14 0.01 -0.12 0.13 0.15 0.19 0.32 -0.07 -0.16 0.09
R Tegmentum -0.50 -0.32 -0.37 0.01 0.24 0.33 0.26 -0.17 0.05 0.13
L SI 0.42 -0.01 0.26 -0.17 -0.30 0.08 -0.17 -0.26 0.37 0.07
R SI 0.27 -0.14 0.18 -0.21 -0.17 0.09 -0.26 -0.16 0.29 -0.06
L Septal n 0.28 -0.12 0.14 -0.13 -0.22 0.23 0.01 -0.26 0.31 0.16
R Septal n 0.20 -0.08 0.13 -0.09 -0.24 0.13 -0.16 -0.24 0.27 0.02
L BF 0.35 -0.06 0.14 -0.14 -0.20 0.20 -0.07 -0.19 0.32 0.16
R BF 0.23 -0.06 0.14 -0.16 -0.22 0.10 -0.14 -0.15 0.32 0.08
Medulla -0.27 -0.24 -0.23 -0.03 0.24 0.29 0.49 -0.38 -0.26 0.16
Caudal Pons -0.17 -0.21 -0.18 -0.06 0.10 0.22 0.21 -0.10 0.20 -0.06
Rostral Pons 0.18 -0.10 0.01 -0.05 -0.01 0.25 -0.02 -0.20 0.36 0.12
L Cerebellum -0.37 -0.22 -0.26 0.08 0.43 0.36 0.43 -0.12 -0.24 0.19
R Cerebellum -0.44 -0.25 -0.18 0.11 0.30 0.13 0.42 -0.08 -0.40 -0.03
L Cerebellum n -0.13 -0.18 -0.08 -0.09 0.16 0.19 0.30 -0.33 -0.03 0.14
R Cerebellum n -0.18 -0.24 -0.09 -0.12 0.11 0.19 0.09 -0.17 0.08 0.05
L M Thalamus 0.15 -0.01 0.08 -0.20 -0.17 0.05 0.00 -0.26 0.25 0.11
R M Thalamus 0.07 -0.05 0.06 -0.19 -0.21 -0.01 -0.04 -0.25 0.36 0.10
L Caudate 0.50 0.26 0.32 -0.14 -0.35 -0.09 -0.13 -0.02 0.35 0.18
R Caudate 0.19 0.02 -0.14 -0.01 0.08 0.21 0.05 -0.02 0.20 0.34
L Putamen 0.30 -0.01 0.06 -0.16 -0.23 -0.01 -0.05 0.09 0.34 0.09
R Putamen 0.28 0.23 0.25 -0.21 -0.21 -0.23 -0.24 -0.22 0.19 -0.02
L Globus Pallidus 0.34 0.23 0.15 -0.05 -0.28 -0.06 -0.27 0.11 0.34 0.01
R Globus Pallidus 0.21 0.17 0.27 -0.25 -0.15 -0.05 -0.09 -0.12 0.26 0.06
L Hippocampus 0.10 -0.03 0.06 -0.15 0.19 0.31 0.10 -0.13 -0.03 0.11
R Hippocampus -0.08 -0.11 -0.33 0.08 0.30 0.43 0.46 0.00 -0.06 0.33
L Amygdala 0.16 -0.12 0.04 -0.22 -0.02 0.42 -0.07 0.01 0.42 0.16
R Amygdala 0.08 -0.24 -0.01 -0.15 0.05 0.24 0.10 -0.12 0.19 -0.03
L Ant Insula -0.07 -0.02 0.05 -0.13 -0.03 0.05 -0.18 -0.07 0.24 -0.22
R Ant Insula 0.26 0.11 0.17 -0.15 -0.06 0.15 -0.32 -0.14 0.25 -0.01
L Post Insula 0.29 -0.04 0.23 0.03 -0.11 -0.16 -0.33 -0.02 0.20 -0.19
R Post Insula 0.22 0.09 -0.12 -0.01 0.08 0.13 -0.02 0.22 0.52 0.11
L Subgenual AC 0.19 -0.06 0.11 -0.37 -0.21 0.17 -0.06 -0.28 0.23 0.17
R Subgenual AC 0.11 -0.02 0.08 -0.32 -0.02 0.22 0.17 -0.23 0.01 0.22
L Drevets 0.29 0.05 0.25 -0.22 -0.33 -0.08 -0.25 -0.21 0.15 0.02
R Drevets 0.31 -0.08 0.11 -0.14 0.09 0.34 -0.06 -0.54 0.33 0.20
L Pregenual AC 0.41 0.06 0.35 -0.38 -0.24 -0.04 -0.31 -0.17 0.30 -0.01
R Pregenual AC 0.39 0.05 0.29 -0.31 -0.25 0.11 -0.33 -0.15 0.33 0.07
L Mayberg 0.35 0.00 0.30 -0.34 -0.19 -0.03 -0.29 -0.07 0.31 -0.10
R Mayberg 0.40 0.13 0.34 -0.39 -0.26 0.09 -0.38 -0.13 0.33 0.05
L Supragenual AC 0.34 -0.06 0.31 -0.23 -0.30 -0.13 -0.26 -0.23 0.24 -0.15
R Supragenual AC 0.36 -0.01 0.26 -0.28 -0.27 0.07 -0.29 -0.24 0.26 0.01
L Dorsal AC 0.28 -0.03 0.18 -0.12 -0.18 -0.05 -0.17 -0.10 0.29 -0.03
R Dorsal AC 0.26 -0.07 0.16 -0.34 -0.21 0.02 -0.17 -0.13 0.26 -0.05
L Post AC -0.30 0.03 -0.27 0.08 0.12 -0.15 0.30 0.04 0.02 -0.01














































L Ant Temporal -0.04 -0.17 -0.06 -0.14 0.16 -0.02 0.31 -0.30 -0.39 -0.10
R Ant Temporal -0.20 -0.15 -0.15 0.03 0.34 0.18 0.13 -0.22 -0.23 0.13
L Post Temporal -0.13 -0.08 -0.02 0.15 0.20 -0.02 0.36 -0.19 -0.54 -0.08
R Post Temporal -0.20 -0.11 -0.23 0.15 0.26 0.04 0.31 0.00 -0.30 0.02
L TP 0.16 -0.18 -0.02 -0.40 0.30 0.30 0.33 -0.33 -0.06 0.11
R TP -0.23 -0.45 -0.34 -0.09 0.37 0.44 0.28 -0.09 -0.06 0.15
L Inf Parietal 0.44 0.26 0.38 -0.29 -0.28 -0.14 -0.17 -0.14 0.18 -0.02
R Inf Parietal 0.28 0.18 0.11 -0.25 -0.01 0.25 -0.05 -0.14 0.28 0.35
L Occipital -0.20 -0.07 -0.20 0.14 0.12 0.05 0.05 0.12 0.13 -0.03
R Occipital 0.09 0.07 -0.07 0.11 0.07 -0.11 0.00 0.09 0.22 -0.06
L DLPFC 0.24 0.24 0.26 0.10 -0.31 -0.43 -0.26 -0.06 -0.09 -0.33
R DLPFC 0.22 0.16 0.31 -0.17 -0.32 -0.32 -0.27 -0.16 0.24 -0.26
L VLPFC 0.13 0.12 0.08 0.07 0.04 0.05 -0.09 -0.15 -0.24 -0.04
R VLPFC -0.08 -0.13 -0.05 0.07 -0.12 0.07 -0.16 -0.14 0.13 -0.01
L MOFC 0.11 0.04 0.12 -0.38 -0.26 -0.05 -0.25 -0.11 0.08 -0.11
R MOFC 0.02 -0.24 -0.07 -0.15 0.15 0.45 0.10 -0.50 0.00 0.19
L LOFC -0.17 0.02 -0.07 0.14 0.11 0.11 0.14 -0.02 -0.16 0.20
R LOFC -0.18 0.00 0.07 -0.05 0.14 0.10 0.13 -0.01 -0.15 0.12
# r > .45 1 0 0 0 0 0 2 0 1 0 4
# r < -.45 1 0 0 0 0 0 0 2 1 0 4
Total 2 0 0 0 0 0 2 2 2 0 8
 
# r > .5 0 0 0 0 0 0 0 0 1 0 1
# r < -.5 1 0 0 0 0 0 0 2 1 0 4
Total 1 0 0 0 0 0 0 2 2 0 5
 
# Positive corrs 43 23 39 16 27 42 26 9 46 38 309
# Negative corrs 20 40 24 47 36 21 37 54 17 25 321
Total 63 63 63 63 63 63 63 63 63 63 630
Euphoria  0.40 0.65 -0.28 -0.24 -0.05 -0.03 -0.19 0.27 0.16
Calmness 0.40  0.59 -0.17 -0.40 -0.51 -0.35 0.10 0.01 0.04
Good/Bad 0.65 0.59  -0.42 -0.53 -0.49 -0.34 -0.16 -0.09 -0.30
Depression -0.28 -0.17 -0.42  0.28 0.07 0.03 0.16 -0.06 -0.02
Fear -0.24 -0.40 -0.53 0.28  0.67 0.36 -0.07 0.10 0.28
Anxiety -0.05 -0.51 -0.49 0.07 0.67  0.33 -0.19 0.32 0.59
Anger -0.03 -0.35 -0.34 0.03 0.36 0.33  -0.20 -0.05 0.34
Tiredness -0.19 0.10 -0.16 0.16 -0.07 -0.19 -0.20  0.03 -0.07
Auditory 0.27 0.01 -0.09 -0.06 0.10 0.32 -0.05 0.03  0.49
Visual 0.16 0.04 -0.30 -0.02 0.28 0.59 0.34 -0.07 0.49  
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Appendix K.  Correlations Between Brain ROIs and Emotional and Sensory












































Global -0.19 -0.18 -0.02 -0.34 -0.01 0.16 -0.16 -0.37 0.03 0.11
L Tegmentum -0.16 -0.11 -0.39 0.07 0.42 0.32 0.45 0.01 0.36 -0.12
R Tegmentum -0.02 0.25 -0.46 0.47 0.35 0.18 0.23 0.05 0.62 -0.16
L SI 0.29 0.09 0.07 0.27 0.17 -0.13 0.50 0.43 -0.14 -0.05
R SI 0.07 -0.21 -0.24 0.38 -0.07 -0.11 -0.07 -0.29 0.15 0.15
L Septal n 0.36 0.30 0.03 0.42 0.23 -0.11 0.54 0.48 -0.08 -0.02
R Septal n 0.29 0.25 -0.23 0.27 0.40 0.27 0.32 0.09 0.22 0.10
L BF 0.21 -0.12 -0.14 0.50 0.24 -0.01 0.49 0.10 0.00 0.09
R BF 0.05 -0.04 -0.37 0.50 0.07 -0.03 0.09 -0.20 0.32 0.04
Medulla 0.03 -0.01 -0.37 0.63 0.23 0.16 -0.12 -0.20 0.46 -0.09
Caudal Pons 0.19 0.26 -0.40 0.43 0.50 0.29 0.54 0.25 0.41 0.03
Rostral Pons 0.13 0.15 -0.50 0.57 0.70 0.43 0.67 0.23 0.44 -0.09
L Cerebellum 0.17 0.37 -0.32 0.37 0.10 0.02 0.19 -0.05 0.48 0.19
R Cerebellum 0.11 0.24 -0.24 0.23 0.39 0.37 0.17 -0.11 0.54 -0.09
L Cerebellum n 0.07 -0.02 -0.28 0.15 0.47 0.51 0.41 -0.06 0.51 -0.07
R Cerebellum n 0.08 0.11 -0.28 0.37 0.40 0.30 0.14 -0.06 0.59 -0.21
L M Thalamus 0.02 -0.21 -0.39 0.66 0.52 0.10 0.34 0.15 0.20 -0.20
R M Thalamus 0.02 -0.17 -0.39 0.27 0.70 0.37 0.63 0.17 0.18 -0.16
L Caudate 0.20 -0.04 0.19 0.09 -0.06 -0.13 0.39 -0.03 -0.18 0.21
R Caudate -0.39 -0.43 -0.31 -0.11 0.26 0.19 0.24 -0.45 0.13 0.00
L Putamen -0.17 -0.26 -0.35 0.27 0.51 0.23 0.64 -0.01 0.32 -0.17
R Putamen -0.17 -0.32 -0.29 0.14 -0.17 -0.18 -0.25 -0.10 0.06 -0.17
L Globus Pallidus 0.22 -0.05 -0.23 0.22 -0.06 0.03 0.18 -0.20 0.15 0.34
R Globus Pallidus -0.27 -0.13 -0.40 0.04 0.07 0.09 -0.03 -0.38 0.37 -0.14
L Hippocampus 0.05 0.08 -0.01 0.39 -0.09 0.09 -0.26 -0.45 0.34 0.02
R Hippocampus -0.11 -0.19 0.15 -0.27 0.18 0.24 0.36 -0.02 -0.20 -0.11
L Amygdala 0.22 0.06 -0.25 0.50 0.28 0.27 -0.01 0.01 0.42 -0.08
R Amygdala 0.32 0.38 0.10 0.33 0.13 -0.08 0.27 0.53 -0.02 -0.23
L Ant Insula 0.09 0.49 0.15 0.24 -0.01 -0.16 0.09 -0.01 0.31 -0.10
R Ant Insula -0.27 0.15 0.09 0.08 -0.08 -0.38 0.12 0.10 0.17 -0.34
L Post Insula 0.06 0.05 0.07 0.04 0.28 0.13 0.30 0.05 0.24 -0.29
R Post Insula 0.05 0.04 0.09 0.14 0.18 0.03 0.15 0.24 0.18 -0.34
L Subgenual AC 0.15 -0.23 0.37 -0.01 -0.33 -0.11 -0.34 -0.42 -0.21 0.34
R Subgenual AC -0.17 -0.40 -0.19 0.11 -0.08 0.04 -0.29 -0.63 0.21 0.16
L Drevets -0.05 0.12 -0.01 0.21 -0.04 -0.27 0.16 -0.12 0.10 -0.15
R Drevets 0.23 0.30 -0.01 0.11 -0.04 -0.22 0.28 0.03 0.03 0.16
L Pregenual AC -0.15 -0.16 -0.14 0.05 0.08 0.07 0.28 -0.41 0.36 0.03
R Pregenual AC -0.17 -0.29 -0.46 0.40 0.34 -0.06 0.46 0.09 0.03 -0.17
L Mayberg 0.03 -0.12 -0.04 -0.03 0.17 0.10 0.49 -0.23 0.16 0.14
R Mayberg -0.27 -0.39 -0.45 0.34 0.38 -0.07 0.56 0.19 -0.08 -0.28
L Supragenual AC -0.01 -0.36 0.09 -0.18 0.19 0.34 0.39 -0.40 -0.08 0.13
R Supragenual AC -0.10 -0.23 -0.02 -0.28 0.38 0.22 0.64 0.06 -0.17 -0.13
L Dorsal AC 0.29 -0.02 0.28 -0.15 0.12 0.19 0.29 0.05 -0.09 0.07
R Dorsal AC 0.12 -0.01 0.27 -0.14 0.02 -0.03 0.21 -0.10 -0.15 -0.09
L Post AC -0.26 -0.04 -0.18 0.26 -0.30 -0.32 -0.36 -0.21 0.24 -0.26














































L Ant Temporal -0.17 0.11 0.13 -0.31 0.02 0.20 -0.03 -0.51 0.19 -0.03
R Ant Temporal -0.11 0.04 0.04 -0.04 0.06 0.16 -0.14 -0.59 0.38 -0.01
L Post Temporal 0.14 0.55 0.37 -0.14 -0.38 -0.51 -0.26 0.22 -0.28 -0.09
R Post Temporal -0.26 -0.04 -0.18 0.26 -0.30 -0.32 -0.36 -0.21 0.24 -0.26
L TP 0.22 0.19 -0.10 0.47 0.23 0.06 0.02 0.16 0.30 -0.09
R TP 0.24 0.31 -0.02 0.38 0.27 0.01 0.14 0.24 0.07 -0.07
L Inf Parietal 0.20 -0.04 -0.07 -0.18 0.35 0.30 0.50 0.34 -0.19 0.16
R Inf Parietal -0.14 -0.49 -0.08 0.00 0.11 -0.09 0.30 0.13 -0.19 -0.18
L Occipital -0.27 0.32 -0.18 -0.03 0.07 -0.19 0.17 0.52 0.03 -0.48
R Occipital -0.20 0.25 -0.27 -0.01 0.27 -0.13 0.38 0.74 -0.04 -0.37
L DLPFC -0.08 0.00 0.41 -0.42 -0.02 -0.19 0.12 -0.07 -0.21 -0.07
R DLPFC 0.20 0.25 0.22 -0.10 0.09 -0.15 0.02 0.46 -0.31 0.08
L VLPFC -0.10 -0.33 -0.16 -0.25 0.20 0.25 0.41 -0.23 -0.13 0.27
R VLPFC 0.43 0.08 0.42 -0.06 -0.34 -0.39 -0.08 0.14 -0.39 0.37
L MOFC 0.16 0.39 0.17 0.08 -0.29 -0.38 -0.12 -0.18 -0.03 0.10
R MOFC 0.37 0.46 0.15 0.02 -0.26 -0.29 -0.08 -0.19 0.03 0.38
L LOFC 0.03 -0.18 -0.14 0.05 -0.27 -0.21 -0.30 -0.09 -0.09 0.33
R LOFC 0.07 -0.27 0.14 -0.25 -0.39 -0.08 -0.59 -0.19 -0.27 0.33
# r > .45 0 3 0 8 6 1 12 5 6 0 41
# r < -.45 0 1 4 0 0 1 1 4 0 1 12
Total 0 4 4 8 6 2 13 9 6 1 53
 
# r > .5 0 1 0 4 4 1 7 3 4 0 24
# r < -.5 0 0 1 0 0 1 1 3 0 0 6
Total 0 1 1 4 4 2 8 6 4 0 30
 
# Positive corrs 38 30 22 44 42 33 44 29 40 25 347
# Negative corrs 25 33 41 19 21 30 19 34 23 38 283
Total 63 63 63 63 63 63 63 63 63 63 630
Euphoria  0.50 0.60 0.02 -0.17 0.07 -0.08 0.09 -0.22 0.82
Calmness 0.50  0.37 -0.07 -0.21 -0.21 0.13 0.28 0.08 0.26
Good/Bad 0.60 0.37  -0.58 -0.60 -0.33 -0.36 -0.15 -0.52 0.54
Depression 0.02 -0.07 -0.58  0.29 0.07 0.11 0.16 0.46 -0.13
Fear -0.17 -0.21 -0.60 0.29  0.77 0.67 0.24 0.33 -0.25
Anxiety 0.07 -0.21 -0.33 0.07 0.77  0.35 -0.16 0.41 0.15
Anger -0.08 0.13 -0.36 0.11 0.67 0.35  0.41 0.14 -0.17
Tiredness 0.09 0.28 -0.15 0.16 0.24 -0.16 0.41  -0.33 -0.30
Auditory -0.22 0.08 -0.52 0.46 0.33 0.41 0.14 -0.33  -0.16
Visual 0.82 0.26 0.54 -0.13 -0.25 0.15 -0.17 -0.30 -0.16  
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Appendix L. Correlations Between Brain ROIs and Emotional and Sensory












































Global 0.13 0.04 -0.43 0.21 0.51 0.54 -0.20 -0.49 0.49 0.21
L Tegmentum -0.06 -0.14 0.25 -0.39 -0.10 0.04 0.48 -0.18 -0.39 -0.13
R Tegmentum 0.12 0.09 0.31 -0.20 -0.01 0.10 0.01 -0.28 -0.20 0.07
L SI 0.01 0.51 0.27 0.23 -0.22 -0.33 0.13 0.46 -0.42 0.14
R SI 0.37 0.79 0.47 0.04 -0.13 -0.43 -0.13 0.00 -0.05 -0.04
L Septal n 0.25 0.72 0.44 0.02 -0.14 -0.36 0.12 0.03 -0.16 -0.03
R Septal n 0.29 0.57 0.27 0.07 0.01 -0.10 0.19 0.04 -0.30 0.18
L BF 0.20 0.73 0.46 0.04 -0.27 -0.47 0.12 0.03 -0.20 -0.09
R BF 0.34 0.75 0.43 0.05 -0.14 -0.36 -0.08 0.00 -0.21 0.12
Medulla 0.09 0.03 -0.11 0.02 0.12 0.25 -0.08 -0.31 -0.21 0.38
Caudal Pons -0.10 0.07 0.32 -0.20 -0.23 -0.04 0.31 0.08 -0.51 -0.01
Rostral Pons -0.04 0.28 0.22 0.12 -0.11 -0.08 0.36 0.27 -0.55 0.17
L Cerebellum -0.06 -0.41 0.27 -0.44 0.17 0.16 0.10 -0.37 -0.16 0.06
R Cerebellum -0.05 -0.42 -0.06 -0.23 0.21 0.32 0.30 -0.18 -0.50 0.28
L Cerebellum n 0.06 -0.02 0.13 -0.19 -0.12 0.02 0.20 -0.14 -0.53 0.31
R Cerebellum n 0.07 0.05 0.09 -0.12 0.03 0.04 0.03 0.00 -0.52 0.35
L M Thalamus 0.11 0.41 0.08 0.34 -0.13 -0.03 0.16 0.12 -0.42 0.31
R M Thalamus 0.14 0.54 0.33 0.21 -0.05 -0.11 0.11 0.13 -0.41 0.26
L Caudate -0.06 0.35 0.37 -0.20 -0.45 -0.53 0.29 0.02 -0.23 -0.46
R Caudate -0.27 0.19 0.16 -0.15 -0.20 -0.14 0.24 -0.16 -0.26 -0.14
L Putamen 0.11 0.26 0.03 0.15 0.05 -0.01 0.43 0.42 -0.32 0.19
R Putamen 0.29 0.29 0.05 0.18 -0.24 -0.28 0.20 0.28 -0.43 0.38
L Globus Pallidus -0.30 0.28 0.19 -0.08 -0.57 -0.52 0.06 0.14 -0.23 0.06
R Globus Pallidus 0.31 0.50 0.42 -0.07 -0.12 -0.44 -0.21 -0.05 -0.12 0.22
L Hippocampus 0.05 0.08 0.53 -0.35 -0.21 -0.29 0.30 0.28 -0.38 -0.21
R Hippocampus 0.12 -0.15 -0.24 0.25 0.32 0.38 0.28 0.60 -0.31 0.17
L Amygdala 0.28 0.42 0.45 -0.03 -0.16 -0.21 0.12 0.20 -0.49 0.04
R Amygdala 0.18 0.20 0.00 0.37 -0.04 -0.15 0.03 0.62 -0.30 0.49
L Ant Insula -0.29 -0.25 -0.20 -0.17 0.23 0.33 0.15 0.12 -0.20 -0.12
R Ant Insula -0.30 -0.33 -0.24 -0.01 0.19 0.15 0.24 0.28 -0.06 -0.14
L Post Insula 0.17 -0.06 -0.02 0.01 0.02 -0.05 0.41 0.43 -0.56 0.31
R Post Insula 0.22 0.19 0.16 0.18 0.00 -0.12 0.31 0.60 -0.50 0.08
L Subgenual AC 0.15 0.28 0.17 -0.18 -0.02 -0.12 0.10 -0.40 0.08 -0.43
R Subgenual AC 0.25 0.53 0.24 -0.21 -0.30 -0.36 -0.02 -0.38 0.07 -0.18
L Drevets 0.24 0.62 0.16 0.21 -0.11 -0.22 0.04 0.41 -0.30 0.11
R Drevets 0.31 0.68 0.48 0.00 -0.25 -0.40 -0.07 0.21 -0.13 -0.03
L Pregenual AC 0.33 0.70 0.32 0.00 -0.05 -0.23 -0.05 0.11 -0.22 0.04
R Pregenual AC 0.25 0.57 0.18 0.31 -0.17 -0.22 -0.05 0.26 -0.24 0.25
L Mayberg 0.34 0.72 0.36 -0.02 0.01 -0.24 -0.05 0.00 -0.15 0.06
R Mayberg 0.28 0.53 0.08 0.35 -0.09 -0.18 0.03 0.22 -0.23 0.37
L Supragenual AC 0.43 0.53 0.35 -0.05 0.14 -0.26 0.16 0.11 -0.13 0.01
R Supragenual AC 0.27 0.31 0.22 -0.08 -0.02 -0.31 0.18 0.01 -0.04 0.10
L Dorsal AC 0.34 0.24 0.22 -0.25 0.10 -0.05 0.48 0.16 -0.17 -0.26
R Dorsal AC 0.37 0.32 0.02 0.09 0.18 -0.05 0.29 0.23 0.02 0.14
L Post AC 0.19 0.22 0.18 0.03 -0.43 -0.47 -0.13 0.27 -0.21 0.01














































L Ant Temporal 0.13 -0.42 -0.04 -0.51 0.29 0.09 0.12 -0.56 0.42 -0.38
R Ant Temporal 0.02 -0.44 0.01 -0.43 0.35 0.20 0.04 -0.33 0.05 -0.24
L Post Temporal 0.14 -0.51 -0.37 0.11 0.41 0.21 -0.13 0.05 0.47 0.05
R Post Temporal 0.19 0.22 0.18 0.03 -0.43 -0.47 -0.13 0.27 -0.21 0.01
L TP 0.22 0.10 0.30 -0.04 0.11 -0.11 0.02 0.00 -0.33 -0.03
R TP 0.22 0.02 0.17 0.11 0.24 -0.07 0.04 -0.02 -0.13 0.23
L Inf Parietal 0.25 0.07 0.09 0.09 0.34 0.20 0.25 0.28 -0.25 0.53
R Inf Parietal 0.08 0.34 0.21 0.18 -0.20 -0.28 0.07 0.45 -0.48 0.15
L Occipital -0.31 -0.43 -0.31 0.20 -0.03 0.09 -0.12 0.19 0.02 0.37
R Occipital -0.41 -0.26 -0.12 0.36 -0.18 0.05 -0.10 0.38 -0.32 0.40
L DLPFC 0.42 0.45 0.42 -0.09 0.03 -0.18 0.10 -0.14 -0.01 -0.19
R DLPFC 0.29 0.49 0.26 0.12 0.14 -0.06 0.04 0.36 -0.13 -0.10
L VLPFC 0.18 0.46 0.02 0.07 0.16 -0.06 0.19 -0.19 0.24 -0.07
R VLPFC 0.35 0.24 -0.01 0.14 0.14 0.16 0.05 0.40 -0.17 0.12
L MOFC 0.38 0.62 0.35 -0.09 0.01 -0.18 -0.22 0.04 -0.05 0.16
R MOFC 0.61 0.81 0.58 -0.07 -0.11 -0.38 -0.31 -0.04 0.10 -0.05
L LOFC 0.47 0.27 0.18 -0.23 0.49 0.23 -0.17 -0.70 0.74 -0.34
R LOFC 0.53 -0.04 0.10 -0.46 0.49 0.21 0.02 -0.56 0.78 -0.33
36 3 21 6 0 2 0 2 4 3 2 43
20 0 1 0 2 2 6 0 3 9 1 24
56 3 22 6 2 4 6 2 7 12 3 67
  
25 2 18 2 0 0 0 0 3 2 1 28
12 0 1 0 1 2 3 0 3 6 0 16
37 2 19 2 1 2 3 0 6 8 1 44
  
377 51 49 51 32 28 19 45 41 11 39 366
253 12 14 12 31 35 44 18 22 52 24 264
630 63 63 63 63 63 63 63 63 63 63 630
Euphoria 1.00 0.45 0.34 -0.18 0.40 0.05 0.00 -0.25 0.53 -0.11
Calmness 0.45 1.00 0.54 0.08 -0.08 -0.29 -0.34 -0.19 0.18 -0.19
Good/Bad 0.34 0.54 1.00 -0.50 -0.19 -0.42 -0.35 -0.36 0.05 -0.43
Depression -0.18 0.08 -0.50 1.00 -0.14 -0.08 -0.07 0.54 -0.08 0.43
Fear 0.40 -0.08 -0.19 -0.14 1.00 0.80 0.13 -0.27 0.40 0.13
Anxiety 0.05 -0.29 -0.42 -0.08 0.80 1.00 0.26 -0.19 0.04 0.20
Anger 0.00 -0.34 -0.35 -0.07 0.13 0.26 1.00 0.29 -0.30 -0.16
Tiredness -0.25 -0.19 -0.36 0.54 -0.27 -0.19 0.29 1.00 -0.37 0.21
Auditory 0.53 0.18 0.05 -0.08 0.40 0.04 -0.30 -0.37 1.00 -0.21
Visual -0.11 -0.19 -0.43 0.43 0.13 0.20 -0.16 0.21 -0.21 1.00
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Appendix M.  Correlations Between Brain ROIs and Emotional and Sensory












































Global 0.19 0.09 -0.49 0.38 0.51 0.65 0.07 -0.37 0.46 0.03
L Tegmentum 0.43 -0.15 -0.20 0.44 0.44 0.21 0.46 -0.44 0.58 -0.08
R Tegmentum 0.65 0.28 -0.04 0.36 0.36 0.05 0.52 -0.47 0.80 -0.26
L SI 0.28 0.42 0.43 -0.19 -0.03 -0.37 -0.23 0.11 -0.13 0.15
R SI 0.34 0.31 0.19 0.19 0.02 -0.40 -0.09 0.19 0.08 0.18
L Septal n 0.38 0.66 0.54 -0.17 0.02 -0.43 -0.07 -0.11 0.20 -0.15
R Septal n 0.26 0.42 0.09 0.37 0.01 -0.32 -0.07 0.10 0.19 0.05
L BF 0.48 0.58 0.60 -0.11 -0.10 -0.55 -0.12 -0.18 0.19 -0.01
R BF 0.43 0.45 0.30 0.13 0.01 -0.40 -0.09 -0.08 0.15 0.18
Medulla 0.44 -0.27 -0.22 0.25 0.45 0.31 0.55 -0.49 0.55 -0.14
Caudal Pons 0.39 0.02 0.03 0.31 0.15 -0.04 0.43 -0.36 0.57 -0.30
Rostral Pons 0.27 0.23 0.15 0.35 0.09 -0.11 0.06 -0.20 0.47 -0.29
L Cerebellum 0.30 0.07 -0.11 0.40 0.11 0.01 -0.17 -0.18 0.14 0.59
R Cerebellum 0.19 0.01 -0.23 0.52 0.12 -0.06 -0.10 0.01 0.32 0.51
L Cerebellum n 0.36 -0.24 -0.06 0.33 0.27 0.13 0.39 -0.60 0.39 0.03
R Cerebellum n 0.19 -0.40 -0.18 0.33 0.34 0.23 0.25 -0.50 0.27 0.22
L M Thalamus 0.26 0.09 0.17 0.19 -0.20 -0.21 -0.10 -0.16 0.01 0.22
R M Thalamus 0.24 0.45 0.25 0.17 -0.04 -0.24 -0.30 0.09 0.09 0.18
L Caudate 0.34 0.26 0.65 -0.38 -0.32 -0.66 0.01 -0.14 -0.17 -0.10
R Caudate -0.13 0.01 -0.05 0.42 -0.16 -0.33 -0.05 0.37 0.00 0.17
L Putamen 0.22 -0.14 -0.16 0.46 0.23 0.05 0.01 -0.06 0.35 0.33
R Putamen 0.11 -0.17 -0.20 0.18 0.25 0.19 -0.16 0.18 -0.16 0.52
L Globus Pallidus 0.05 -0.03 -0.08 0.42 -0.36 -0.45 0.14 -0.05 0.20 0.14
R Globus Pallidus 0.45 0.36 0.09 0.35 0.20 -0.17 0.06 0.10 0.24 -0.03
L Hippocampus 0.26 -0.05 0.37 -0.23 0.08 -0.16 0.20 -0.35 -0.01 0.00
R Hippocampus -0.05 0.06 0.36 -0.12 -0.06 -0.17 0.02 -0.05 -0.07 -0.09
L Amygdala 0.04 0.17 0.41 0.09 -0.03 -0.28 -0.30 -0.11 0.08 0.05
R Amygdala 0.04 0.08 0.36 -0.17 0.05 0.04 -0.61 -0.16 -0.02 0.37
L Ant Insula -0.09 0.30 0.13 -0.11 -0.07 -0.17 -0.41 0.29 -0.24 0.21
R Ant Insula 0.12 0.34 0.25 0.08 0.05 -0.18 -0.60 0.01 0.09 0.26
L Post Insula 0.04 -0.29 0.00 0.04 -0.10 -0.24 -0.14 0.11 -0.19 0.62
R Post Insula -0.23 -0.05 0.12 0.11 -0.03 -0.05 -0.57 0.23 -0.26 0.33
L Subgenual AC 0.25 0.01 0.20 0.08 0.09 0.00 -0.32 -0.39 0.01 0.23
R Subgenual AC 0.12 0.07 -0.04 0.29 -0.24 -0.49 0.25 0.15 0.08 0.35
L Drevets 0.31 0.23 0.02 0.24 0.15 0.03 -0.08 0.22 0.07 0.16
R Drevets 0.39 0.41 0.30 0.19 -0.23 -0.62 0.02 0.13 0.11 0.23
L Pregenual AC 0.41 0.38 0.11 0.07 0.19 -0.10 -0.21 0.15 0.09 0.35
R Pregenual AC 0.36 -0.06 -0.05 0.09 0.13 0.01 0.12 0.30 -0.04 0.27
L Mayberg 0.48 0.52 0.26 -0.06 0.13 -0.22 -0.27 0.06 0.07 0.31
R Mayberg 0.43 -0.10 -0.11 0.04 0.25 0.15 0.11 0.21 -0.03 0.30
L Supragenual AC 0.50 0.32 0.35 -0.17 0.10 -0.24 -0.14 0.02 -0.04 0.10
R Supragenual AC 0.54 0.31 0.32 0.06 -0.06 -0.38 -0.32 -0.13 0.14 0.32
L Dorsal AC 0.28 0.00 0.26 -0.13 0.12 0.00 -0.21 -0.33 0.07 0.06
R Dorsal AC 0.41 0.15 0.27 0.15 -0.02 -0.17 -0.26 -0.43 0.23 0.28
L Post AC 0.11 -0.02 -0.05 0.20 0.13 0.05 0.08 0.21 -0.03 0.28
R Post AC 0.14 0.28 0.20 0.04 -0.15 -0.13 -0.15 0.21 -0.22 0.13
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L Ant Temporal 0.29 0.01 0.15 -0.04 0.01 -0.05 0.36 -0.56 0.41 -0.48
R Ant Temporal -0.02 -0.39 -0.04 0.00 0.09 0.15 0.39 -0.37 0.19 -0.36
L Post Temporal 0.03 -0.23 0.08 -0.10 -0.10 -0.13 0.34 -0.45 0.10 -0.08
R Post Temporal -0.04 -0.28 0.08 0.02 -0.04 -0.11 0.22 -0.33 0.05 -0.11
L TP 0.25 -0.12 0.19 -0.28 0.29 0.11 0.37 -0.39 0.11 -0.41
R TP 0.26 0.04 0.35 -0.25 -0.05 -0.18 0.40 -0.57 0.27 -0.38
L Inf Parietal 0.34 -0.02 0.03 -0.25 0.06 -0.20 0.09 0.37 -0.40 0.37
R Inf Parietal -0.18 -0.30 -0.04 -0.18 -0.07 0.08 -0.33 0.26 -0.49 0.55
L Occipital 0.08 0.18 0.05 -0.09 -0.16 -0.01 -0.22 0.06 -0.11 0.25
R Occipital 0.01 0.25 0.05 -0.22 -0.03 0.00 -0.17 0.35 -0.20 0.11
L DLPFC 0.31 0.47 0.51 -0.27 -0.21 -0.53 -0.19 0.13 -0.18 0.20
R DLPFC -0.10 0.38 0.23 -0.29 -0.21 -0.36 -0.21 0.63 -0.39 0.01
L VLPFC 0.37 0.32 -0.28 0.37 0.21 -0.10 0.18 0.26 0.25 0.16
R VLPFC -0.05 -0.47 -0.11 -0.05 -0.12 -0.06 -0.17 0.23 -0.62 0.71
L MOFC 0.46 0.36 0.23 0.00 -0.01 -0.19 0.20 0.16 -0.01 -0.19
R MOFC 0.45 0.45 0.25 0.10 -0.25 -0.67 0.31 0.16 0.06 0.08
L LOFC 0.42 0.02 -0.24 0.13 0.49 0.30 0.55 -0.41 0.42 -0.20
R LOFC -0.03 -0.32 -0.29 0.03 0.36 0.36 0.36 -0.26 0.17 -0.08
36 8 5 4 2 1 0 4 1 5 6 36
20 0 1 0 0 0 6 3 7 2 1 20
56 8 6 4 2 1 6 7 8 7 7 56
  
25 3 3 4 1 0 0 3 1 4 6 25
12 0 0 0 0 0 5 3 3 1 0 12
37 3 3 4 1 0 5 6 4 5 6 37
  
377 53 41 42 40 35 20 30 32 40 44 377
253 10 22 21 23 28 43 33 31 23 19 253
630 63 63 63 63 63 63 63 63 63 63 630
Euphoria  0.37 0.13 0.04 0.35 -0.08 0.43 -0.31 0.46 -0.09
Calmness 0.37  0.50 -0.24 -0.16 -0.42 -0.08 -0.14 0.21 -0.30
Good/Bad 0.13 0.50  -0.64 -0.37 -0.60 -0.40 -0.33 -0.18 -0.28
Depression 0.04 -0.24 -0.64  0.25 0.26 0.13 -0.08 0.57 0.25
Fear 0.35 -0.16 -0.37 0.25  0.79 0.22 -0.09 0.50 -0.14
Anxiety -0.08 -0.42 -0.60 0.26 0.79  0.06 -0.04 0.23 -0.01
Anger 0.43 -0.08 -0.40 0.13 0.22 0.06  0.18 0.21 -0.30
Tiredness -0.31 -0.14 -0.33 -0.08 -0.09 -0.04 0.18  -0.45 -0.02
Auditory 0.46 0.21 -0.18 0.57 0.50 0.23 0.21 -0.45  -0.25
Visual -0.09 -0.30 -0.28 0.25 -0.14 -0.01 -0.30 -0.02 -0.25  
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Appendix N.  Multivariate Multiple Regression Analysis of the Relationship Between Change in Emotion Ratings and Change in
rCBF – 32 Healthy Controls – Negative Emotions
Multivariate Analysis Univariate Analysis Regression Analysis
Model L/R Regions RGR R2  Emotion R2  Model R2  Region B (SE)
dCBF AChNet L All 0.70 0.41 * Anxiety 0.27  AM, SI, SGAC 0.25 * AM .19 (.07)
Predicts dEmotion    SI -.07 (.04)
Anxiety    SGAC .03 (.04)
Fear   AM, SI 0.24 * AM .20 (.07)
   SI -.05 (.04)
  AM 0.17 * AM .13 (.05)
  SI 0.01 SI .01 (.03)
 Fear 0.18       
Alternative Models L BF 0.74 0.43 * Anxiety 0.24  AM, BF, SGAC 0.20    
Drevet 0.61 0.38 *  0.25 AM, SI, DRE 0.24 *  
Mayberg 0.67 0.40 *  0.27 AM, SI, SGAC, MAY 0.26  
DLPFC 1.03 0.51 *  0.36 AM, SI, SGAC, DLPFC 0.34 *  
D, M 0.60 0.37 *  0.25 AM, SI, DRE, MAY 0.25  
D,M, D 0.90 0.47 *  0.37 AM, SI, DRE, DLPFC 0.37 *  
B, D, M 0.66 0.40 *  0.26 AM, BF, DRE, MAY 0.26  
B, D,M, D 1.10 0.52 *  0.43 * BF, DRE, DLPFC 0.41 * BF .20 (.06)
   DRE -.07 (.03)
   DLPFC -.10 (.03)
BF  Fear 0.13       
Drevet   0.21   
Mayberg   0.17   
DLPFC   0.17 SI, PGAC, AINS, DLPFC 0.14  
D, M   0.20   
D,M, D   0.21 SI, MAY, AINS, DLPFC 0.14  
B, D, M   0.18   
B, D,M, D   0.22   
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Appendix N. Cont’d.
Multivariate Analysis Univariate Analysis Regression Analysis
Model L/R Regions RGR R2  Emotion R2  Model R2  Region B (SE)
dCBF AChNet R All 0.73 0.42 * Anxiety 0.38 * AM, MOFC 0.25 * AM .07 (.06)
Predicts dEmotion    MOFC .14 (.05)
Anxiety   PGAC, MOFC 0.22 * PGAC -.04 (.05)
Fear    MOFC .16 (.06)
  MOFC 0.20 * MOFC .14 (.05)
  AM, PGAC, MOFC 0.28 *  
 Fear 0.21  PGAC, MOFC 0.17    
Alternative Models R BF 0.56 0.36  Anxiety 0.35  AM, BF, MOFC 0.33 * AM -.09 (.05)
   BF .17 (.06)
   MOFC .19 (.04)
Drevet 0.71 0.41 *  0.38 * AM, DRE, PGAC, MOFC 0.28  
  AM, DRE, MOFC 0.25 *  
  ADRE, MOFC 0.20 *  
  DRE, PGAC 0.15 DRE .15 (.07)
   PGAC -.06 (.06)
Mayberg 0.69 0.41 *  0.38 * AM, MAY, MOFC 0.27 *  
  MAY, MOFC 0.22 *  
DLPFC 0.51 0.34  0.28 AM, PGAC, DLPFC 0.23  
D, M 0.66 0.40 *  0.38 * AM, DRE, MAY, MOFC 0.27  
  DRE, MAY, MOFC 0.22  
  DRE, MAY 0.14  
D, M, D 0.80 0.44 *  0.44 * AM, DRE, MAY, DLPFC 0.33 *  
B, D, M 0.54 0.35  0.35 AM, BF, DRE, MAY, MOFC 0.34 *  
B, D, M, D 0.73 0.42  0.41 * AM, BF, DRE, MAY, DLPFC 0.41 *  
  BF, DRE, DLPFC 0.29 *  
BF  Fear 0.26  BF, PGAC, MOFC 0.18    
Drevet   0.24 DRE, PGAC, MOFC 0.21  
Mayberg   0.21 MAY, MOFC 0.16  
DLPFC   0.17 PGAC, DLPFC 0.14  
D, M   0.24 DRE, MAY, MOFC 0.19  
D, M, D   0.32 DRE, MAY, DLPFC 0.26  
B, D, M   0.31 BF, DRE, MAY, MOFC 0.25  
B, D, M, D   0.38 BF, DRE, MAY, DLPFC 0.32  
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Appendix O. Multivariate Multiple Regression Analysis of the Relationship Between Change in Emotion Ratings and Change in rCBF
– 32 Healthy Controls – Positive Emotions
Multivariate Analysis Univariate Analysis Regression Analysis
Model L/R Regions RGR R2 Emotion R2 Model R2 Region B (SE)
dCBF AChNet L All 0.34 0.25  Euphoria 0.24  SGAC, PGAC, AINS, MOFC 0.19  SGAC -.01 (.06)
Predicts dEmotion    PGAC .12 (.05)
euphoria    AINS -.02 (.03)
calmness    MOFC -.04 (.11)
 Calmness 0.04  SI, SGAC, PGAC 0.02  SI -.01 (.05)
   SGAC -.02 (.05)
   PGAC .03 (.06)
  SI, PGAC 0.01
  SI 0.00 SI .00 ( .03)
Alternative Models L BF 0.28 0.22  Euphoria 0.20  BF, SGAC, PGAC, AINS, MOFC 0.20    
   AM, BF, PGAC, AINS 0.19 AM -.03 (.11)
    BF .05 (.11)
    PGAC .09 (.06)
    AINS -.01 (.04)
Drevet 0.41 0.29  0.26 DRE, PGAC, AINS, MOFC 0.19
Mayberg 0.35 0.26  0.23 SGAC, MAY, AINS, MOFC 0.16
DLPFC 0.34 0.25  0.23 SGAC, PGAC, AINS, DLPFC 0.20
D, M 0.44 0.30  0.26 DRE, MAY, AINS, MOFC 0.16
D,M, D 0.45 0.31  0.26 DRE, MAY, AINS, DLPFC 0.18
B, D, M 0.34 0.25  0.19 AM, BF, MAY, AINS 0.18
B, D,M, D 0.35 0.26  0.20 BF, DRE, MAY, AINS, DLPFC 0.20
BF  Calmness 0.04  BF, SGAC, PGAC 0.02    
Drevet   0.03 SI, DRE, PGAC 0.01
Mayberg   0.03 SI, SGAC, MAY 0.01
DLPFC   0.08 SI, SGAC, PGAC, DLPFC 0.07
D, M   0.03 SI, DRE, MAY 0.01
D,M, D   0.09 SI, DRE, MAY, DLPFC 0.09
B, D, M   0.03 BF, DRE, MAY 0.03
B, D,M, D   0.11 BF, DRE, MAY, DLPFC 0.10
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Appendix O. Cont’d.
Multivariate Analysis Univariate Analysis Regression Analysis
Model L/R Regions RGR R2 Emotion R2 Model R2 Region B (SE)
dCBF AChNet R All 0.27 0.21  Euphoria 0.21  SGAC, PGAC, MOFC 0.21  SGAC .02 (.04)
Predicts dEmotion    PGAC .16 (.06)
Euphoria    MOFC -.11 (.08)
Calmness  Calmness 0.19  SI, AINS, MOFC 0.09  SI -.02 (.04)
   AINS .02 (.02)
   MOFC -.07 (.07)
Alternative Models R BF 0.27 0.21  Euphoria 0.21  BF, SGAC, PGAC, MOFC 0.21    
   BF, SGAC, MAY, MOFC 0.20
Drevet 0.40 0.29  0.28 DRE, PGAC, MOFC 0.26
Mayberg 0.28 0.22  0.20 SGAC, MAY, MOFC 0.20
DLPFC 0.23 0.19  0.18 SGAC, PGAC, DLPFC 0.17
D, M 0.41 0.29  0.28 DRE, MAY, MOFC 0.27
D,M, D 0.23 0.18  0.18 DRE, MAY, DLPFC 0.17
B, D, M 0.40 0.28  0.28 BF, DRE, MAY, MOFC 0.27
   BF, MAY, MOFC 0.20
B, D,M, D 0.24 0.19  0.18 BF, MAY, DLPFC 0.17 BF .00 (.07)
    MAY .09 (.05)
    DLPFC .03 (.05)
BF  Calmness 0.20  BF, AINS, MOFC 0.08    
Drevet   0.21 SI, DRE, AINS, MOFC 0.12 SI -.15 (.05)
    DRE .11 (.11)
    AINS .01 (.02)
    MOFC -.13 (.09)
Mayberg   0.20 SI, MAY, AINS, MOFC 0.19  
DLPFC   0.15 SI, AINS, DLPFC 0.09  
D, M   0.23 SI, DRE, MAY, AINS, MOFC 0.21  
D,M, D   0.17 SI, DRE, MAY, AINS, DLPFC 0.15  
B, D, M   0.22 BF, DRE, MAY, AINS, MOFC 0.14  
B, D,M, D   0.16 BF, DRE, MAY, AINS, DLPFC 0.10  
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Appendix P. Multivariate Multiple Regression Analysis of the Relationship Between Change in Emotion Ratings and Change in rCBF
– 15 Patients with Bipolar Disorder – Negative Emotions
Multivariate Analysis Univariate Analysis Regression Analysis
Model L/R Regions RGR R2  Emotion R2  Model R2  Region B (SE)
dCBF AChNet L 1.45 0.59  Anxiety 0.29  AM, SI, SGAC 0.23  AM -.11 (.12)
Predicts dEmotion    SI -.10 (.07)
Anxiety    SGAC .09 (.10)
Fear   AM, SI 0.16 AM -.07 (.11)
   SI -.07 (.06)
  AM 0.08 AM -.11 (.11)
  SI 0.14 SI -.09 (.06)
  Fear 0.13       
Alternative Models L BF 3.03 0.75 * Anxiety 0.45  AM, BF, SGAC 0.39    
Drevet 3.60 0.78 *  0.39 AM, SI, DRE 0.26
Mayberg 1.67 0.63  0.27 AM, SI, SGAC, MAY 0.24
DLPFC 1.27 0.56  0.44 AM, SI, SGAC, DLPFC 0.31
D, M 2.93 0.75 *  0.39 AM, SI, DRE, MAY 0.26
D,M, D 2.33 0.70  0.53 AM, SI, DRE, DLPFC 0.37 *
B, D, M 3.92 0.80 *  0.44 AM, BF, DRE, MAY 0.41
B, D,M, D 5.03 0.83 *  0.58 BF, DRE, DLPFC 0.53 * BF -.22 (.13)
   DRE .10 (.05)
   DLPFC -.13 (.08)
BF   Fear 0.15       
Drevet  0.11  
Mayberg  0.08  
DLPFC  0.43 SI, PGAC, AINS, DLPFC 0.34
D, M  0.11  
D,M, D  0.36 SI, MAY, AINS, DLPFC 0.28
B, D, M  0.11  
B, D,M, D  0.23  
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Appendix P. Cont’d
Multivariate Analysis Univariate Analysis Regression Analysis
Model L/R Regions RGR R2  Emotion R2  Model R2  Region B (SE)
dCBF AChNet R 3.82 0.64 * Anxiety 0.61  AM, MOFC 0.45 * AM .00 (.11)
Predicts dEmotion   MOFC -.22 (.07)
Anxiety  PGAC, MOFC 0.53 * PGAC .12 (.08)
Fear   MOFC -.27 (.07)
 MOFC 0.45 * MOFC -.22 (.07)
 AM, PGAC, MOFC 0.57 *
  Fear 0.26  PGAC, MOFC 0.12    
Alternative Models R 3.91 0.80 * Anxiety 0.60  AM, BF, MOFC 0.45  AM .00 (.13)
   BF -.07 (.15)
   MOFC -.13 (.11)
3.83 0.79 *  0.61 AM, DRE, MOFC 0.45
 DRE, MOFC 0.45 *
 DRE, PGAC 0.59 * DRE -.27 (.07)
  PGAC .21 (.09)
3.50 0.78 *  0.61 AM, MAY, MOFC 0.58 *
  MAY, MOFC 0.54 *
1.33 0.57  0.37 AM, PGAC, DLPFC 0.14
3.70 0.79 *  0.61 AM, DRE, MAY, MOFC 0.59 *
  DRE, MAY, MOFC 0.59 *
  DRE, MAY 0.58 *
2.48 0.71  0.59 AM, DRE, MAY, DLPFC 0.60 *
3.82 0.79 *  0.58 AM, BF, DRE, MAY, MOFC 0.59
2.57 0.72 *  0.62 AM, BF, DRE, MAY, DLPFC 0.61
  BF, DRE, DLPFC 0.41
  Fear 0.24  BF, PGAC, MOFC 0.15    
 0.29 DRE, PGAC, MOFC 0.16
 0.28 MAY, MOFC 0.16
 0.26 PGAC, DLPFC 0.08
 0.30 DRE, MAY, MOFC 0.20
 0.42 SI, DRE, MAY, DLPFC 0.41
 0.27 BF, DRE, MAY, MOFC 0.26
 0.33 BF, DRE, MAY, DLPFC 0.32
286
 Appendix Q. Multivariate Multiple Regression Analysis of the Relationship Between Change in Emotion Ratings and Change in
rCBF – 15 Patients with Bipolar Disorder – Positive Emotions
Multivariate Analysis Univariate Analysis Regression Analysis
Model L/R Regions RGR R2  Emotion R2  Model R2  Region B (SE)
dCBF AChNet L All 1.75 0.64  Euphoria 0.63  SGAC, PGAC, AINS, MOFC 0.49  SGAC .10 (.09)
Predicts dEmotion    PGAC .11 (.06)
Euphoria    AINS -.10 (.05)
Calmness    MOFC .16 (.09)
  Calmness 0.29  SI, SGAC, PGAC 0.28  SI .14 (.10)
   SGAC -.11 (.12)
   PGAC .08 (.09)
  SI, PGAC 0.23
  SI 0.18 SI .14 (.08)
Alternative Models L BF 5.44 0.84 * Euphoria 0.82 * BF, SGAC, PGAC, AINS, MOFC 0.55    
   AM, BF, PGAC, AINS 0.71 * AM -.33 (.11)
    BF .51 (.14)
    PGAC .15 (.05)
    AINS -.11 (.04)
Drevet 3.12 0.76 *  0.70 DRE, PGAC, AINS, MOFC 0.68 *
Mayberg 2.38 0.70  0.70 SGAC, MAY, AINS, MOFC 0.60 *
DLPFC 1.58 0.61  0.60 SGAC, PGAC, AINS, DLPFC 0.40
D, M 4.39 0.81 *  0.72 DRE, MAY, AINS, MOFC 0.70 *
D,M, D 1.74 0.63  0.63 DRE, MAY, AINS, DLPFC 0.42
B, D, M 6.03 0.86 *  0.75 * AM, BF, MAY, AINS 0.70 *
B, D,M, D 5.94 0.86 *  0.78 * BF, DRE, MAY, AINS, DLPFC 0.52
BF  Calmness 0.52  BF, SGAC, PGAC 0.44    
Drevet   0.40 SI, DRE, PGAC 0.24
Mayberg   0.40 SI, SGAC, MAY 0.37
DLPFC   0.28 SI, SGAC, PGAC, DLPFC 0.28
D, M   0.48 SI, DRE, MAY 0.30
D,M, D   0.33 SI, DRE, MAY, DLPFC 0.33
B, D, M   0.50 BF, DRE, MAY 0.39
B, D,M, D   0.49 BF, DRE, MAY, DLPFC 0.40
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Multivariate Analysis Univariate Analysis Regression Analysis
Model L/R Regions RGR R2  Emotion R2  Model R2  Region B (SE)
dCBF AChNet R All 1.02 0.50  Euphoria 0.34  SGAC, PGAC, MOFC 0.30  SGAC -.12 (.13)
Predicts dEmotion    PGAC .10 (.12)
Euphoria    MOFC .21 (.13)
Calmness   Calmness 0.50  SI, AINS, MOFC 0.42  SI -.26 (.16)
   AINS .24 (.12)
  AINS 0.11 MOFC .42 (.18)
Alternative Models R BF 1.50 0.60  Euphoria 0.46  BF, SGAC, PGAC, MOFC 0.39    
   BF, SGAC, MAY, MOFC 0.43
Drevet 1.03 0.51  0.39 DRE, PGAC, MOFC 0.28
Mayberg 1.02 0.50  0.40 SGAC, MAY, MOFC 0.36
DLPFC 1.37 0.58  0.42 SGAC, PGAC, DLPFC 0.16
D, M 1.03 0.51  0.45 DRE, MAY, MOFC 0.38
D,M, D 2.24 0.69  0.44 DRE, MAY, DLPFC 0.30
B, D, M 0.97 0.49  0.48 BF, DRE, MAY, MOFC 0.46
   BF, MAY, MOFC 0.34
B, D,M, D 1.53 0.60  0.48 BF, MAY, DLPFC 0.45 BF .30 (.14)
   MAY .11 (.08)
   DLPFC -.11 (.06)
BF   Calmness 0.53  BF, AINS, MOFC 0.29    
Drevet  0.49 SI, DRE, AINS, MOFC 0.48 SI -.28 (.16)
   DRE -.29 (.27)
   AINS .31 (.13)
   MOFC .74 (.34)
Mayberg  0.50 SI, MAY, AINS, MOFC 0.46
DLPFC  0.21 SI, AINS, DLPFC 0.16
D, M  0.50 SI, DRE, MAY, AINS, MOFC 0.49
D,M, D  0.40 SI, DRE, MAY, AINS, DLPFC 0.39
B, D, M  0.43 BF, DRE, MAY, AINS, MOFC 0.35
B, D,M, D  0.35 BF, DRE, MAY, AINS, DLPFC 0.33
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